US 3,979, 399, US 3,840, 546, and US 3,966, 746 (E. R. Squibb & Sons) disclose 4-amino derivatives of pyrazolo [3,4-b] pyridine-5-carboxamides wherein the 4-amino group NR3R4 can be an acyclic amino group wherein R3 and R4 may each be hydrogen, lower alkyl (e. g. butyl), phenyl, etc.; NR3R4 can alternatively be a 3-6-membered heterocyclic group such as pyrrolidino, piperidino and piperazino. The compounds are disclosed as central nervous system depressants useful as ataractic, analgesic and hypotensive agents.

US 3,925, 388, US 3,856, 799, US 3,833, 594 and US 3,755, 340 (E. R. Squibb & Sons) disclose 4-amino derivatives of pyrazolo [3,4-b] pyridine-5-carboxylic acids and esters.

The 4-amino group NR3R4 can be an acyclic amino group wherein R3 and R4 may each be hydrogen, lower alkyl (e. g. butyl), phenyl, etc.; NR3R4 can alternatively be a 5-6- membered heterocyclic group in which an additional nitrogen is present such as pyrrolidino, piperidino, pyrazolyl, pyrimidinyl, pyridazinyl or piperazinyl. The compounds are mentioned as being central nervous system depressants useful as ataractic agents or tranquilisers, as having antiinflammatory and analgesic properties. The compounds are mentioned as increasing the intracellular concentration of adenosine-3', 5'- cyclic monophosphate and for alleviating the symptoms of asthma.

H. Hoehn et al., J. Heterocycl. Chem., 1972,9 (2), 235-253 discloses a series of 1H pyrazolo [3,4-b] pyridine-5-carboxylic acid derivatives with 4-hydroxy, 4-chloro, 4-alkoxy, 4-hydrazino, and 4-amino substituents.

CA 1003419, CH 553 799 and T. Denzel, Archiv def° Pharmazie, 1974, 307 (3), 177-186 disclose 4,5-disubstituted 1H pyrazolo [3,4-b] pyridines unsubstituted at the 1-position.

Japanese laid-open patent application JP-2002-20386-A (Ono Yakuhin Kogyo KK) published on 23 January 2002 discloses pyrazolopyridine compounds of the following formula:

wherein R1 denotes 1) a group-OR6, 2) a group-SR7, 3) a C2-8 alkynyl group, 4) a nitro group, 5) a cyano group, 6) a C1-8 alkyl group substituted by a hydroxy group or a C1-8 alkoxy group, 7) a phenyl group, 8) a group-C (O) R8, 9) a group-SO2NR9Rl°, 10) a group-NRllSO2Rl2, 11) a group-NRl3C (o) Rl4 or 12) a group-CH=NRI5. R6 and R denote i) a hydrogen atom, ii) a C1-8 alkyl group, iii) a C1-8 alkyl group substituted by a C 1-8 alkoxy group, iv) a trihalomethyl group, v) a C3-7 cycloalkyl group, vi) a C 1-8 alkyl group substituted by a phenyl group or vii) a 3-15 membered mono-, di-or tricyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and/or 1-3 sulphur atoms.

R2 denotes 1) a hydrogen atom or 2) a C1-8 alkoxy group. R3 denotes 1) a hydrogen atom or 2) a C1-8 alkyl group. R4 denotes 1) a hydrogen atom, 2) a C1-8 alkyl group, 3) a C3-7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group, 5) a phenyl group which may be substituted by 1-3 halogen atoms or 6) a 3-15 membered mono-, di-or tricyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and/or 1-3 sulphur atoms. R5 denotes 1) a hydrogen atom, 2) a Cl-8 alkyl group, 3) a C3- 7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group or 5) a phenyl group which may be substituted by 1-3 substituents. In group R3, a hydrogen atom is preferred. In group R4, methyl, ethyl, cyclopropyl, cyclobutyl or cyclopentyl are preferred. The compounds of JP-2002-20386-A are stated as having PDE4 inhibitory activity and as being useful in the prevention and/or treatment of inflammatory diseases and many other diseases.

EP 0 076 035 Al (ICI Americas) discloses pyrazolo [3,4-b] pyridine derivatives as central nervous system depressants useful as tranquilisers or ataractic agents for the relief of anxiety and tension states.

The compound cartazolate, ethyl 4-(n-butylamino)-1-ethyl-1H-pyrazolo [3,4-b]-pyridine- 5-carboxylate, is known. J. W. Daly et al., Med. Chem. Res., 1994,4, 293-306 and D. Shi et al., Drug Development Research, 1997,42, 41-56 disclose a series of 4- (amino) substituted 1H-pyrazolo [3,4-b] pyridine-5-carboxylic acid derivatives, including ethyl 4-cyclopentylamino-l-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxylate, and their affinities and antagonist activities at A1-and A2A-adenosine receptors, and the latter paper discloses their affinities at various binding sites of the GABAA-receptor channel.

S. Schenone et al., Bioorg Med. Chem. Lett., 2001,11, 2529-2531 and F. Bondavalli et al. , J ; Med. Chem., 2002, vol. 45 (Issue 22,24 October 2002, allegedly published on Web 09/24/2002), pp. 4875-4887 disclose a series of 4-amino-1- (2-chloro-2-phenylethyl)-lH- pyrazolo [3,4-b] pyridine-5-carboxylic acid ethyl esters as Al-adenosine receptor ligands.

WO 02/060900 A2 appears to disclose, as MCP-1 antagonists for treatment of allergic, inflammatory or autoimmune disorders or diseases, a series of bicyclic heterocyclic compounds with a-C (O)-NR4-C (O)-NR5R6 substituent, including isoxazolo [5,4- b] pyridines and 1H pyrazolo [3,4-b] pyridines (named as pyrazolo [5,4-b] pyridines) with the-C (O)-NR4-C (O)-NR5R6 group as the 5-substituent and optionally substituted at the 1-, 3-, 4-, and/or 6-positions. Bicyclic heterocyclic compounds with a-C (O) NH2 substituent instead of the-C (O)-NR4-C (O)-NR5R6 substituent are alleged to be disclosed in WO 02/060900 as intermediates in the synthesis of the-C (O)-NR4-C(O)-NR5R6 substituted compounds.

It is desirable to find new compounds which bind to, and preferably inhibit, phosphodiesterase type IV (PDE4).

The present invention provides a compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof): wherein: Rl is Cl 4alkyl, Cl 3fluoroalkyl,-CH2CH2OH or-CH2CH2CO2Cl 2alkyl ; R2 is a hydrogen atom (H), methyl or Clfluoroalkyl ; R3 is optionally substituted C3 gcycloalkyl or optionally substituted mono-unsaturated-Cs 7cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc);

(aa) (bb) (cc) in which nl and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10 ; where R10 is a hydrogen atom (H), Cl 4alkyl (e. g. methyl or ethyl), C1-2fluoroalkyl, CH2C (O) NH2, C (O) NH2, C (O)-C1-2alkyl, C (O)-C 1 fluoroalkyl or -C(O)-CH2O-C1-2alkyl ; and wherein in R3 the C3 gcycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally substituted with one or two substituents independently being (e. g. being) oxo (=O) ; OH; Cl 2alkoxy ; C1-2fluoroalkoxy (e. g. trifluoromethoxy); NHR21 wherein R21 is a hydrogen atom (H) or C1 5 straight-chain alkyl (e. g. H or C1-4 straight- chain alkyl) ; Cl 2alkyl ; C1-2fluoroalkyl (e. g. C 1 fluoroalkyl such as-CH2F or-CHF2) ; -CH2OH ;-CH2CH2OH ;-CH2NHR22 wherein R22 is H or Cl 2alkyl ; -C (O) OR23 wherein R23 is H or Cl 2alkyl ; -C (O) NHR24 wherein R24 is H or Cl 2alkyl ; -C (O) R25 wherein R25 is Cl 2alkyl ; fluoro ; hydroxyimino (=N-OH) ; or (Cl 4alkoxy) imino (=N-OR26 where R26 is Cl 4alkyl) ; and wherein any OH, alkoxy, fluoroalkoxy or NHR21 substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH- group of formula (1) and is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc); and wherein, when R3 is optionally substituted mono-unsaturated-Cs 7cycloalkenyl, then the cycloalkenyl is optionally substituted with one or two substituents being fluoro or Cl 2alkyl provided that if there are two substituents then they are not both C2alkyl, and the R3 ring carbon bonded to the-NH-group of formula (I) does not partake in the cycloalkenyl double bond; or R3 is a bicyclic group of sub-formula (dd): (dd) or of sub-formula (ee): (ee) wherein yl, y2 and Y3 independently are CH2 or oxygen (O) provided that no more than one of Yl, Y2 and Y3 is oxygen (O) ;

and X is NR4R5 or OR5a, in which: R4 is a hydrogen atom (H); C1-6alkyl; C1-3fluoroalkyl ; or C2-6alkyl substituted by one substituent Rl 1 ; and R5 is a hydrogen atom (H) ; Cl 8alkyl ; C1 8 fluoroalkyl ; C3-8cycloalkyl optionally substituted by a Cl 2alkyl group ; or-(CH2)n4-C3-8cycloalkyl optionally substituted, in the- (CH2) n4- moiety or in the C3 gcycloalkyl moiety, by a Cl 2alkyl group, wherein n4 is 1, 2 or 3 ; or R5 is C2-6alkyl substituted by one or two independent substituents R11 ; wherein each substituent Rl 1, independently of any other Rl 1 substituent present, is: hydroxy (OH); C1 6alkoxy ; phenyloxy; benzyloxy ;-NR12Rl3 ;-NR15-C (O) Rl6 ; -NR15-C(O)-O-R16; -NR 15-C(O)-NII-R15; or-NR15-SO2R16 ; and wherein any Rl l substituent which is OH, alkoxy or-NR12Rl3 is not substituted at any carbon atom, of any R4 or R5 substituted alkyl, which is bonded to the nitrogen of NR4R5 ; or R5 is-(CH2)n11-C(O)R16; -(CH2)n12-C(O)NR12R13;-CHR19-C(O)NR12R13 ; -(CH2)n12-C(O)OR16;-(CH2)n12-C(O)OH; -CH419-C(O)OR16; -CHR19-C(O)OH ; -(CH2)n12-SO2-NR12R13; -(CH2)n12-SO2R16 ; or- (CH2) n12-CN ; wherein n11 is 0,1, 2, 3 or 4 and n 12 is 1, 2, 3 or 4 ; or R5 is- (CH2) n13-Het wherein n 13 is 0,1, 2,3 or 4 and Het is a 4-, 5-, 6-or 7-membered saturated or partly-saturated heterocyclic ring containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the- (CH2) nl3- moiety when nl3 is 1 and are not bound to the nitrogen of NR4R5 when nl3 is 0; wherein any ring-nitrogens which are present and which are not unsaturated (i. e. which do not partake in a double bond) are present as NR17 where R17 is as defined herein; and wherein one or two of the carbon ring-atoms independently are optionally substituted by Cl 2alkyl ; or R5 is phenyl optionally substituted with, independently, one, two or three of : a halogen atom; C1-6alkyl (e. g. Cl 4alkyl or C1-2alkyl); C1-2fluoroalkyl (e. g. trifluoromethyl) ; Cl 4alkoxy (e. g. Cl 2alkoxy) ; Cl 2fluoroalkoxy (e. g. trifluoromethoxy) ;

C3 6cycloalkyloxy ; -C (O) Rl6a ;-C (O) OR30 ; -S (0) 2-R16a (e. g. Cl 2alkylsulphonyl or Cl 2alkyl-SO2-) ; R16a-S (0) 2-NRl5a- (e. g. Cl 2alkyl-SO2-NH-) ; R7R8N-S (0) 2-; C1-2alkyl-C(O)-R15aN-S(O)2-; C1-4alkyl-S(O)-, Ph-S (O)-, R7R8N-CO-; -NR15-C(O)R16 ; R7R8N ; OH; Cl 4alkoxymethyl ; C1-4alkyoxyethyl ; C1-2alkyl-S(O)2-CH2-; R7R8N-S(O)2-CH2-; C1-2alkyl-S(O)2-NR15a-CH2-; -CH2-OH;-CH2CH2-OH; -CH2-NR7R8; -CH2-CH2-NR7R8; -CH2-C(O)OR30; -CH2-C(O)-NR7R8;-CH2-NR15a-C(O)-C1-3alkyl; -(CH2)n14-Het1 where nl4 is 0 or 1; cyano (CN) ; Ar5a ; or phenyl, pyridinyl or pyrimidinyl wherein the phenyl, pyridinyl or pyrimidinyl independently are optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C 1 fluoroalkoxy ; or where two adjacent substituents taken together are-O-(CMe2)-O-or-O-(CH2)n14-O-where n14 is 1 or 2; wherein R7 and R8 are independently a hydrogen atom (H); Cl 4alkyl (e. g.

C1 2alkyl such as methyl); C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C 1 fluoroalkoxy ; or R7 and R8 together are-(CH2)n6-or-C(O)-(CH2)n7-or-C(O)-(CH2)N7-C(O)-or -(CH2) n8-X7-(CH2) n9-or-C (o)-X7-(CH2) nl0-inwhich : n6 is 3,4, 5 or 6, n7 is 2,3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and neo independently are 2 or 3 (preferably independently 2), and X7 is O or NR14 wherein R14 is H, Cl 2alkyl or C (O) Me (preferably H or Cl 2alkyl) ; or R5 has the sub-formula (x), (y), (yl) or (z): (x) (y1) (y1) (Z) wherein in sub-formula (x), n = 0,1 or 2; in sub-formula (y) and (yl), m = 1 or 2; and in sub-formula (z), r = 0,1 or 2; wherein in sub-formula (x) and (y) and (yl), none, one or two of A, B, D, E and F are independently nitrogen or nitrogen-oxide (N+-O-) provided that no more than one of A, B, D, E and F is nitrogen-oxide; and the remaining of A, B, D, E and F are independently CH or CR6 ;

provided that when n is 0 in sub-formula (x) then one or two of A, B, D, E and F are independently nitrogen or nitrogen-oxide (N+-O-) and no more than one of A, B, D, E and F is nitrogen-oxide; wherein, each R6, independently of any other R6 present, is: a halogen atom; Cl 6alkyl (e. g. Cl 4alkyl or C1-2alkyl); C1-4fluoroalkyl (e. g. C1-2fluoroalkyl) ; Cl 4alkoxy (e. g.

Cl 2alkoxy) ; Cl 2fluoroalkoxy ; C3-6cycloalkyloxy ; -C (O) Rl6a ;-C (O) OR30 ; -S(O)2-R16a(e.g. C1-2alkylsulphonyl, that is Cl 2alkyl-SO2-) ; R16a-S (0) 2-NR5a- (e. g. C1 2alkyl-SO2-NH-) ; R7R8N-S (0) 2-; C1-2alky-C(O)-R15aN-S(O)2-; Ci. 4alkyl-S (0)-, Ph-S (O)-, R7R8N-CO-; -NR15-C(O)R16 ; R7R8N ; OH; C1-4alkoxymethyl; C1-4alkyoxyethyl ; Cl 2alkyl-S (0) 2-CH2-; R7R8N-S (0) 2-CH2-; Cl 2alkyl-S (0) 2-NR1 5a-CH2-;-CH2-OH ;-CH2CH2-OH ;-CH2-NR7R8 ; -CH2-CH2-NR7R8 ; -CH2-C (O) OR30 ;-CH2-C (O)-NR7R8 ; -CH2-NR15a-C(O)-C1-3alkyl; -(CH2)n14-Het1 where nl4 is 0 or 1; cyano (CN); Ar5b ; or phenyl, pyridinyl or pyrimidinyl wherein the phenyl, pyridinyl or pyrimidinyl independently are optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C 1 fluoroalkyl, C 1-2alkoxy or C 1 fluoroalkoxy ; or where two adjacent R6 taken together are-O-(CMe2)-O-or-o-(CH2) nl4-o-where nl4 is 1 or 2; wherein R7 and R8 are as herein defined ; wherein sub-formula (y) and (yl), independently, are optionally substituted by oxo (=O) at a ring carbon adjacent the 6-membered aromatic ring (for example, sub-formula (y) can optionally be or sub-formula (yl) can optionally wherein in sub-formula (z), G is O or S or NR9 wherein R9 is a hydrogen atom (H), C1-4alkyl or C1-4fluoroalkyl ; none, one, two or three of J, L, M and Q are nitrogen; and the remaining of J, L, M and Q are independently CH or CR6 where R6, independently of any other R6 present, is as defined herein;

or R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2)p2-or -(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-, in which: pi = 3,4, 5 or 6 (preferably p = 4 or 5), p2 is 2,3, 4, or 5 (preferably p2 is 2,3 or 4), and p3 and p4 and p5 independently are 2 or 3 (independently preferably 2) and X5 is O or NR17 ; and wherein, when R4 and R5 taken together are- (CH2) p 1-or-C (O)- (CH2) p2-, the NR4R5 heterocycle is optionally substituted by one Rl 8 substituent wherein R18 is : Cl 4alkyl (e. g. Cl 2alkyl) ; C1-2fluoroalkyl ; C3 6cycloalkyl ; Cl 2alkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); C 1 fluoroalkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); OH (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen) ;- (CH2) p7-C (O) Rl6 wherein p7 is 0,1, 2 or 3 (preferably p7 is 0 or 1) ;- (CH2) p7-C (O) OR16 ;- (CH2) p7-OC (O) R16 ; -(CH2)p7-C(O)NR12R13;-(CH2)p7-NR15C(O)R16; -(CH2)p7-NR15C(O)NR12R13 ; -(CH2)p7-NR15C(O)OR16;-(CH2)p7-SO2R16;-(CH2)p7-SO2NR12R13 ; -(CH2)p7-NR15SO2R16;-(CH2)p7-OH;-(CH2)p7-OR16 ; or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2)p2-or -(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-as defined herein, and wherein the NR4R5 heterocycle is fused to a phenyl ring optionally substituted on the phenyl by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkyoxy or C1fluoroalkyoxy ; and R5a is Cul alkyl ; C1-8 fluoroalkyl ; C3-8cycloalkyl; -(CH2)n4a-C3-6cycloalkyl wherein n4a is 1 or 2; phenyl optionally substituted with one or two of: a halogen atom, C- 1-2alkyl, trifluoromethyl, Cl 2alkoxy or trifluoromethoxy; or R5a has the sub-formula (x), (y) or (z) as defined herein and wherein: R12 and R13 independently are H; Cul alkyl (e. g. Cl 3alkyl) ; C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : a halogen atom, Cl 2alkyl, Clfluoroalkyl, C1-2alkoxy or C1fluoroalkyoxy ; or R12 and R13 together are-(CH2) n6-or-C (o)-(CH2) n7-or-C (o)-(CH2) n7-C (o)-or (CH2)n8-X12-(CH2)n9-or-C(O)-X12-(CH2)n10-in which: n6 is 3, 4, 5 or 6 (preferably n6 is 4 or 5), n7 is 2,3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and nl°

independently are 2 or 3 (independently preferably 2) and X12 is O or NR14a wherein Rl4a is H, Cl 2alkyl or C (O) Me (preferably H or Cl 2alkyl) ; Rl 5 is a hydrogen atom (H); C 1 4alkyl (e. g. tBu or C1-2alkyl e. g. methyl); C3-6cycloalkyl ; or phenyl optionally substituted by one or two of : a halogen atom, c1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; Rl5a independent of other Rusa, is a hydrogen atom (H) or C1-4alkyl (e. g. H, tBu or Cl 2alkyl such as methyl; preferably R15a is H or Cl 2alkyl, more preferably H); R16 and R16a independently are: Cl-6alkyl (e. g. Cl-4alkyl or Cl 2alkyl) ; C3-6cycloalkyl (e. g. C5-6cycloalkyl) optionally substituted by one oxo (=O), OH or C1-2alkyl substituent (e. g. optionally substituted at the 3-or 4-position of a Cs 6cycloalkyl ring; and/or preferably unsubstituted C3 6cycloalkyl) ; C3-6cycloalkyl-CH2- (e. g. C5-6cycloalkyl-CH2-) ; pyridinyl (e. g. pyridin-2-yl) optionally substituted on a ring carbon atom by one of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; Ar5c; phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; benzyl optionally substituted at an aromatic carbon atom by one or two of : a halogen atom, C1-2alkyl, C1fluoroalky, C1-2alkoxy or Clfluoroalkoxy ; or a 4-, 5-, 6-or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-nitrogens which are present are present as NR27 where R27 is H, Cl 2alkyl or-C (O) Me; and wherein the ring is optionally substituted at carbon by one Cl 2alkyl or oxo (=O) substituent, provided that any oxo (=O) substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen ; wherein Ar5a, Ar5b and Ar5c independently is/are a 5-membered aromatic heterocyclic ring containing one O, S or NR15a in the 5-membered ring, wherein the 5-membered ring can optionally additionally contain one or two N atoms, and wherein the heterocyclic ring is optionally substituted on a ring carbon atom by one of : a halogen atom, C1-2alkyl, C1fluoroalkyl, -CH2OH, -CH2-OC1-2alkyl, OH (including the keto tautomer thereof) or -CH2-NR28R29 wherein R28 and R29 independently are H or methyl; and R17 is a hydrogen atom (H); Cl 4alkyl (e. g. C1-2alkyl) ; C1-2fluoroalkyl ; C3-6cycloalkyl; -(CH2)p6-C(O)R16 wherein p6 is 0,1, 2 or 3 (preferably p6 is 0);

-(CH2)p6-C(O)NR12R13; -(CH2) p6-C (O) OR16 ;-(CH2) p6-C (O) OH ;-SO2R16 ; <BR> <BR> -C(O)-CH2-NR12R13; -C(O)-CH2-NR15a-C(O)-C1-3alkyl ; -C (O)-CH2-0-Cl-3alkyl ; or phenyl or benzyl wherein the phenyl or benzyl is optionally substituted at an aromatic carbon atom by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C 1 fluoroalkoxy ; R19is Cl 4alkyl ;-(CH2) n20-oR20 wherein n20 is 1,2, 3 or 4 and R20 is a hydrogen atom (H) or C1-4alkyl ; -CH (Me) -OH ;-CH2-SH ;-CH2-CH2-S-Me ; benzyl; or (4-hydroxyphenyl) methyl (i. e. 4-hydroxy-benzyl) ; and R30, independent of other R30, is a hydrogen atom (H), Cl 4alkyl or C3 6cycloalkyl ; and Hetl, independent of other Hetl, is a 4-, 5-, 6-or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-nitrogens which are present are present as NR31 where R31 is H, Cl 2alkyl or-C (O) Me; and wherein the ring is optionally substituted at carbon by one Cl 2alkyl or oxo (=O) substituent, provided that any oxo (=O) substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen; provided that: when R3 is the heterocyclic group of sub-formula (bb), nl is 1, and Y is NR10, then: either (a) R10 is not C104alkyl, C1-2fluoroalkyl or CH2C (O)NH2; or (b) R10 is methyl and the compound is: 1-ethyl-N-(2-ethylbutyl)-4-[(1- methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5-carboxamide or 1-ethyl-N- (4- fluorophenyl)-4- [ (l-methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide.

Preferably, where X is OR5a, the compound is other than the compound wherein Rl is methyl, X is OEt, and R3 is cyclopentyl.

In one optional embodiment of the invention, RI is C1-4alkyl or C1-2fluoroalkyl.

Alternatively or additionally, in one optional embodiment of the invention, R2 is a hydrogen atom (H).

Alternatively or additionally, in one optional embodiment of the invention, R3 is C3 gcycloalkyl or a heterocyclic group being in which Y is O, S, SO2, or NR10 ; where R10 is hydrogen, Cl 4alkyl, Cl 2fluoroalkyl, C (0)-Ci.

2alkyl, or C (O)-CF3 ; and wherein in R3 the C3 gcycloalkyl or heterocyclic group is optionally substituted with one or two substituents being OH, C1-2alkoxy, trimethoxy, or Cl 2alkyl ; and wherein any OH, alkoxy or trimethoxy substituent is not substituted at the (R3) ring carbon attached (bonded) to the-NH-group of formula (I) and is not substituted at either (R3) ring carbon bonded to the Y group of the heterocyclic group.

Alternatively or additionally, in one optional embodiment of the invention, R4 is hydrogen, Cl-2alkyl or Cl-2fluoroalkyl.

Alternatively or additionally, in one optional embodiment of the invention, R5 is hydrogen, C1-8alkyl, C1-8 fluoroalkyl, or C3 gcycloalkyl ; or phenyl optionally substituted with one or two of : a halogen atom, C1-2alkyl, trifluoromethyl, C1-2alkoxy or trifluoromethoxy ; or R5 has the sub-formula (x), (y) or (z): (x) (y) (z) wherein in sub-formula (x), n =1 or 2; in sub-formula (y), m = 1 or 2; and in sub- formula (z), r = 1 or 2; wherein in sub-formula (x) and (y), none, one or two of A, B, D, E and F are nitrogen; and the remaining of A, B, D, E and F are CH or CR6 where R6 is a halogen atom, Cl 4alkyl, Cl 4fluoroalkyl, Cl 2alkoxy, Cl 2fluoroalkoxy, Cl 2alkylsulphonyl (C1-2alkyl-SO2-), C1-2alkyl-SO2-NH-, R7R8N-SO2-, R7R8N-CO-, R7R8N, OH, Cl 4alkoxymethyl, or C1-2alkyl-SO2-CH2-, wherein R7 and R8 are independently hydrogen or C1-2alkyl; wherein in sub-formula (z), G is O or S or NR9 wherein R9 is Cl 4alkyl or C1-4fluoroalkyl ; none, one or two of J, L, M and Q are nitrogen ; and the remaining of J, L, M and Q are CH or CR6 where R6 is as defined herein.

In the alternative to the above R4 and/or R5 optional embodiments, in one optional embodiment of the invention, R4 and R5 taken together can be- (CH2) pl- where p1= 3,4 or 5 (preferably p1= 4 or 5).

In one optional embodiment of the invention, R3 is optionally substituted C3 gcycloalkyl or an optionally substituted heterocyclic group of sub-fonnula (aa), (bb) or (cc); (aa) (bb) (cc) in which nl and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10 ; where R10 is a hydrogen atom (H), Cl 4alkyl (e. g. methyl or ethyl), C 1-2fluoroalkyl, CH2C (O) NH2, C (O) NH2, C (O)-Cl 2alkyl, or C (O)-Clfluoroalkyl ; and wherein in R3 the C3 gcycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally substituted with one or two substituents being oxo (=O), OH, C1-2alkoxy, C1-2fluoroalkoxy (e. g. trifluoromethoxy), or Cl 2alkyl ; and wherein any OH, alkoxy or fluoroalkoxy substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH-group of formula (1) and is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc).

Alternatively or additionally to the above optional R3 definition, in one optional embodiment of the invention, X is NR4R5 or OR5a, in which: R4 is a hydrogen atom (H); Cl 6alkyl ; C1-3fluoroalkyl ; or C2-6alkyl substituted by one substituent Rl 1 ; and R5 is a hydrogen atom (H); Cul alkyl ; C1-8 fluoroalkyl ; C3-8cycloalkyl optionally substituted by a C1-2alkyl group; or-(CH2)n4-C3-8cycloalkyl optionally substituted, in the-(CH2)n4-moiety or in the C3 gcycloalkyl moiety, by a Cl 2alkyl group, wherein n4 is 1, 2 or 3 ; or R5 is C2-6alkyl substituted by one or two independent substituents Rl 1 ; wherein each substituent Ri 1, independently of any other Rl 1 substituent present, is: hydroxy (OH); Cl 6alkoxy ; phenyloxy; benzyloxy ;-NR12R13 ; -NR15-C(O)R16 ; -NR15-C(O)-O-R16; -NR15-C(O)-NH-R15 ; or-NR15-SO2Rl6 ; and wherein any R11 substituent which is OH, alkoxy or-NR12Rl3 is not substituted at any carbon atom, of any R4 or R5 substituted alkyl, which is bonded to the nitrogen of NR4R5 ;

or R5 is -(CH2)n11-C(O)R16; -(CH2)n12-C(O)NR12R13; -CHR19-C(O)NR12R13 ; - (CH2) n12-C (O) OR16 ;-CHR19-C (O) OR16 ;- (CH2) n12-S02-N12Rl3 ; - (CH2) nl2-S02Rl6 ; or- (CH2) n12-CN ; wherein nl l is 0,1, 2,3 or 4 and nl2 is 1,2, 3 or 4; or R5 is- (CH2) n13-Het wherein nl3 is 0,1, 2,3 or 4 and Het is a 4-, 5-, 6-or 7-membered saturated or partly-saturated heterocyclic ring containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the -(CH2)n13-moiety when n13 is 1 and are not bound to the nitrogen of NR4R5 when n13 is 0; wherein any ring-nitrogens which are present and which are not unsaturated (i. e. which do not partake in a double bond) are present as NR17 where R17 is as defined herein; and wherein one or two of the carbon ring-atoms independently are optionally substituted by Cl 2alkyl ; or R5 is phenyl optionally substituted with one or two of : a halogen atom; Cl 4alkyl (e. g.

Cl 2alkyl) ; C1-2fluoroalkyl (e. g. trifluoromethyl); C1-4alkoxy (e. g. C1-2alkoxy); C1- 2fluoroalkoxy (e. g. trifluoromethoxy); C1-2alkylsulphonyl (C1-2alkyl-SO2-) ; C1-2alkyl-SO2-NH-; R7R8N-SO2-; R7R8N-CO-;-NR15-C(O)R16 ; R7R8N ; OH; C104alkoxymethyl; C1-4alkoxyethyl ; C1-2alkyl-SO2-CH2-; cyano (CN); or phenyl optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; wherein R7 and R8 are independently a hydrogen atom (H); C1-4alkyl (e. g.

C1-2alkyl such as methyl); C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R7 and R8 together are-(CH2)n6-or-C(O)-(CH2)n7-or-C(O)-(CH2)n7-C(O)-or -(CH2)n-X7-(CH2)n9-or-C(O)-X7-(CH2)n10-in which: n6 is 3, 4, 5 or 6, n7 is 2, 3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and nl ° independently are 2 or 3, and X7 is O or NR14 wherein R14 is H or C1-2alkyl ; or R5 has the sub-formula (x), (y) or (z):

wherein in sub-formula (x), n = 1 or 2; in sub-formula (y), m = 1 or 2; and in sub-formula (z), r = 0, 1 or 2 ; wherein in sub-formula (x) and (y), none, one or two of A, B, D, E and F are nitrogen; and the remaining of A, B, D, E and F are independently CH or CR6 ; where R6 is a halogen atom; Cl 4alkyl (e. g. C1-2alkyl); C1-4fluoroalkyl (e. g.

C1-2fluoroalkyl) ; Cl 4alkoxy (e. g. Cl 2alkoxy) ; C1-2fluoroalkoxy ; C1-2alkylsulphonyl (C1 2alkyl-SO2-) ; C1-2alkyl-SO2-NH-; R7R8N-SO2-; R7R8N-CO-; -NR15-C(O)R16 ; R7R8N ; OH; C 1 4alkoxymethyl ; Cl 4alkoxyethyl ; Cl 2alkyl-SO2-CH2-; cyano (CN); or phenyl optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; wherein R7 and R8 are as herein defined; wherein in sub-fonnula (z), G is O or S or NR9 wherein R9 is a hydrogen atom (H), C1 4alkyl or C1-4fluoroalkyl ; none, one, two or three of J, L, M and Q are nitrogen; and the remaining of J, L, M and Q are independently CH or CR6 where R6 is as defined herein; or R4 and R5 taken together are-(CH2) pl-or-C (O)-(CH2) p2-or - (CH2) p3-X5- (CH2) p4- or-C (o)-X5- (CH2) p5-, in which: pi = 3,4, 5 or 6 (preferably p = 4 or 5), p2 is 2,3, 4, or 5 (preferably p2 is 2,3 or 4), and p3 and p4 and p5 independently are 2 or 3 (independently preferably 2) and X5 is O or NR17 ; wherein R17 is a hydrogen atom (H) ; Cl 4alkyl (e. g. Cl 2alkyl) ; C1-2fluoroalkyl ; C3 6cycloalkyl ;-(CH2) p6-C (O) R16 whereinp6 is 0,1, 2 or 3 (preferably p6 is 0); -(CH2) p6-C (o) NR12Rl3 ;-(CH2) p6-C (O) OR16 ;-SO2R16 ; or phenyl or benzyl wherein the phenyl or benzyl is optionally substituted at an aromatic carbon atom by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; and wherein, when R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2)P2-, the NR4R5 heterocycle is optionally substituted by one RiS substituent wherein Ru 8 ils : Cl 4alkyl (e. g. C1-2alkyl); C1-2fluoroalkyl ; C3 6cycloalkyl ; Cl 2alkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); C I fluoroalkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); OH (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen) ;- (CH2) p7-C (O) Rl6 wherein p7 is 0,1, 2 or 3 (preferably p7 is 0 or 1) ;-(CH2)p7-C(O)OR16;-(CH2)p7-OC(O)R16 ; -(CH2)p7-C(O)NR12R13;-(CH2)p7-NR15C(O)R16;-(CH2)p7-NR15C(O)N R12R13; -(CH2)p7-NR15C(O)OR16;-(CH2)p7-SO2R16;-(CH2)p7-SO2NR12R13; -(CH2)p7-NR15SO2R16;-(CH2)p7-OH; -(CH2)p7-OR16 ; or phenyl optionally

substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2)p2-or -(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-as defined herein, and wherein the NR4R5 heterocycle is fused to a phenyl ring optionally substituted on the phenyl by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C 1 fluoroalkoxy ; and R5a is Cl alkyl ; C1-8 fluoroalkyl ; C3gcycloalkyl ; phenyl optionally substituted with one or two of : a halogen atom, Cl 2alkyl, trifluoromethyl, Cl 2alkoxy or trifluoromethoxy; or R5a has the sub-formula (x), (y) or (z) as defined herein and wherein: R12 and R13 independently are H; Cul alkyl (e. g. Cl 3alkyl) ; C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : a halogen atom, C1-2 alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R12 and R13 together are-(CH2)n6 -or-C(O)-(CH2)n7-or-C(O)-(CH2)n7-C(O)-or -(CH2)n8-X12-(CH2)n9-or-C(O)-X12-(CH2)n10-IN which: n6 is 3, 4, 5 or 6 (preferably n6 is 4 or 5), n7 is 2,3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and nl 0 independently are 2 or 3 (independently preferably 2) and X12 is O or NR14 wherein R14 is H or Cl 2alkyl ; RI 5 is a hydrogen atom (H); Cl 4alkyl (e. g. tBu or Cl 2alkyl e. g. methyl); C3 6cycloalkyl ; or phenyl optionally substituted by one or two of: a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; R16 is C1-4alkyl (e. g. Cl 2alkyl) ; C3 6cycloalkyl ; pyridinyl (e. g. pyridin-2-yl); or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, Cl 2alkoxy or Clfluoroalkoxy ; and R19is Ci4alkyl ;- (CH2) n-OR20 wherein n20 is 1,2, 3 or 4 and R20 is a hydrogen atom (H) or Cl 4alkyl ; -CH (Me) -OH ; -CH2-SH ; -CH2-CH2-S-Me ; benzyl; or (4-hydroxyphenyl) methyl (i. e. 4-hydroxy-benzyl).

In compounds, for example in the compounds of formula (I) (or formula (IA) or formula (IB), see later), an"alkyl"group or moiety may be straight-chain or branched.

Alkyl groups, for example Cl alkyl or Cl 6alkyl or Cl 4alkyl or Cl 3alkyl or Cl 2alkyl, which may be employed include Cl 6alkyl or Cl 4alkyl or C 1-3alkyl or Cl 2alkyl such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, or n-hexyl or any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, isobutyl, 3-methylbutan-2-yl, 2-ethylbutan-1-yl, or the like.

A corresponding meaning is intended for"alkoxy", "alkylene", and like terms derived from alkyl. For example, "alkoxy"such as Cl 6alkoxy or Cl 4alkoxy or C 1-2alkoxy includes methoxy, ethoxy, propyloxy, and oxy derivatives of the alkyls listed above."Alkylsulfonyl"such as Cl 4alkylsulfonyl includes methylsulfonyl (methanesulfonyl), ethylsulfonyl, and others derived from the alkyls listed above.

"Alkylsulfonyloxy"such as C 1-4alkylsulfonyloxy includes methanesulfonyloxy (methylsulfonyloxy), ethanesulfonyloxy, et al.

"Cycloalkyl", for example C3 gcycloalkyl, includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Preferably, a C3 gcycloalkyl group is C3 6cycloalkyl or Cs 6cycloalkyl, that is contains a 3-6 membered or 5-6 membered carbocyclic ring.

"Fluoroalkyl"includes alkyl groups with one, two, three, four, five or more fluorine substituents, for example Cl 4fluoroalkyl or C 1-3 fluoroalkyl or Cl 2fluoroalkyl such as monofluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 2,2, 2-trifluoroethyl (CF3CH2-), 2,2-difluoroethyl (CHF2CH2-), 2-fluoroethyl (CH2FCH2-), etc."Fluoroalkoxy"includes C 1 4fluoroalkoxy or Cl 2fluoroalkoxy such as trifluoromethoxy, pentafluoroethoxy, monofluoromethoxy, difluoromethoxy, etc.

"Fluoroalkylsulfonyl"such as Cl 4fluoroalkylsulfonyl includes trifluoromethanesulfonyl, pentafluoroethylsulfonyl, etc.

A halogen atom ("halo") present in compounds, for example in the compounds of formula (I), can be a fluorine, chlorine, bromine or iodine atom ("fluoro","chloro", "bromo"or"iodo").

When the specification states that atom or moiety A is"bonded"or"attached"to atom or moiety B, it means that atom/moiety A is directly bonded to atom/moiety B usually by means of one or more covalent bonds, and excludes A being indirectly attached to B via one or more intermediate atoms/moieties (e. g. excludes A-C-B); unless it is clear from the context that another meaning is intended.

Preferably, RI is Cl 4alkyl (e. g. methyl, ethyl, n-propyl, isopropyl or n-butyl), Cl 3fluoroalkyl or-CH2CH2OH ; Rl is more preferably Cl 3alkyl (e. g. methyl, ethyl or n-propyl), Cl 2fluoroalkyl, or-CH2CH2OH ; still more preferably C 1-3alkyl, C2fluoroalkyl or-CH2CH2OH such as methyl, ethyl, n-propyl or-CH2CH2OH. Yet more preferably, R1 is C2 3alkyl (e. g. ethyl or n-propyl), C2fluoroalkyl (e. g.

Clfluoroalkyl-CH2-such as CF3-CH2-) or-CH2CH2OH ; in particular ethyl, n-propyl or -CH2CH2OH. R1 is most preferably ethyl.

Preferably, R2 is a hydrogen atom (H) or methyl, more preferably a hydrogen atom (H).

Preferably, in R3 there is one substituent or no substituent.

In one optional embodiment, R3 is the optionally substituted C3 gcycloalkyl or the optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc). In this embodiment, optionally, in R3, the C3 gcycloalkyl or the heterocyclic group of sub- formula (aa), (bb) or (cc) is optionally substituted with one or two substituents independently being (e. g. being) oxo (=O), OH, Cl 2alkoxy, Cl 2fluoroalkoxy (e. g. trifluoromethoxy), or Cl 2alkyl ; and wherein any OH, alkoxy or fluoroalkoxy substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH-group of formula (I) and is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc).

In one optional embodiment, where R3 is optionally substituted C3 gcycloalkyl, it is not optionally substituted Cscycloalkyl, i. e. not optionally substituted cyclopentyl. In this case, more preferably, R3 is optionally substituted C6-8cycloalkyl.

Where R3 is optionally substituted C3 gcycloalkyl, it is more preferably optionally substituted C6cycloalkyl (i. e. cyclohexyl); for example C6cycloalkyl optionally substituted with one or two substituents independently being (e. g. being) oxo (=O), OH, Cl 2alkoxy, Cl 2fluoroalkoxy (e. g. trifluoromethoxy), or Cl 2alkyl, and wherein any OH, alkoxy or fluoroalkoxy substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH-group of formula (I).

Where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents preferably comprise (e. g. is or independently are (e. g. is or are) ) oxo (=O) ; OH; C 1 alkoxy ; C 1 fluoroalkoxy (e. g. trifluoromethoxy); NHR21 wherein R21 is a hydrogen atom (H) or Cl-2 straight-chain alkyl ; C1-2alkyl such as methyl ; C1fluoroalkyl such as -CH2F or-CHF2 ;-CH2OH ;-CH2NHR22 wherein R22 is H;-C (O) OR23 wherein R23 is H or methyl;-C (O) NHR24 wherein R24 is H or methyl;-C (O) R25 wherein R25 is methyl ; fluoro; hydroxyimino (=N-OH) ; or (Cl 2alkoxy) imino (=N-OR26 where R26 is Cl 2alkyl) ; and wherein any OH, alkoxy, fluoroalkoxy or NHR21 substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH-group of formula (I) and is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc).

More preferably, where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents comprise (e. g. is or independently are (e. g. is or are) ) oxo (=O) ; OH; NHR21 wherein R21 is a hydrogen atom (H); Cl 2alkyl such as methyl; C 1 fluoroalkyl such as-CH2F or-CHF2 ; -C (O) OR23 wherein R23 is H or methyl;-C (O) NHR24 wherein R24 is H or methyl; fluoro; hydroxyimino (=N-OH); or (C1-2alkoxy) imino (--N-OR26 where R26 is C1-2alkyl).

Still more preferably, where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents comprise (e. g. is or independently are (e. g. is or are) ) oxo (=O) ; OH; NHR21 wherein R21 is a hydrogen atom (H); methyl ;-CH2F ;-CHF2 ; -C (O) OR23 wherein R23 is H; fluoro; hydroxyimino (=N-OH); or (Cl 2alkoxy) imino (=N-OR26 where R26 is Cl 2alkyl). Yet more preferably, where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents comprise (e. g. is or independently are (e. g. is or are) ) oxo (=O) ; OH; methyl; fluoro; hydroxyimino (=N-OH); or (Cl 2alkoxy) imino (=N-OR26 where R26 is Cl 2alkyl).

Most preferably, where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents comprise (e. g. is or independently are (e. g. is or are) ) OH, oxo (=O) or oximo (=N-OH). For example, the one or two optional substituents can comprise (e. g. is or are) OH and/or oxo (=O).

Optionally, in R3, the C3 gcycloalkyl can be unsubstituted.

Where R3 is optionally substituted C3 gcycloalkyl, e. g. optionally substituted C5-8cycloalkyl such as optionally substituted C6cycloalkyl (optionally substituted cyclohexyl), the one or two optional substituents if present preferably comprise a substituent (for example is or are substituent (s) ) at the 3-, 4-or 5-position (s) of the R3 cycloalkyl ring. (In this connection, the 1-position of the R3 cycloalkyl ring is deemed to be the connection point to the-NH-in formula (I)).

Where R3 is optionally substituted C3 gcycloalkyl, any OH, alkoxy, fluoroalkoxy, -CH2OH,-CH2CH2OH, -CH2NHR22, -C(O)OR23, -C(O)NHR24,-C(O)R25 or fluoro substituent (particularly any OH substituent) is more preferably at the the 3-, 4-or 5- position, e. g. 3-or 5-position, of the R3 cycloalkyl (e. g. C6-gcycloalkyl) ring. For example, any OH, alkoxy, fluoroalkoxy,-CH2OH,-CH2CH2OH,-CH2NHR22, - C (O) OR23,-C (O) NHR24, -C (O) R25 or fluoro substituent (particularly any OH substituent) can be at the 3-position of a R3 Cscycloalkyl (cyclopentyl) ring or at the 3-,

4-or 5-position, e. g. 3-or 5-position, of a R3 C6cycloalkyl (cyclohexyl) ring. (In this connection, and also below, the 1-position of the R3 cycloalkyl ring is deemed to be the connection point to the-NH-in formula (I)).

Where R3 is optionally substituted C3. gcycloalkyl, anyNHR substituent is preferably at the 2-, 3-, 4-or 5-position, preferably the 2-or 3-position or more preferably the 3-position, of the R3 cycloalkyl (e. g. C6 gcycloalkyl e. g. cyclohexyl) ring.

Where R3 is optionally substituted C3 gcycloalkyl, any alkyl or fluoroalkyl substituent is preferably at the 1-, 2-, 3-, 4-or 5-position, more preferably the 1-, 2-, 3-or 5-position, still more preferably the 1-or 3-position, of the R3 cycloalkyl (e. g. C6-gcycloalkyl e. g. cyclohexyl) ring.

Where R3 is optionally substituted C3 gcycloalkyl, any oxo (=O), hydroxyimino (=N-OH) ; or (Cl 4alkoxy) imino (=N-OR26) substituent is preferably at the 3-or 4-position, preferably at the 4-position, of the R3 cycloalkyl (e. g. C6 gcycloalkyl e. g. cyclohexyl) ring.

Where R3 is optionally substituted C3 gcycloalkyl, R3 is preferably cyclohexyl (i. e. unsubstituted), or cyclohexyl substituted by one oxo (=O), OH, NHR21, Cl 2alkyl, Cl 2fluoroalkyl,-CH2OH,-C (o) oR23,-C (o) NHR24,-C (o) R25, fluoro, hydroxyimino (=N-OH), (Cl 4alkoxy) imino (=N-OR26) substituent, or cyclohexyl substituted by two fluoro substituents. More preferably, R3 is cyclohexyl (i. e. unsubstituted), or cyclohexyl substituted by one oxo (=O), OH, NHR21, Cl 2alkyl, Cl 2fluoroalkyl,-C (o) oR23, fluoro, hydroxyimino (=N-OH) or (Cl 4alkoxy) imino (=N-OR26) substituent, or cyclohexyl substituted by two fluoro substituents. Still more preferably R3 is cyclohexyl (i. e. unsubstituted) or cyclohexyl substituted by one oxo (=O), hydroxyimino (=N-OH), Cl 2alkyl or OH substituent. The optional substituent can be at the 3-or 4-position, e. g.

3-position, of the R3 cyclohexyl ring; more preferably any OH substituent is preferably at the 3-position of the R3 cyclohexyl ring, and/or any oxo (=O), hydroxyimino (=N-OH) or (Cl 4alkoxy) imino (=N-OR26) substituent is preferably at the 4-position of the R3 cyclohexyl ring.

Where R3 is optionally substituted C6cycloalkyl, R3 can for example be 4-hydroxy- cyclohexyl (i. e. 4-hydroxycyclohexan-1-yl), but R3 is more preferably cyclohexyl (i. e. unsubstituted), 3-hydroxy-cyclohexyl (i. e. 3-hydroxycyclohexan-1-yl), 4-oxo-cyclohexyl (i. e. 4-oxocyclohexan-1-yl), 4- (hydroxyimino) cyclohexyl (i. e.

4- (hydroxyimino) cyclohexan-1-yl), 4- 1 2alkoxyimino) cyclohexyl, 1-methylcyclohexyl

or 3-methylcyclohexyl. Where R3 is optionally substituted C6cycloalkyl, R3 is most preferably cyclohexyl (i. e. unsubstituted), 4-oxo-cyclohexyl (i. e. 4-oxocyclohexan-1-yl) or 4- (hydroxyimino) cyclohexyl (i. e. 4- (hydroxyimino) cyclohexan-1-yl).

Where R3 is optionally substituted Cscycloalkyl (optionally substituted cyclopentyl), R3 can for example be cyclopentyl (i. e. unsubstituted) or 3-hydroxy-cyclopentyl.

Where R3 is optionally substituted mono-unsaturated-Cs 7cycloalkenyl, preferably it is optionally substituted mono-unsaturated-Cs 6cycloalkenyl, more preferably optionally substituted mono-unsaturated-C6cycloalkenyl (i. e. optionally substituted mono-unsaturated-cyclohexenyl = optionally substituted cyclohexenyl). Still more preferably, the R3 cyclohexenyl is optionally substituted cyclohex-3-en-1-yl.

Where R3 is optionally substituted mono-unsaturated-CS-7cycloalkenyl, preferably the R3 cycloalkenyl is optionally substituted with one or two substituents being fluoro or methyl provided that if there are two substituents then they are not both methyl.

Preferably, the R3 cycloalkenyl is optionally substituted with one substituent being fluoro or Cl 2alkyl (e. g. methyl); more preferably the R3 cycloalkenyl is substituted with one fluoro substituent or is unsubstituted. For R3 cycloalkenyl, the optional substituent (s) can be at the 1-, 2-, 3-, 4-or 5-position (s) of the cycloalkenyl ring.

Where R3 is the heterocyclic group of sub-formula (aa), (bb) or (cc), then Y is preferably O, S, S02, NH or N-C (O) methyl, more preferably O, NH or N-C (O) methyl, still more preferably O or N-C (O) methyl, most preferably O. (When Y is NH or N-C (O) methyl, then R10 is H or C (O) methyl).

Preferably, R10 is a hydrogen atom (H), methyl, ethyl, C (O) NH2, C (O) methyl or C (O)-CF3. Optionally, R10 can be a hydrogen atom (H), methyl, ethyl, C (O) methyl or C (O)-CF3, more preferably H, C (O) methyl or C (O)-CF3, still more preferably H or C (O) methyl.

Where R3 is the heterocyclic group of sub-formula (aa), (bb) or (cc), then it is preferable that R3 is the heterocyclic group of sub-formula (aa) or (bb), more preferably of sub- formula (bb).

In sub-formula (bb), nl is preferably 1. In sub-formula (cc), n2 is preferably 1. That is, six-membered rings are preferred in the R3 heterocyclic group.

Suitably, in R3, the heterocyclic group of sub-formula (aa), (bb) or (cc) is unsubstituted (Li this connection, where Y is Nu10, R10 is not classified as a substituent).

In the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), the one or two optional substituents preferably comprise (e. g. is or independently are ( (e. g. is or are) ) OH; oxo (=O) ; C1 2alkyl (e. g. methyl) or C1 2fluoroalkyl (e. g. Clfluoroalkyl such as-CH2F or -CHF2). More preferably, in the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), the one or two optional substituents comprise (e. g. is or independently are ( (e. g. is or are) ) OH and/or oxo; most preferably the one or two optional substituents comprise (e. g. is or are) oxo (=O). In the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), any oxo (=O) substituents are preferably on a carbon atom bonded (adjacent) to X, and/or can be at the 2-, 3-, 4-or 5-position (s) of the R3 heterocyclic ring. (In this connection, the 1- position of the R3 heterocyclic ring is deemed to be the connection point to the-NH-in formula (I) ). Preferably, only Cl 2alkyl, Cl 2fluoroalkyl, fluoro or oxo (=O) substitution or no substitution is allowed at each of the 2-and 6-positions of the R3 heterocyclic ring.

When R3 is the heterocyclic group of sub-formula (aa) and Y is NR10, then preferably R10 is not C (O)-Me. More preferably, when R3 is the heterocyclic group of sub-formula (aa) and Y is NR10, then R10 is preferably not C (O) R, i. e. or e. g. R10 is preferably not C (O) NH2, C (O)-C1 2alkyl or C (O)-Clfluoroalkyl. In one embodiment, Y is O, S, SO2 or NH when R3 is the heterocyclic group of sub-formula (aa).

Optionally, according to one embodiment of the invention, NHR3 is not More preferably, when R3 is the heterocyclic group of sub-formula (bb) and Y is NR10, and optionally when nl is 1, then preferably R10 is not methyl. More preferably, when R3 is the heterocyclic group of sub-formula (bb) and Y is NRLO, and optionally when nl is 1, then RIO is preferably not alkyl or substituted alkyl, i. e. or e. g. R10 is preferably not Cl 4alkyl (e. g. methyl or ethyl), Cl 2fluoroalkyl or CH2C (O) NH2. In one embodiment, when R3 is the heterocyclic group of sub-formula (bb), Y is preferably O, S, SO2 or NR10, wherein R10 is H, C (O) NH2, C (O)-Cl 2alkyl or C (O)-Clfluoroalkyl, or more preferably Y is H or C (O) Me. More preferably, for sub-formula (bb), Y is O or NR10.

Where R3 is a bicyclic group of sub-formula (dd) or (ee), preferably it is of sub-formula (ee). In sub-formula (ee), preferably Yl, y2 and Y3 are all CH2.

Preferably, NHR3 is of sub-formula (a), (al), (b), (c), (c 1), (c 2), (c 3), (c 4), (c 5), (c 6), (c 7), (d), (e), (f), (g), (gl), (g2), (g3), (g4), (h), (i), (j), (k), (kl), (L), (m), (ml), (m2), (m3), (m4), (m5), (n), (o), (ol), (o2), (o3), (o4), (o5), (p), (pl), (p2), (p3), (p4), (p5), (p6), (p7), (p8) or (q) :

In the sub-formulae (a) to (q) etc above, the-NH-connection point of the NHR3 group to the 4-position of the pyrazolopyridine of formula (I) is underlined.

Preferably, NHR3 is of sub-formula (c), (cl), (c 2), (c 3), (c 4), (c 5), (c 6), (c 7), (d), (e), (f), (gl), (g4), (h), (i), (j), (k), (kl), (L), (m), (ml), (m2), (m3), (m5), (n), (o), (ol), (o2), (o3), (o4), (o5), (p), (p2), (p3), (p5), (p6), (p7) or (q). More preferably, NHR3 is of sub- formula (c), (cl), (c 4), (c 5), (h), (i), (j), (k), (ml), (m2), (n), (o), (o2), (o3), (p2), (p5), (p6) or (q). Still more preferably, NHR3 is of sub-formula (c), (h), (k), (n), (o) or (o2) ; for example (c), (h), (o) or (o2). Most preferably, R3 is tetrahydro-2H-pyran-4-yl; that is NHR3 is most preferably of sub-formula (h), as shown above.

According to one embodiment, NHR3 is of sub-formula (a), (b), (c), (d), (e), (f), (g), (gl), (g2), (g3), (h), (i), (j), (k), (L), (m), (ml), (n), (o), (ol), (p) or (q). In this embodiment, preferably, NHR3 is of sub-formula (c), (d), (e), (f), (gl), (h), (i), (j), (k), (m), (ml), (n), (o), (ol), (p), or (q); and more preferably in this embodiment, NHR3 is of sub-formula (c), (h), (i), (j), (k), (ml), (n), (o) or (q). Still more preferably in this embodiment, NHR3 is of sub-formula (c), (h), (k), (n) or (o). Most preferably, R3 is tetrahydro-2H-pyran-4- yl; that is NHR3 is most preferably of sub-formula (h), as shown above.

According to another embodiment, NHR3 is of sub-formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k). In this embodiment, preferably, NHR3 is of sub-formula (c), (d), (e), (f), (h), (i), (j) or (k); and more preferably in this embodiment, NHR3 is of sub-formula (c), (h), (i), (j) or (k). Most preferably, R3 is tetrahydro-2H-pyran-4-yl; that is NHR3 is most preferably of sub-formula (h), as shown above.

When NHR3 is of sub-formula (n), then preferably it is a cis- (3-hydroxycyclohex-1- yl) amino group, eg in any enantiomeric form or mixture of forms but preferably racemic.

Preferably, X is NR4R5.

Where R4 is Cl 6alkyl, then preferably it is Cl 4alkyl or Cl 2alkyl. Where R4 is C 1-3 fluoroalkyl then preferably it is C1_2fluoroalkyl.

Most preferably, R4 is a hydrogen atom (H).

Where R4 is C2 6alkyl substituted by one substituent Rl 1, then preferably R4 is C2 4alkyl (e. g. C2 3alkyl) substituted by one substituent Rl l. More preferably, R4 is

- (CH2) n3-Rl 1 wherein n3 is 2,3 or 4. Still more preferably, n3 is 2 and/or R4 is - (CH2) n3-OH.

When R5 is C2-6alkyl substituted by one or two independent substituents R11, it is preferable that R5 is C2-4alkyl (e. g. C2-3alkyl) substituted by one or two independent substituents R11. When R5 is C2-6alkyl (e. g. C2-4alkyl or C2 3alkyl) substituted by one or two independent substituents Ri 1, it is preferable that R5 is C2-6alkyl (e. g. C2-4alkyl or C2-3alkyl) substituted by one substituent R11. It is more preferable that R5 is -(CH2)n5-R11 wherein n5 is 2,3 or 4. Preferably n5 is 2 or 3, more preferably 2.

Preferably, each substituent Ri 1, independently of any other R11 substituent present, is: hydroxy (OH); Cl 6alkoxy (e. g. Cl 4alkoxy such as t-butyloxy, ethoxy or methoxy); phenyloxy; benzyloxy ;-NR12R13 ;-NR15-C(O)R16;-NR15-C(O)-NH-R15 ; or -NR15-SO2R16 (more preferably C1-6alkoxy, -NR15-C(O)-NH-R15, or -NR15-SO2R16 ; most preferably-NR15-SO2R16). In all cases, any Rl 1 substituent which is OH, alkoxy or-NR12Rl3 is not substituted at any carbon atom, of any R4 or R5 substituted alkyl, which is bonded to the nitrogen of NR4R5.

Where R5 is Cl galkyl, then preferably it is Cul alkyl or Cl 3alkyl. Where R5 is C1-8fluoroalkyl then preferably it is C1-3fluoroalkyl or C1-2fluoroalkyl. Where R5 is C3 gcycloalkyl optionally substituted by a Cl 2alkyl group, then preferably the C3-8cycloalkyl is not substituted at the ring-carbon bonded to the nitrogen of NR4R5.

Where R5 is optionally substituted C3 gcycloalkyl, then more preferably it is C3-8cycloalkyl (i. e. unsubstituted).

When R5 is optionally substituted -(CH2)n4-C3-8cycloalkyl wherein n4 is 1,2 or 3, then n4 is preferably 1 or 2 or more preferably 1, and/or preferably R5 is optionally substituted -(CH2)n4-C5-6cycloalkyl or optionally substituted-(CH2)n4-C6cycloalkyl. When R5 is optionally substituted-(CH2)n4-C3-8cycloalkyl, preferably it is not substituted. Most preferably R5 is (cyclohexyl) methyl-, that is-CH2-cyclohexyl.

When Rl9 is Cl 4alkyl, then preferably it is isobutyl, sec-butyl, or C 1-3alkyl such as methyl or isopropyl. When R19 is -(CH2)N20-OR20, then preferably n20 is 1 and/or preferably R20 is a hydrogen atom (H).

When R5 is-(CH2)n11-C(O)R16; -(CH2)n12-C(O)NR12R13; -CHR19-C(O)NR12R13 ; -(CH2)n12-C(O)OR16; -CH419-C(O)OR16; -(CH2)n12-SO2-NR12R13 ; - (CH2) 1112-S02Rl6 ; or- (CH2) n12-CN ; then in one embodiment of the invention R5 can be :-(CH2)n11-C(O)R16; -(CH2)n12-C(O)NR12R13; -(CH2)n12-C(O)OR16 ; -(CH2)n12-SO2-NR12R13; -(CH2)n12-SO2R16 ; or- (CH2) n12-CN.

When R5 is-(CH2)n11-C(O)R16; -(CH2)n12-C(O)NR12R13; -(CH2)n12-C(O)OR16 ; -(CH2)n12-SO2-NR12R13; -(CH2)n12-SO2R16 ; or- (CH2) n12-CN ; then R5 can for example be- (CH2) nl l-C (O) R16 ;- (CH2) n12-C (p) NR12R13 ; or- (CH2) n12-CN ; preferably- (CH2) nl 1-C (O) R16.

Preferably, nl is 1,2, 3 or 4; more preferably nl l is 1 or 2. Advantageously, nl2 is 1 or 2.

When R5 is- (CH2) n13-Het, it is preferable that nl3 is 0,1 or 2, more preferably 0 or 1.

Preferably, Het is a 5-or 6-membered saturated or partly-saturated heterocyclic ring and/or preferably is a 4-, 5-, 6-or 7-membered saturated heterocyclic ring. Preferably, the heterocyclic ring Het contains one ring-hetero-atom selected from O, S and N.

Preferably, the carbon ring-atoms in Het are not substituted. Het is most preferably one When R5 is optionally substituted phenyl, then preferably it is phenyl optionally substituted with one or two of the substituents defined herein.

When R5 is optionally substituted phenyl, then preferably R5 is phenyl optionally substituted with, independently, one, two or three (preferably one or two; or one) of : a halogen atom (preferably fluoro and/or chloro); C1-2alkyl; C1-2fluoroalkyl (e. g. trifluoromethyl); C1-2alkoxy (e.g. methoxy) ; trifluoromethoxy; Cl 2alkylsulphonyl (C1-2alkyl-SO2-); C1-2alkyl-SO2-NH-; R7R8N-SO2-; R7R8N-CO-; -NR15-C(O)R16 ; R7R8N ; OH; Cl 2alkoxymethyl ; C1-2alkyl-SO2-CH2-; cyano (CN); or phenyl optionally substituted by one of fluoro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C I fluoroalkoxy. More preferably R5 is phenyl optionally substituted with one or two (preferably one) of : a halogen atom, C1-2alkyl, trifluoromethyl, Cl 2alkoxy,

trifluoromethoxy, R7R8N-S02-, R7R8N-CO-, or Cl 2alkyl-SO2-CH2-. When R5 is optionally substituted phenyl, then preferably one or all of the one or two optional substituents are substituted at the meta- (3-andlor 5-) and/orpara- (4-) position (s) of the phenyl ring with respect to the phenyl ring-carbon bonded to the nitrogen of NR4R5.

Preferably, R7 and/or R8 are independently a hydrogen atom (H); Cl 2alkyl such as methyl; C3 6cycloalkyl ; or phenyl optionally substituted by one of : fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R7 and R8 together are -(CH2) n6-or-(CH2) n8-X7-(CH2) n9-wherein X7 is NR14 or preferably O.

When R7 is cycloalkyl or optionally substituted phenyl, then preferably R8 is neither cycloalkyl nor optionally substituted phenyl.

Most preferably, R7 and/or R8 independently are a hydrogen atom (H) or C1-2alkyl. It is preferable that R7 is a hydrogen atom (H).

Preferably n6 is 4 or 5. Preferably n7 is 2,3 or 4. Preferably, n8, n9 and/or nl 0 is/are independently 2.

In general, it is preferable that R5 has the sub-formula (x) or (y) or (yl) or (z).

When R5 has the sub-formula (x) or (y) or (yl) or (z), then preferably R5 has the sub- formula (x) or (y) or (yl) or has the sub-formula (x) or (y) or (z). More preferably R5 has the sub-formula (x) or (y), most preferably (x). In one embodiment, R5 has the sub- formula (z).

Preferably, n is 1 or 2. More preferably, n = 1. Preferably, m = 1. Preferably, r = 1 or 2, more preferably 1.

In sub-formula (x), (y) and/or (yl), it is preferred that none, one or two of A, B, D, E and F are nitrogen; none, one, two or three of A, B, D, E and F are CR6 ; and the remaining of A, B, D, E and F are CH. More preferably, none, one or two of A, B, D, E and F are nitrogen; none, one or two of A, B, D, E and F are CR6 ; and the remaining of A, B, D, E and F are CH.

In sub-formula (x), (y) and/or (yl), preferably, none or one of A, B, D, E and F are nitrogen, and/or preferably none, one or two of A, B, D, E and F are CR6.

Preferably, sub-formula (x) is: benzyl; phenethyl (Ph-C2H4-) ; benzyl substituted on the phenyl ring with one or two R6 substituents ; phenethyl (Ph-C2H4-) substituted on the phenyl ring with one or two R6 substituents; or one of the following:

, wherein R6a is either R6 as defined herein or (preferably) hydrogen.

Most preferably, sub-formula (x) is benzyl or pyridinylmethyl [e. g. pyridin-4-ylmethyl (i. e. pyridin-3-ylmethyl, or preferably pyridin-2-ylmethyl (i. e.

Preferably, sub-formula (y) is: wherein R6a is or independently are either R6 as defined herein of preferably hydrogen. Preferably, sub-formula (y) is not substituted by oxo (=O) at the carbon between the 6-membered aromatic ring and the carbon bonded to the nitrogen of NR4R5.

Preferably, sub-formula (yl) is: wherein R6a is or independently are either R6 as defined herein or preferably hydrogen.

Preferably, in sub-formula (z), none, one or two of J, L, M and Q are nitrogen.

In sub-formula (x), (y) and/or (z), preferably, each R6, independently of any other R6 present, is a fluorine, chlorine, bromine or iodine atom, methyl, ethyl, n-propyl, isopropyl, C4alkyl, trifluoromethyl,-CH2OH, methoxy, ethoxy, Clfluoroalkoxy (e. g. trifluoromethoxy or difluoromethoxy), OH, Cl 3alkylS (O) 2- (such as methylsulphonyl which is MeS (O) 2-), Cl-3alkylS (0) 2-NH- such as methyl-S02-NH-, Me2N-S (O) 2-, H2N-S (0) 2-,-CONH2,-CONHMe,-C02H, cyano (CN), NMe2, t-butoxymethyl, or C1-3alkylS(O)2-CH2-such as methyl-S02-CH2-. More preferably, each R6, independently of any other R6 present, is a fluorine, chlorine, bromine or iodine atom, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl,-CH2OH, methoxy, ethoxy, Clfluoroalkoxy (e. g. trifluoromethoxy or difluoromethoxy), Cl-3alkylS (O) 2- such as methylsulphonyl, Cl 3alkylS (O) 2-NH-such as methyl-SO2-NH-, Me2N-S (O) 2-, H2N-S (O) 2-,-CONH2, or C1-3alkylS(O)2-CH2-such as methyl-S02-CH2. Still more preferably, each R6, independently of any other R6 present, is a fluorine, chlorine or bromine atom, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, -CH2OH, methoxy, difluoromethoxy, methylsulphonyl, methyl-S02-NH-or methyl-S02-CH2-.

The above preferred R6 substituents are also, independently, the preferred phenyl optional and independent substituents for where R5 is optionally substituted phenyl.

In sub-fonnula (x) and/or (y), preferably, one, two or three R6 substituents are present in B, D and/or E; so that for example in sub-formula (x), one, two or three R6 substituents are present in the meta- (3-and/or 5-) and/or para- (4-) positions with respect to the- (CH2) n-side-chain.

Preferably, R5 has the sub-formula (x), n is 1 and none of A, B, D, E and F are nitrogen or nitrogen-oxide (N+-O-) ; and all of A, B, D, E and F are independently CH or CR6 ; that

is R5 has the sub-formula (x) and is optionally substituted benzyl. In this embodiment, preferably, a R6 substituent is present at the 4-position with respect to the- (CH2) n side- chain (that is D is CR6 : i. e. a R6 substituent is present in D); and/or preferably a R6 substituent is present at the 3-and/or 5-position with respect to the- (CH2) n side-chain (that is B and/or E is CR6 : i. e. one or two R6 substituents are present in B and/or E).

For monosubstitution, i. e. where one of A, B, D, E and F is CR6, then the one R6 substituent is preferably present at the 4-position with respect to the-(CH2) n-side-chain (i. e. D is CR6). Where there is disubstitution, that is where two of A, B, D, E and F are independently CR6, then 3,4-disubstitution (B+D or D+E are independently CR6), 2,4- disubstitution (A+D or D+F are independently CR6) or 2,3-disubstitution (A+B or E+F are independently CR6) is preferred.

In sub-fonnula (x) and/or (y), any optional R6 substituent can optionally be present only in B, D and/or E, so that in sub-formula (x) any optional R6 substituent is present only in the meta- (3-and/or 5-) and/or para- (4-) positions with respect to the- (CH2) n7- side- chain. Alternatively, in sub-formula (x), any optional R6 substituent can be present in the ortho- (2-and/or 6-) position with respect to the- (CH2) n7- side-chain, either alone or in combination with one or more other optional R6 substituents.

Overall for R5, it is preferable that R5 is a hydrogen atom (H); Cl 6alkyl (e. g.

Cl, 2or3alkyl or C3-6alkyl) ; Cl 4fluoroalkyl, C3 6cycloalkyl (e. g. Cs 6cycloalkyl), (Cs 6cycloalkyl) methyl-, phenyl optionally substituted with one or two of : a fluorine or chlorine atom, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or R5 has the sub- formula (x), (y) or (z), for example as described above.

Still more preferably, R5 is a hydrogen atom (H), methyl, ethyl, n-propyl, iso-propyl, 2-ethylbutan-1-yl, cyclopentyl, cyclohexyl, (cyclohexyl) methyl-, optionally substituted phenyl e. g. fluorophenyl e. g. 4-fluorophenyl, optionally substituted benzyl, or optionally substituted pyridinylmethyl, or R5 has the sub-formula (z).

Optionally, R5 can be benzyl, pyridinyhnethyl (e. g. pyridin-4-ylmethyl, pyridin-3- methyl, or preferably pyridin-2-ylmethyl), or 4-fluorophenyl.

In one preferable embodiment, R5 has the sub-formula (x) and is: benzyl, (monoalkyl- phenyl) methyl, [mono (fluoroalkyl) -phenyl] methyl, (monohalo-phenyl) methyl, (monoalkoxy-phenyl) methyl, [mono (fluoroalkoxy) -phenyl] methyl, [mono (N, N- dimethylamino) -phenyl] methyl, [mono (methyl-S02-NH-)-phenyl] methyl, [mono (methyl-S02-)-phenyl] methyl, (dialkyl-phenyl) methyl, (monoalkyl-monohalo- phenyl) methyl, [mono (fluoroalkyl) -monohalo-phenyl] methyl, (dihalo-phenyl) methyl, (dihalo-monoalkyl-phenyl) methyl, [dihalo-mono (hydroxymethyl) -phenyl] methyl, or

(dialkoxy-phenyl) methyl such as (3,4-dimethoxy-phenyl) methyl. The substituents can preferably be further defined, as defined in preferable embodiments herein.

In one preferable embodiment, R5 is of sub-formula (x) and is: (monoalkyl- phenyl) methyl, [mono (fluoroalkyl) -phenyl] methyl, (monohalo-phenyl) methyl, (monoalkoxy-phenyl) methyl, [mono (fluoroalkoxy) -phenyl] methyl, [mono (N, N- dimethylamino)-phenyl] methyl, (dialkyl-phenyl) methyl, (monoalkyl-monohalo- phenyl) methyl, (dihalo-phenyl) methyl or (dihalo-monoalkyl-phenyl) methyl or [dihalo- mono (hydroxymethyl) -phenyl] methyl. More preferably, in this embodiment, R5 is: - (monoCl 3alkyl-phenyl) methyl such as (4-Cl 3alkyl-phenyl) methyl; - (monoClfluoroalkyl-phenyl) methyl such as (4-Clfluoroalkyl-phenyl) methyl; - (monoC 1 _alkoxy-phenyl) methyl such as (4-C 1 _2alkoxy-phenyl) methyl; - [mono (Clfluoroalkoxy)-phenyl] methyl such as (4-Clfluoroalkoxy-phenyl) methyl; - (diCl 2alkyl-phenyl) methyl or (dimethyl-phenyl) methyl such as (3,4-dimethyl- phenyl) methyl, (2,4-dimethyl-phenyl) methyl, (3,5-dimethyl-phenyl) methyl, (2,3- dimethyl-phenyl) methyl or (2,5-dimethyl-phenyl) methyl; more preferably (3,4-dimethyl- phenyl) methyl or (2,4-dimethyl-phenyl) methyl; - (monoCl 2alkyl-monohalo-phenyl) methyl or (monoCl 2alkyl-monochloro- phenyl) methyl such as (4-methyl-3-chloro-phenyl) methyl, (3-methyl-4-chloro-phenyl) methyl, (2-methyl-4-chloro-phenyl) methyl; - (dihalo-phenyl) methyl such as (2-chloro-4-fluorophenyl) methyl or (2,4-difluoro- phenyl) methyl or (4-bromo-2-fluorophenyl) methyl or preferably (4-chloro- 2-fluorophenyl) methyl; for example (dichloro-phenyl) methyl such as (3,4-dichloro- phenyl) methyl or (2,4-dichloro-phenyl) methyl or (2,6-dichloro-phenyl) methyl or preferably (2,3-dichloro-phenyl) methyl; - (dihalo-monoCl 2alkyl-phenyl) methyl e. g. (2,4-dichloro-6-methyl-phenyl) methyl; or - [dihalo-mono (hydroxymethyl) -phenyl] methyl such as [2, 3-dichloro-6- (hydroxymethyl)- phenyl] methyl.

In an alternative preferable embodiment, R5 has the sub-formula (z), and one or preferably none of J, L, M or Q is CR6, and/or R9 is a hydrogen atom (H) or methyl.

Preferably r is 1. Preferably, for (z), R6 is independently OH (including any keto tautomer thereof), or more preferably C1 2alkyl (e. g. methyl) or Clfluoroalkyl.

Preferably NR4R5 is not NH2. R5 is preferably not a hydrogen atom (H).

When R4 and R5 taken together are optionally substituted- (CH2) p 1-or optionally substituted-C (O)-(CH2) p2-or-(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-or a partially unsaturated derivative of any of the foregoing, preferably R4 and R5 taken together are optionally substituted- (CH2) pl- or optionally substituted-C (O)- (CH2) p2- or-(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5- (i. e. not a partially unsaturated derivative of any of these).

When R4 and R5 taken together are- (CH2) p 1-optionally substituted by R18, or -C(O)-(CH2)p2-optionally substituted by R18, or -(CH2)p3-X5-(CH2)p4-, NR4R5 can for example be optionally substituted by RI 8, or optionally substituted by R18 or optionally substituted by R18, or (i. e. R4 and R5 taken together are- (CH2) 2-N (R17)-(CH2)2-), OR (i. e. R4 and R5 taken together are-(CH2)2-O-(CH2)2-).

Preferably, Rl 7 is a hydrogen atom (H); Cl 4alkyl (e. g. Cl 2alkyl) ; C3 6cycloalkyl ; - (CH2) p6-C (O) Rl 6, or the optionally substituted phenyl or benzyl. More preferably, Rl 7 is H; C1-2alkyl; -(CH2)p6-C(O)R16 or the optionally substituted phenyl.

When R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2) p2-, the NR4R5 heterocycle is preferably not substituted by R18.

When R4 and R5 taken together are-(CH2) pl-or-C (O)-(CH2) p2-, and if the NR4R5 heterocycle is substituted by R18, then optionally R18 is not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen.

When R4 and R5 taken together are-(CH2) pl-or-C (O)-(CH2) p2-or -(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-or a partially unsaturated derivative of any of these, and wherein the NR4R5 heterocycle is fused to a phenyl ring optionally substituted on the phenyl by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, Cl 2alkoxy or Clfluoroalkoxy ; then in one embodiment of the invention NR4R5 is wherein the phenyl is optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoxroalkoxy.

In one embodiment of the invention, NR7R8 and/or NR12Rl3 can for example independently be

(i. e. R12 and R13 together or R7 and R8 together are-(CH2) 2-N (R14)-(CH2) 2-) or (i. e. R12 and R13 together or R7 and R8 together are-(CH2)2-O-(CH2)2-), or NMe2.

Preferably, Rl 5 is a hydrogen atom (H) or Cl 4alkyl (e. g. tBu or Cl 2alkyl e. g. methyl); more preferably, R15 is a hydrogen atom (H).

Preferably, however, R4 and R5 are not taken together, i. e. are not taken together to form the NR4R5 ring systems described herein.

(Similar preferances apply for R5a as for R5, except that R5a cannot be a hydrogen atom.

Most preferably, R5a is ethyl.) In an especially preferable embodiment, NR4R5 is the NR4R5 group as defined in any one of : Examples 21-98,100-182, 187-188,191-200, 201-203,210-353, 355-651, 653-658,660-664 and 665-686.

It is particularly preferred that the compound of formula (I) or the salt thereof is: Ethyl 4- (cyclopentylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 4- (cyclohexylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 1-ethyl-4-(tetrahydro-sH-pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxylate, Ethyl 4- [ (1-acetylpiperidin-4-yl) amino]-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 4-(cyclopentylamino)-1-methyl-1 H-pyrazolo [3, 4-b] pyridine-5-carboxylate (not this compound per se, and for the use or method of treatment preferably not this compound), Ethyl 1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-IH-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 1-ethyl-4-[(3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 1-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxylate, Ethyl 1-ethyl-4-(tetrahydrothien-3-ylamino)-1H-pyrazolo[3, 4-b] pyridine-5-carboxylate, Ethyl 4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3, 4-b] pyridine-5-carboxylate, Ethyl 4- [ ( 1, 1-dioxidotetrahydrothien-3-yl) amino]-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxylate, Ethyl 4- [ (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxylate, N-Benzyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazo lo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N-(fluorophenyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo[3, 4-b] pyridine-5- carboxamide, N-Cyclopentyl-4- (cyclopentylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide,

4-(Cyclohexylamino)-N-cyclopentyl-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Cyclopentyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-p yrazolo [3,4-b] pyridine-5- carboxamide, 4- [ (l-Acetylpiperidin-4-yl) amino]-N-cyclopentyl- 1-ethyl-1H-pyrazolo [3,4-b] pyridine-5- carboxamide, N-Cyclopentyl-1-ethyl-5-(pyrrolidin-1-ylcarbonyl)-lH-pyrazol o [3,4-b] pyridin-4-amine, N-Cyclohexyl-1-ethyl-5-(pyrrolidin-1-ylcarbonyl)-1 H-pyrazolo [3, 4-b] pyridin-4-amine, 1-Ethyl-5- (pyrrolidin-1-ylcarbonyl)-N-tetrahydro-2H-pyran-4-yl-lH-pyra zolo [3,4-b] pyridin-4- amine, 4-(Cyclopentylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-1H-pyraz olo [3,4-b] pyridine-5- carboxamide, 4-(Cyclohexylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-1H-pyrazo lo [3, 4-b] pyridine-5- carboxamide, 1-Ethyl-N-(pyridin-4-ylmethyl)-4-(tetrahydro-2H-pyran-4-ylam ino)-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide, 4- (Cyclopentylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, 4- (Cyclohexylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-4-(cyclopentylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-4- (cyclohexylamino)-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4-[(1-Acetylpiperidin-4-yl)amino]-N-benzyl-1-ethyl-1H-pyrazo lo [3,4-b] pyridine-5-carboxamide, 4-(Cyclopentylamino)-1-ethyl-N-(2-ethylbutyl)-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4-(Cyclohexylamino)-1-ethyl-N-(2-ethylbutyl)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, 1-Ethyl-N-(2-ethylbutyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, l-Ethyl-N-(2-ethylbutyl)-4-[(1-methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide, 4- [ (1-Acetylpiperidin-4-yl) amino]-1-ethyl-N- (2-ethylbutyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide, 4- (Cyclopentylamino)-1-ethyl-N- (4-fluorophenyl)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4-(Cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, 1-Ethyl-N-(4-fluorophenyl)-4-[(1-methylpiperidin-4-yl)amino] -1H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4- [ (l-Acetylpiperidin-4-yl) amino]-l-ethyl-N- (4-fluorophenyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide, 4-(Cyclopentylamino)-1-ethyl-N-n-propyl-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4-(Cyclohexylamino)-1-ethyl-N-n-propyl-1H-pyrazolo[3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-n-propyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4-[(1-Acetylpiperidin-4-yl) amino]-1-ethyl-N-n-propyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide,

4- [ (l-Acetylpiperidin-4-yl) amino]-1-ethyl-N- (pyridin-4-ylmethyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide, N-Benzyl-4-(cyclopentylamino)-1-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-4- (cyclohexylamino)-1-methyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4-(Cyclopentylamino)-N-(2-ethylbutyl)-1-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, 4- (Cyclohexylamino)-N- (2-ethylbutyl)-1-methyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide, N- (2-Ethylbutyl)-1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4- (Cyclopentylamino)-N- (4-fluorophenyl)-1-methyl-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4- (Cyclohexylamino)-N- (4-fluorophenyl)-l-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, N- (4-Fluorophenyl)-1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4- (Cyclopentylamino)-1-methyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4- (Cyclohexylamino)-1-methyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4- [ (1-Acetylpiperidin-4-yl) amino]-N-benzyl-1-methyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazo lo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N, N-dimethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazol o [3,4-b] pyridine-5-carboxamide, 1-Ethyl-N-isopropyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide, N-Benzyl-1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-1H-pyrazolo [3,4-b] pyridine-5- carboxamide, N-Benzyl-1-ethyl-4-[(3R)-tetrahydrofuran-3-ylamino]-1H-pyraz olo [3,4-b] pyridine-5- carboxamide, N-Benzyl-1-ethyl-4-(tetrahydrothien-3-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-4- (cyclopropylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide, N-Benzyl-4- [ (1, 1-dioxidotetrahydrothien-3-yl) amino]-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, N-Benzyl-4- [ (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide, N-Benzyl-1-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-lH-py razolo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N- (4-fluorophenyl)-4- [ (3 S)-tetrahydrofuran-3-ylamino]-1H-pyrazolo [3,4-b] pyridine-5- carboxamide, 1-Ethyl-N- (4-fluorophenyl)-4- [ (3R)-tetrahydrofuran-3-ylamino]-1H-pyrazolo [3,4-b] pyridine-5- carboxamide,

1-Ethyl-N- (4-fluorophenyl)-4- (tetrahydro-2H-thiopyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine- 5-carboxamide, 1-Ethyl-N- (4-fluorophenyl)-4- (tetrahydrothien-3-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide, 4-(Cyclopropylamino)-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo [3,4-b] pyridine-5-carboxamide, 4-[(1,1-Dioxoidotetrahydrothien-3-yl)amino]-1-ethyl-N-(4-flu orophenyl)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide, or 4- [ (1, 1-Dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-N-(4-fluorophenyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide; or a salt thereof, e. g. a pharmaceutically acceptable salt thereof.

The structures of these specific compounds are given in Examples 1-98 hereinafter.

Alternatively, it is particularly preferred that the compound of formula (I) or the salt thereof is : 1-Ethyl-N [4- (methylsulfonyl) benzyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N [3- (methylsulfonyl) benzyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-5- { [5-methoxy-6- (trifluoromethyl)-2, 3-dihydro-1H indol-1-yl] carbonyl)-N tekahydro-2H-pyran-4-yl-lH-pyrazolo [3, 4-b] pyridin-4-amine, N-[(5-Chloropyridin-2-yl) methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N-(4-Chlorobenzyl)-1-ethyl-N-isopropyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, <BR> <BR> N-(3-Chlorobenzyl)-1-ethyl-N-(2-hydroxyethyl)-4-(tetrahydro- 2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-[(5-methyl-3-phenylisoxazol-4-yl) methyl]-4-(tekahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-S-carboxamide, N-(2-tert-Butoxyethyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylam ino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(1, 3-thiazol-2-ylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-N-(pyrimidin-4-ylmethyl)-4-(tetrahydro-2H-pyran-4-yl amino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-N-[(2-methyl-1, 3-thiazol-4-yl) methyl]-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N-[3- (tert-Butoxymethyl) benzyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide,

1-Ethyl-N- {2-[methyl (methylsulfonyl) amino] ethyl}-4-(tekahydro-2H-pyran-4-ylamino)- 1H pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-(pyrazin-2-ylmethyl)-4-(tetrahydro-2H-pyran-4-ylam ino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-5- {[4-(pyridin-2-ylcarbonyl) piperazin-1-yl] carbonyl}-N-tekahydro-2H-pyran-4- yl-1H-pyrazolo [3, 4-b] pyridin-4-amine, N (2-Chloro-6-fluorobenzyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Etyl-N-[(6-oxo-1,6-dihydropyridin-3-yl)methyl]-4-(tetrahyd ro-2H-pyran-4-ylamino)- 1H pyrazolo [3, 4-b] pyridine-5-carboxamide, N-[3-(Aminocarbonyl)benzyl]-1-ethyl-4-(tetrahydro-2H-pyran-4 -ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-{4-[(methylamino) carbonyl] phenyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-4-(tetrahydro -2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N-{2-[(Anilinocarbonyl) amino] ethyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-(1H-tetraazol-5-ylmethyl)-4-(tetrahydro-2H-pyran-4 -ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-[2-(1H-1, 2, 4-triazol-1-yl) ethyl]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-4-(tekahydro-2H-pyran-4-ylamino)-N-[4-(trifluorometh yl) phenyl]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, tert-Butyl 4- ( [1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} amino) piperidine-l-carboxylate, 1-Ethyl-N {3- [ (methylsulfonyl) amino] propyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N-[2-(Dimethylamino) benzyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-[(l-ethylpyrrolidin-2-yl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N (tetrahydrofuran-2-ylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-ethyl-N-tetrahydro-2H-pyran-4-yl-4-(tetrahydro-2H-pyran-4- ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, <BR> <BR> N-f 4- [ (Dimethylamino) sulfonyl] benzyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-{3-[(methylsulfonyl)amino]benzyl}-4-(tetrahydro-2H -pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-(4-methoxyphenyl)-4-(tetrahydro-2H-pyran-4-ylamino )-lH-pyrazolo [3,4- b] pyridine-5-carboxamide,

l-Ethyl-N [3- (2-oxopyrrolidin-1-yl) propyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N [2- (l-methylpyrrolidin-2-yl) ethyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-(pyridin-3-ylmethyl)-4-(tetrahydro-2H-pyran-4-ylam ino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-N-(1-methylpiperidin-4-yl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, l-Ethyl-N (l-ethylpropyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-N-(2-piperidin-1-ylethyl)-4-(tekahydro-2H-pyran-4-yl amino)-lH-pyrazolo [3,4- <BR> <BR> b] pyridine-5-carboxamide,<BR> <BR> <BR> <BR> <BR> 1-Ethyl-N-(3-morpholin-4-ylpropyl)-4-(tetrahydro-2H-pyran-4- ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N-(3-Ethoxypropyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N (Cyclohexylmethyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N [3- (Dimethylamino) propyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-neopentyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, 1-ethyl-N-(4-methoxybenzyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4- b] pyridine-5-carboxamide, l-Ethyl-N- {2-[(phenylsulfonyl) amino] ethyl}-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, N [2- (Acetylamino) ethyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-N- {2-[(methylsulfonyl) amino] ethyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, l-Ethyl-N- {2-[(2-methoxyphenyl) (methyl) amino] ethyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide, l-Ethyl-N-(2-oXo-2-phenylethyl)-4-(tekahydro-2H-pyran-4-ylam ino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide, N (2, 5-Difluorobenzyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide, l-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N [4- (trifluoromethyl) benzyl]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N, l-Diethyl-N-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyra zolo [3, 4-b] pyridine-5- carboxamide, N-Cyclopropyl-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine- 5-carboxamide,

N- (2-amino-2-oxoethyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, l-Ethyl-N- (3-methoxyphenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N-(3, 4-Difluorobenzyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, Ethyl 3- ( { [1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} amino) propanoate, N (l-Benzylpiperidin-4-yl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N-Butyl-4- { [1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} piperazine-l-carboxamide, 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(1, 3, 4-thiadiazol-2-yl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N (2, 3-Dihydro-lH-inden-2-yl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-[2-(2-oxoimidazolidin-l-y)ethyl]-4-(tetrahydro-2H- pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, <BR> <BR> <BR> N- (3, 4-Dimethoxybenzyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide, N-(3-Chlorobenzyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 1-Ethyl-5- [ (4-methylpiperazin-1-yl) carbonyl]-N-tetrahydro-2H-pyran-4-yl-1H- pyrazolo [3, 4-b] pyridin-4-amine, 1-Ethyl-N (2-hydroxyethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, <BR> <BR> <BR> 1-Ethyl-5- {[4-(4-methoxyphenyl) piperazin-1-yl] carbonyl}-N-tekahydro-2H-pyran-4-yl- 1H-pyrazolo [3, 4-b] pyridin-4-amine, 1-Ethyl-N-{4-[(methylsulfonyl) methyl] phenyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, N- [3- (dimethylamino)-3-oxopropyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide, <BR> <BR> <BR> 1-Ethyl-N-[(l-methyl-lH-imidazol-5-yl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, <BR> <BR> <BR> 1-Ethyl-N- {4-[(methylamino) sulfonyl] phenyl}-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, N (2-Cyanoethyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- <BR> <BR> b] pyridine-5-carboxamide,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 1-Ethyl-N-[(l-methyl-lH-pyrazol-4-yl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, 1-Ethyl-N-methyl-N-[(l-methyl-lH-imidazol-2-yl) methyl]-4-(tekahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide,

1-Ethyl-4-(tekahydro-2H-pyran-4-ylamino)-N-(2-thien-2-ylethy l)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N [2- (4-Chlorophenyl) ethyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide, l-Ethyl-N [2- (2-methoxyphenyl) ethyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, Ethyl 4- (cyclohexylamino)-l- (3-ethoxy-3-oxopropyl)-lH-pyrazolo [3, 4-b] pyridine-5- carboxylate, Ethyl l-n-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5- carboxylate, Ethyl 1- (2-hydroxyethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxylate, N- [4- (Methylsulfonyl) benzyl]-l-n-propyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide, N- (4-Fluorophenyl)-1-n-propyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide, Ethyl 1-ethyl-6-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine- 5-carboxylate, Ethyl 4- (cyclohexylamino)-l-ethyl-6-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate, 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(methylsulfonyl) benzyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, N-Benzyl-4-(cyclohexylamino)-1-ethyl-6-methyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, 4- (Cyclohexylamino)-l-ethyl-N- (4-fluorophenyl)-6-methyl-lH-pyrazolo [3, 4-b] pyridine- 5-carboxamide, 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(trifluoromethyl) benzyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide, 4- (Cyclohexylamino)-N (2, 3-dihydro-1H-inden-2-yl)-1-ethyl-6-methyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide, N-Benzyl-l-ethyl-6-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide, N-Benzyl-l-ethyl-4-[(2-oXoazepan-3-yl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, N-Benzyl-1-ethyl-4- [ (3-hydroxycyclohexyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, N-Benzyl-l-ethyl-4- [ (4-hydroxycyclohexyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, N-Benzyl-1-ethyl-4-[(3-hydroxycyclopentyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide, or N-Benzyl-l-ethyl-4-[(4-oXocyclohexyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide ; or a salt thereof, e. g. a pharmaceutically acceptable salt thereof.

The structures of these specific compounds are given in Examples 100-201 hereinafter.

Alternatively, the compound of formula (I) or the salt thereof can be: 1-Ethyl-N (2-hydroxy-1-methylethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide, or Methyl (2S)-2- ( { [1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridin- 5-yl] carbonyl} amino) -3-hydroxypropanoate; or a salt thereof, e. g. a pharmaceutically acceptable salt thereof. (See for example Examples 202-203).

Alternatively, it is particularly preferred that the compound of formula (I) or the salt thereof is one of Examples 204 to 664 or one of Examples 665 to 686, as a compound or a salt thereof, e. g. a pharmaceutically acceptable salt thereof. The structures of these specific compounds are given in Examples 204 to 664 and Examples 665 to 686 hereinafter, and their names are given in the Examples section.

In one embodiment, is still further preferred that the compound of formula (I) or the salt thereof is a compound of Example 260,261, 263,266, 431,493, 494,518, 528,584, 626, 643,653, 679,680, 681,682, 683,684, 685 or 686 (more preferably Example 260,518, 653,679, 680,681 or 684), as defined by the structures and/or names described herein, or a salt thereof, e. g. a pharmaceutically acceptable salt thereof. The structures and names of these Examples are described in the Examples section. These Examples are thought to be suitable for inhaled administration.

In another embodiment, is still further preferred that the compound of formula (I) or the salt thereof is a compound of Example 21,22, 83,100, 109,167, 172,178 or 600, as defined by the structures and/or names described herein, or a salt thereof, e. g. a pharmaceutically acceptable salt thereof. The structures and names of these Examples are described in the Examples section. These Examples are thought to be suitable for oral administration.

A second aspect of the present invention provides a compound of formula (IA) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof) : (IA)

wherein: X is NR4R5 or OR5a, in which: R4 is hydrogen, Cl-2alkyl or Cl-2fluoroalkyl, and R5 is hydrogen, Cl galkyl, C1 8 fluoroalkyl, or C3-8cycloalkyl, phenyl optionally substituted with one or two of : a halogen atom, C1-2alkyl, trifluoromethyl, Cl 2alkoxy or trifluoromethoxy; or R5 has the sub-formula (x), (y) or (z): (x) (y) (z) wherein in sub-formula (x) and (z), n =1 or 2; and in sub-formula (y), m =1 or 2; wherein in sub-formula (x) and (y), none, one or two of A, B, D, E and F are nitrogen; and the remaining of A, B, D, E and F are CH or CR6 where R6 is a halogen atom, C1-4alkyl, C1-4fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy, C1-2alkylsulphonyl (C1-2alkyl-SO2-), C1-2alkyl-SO2-NH-, R7R8N-SO2-, R7R8N-CO, R7R8N, OH, Cl 4alkoxymethyl, or C1-2alkyl-SO2-CH2- wherein R7 and R8 are independently hydrogen or Cl 2alkyl ; wherein in sub-formula (z), G is O or S or NR9 wherein R9 is Cl 4alkyl or Cl 4fluoroalkyl ; none, one or two of J, L, M and Q are nitrogen ; and the remaining of J, L, M and Q are CH or CR6 where R6 is as defined herein; or R4 and R5 taken together are- (CH2) p- where p = 3,4 or 5 (preferably p = 4); R5a is Cl alkyl ; C1-8 fluoroalkyl ; C3-8cycloalkyl ; phenyl optionally substituted with one or two of : a halogen atom, C1-2alkyl, trifluoromethyl, Cl 2alkoxy or trifluoromethoxy ; or R5a has the sub-formula (x), (y) or (z) as defined herein; R3 is C3 gcycloalkyl or a heterocyclic group being which Y is O, S, SO2, or NR10 ; where R10 is hydrogen, C1-4alkyl, C1-2fluoroalkyl, C (O)-Cl 2alkyl, or C (O)-CF3 ;

and wherein in R3 the C3 gcycloalkyl or heterocyclic group is optionally substituted with one or two substituents being OH, C 1 _2alkoxy, trimethoxy, or Cl 2alkyl group; and wherein any OH, alkoxy or trimethoxy substituent is not substituted at the ring carbon attached to the-NH-group of fonnula (IA) and is not substituted at either ring carbon bonded to the Y group of the heterocyclic group; and Rl = Cl 4alkyl or Cl 2fluoroalkyl.

In formula (IA), preferably, when R3 is the heterocyclic group being is NR10, then : either (a) R10 is hydrogen, C (O)-Cl 2alkyl, or C (O)-CF3 ; or (b) R10 is methyl and the compound is: 1-ethyl-N-(2-ethylbutyl)-4-[(1- methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5-carboxamide or 1-ethyl-N- (4- fluorophenyl)-4- [ (l-methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide.

In formula (IA), preferably, where X is OR5 a, the compound is other than the compound wherein Rl is methyl, X is OEt, and R3 is cyclopentyl.

In formula (IA), in sub-formula (x) and/or (y), it is preferred that none, one or two of A, B, D, E and F are nitrogen; none, one, two or three of A, B, D, E and F are CR6 ; and the remaining of A, B, D, E and F are CH. More preferably, none, one or two of A, B, D, E and F are nitrogen; none or one or two of A, B, D, E and F are CR6 ; and the remaining of A, B, D, E and F are CH. In formula (IA), in sub-formula (x) and/or (y), preferably, none or one of A, B, D, E and F are nitrogen.

In formula (IA), preferably, sub-formula (x) is: benzyl; phenethyl (Ph-C2H4-) ; benzyl or phenethyl being substituted on the phenyl ring with a single R6 substituent, or one of the following: , wherein R6a is either R6 as defined herein or (preferably) hydrogen.

In formula (IA), preferably, sub-formula (y) is: wherein R6a is either R6 as defined herein or preferably hydrogen. Examples 1-99 are examples of compounds or salts of the second aspect of the invention (Formula (IA)).

A third aspect of the present invention provides a compound of formula (IB) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof): wherein: Rl is Cl 4alkyl, Cl 3fluoroalkyl,-CH2CH2OH or-CH2CH2CO2Cl 2alkyl ; R2 is a hydrogen atom (H), methyl or Clfluoroalkyl ; R3 is optionally substituted C3 gcycloalkyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc);

(aa) (bb) (cc) in which nl and n2 independently are 1 or 2; and in which Y is O, S, SO2, or NR10 ; where RI 0 is a hydrogen atom (H), Cl 4alkyl (e. g. methyl or ethyl), C 1-2fluoroalkyl, CH2C (O) NH2, C (O) NH2, C (O)-Cl 2alkyl, or C (O)-Clfluoroalkyl ; and wherein in R3 the C3 gcycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally substituted with one or two substituents being oxo (=O), OH, C1-2alkoxy, C1-2fluoroalkoxy (e. g. trifluoromethoxy), or Cl 2alkyl ; and wherein any OH, alkoxy or fluoroalkoxy substituent is not substituted at the R3 ring carbon attached (bonded) to the-NH-group of formula (IB) and is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc); and X is NR4R5 or OR5a, in which: R4 is a hydrogen atom (H); C1-6alkyl; C1-3fluoroalkyl ; or C2-6alkyl substituted by one substituent Ru 1 ; and R5 is a hydrogen atom (H); Cul alkyl ; C1-8 fluoroalkyl ; C3-8cycloalkyl optionally substituted by a Cl 2alkyl group; or-(CH2) n4-C3 gcycloalkyl optionally substituted, in the- (CH2) n4- moiety or in the C3 gcycloalkyl moiety, by a Cl 2alkyl group, wherein n4 is 1, 2 or 3 ; or R5 is C2-6alkyl substituted by one or two independent substituents R11; wherein each substituent RI 1, independently of any other Rl l substituent present, is: hydroxy (OH); Cl 6alkoxy ; phenyloxy; benzyloxy ;-NR12Rl3 -NR15-C(O)R16; -NR15-C(O)-O-R16; -NR15-C(O)-NH-R15 ; or-NR15-s02Rl6 ; and wherein any Rl 1 substituent which is OH, alkoxy or-NR12Rl3 is not substituted at any carbon atom, of any R4 or R5 substituted alkyl, which is bonded to the nitrogen of NR4R5 ; or R5 is -(CH2)n11-C(O)R16; -(CH2)n11-C(O)NR12R13; -CHR19-C(O)NR12R13 ; - (CH2) n 12-C (O) OR16 ;-CHR19-C (O) OR16 ;- (CH2) n 12-SO2-NR 12Rl3 ;

-(CH2) nl2-So2Rl6 ; or-(CH2)n12-CN ; wherein nl l is 0,1, 2,3 or 4 and nl2 is 1,2, 3 or 4; or R5 is- (CH2) n13-Het wherein n13 is 0,1, 2,3 or 4 and Het is a 4-, 5-, 6-or 7-membered saturated or partly-saturated heterocyclic ring containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the-(CH2)n13-moiety when n13 is 1 and are not bound to the nitrogen of NR4R5 when nl3 is 0; wherein any ring-nitrogens which are present and which are not unsaturated (i. e. which do not partake in a double bond) are present as NR17 where R17 is as defined herein; and wherein one or two of the carbon ring-atoms independently are optionally substituted by Cl 2alkyl ; or R5 is phenyl optionally substituted with one or two of : a halogen atom; Cl 4alkyl (e. g.

C1-2alkyl); C1-2fluoroalkyl (e. g. trifluoromethyl); Cl 4alkoxy (e. g. C1-2alkoxy) ; Cl- 2fluoroalkoxy (e. g. trifluoromethoxy) ; C1-2alkylsulphonyl (C1-2alkyl-SO2-) ; C1-2alkyl-SO2-NH-; R7R8N-SO2-; R7R8N-CO-;-NR15-C(O)R16 ; R7R8N ; OH ; C1-4alkoxymethyl; C1-4alkoxyethyl ; Cl 2alkyl-SO2-CH2-; cyano (CN); or phenyl optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C1fluoralkyl, C1-2alkoxy or C1fluoroalkoxy ; wherein R7 and R8 are independently a hydrogen atom (H); Cl 4alkyl (e. g.

Cl 2alkyl such as methyl); C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R7 and R8 together ar3-(CH2)n6-or-C(O)-(CH2)n7-or-C(O)-(CH2)n7-C(O)-or -(CH2)n8-X7-(CH2)n9-or-C(O)-X7-(CH2)n10 -in which: n6 is 3,4, 5 or 6, n7 is 2,3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and n10 independently are 2 or 3, and X7 is O or NR14 wherein R14 is H or Cl 2alkyl ; or R5 has the sub-formula (x), (y) or (z): (x) (y) (z) wherein in sub-formula (x), n = 1 or 2; in sub-formula (y), m = 1 or 2; and in sub-formula (z), r = 0, 1 or 2 ;

wherein in sub-formula (x) and (y), none, one or two of A, B, D, E and F are nitrogen; and the remaining of A, B, D, E and F are independently CH or CR6; where R6 is a halogen atom; Cl 4alkyl (e. g. Cl 2alkyl) ; C1-4fluoroalkyl (e. g.

Cl 2fluoroalkyl) ; Cl 4alkoxy (e. g. Cl 2alkoxy) ; C1-2fluoroalkoxy ; C1-2alkylsulphonyl (C1-2alkyl-SO2-) ; Cl 2alkyl-S02-NH-; R7R8N-So2-; R7R8N-Co-;-NR15-C (o) Rl6 ; R7R8N ; OH; C1-4alkoxymethyl; C1-4alkoxyethyl ; Ci2alkyl-S02-CH2- ; cyano (CN); or phenyl optionally substituted by one or two of fluoro, chloro, C1-2alkyl, C 1 fluoroalkyl, C 1-2alkoxy or C 1 fluoroalkoxy ; wherein R7 and R8 are as herein defined; wherein in sub-formula (z), G is O or S or NR9 wherein R9 is a hydrogen atom (H), Ci.

4alkyl or Cl 4fluoroalkyl ; none, one, two or three of J, L, M and Q are nitrogen ; and the remaining of J, L, M and Q are independently CH or CR6 where R6 is as defined herein; or R4 and R5 taken together are- (CH2) pl- or-C (O)- (CH2) p2- or - (CH2) p3-X5- (CH2) p4- or-C (o)-X5- (CH2) p5-, in which: p 1 = 3,4, 5 or 6 (preferably p = 4 or 5), p2 is 2,3, 4, or 5 (preferably p2 is 2,3 or 4), and p3 and p4 and p5 independently are 2 or 3 (independently preferably 2) and X5 is O or NR17 ; wherein R17 is a hydrogen atom (H); Cl 4alkyl (e. g. C1-2alkyl); C1-2fluoroalkyl ; C3-6cycloalkyl; -(CH2)p6-C(O)R16 wherein p6 is 0,1, 2 or 3 (preferably p6 is 0); -(CH2)p6-C(O)NR12R13; -(CH2)p6-C(O)OR16; -SO2R16 ; or phenyl or benzyl wherein the phenyl or benzyl is optionally substituted at an aromatic carbon atom by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; and wherein, when R4 and R5 taken together are-(CH2)p1-or-C(O)-(CH2)p2-, the NR4R5 heterocycle is optionally substituted by one R18 substituent wherein RiS is: Cl 4alkyl (e. g. CI-2alkyl) ; Cl-2fluoroalkyl ; C3 6cycloalkyl ; Cl 2alkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); Clfluoroalkoxy (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen); OH (not substituted at a ring-carbon bonded to the NR4R5 ring-nitrogen) ;-(CH2) p7-C (o) R16 wherein p7 is 0,1, 2 or 3 (preferably p7 is 0 or 1) ;-(CH2)p7-C(O)OR16; -(CH2)p7-OC(O)R16 ; -(CH2)p7-C(O)NR12R13; -(CH2)p7-NR15C(O)R16; -(CH2)p7-NR15C(O)NR12R13 ; -(CH2)p7-NR15C(O)OR16; -(CH2)p7-SO2R16; -(CH2)p7-SO2 NR 12R13 ; -(CH2)p7-NR15SO2R16; -(CH2)p7-OH; -(CH2)p7-OR16 ; or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ;

or R4 and R5 taken together are-(CH2) pl-or-C (O)-(CH2) p2-or -(CH2) p3-X5-(CH2) p4-or-C (o)-X5-(CH2) p5-as defined herein, and wherein the NR4R5 heterocycle is fused to a phenyl ring optionally substituted on the phenyl by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; and R5a is Cl alkyl ; C1-8 fluoroalkyl ; C3-8cycloalkyl ; phenyl optionally substituted with one or two of : a halogen atom, C1-2alkyl, trifluoromethyl, C1-2alkoxy or trifluoromethoxy; or R5 a has the sub-formula (x), (y) or (z) as defined herein and wherein: R12 and R13 independently are H; Cul alkyl (e. g. Cl 3alkyl) ; C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; or R12 and R13 together are-(CH2)n6-or-C(O)-(CH2)n7-or-C(O)-(CH2)n7-C(O)-or -(CH2) n8-X12-(CH2) n9-or-C (O)-X12-(CH2) nl0-in which: n6 is 3, 4, 5 or 6 (preferably n6 is 4 or 5), n7 is 2,3, 4, or 5 (preferably n7 is 2,3 or 4), n8 and n9 and n10 independently are 2 or 3 (independently preferably 2) and X12 is O or NR14 wherein R14 is H or Cl 2alkyl ; Rl 5 is a hydrogen atom (H); Cl 4alkyl (e. g. tBu or Cl 2alkyl e. g. methyl); C3 6cycloalkyl ; or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy ; R16 is C 1 4alkyl (e. g. C1-2alkyl) ; C3 6cycloalkyl ; pyridinyl (e. g. pyridin-2-yl); or phenyl optionally substituted by one or two of : a halogen atom, C1-2alkyl, C1fluoroalkyl, Cl 2alkoxy or C 1 fluoroalkoxy ; and R19is a hydrogen atom (H); C1-4alkyl (e. g. isobutyl, sec-butyl, or Cl 3alkyl such as methyl or isopropyl) ;- (CH2) n20-OR20 wherein n2O is 1,2, 3 or 4 (preferably 1) and R20 is a hydrogen atom (H) or Cl 4alkyl (preferably R20 is H);-CH (Me)-OH ;-CH2-SH ; -CH2-CH2-S-Me ; benzyl; or (4-hydroxyphenyl) methyl (i. e. 4-hydroxy-benzyl).

In formula (IB), preferably, when R3 is the heterocyclic group of sub-formula (bb), nl is 1, and Y is NRl 0, then : either (a) R10 is not Cl 4alkyl, Cl 2fluoroalkyl or CH2C (O) NH2 ;

or (b) R10 is methyl and the compound is: 1-ethyl-N- (2-ethylbutyl)-4- [ (1- methylpiperidin-4-yl) amino]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide or 1-ethyl-N- (4- fluorophenyl)-4- [ (l-methylpiperidin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide.

In formula (IB), preferably, where X is OR5a, the compound is other than the compound wherein Rl is methyl, X is OEt, and R3 is cyclopentyl.

In formula (IB), where R3 is optionally substituted C3 gcycloalkyl, the one or two optional substituents preferably comprise (e. g. is or are) OH and/or oxo (=O). In formula (IB), in the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), the one or two optional substituents preferably comprise (e. g. is or are) OH and/or oxo.

Examples 1-203 are examples of compounds or salts of the third aspect of the invention (Formula (IB)).

The preferred or optional features for the compound or salt of formula (IA) and for the compound or salt of formula (IB) are the same as or similar to the preferred or optional features for the compound or salt of formula (I), with all necessary changes (for example to the formula, to the R groups and/or to substituents) having been made. Generally, whenever formula (I) is mentioned herein, then in alternative embodiments the statement mentioning formula (1) applies to formula (IA) or formula (IB), with all necessary changes having been made.

Salts, solvates, isomers, tautomeric forms, molecular weights, etc.

Because of their potential use in medicine, the salts of the compounds of formula (1) are preferably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts can include acid or base addition salts. A pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration. A pharmaceutically acceptable acid addition salt of a compound of formula (I) can be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate, fumarate, citrate, tartrate, benzoate, p-toluenesulfonate, methanesulfonate or naphthalenesulfonate salt. A pharmaceutically acceptable base addition salt can be

formed by reaction of a compound of formula (I) with a suitable inorganic or organic base, optionally in a suitable solvent such as an organic solvent, to give the base addition salt which is usually isolated for example by crystallisation and filtration. Other suitable pharmaceutically acceptable salts include pharmaceutically acceptable metal salts, for example pharmaceutically acceptable alkali-metal or alkaline-earth-metal salts such as sodium, potassium, calcium or magnesium salts; in particular pharmaceutically acceptable metal salts of one or more carboxylic acid moieties that may be present in the the compound of formula (I).

Other non-pharmaceutically acceptable salts, eg. oxalates, may be used, for example in the isolation of compounds of the invention, and are included within the scope of this invention.

The invention includes within its scope all possible stoichiometric and non- stoichiometric forms of the salts of the compounds of formula (I).

Also included within the scope of the invention are all solvates, hydrates and complexes of compounds and salts of the invention.

Certain groups, substituents, compounds or salts included in the present invention may be present as isomers. The present invention includes within its scope all such isomers, including racemates, enantiomers and mixtures thereof.

Certain of the groups, e. g. heteroaromatic ring systems, included in compounds of formula (I) or their salts may exist in one or more tautomeric forms. The present invention includes within its scope all such tautomeric forms, including mixtures.

Especially when intended for oral medicinal use, the compound of formula (I) can optionally have a molecular weight of 1000 or less, for example 800 or less, in particular 650 or less or 600 or less. Molecular weight here refers to that of the unsolvated"free base"compound, that is excluding any molecular weight contributed by any addition salts, solvent (e. g. water) molecules, etc.

Synthetic Process Routes The following processes can be used to make the compounds of the invention: Most of the following synthetic processes following are exemplified for compounds of Formula (I) wherein R2 is a hydrogen atom (H). However, some or all of these processes

can also be used with appropriate modification, e. g. of starting materials and reagents, for making compounds of Formula (I) wherein R2 is other than H.

Process A Compounds of formula (I) where X = OR5a, can be prepared according to a method, for example as described by Yu et. al. in J. Med Claem., 2001,44, 1025-1027, by reaction of a compound of formula (II) with an amine of formula R3NH2. The reaction is preferably carried out in the presence of a base such as triethylamine or N, N-diisopropylethylamine, and/or in an organic solvent such as ethanol, dioxane or acetonitrile. The reaction may require heating e. g. to ca. 60-100 °C, for example ca. 80-90 °C :

(I) Compounds of formula (II) are also described in the above reference and can be prepared by reaction of a compound of formula (III) with, for example, diethylethoxymethylene malonate (where R5a = Et) with heating, followed by reaction with phosphorous oxychloride, again with heating:

Formula III Formula II Where the desired amino pyrazole of formula (III) is not commercially available, preparation can be achieved using methods described by Dorgan et. al. in J. Chem. Soc., Perkin Trans. 1, (4), 938-42; 1980, by reaction of cyanoethylhydrazine with a suitable aldehyde of formula R40CHO in a solvent such as ethanol, with heating, followed by reduction with, for example sodium in a solvent such as t-butanol. R40 should be chosen so as to contain one less carbon atom than Rl, for example R40 = methyl will afford Rl = ethyl.

Formula III In an alternative embodiment of Process A, the 4-chloro substituent in the compound of formula (II) can be replaced by a halogen atom, such as a bromine atom or preferably a chlorine atom, in a compound of formula (IIA) as defined below. In this embodiment of Process A, the compound of formula (IIA) is reacted with the amine of formula R3NH2.

Process B Compounds of formula (I) where X = NR4R5, can be prepared by reaction of a compound of formula (IV) with an amine of formula R3NH2. The reaction is preferably carried out in the presence of a base, such as triethylamine or N, N-diisopropylethylamine, and/or in an organic solvent such as ethanol, THF, dioxane or acetonitrile. The reaction may require heating, e. g. to ca. 60-100 °C or ca. 80-90 °C, for example for 8-48 or 12-24 hours: Formula IV Formula I Compounds of formula (IV) can be prepared in a two step procedure as described by Bare et. al. in J. Med. Chem. 1989,32, 2561-2573. This process involves, first, reaction of a compound of formula (V) with thionyl chloride (or another agent suitable for forming an acid chloride from a carboxylic acid), either in an organic solvent such as chloroform or THF, or as a neat solution. This reaction may require heating and the thus-formed intermediate may or may not be isolated. Step two involves reaction with an amine of formula R4R5NH, in an organic solvent such as THF or chloroform and may also involve the use of a base such as triethylamine or diisopropylethyl amine:

Formula V Formula IV Compounds of formula (V) can be prepared by hydrolysis of an ester of formula (II) according to the method described by Yu et. al. in J. Med Chem., 2001,44, 1025-1027.

This procedure preferably involves reaction with a base such as sodium hydroxide or potassium hydroxide in a solvent e. g. an aqueous solvent such as aqueous ethanol or aqueous dioxane: Formula 11 Formula V In an alternative embodiment of Process B, the 4-chloro substituent in the compound of formula (IV) can be replaced by a halogen atom, such as a bromine atom or preferably a chlorine atom, in a compound of formula (IVA) as defined below. In this embodiment of Process B, the compound of formula (IVA) is reacted with the amine of formula R3NH2.

Process C Compounds of formula (I) can also be prepared according to a method, for example as described by Bare et. al. in J. Med. Chem. 1989, 32,2561-2573, which involves reaction of a compound of formula (VI), in which-O-R35 is a leaving group displaceable by an amine, with an amine of formula R3NHz. The-0-R35 leaving group can be - 0-Ci. 4alkyl (in particular-O-Et) or-0-S (0) 2-R37, wherein R37 is C1-8alkyl (e. g.

Cl 4alkyl or Cl 2alkyl such as methyl), C 1 _6fluoroalkyl (e. g. Cl 4fluoroalkyl or C1-2fluoroalkyl such as CF3 or C4F9), or phenyl wherein the phenyl is optionally substituted by one or two of independently Cl 2alkyl, halogen or Cl 2alkoxy (such as phenyl or 4-methyl-phenyl). The reaction may be carried out with or without solvent and may require heating:

Formula VI Formula I Compounds of formula (VI) (also described in the above reference) can be prepared by reaction of a compound of formula (VII) with a suitable alkylating agent of formula Rl-X, where X is a leaving group such as halogen. The reaction is preferably carried out in the presence of a base such as potassium carbonate, in an anhydrous solvent such as DMF: O R35 O O R35 O 99 ORO Nx > Ns, 1 N K2C03 N N DMF R Formula VII Formula VI

The preparation of compounds of formula VII, e. g. where OR35 is OEt, by oxidative cleavage of compounds of formula VIII is described by Bare et. al. in J. Med. Chem.

1989,32, 2561-2573 (further referred to Zuleski et. al. in J. Drug. Metab. Dispos., 1985, 13,139). OEt O OEt O N /I OR 5a Se02-1- : OR 5a \/-1-N// N r, & I, ° Formula VIII Formula VII In another embodiment of Process C, the compound of formula (VI) can be replaced by a compound of formula (VIA), wherein X is NR4R5 or oR5a as defined herein: (VIA) In this embodiment of Process C, the compound of formula (VIA) is reacted with the amine of formula R3NH2.

Process D: To form a compound of formula (I) wherein X = NR4R5, a compound of formula (I) but wherein X = OH (a carboxylic acid, the compound of formula (IX) as defined below) can be converted into an activated compound of formula (I) but wherein X = a leaving group Xl substitutable by an amine (a compound of formula (X) as defined below, wherein XI is a leaving group substitutable by an amine) ; and subsequently the activated compound can be reacted with an amine of formula R4R5NH : For example, the activated compound (the compound of formula (X) ) can be the acid chloride i. e. an activated compound of formula (I) but wherein the leaving group Xl = Cl.

This can be formed from the carboxylic acid (X = OH, the compound of formula (IX)) e. g. by reaction with thionyl chloride, either in an organic solvent such as chloroform or without solvent. See for example Examples 81-85. Alternatively, the activated compound (the compound of formula (X) ) can be an activated ester wherein the leaving group Xl is The latter activated compound of formula (X) can be formed from the carboxylic acid (X = OH, the compound of formula (IX)) either:

(a) by reaction of the carboxylic acid with a carbodiimide such as EDC, which is 1-ethyl- 3- (3'-dimethylaminopropyl) carbodiimide and is also 1- (3-dimethylaminopropyl)-3- ethylcarbodiimide, or a salt thereof e. g. hydrochloride salt, preferably followed by reaction of the resulting product with 1-hydroxybenzotriazole (HOBT); reaction (a) usually being carried out in the presence of a solvent (preferably anhydrous) such as dimethyl formamide (DMF) or acetonitrile and/or preferably under anhydrous conditions and/or usually at room temperature (e. g. about 20 to about 25 °C) ; or (b) by reaction with 2- (1H-benzotriazole-1-yl)-1, 1, 3,3-tetramethyluronium tetrafluoroborate (TBTU) or O- (7-Azabenzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU), in the presence of a base such as diisopropylethylamine (iPr2NEt = DIPEA), and usually in the presence of a solvent such as dimethyl formamide (DMF) or acetonitrile and/or preferably under anhydrous conditions and/or usually at room temperature (e. g. about 20 to about 25 °C).

The carboxylic acid wherein X = OH (the compound of formula (IX) below) is usually prepared by hydrolysis of the corresponding ester of formula (I) wherein X is OR5a. This ester can itself be prepared by any of Processes A, C, E or F as described herein.

Process Dl This is the same as Process D, but involves reaction of the activated compound of formula (X), wherein Xl = a leaving group substitutable by an amine (for example a leaving group as defined herein), with an amine of formula R4RSNH.

Process E Compounds of formula (I) can be prepared by reaction of a compound of formula (XI) with an alkylating agent of formula Rl-X3, where X3 is a leaving group displaceable by the 1-position pyrazolopyridine nitrogen atom of the compound of formula (XI): A suitable alkylating agent of formula R1-X3 can be used. For example, X3 can be a halogen atom such as a chlorine atom or more preferably a bromine or iodine atom, or X3 can be-0-S (0) 2-R36 wherein R36 is Cl alkyl (e. g. Cl 4alkyl or Cl 2alkyl such as methyl), Cl 6fluoroalkyl (e. g. Cl 4fluoroalkyl or Cl 2fluoroalkyl such as CF3 or C4F9), or phenyl wherein the phenyl is optionally substituted by one or two of independently Cl 2alkyl, halogen or Cl 2alkoxy (such as phenyl or 4-methyl-phenyl). The reaction is

preferably carried out in the presence of a base; the base can for example comprise or be potassium carbonate, sodium carbonate, sodium hydride, potassium hydride, or a basic resin or polymer such as polymer-bound 2-tert-butylimino-2-diethylamino-1, 3-dimethyl- perhydro-1, 3,2-diazaphosphorine. The reaction is preferably carried out in the presence of a solvent, e. g. an organic solvent such as DMF; the solvent is preferably anhydrous.

Examples of alkylation Process E include Examples 183,185, 186 and 354.

For preferable methods of making compounds of formula (XI), see for example (Reference) Examples 19-20, and Intermediates 48 and 54A.

Process F: Conversion, of one compound offormula (I) or salt thereof into another compound offormula (I) or salt thereof One compound of formula (I) or salt thereof can be converted into another compound of formula (I) or salt thereof. This conversion preferably comprises or is one or more of the following processes F1 to F10 : F1. An oxidation process. For example, the oxidation process can comprise or be oxidation of an alcohol to a ketone (e. g. using Jones reagent, e. g. see Example 205) or oxidation of an alcohol or a ketone to a carboxylic acid. The oxidation process can e. g. comprise or be conversion of a nitrogen-containing compound of formula (I) or salt thereof to the corresponding N-oxide (e. g. using meta-chloroperoxybenzoic acid), for example conversion of a pyridine-containing compound to the corresponding pyridine N-oxide (e. g. Examples 210-212).

F2. A reduction process, for example reduction of a ketone or a carboxylic acid to an alcohol.

F3. Acylation, for example acylation of an amine (e. g. Examples 329-349, Example 353) or hydroxy group.

F4. Alkylation, for example alkylation of an amine or of a hydroxy group.

F5. Hydrolysis, e. g. hydrolysis of an ester to the corresponding carboxylic acid or salt thereof (e. g. Examples 351,488, 489,650, 651).

F6. Deprotection, e. g. deprotection (e. g. deacylation or t-butyloxycarbonyl (BOC) removal) of an amine group (e. g. Examples 320, (321), and (352)).

F7. Formation of an ester or amide, for example from the corresponding carboxylic acid.

F8. Conversion of a ketone into the corresponding oxime (e. g. Examples 652,653, 654 and 680-686).

F9. Sulfonylation, e. g. sulfonamide formation by reaction of an amine with a sulfonyl halide e. g. a sulfonyl chloride (e. g. Examples 322-328). and/or

F10. Beckmann rearrangement of one compound of formula (I) into another compound of formula (I), preferably using cyanuric chloride (2,4, 6-trichloro-1, 3,5-triazine) together with a formamide such as DMF, e. g. at room temperature (see L. D. Luca, J. Org. Chem., 2002,67, 6272-6274). The Beckmann rearrangement can for example comprise conversion of a compound of formula (I) wherein NHR3 is of sub-formula (o2) 'OH NH) into a compound of formula (1) wherein NHR3 is of sub-formula H O o (m3) (NH), e. g. as illustrated in Examples 658 and 659.

The present invention therefore also provides a method of preparing a compound of formula (I) or a salt thereof : wherein Rl, R2 and R3 are as defined herein and X is NR4R5 or OR5a as defined herein, the method comprising:

(a) for a compound of formula (I) wherein X = OR5a, reaction of a compound of formula (IIA) :

(IIA) wherein Hal is a halogen atom (such as a bromine atom or preferably a chlorine atom), with an amine of formula R3NH2, or (b) for a compound of formula (I) wherein X = NR4R5, reaction of a compound of formula (IVA):

(IVA) wherein Hal is a halogen atom (such as a bromine atom or preferably a chlorine atom), with an amine of formula R3NH2, or (c) reaction of a compound of formula (VIA):

(VIA) , in which-O-R35 is a leaving group displaceable by an amine (such as-O-Cl 4alkyl or - (0) 2-R37), with an amine of formula R3NH2 ; or (d) to form a compound of formula (1) wherein X = NR4R5, conversion of a compound of formula (IX) into an activated compound of formula (X) wherein XI = a leaving group substitutable by an amine:

, and subsequent reaction of the activated compound of formula (X) with an amine of formula R4R5NH ; or (dl) to form a compound of formula (1) wherein X = NR4R5, reaction of an activated compound of formula (X) as defined above with an amine of formula R4R5NH ; or (e) reaction of a compound of formula (XI): (Xl) with an alkylating agent of formula Rl-X2, where x2 is a leaving group displaceable by the 1-position pyrazolopyridine nitrogen atom of the compound of formula (XI); or (f) conversion of one compound of formula (I) or salt thereof into another compound of formula (I) or salt thereof; and optionally converting the compound of formula (I) into a salt thereof e. g. a pharmaceutically acceptable salt thereof.

In methods (d) and/or (dl), the activated compound of formula (X) wherein XI = a leaving group substitutable by an amine can be the acid chloride i. e. an activated compound of formula (X) wherein Xl = Cl. Alternatively, the activated compound of formula (X) can be an activated ester wherein the leaving group Xl is

Preferred features of methods (a), (b), (c), (d), (dl) and (e), independently of each other, are as described above for Processes A, B, C, D, Dl and E, with all necessary changes being made.

The present invention also provides: (g) a method of preparing a pharmaceutically acceptable salt of a compound of formula (I) comprising conversion of the compound of formula (1) or a salt thereof into the desired pharmaceutically acceptable salt thereof.

(See for example Examples 490,491, 518A, 593).

The present invention also provides a compound of formula (I) or a salt thereof, prepared by a method as defined herein.

Medical uses The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance in a mammal such as a human. The compound or salt can be for use in the treatment and/or prophylaxis of any of the diseases/conditions described herein (e. g. for use in the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal) and/or for use as a phosphodiesterase inhibitor e. g. for use as a phosphodiesterase 4 (PDE4) inhibitor.

"Therapy"may include treatment and/or prophylaxis.

Also provided is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament (e. g. pharmaceutical composition) for the treatment and/or prophylaxis of any of the diseases/conditions described herein in a mammal such as a human, e. g. for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human.

Also provided is a method of treatment and/or prophylaxis of any of the diseases/ conditions described herein in a mammal (e. g. human) in need thereof, e. g. a method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal (e. g. human) in need thereof, which method comprises administering to the mammal (e. g. human) a therapeutically effective amount of a compound of formula (I) as herein defined or a pharmaceutically acceptable salt thereof.

Phosphodiesterase 4 inhibitors are thought to be useful in the treatment and/or prophylaxis of a variety of diseases/conditions, especially inflammatory and/or allergic diseases, in mammals such as humans, for example: asthma, chronic obstructive pulmonary disease (COPD) (e. g. chronic bronchitis and/or emphysema), atopic

dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, multiple sclerosis, cognitive impairment (e. g. in a neurological disorder such as Alzheimer's disease), depression, or pain. Ulcerative colitis and/or Crohn's disease are collectively often referred to as inflammatory bowel disease.

In the treatment and/or prophylaxis, the inflammatory and/or allergic disease is preferably chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis in a mammal (e. g. human). More preferably, the treatment and/or prophylaxis is of COPD or asthma in a mammal (e. g. human).

PDE4 inhibitors are thought to be effective in the treatment of asthma (e. g. see M. A. Giembycz, Drugs, Feb. 2000,59 (2), 193-212; Z. Huang et al., Current Opinion in Chemical Biology, 2001,5 : 432-438; H. J. Dyke et al., Expert Opinion on Investigational Drugs, January 2002,11 (1), 1-13; C. Burnouf et al., CurrentPharmaceutical Design, 2002,8 (14), 1255-1296; A. M. Doherty, Current Opinion Chem. Biol., 1999,3 (4), 466- 473; and refs cited therein).

PDE4 inhibitors are thought to be effective in the treatment of COPD (e. g. see S. L.

Wolda, Emerging Drugs, 2000,5 (3), 309-319; Z. Huang et al., Current Opinion in Chemical Biology, 2001,5 : 432-438; H. J. Dyke et al., Expert Opinion on Investigational Drugs, January 2002,11 (1), 1-13; C. Burnouf et al., Current Pharmaceutical Design, 2002,8 (14), 1255-1296; A. M. Doherty, Current Opinion Chem. Biol., 1999,3 (4), 466- 473; and refs cited therein). COPD is often characterised by the presence of airflow obstruction due to chronic bronchitis and/or emphysema (S. L. Wolda, Emerging Drugs, 2000,5 (3), 309-319).

PDE4 inhibitors are thought to be effective in the treatment of allergic rhinitis (e. g. see B. M. Schmidt et al., J. Allergy & Clinical Immunology, 108 (4), 2001,530-536).

PDE4 inhibitors are thought to be effective in the treatment of rheumatoid arthritis and multiple sclerosis (e. g. see H. J. Dyke et al., Expert Opinion on Investigational Drugs, January 2002,11 (1), 1-13; C. Burnouf et al. , Current Pharmaceutical Design, 2002, 8 (14), 1255-1296; and A. M. Doherty, Cuy°r-ent Opinion Chem. Biol., 1999,3 (4), 466-473; and refs cited therein). See e. g. A. M. Doherty, Current Opinion Chem. Biol., 1999,3 (4), 466-473 and refs cited therein for atopic dermatitis use.

PDE4 inhibitors have been suggested as having analgesic properties and thus being effective in the treatment of pain (A. Kumar et al., Indian J. Exp. Biol., 2000,38 (1), 26- 30).

In the invention, the treatment and/or prophylaxis can be of cognitive impairment e. g. cognitive impairment in a neurological disorder such as Alzheimer's disease. For example, the treatment and/or prophylaxis can comprise cognitive enhancement e. g. in a neurological disorder. See for example: H. T. Zhang et al. in: Psychopharmacology, June 2000,150 (3), 311-316 and Neuropsychopharmacology, 2000,23 (2), 198-204; and T.

Egawa et al., Japanese J. Pharmacol., 1997,75 (3), 275-81.

PDE4 inhibitors such as rolipram have been suggested as having antidepressant properties (e. g. J. Zhu et al., CNS Drug Reviews, 2001,7 (4), 387-398; O'Donnell, Expert Opinion on Investigational Drugs, 2000,9 (3), 621-625; and H. T. Zhang et al., Neuropsychopharmacology, October 2002,27 (4), 587-595).

Pharmaceutical compositions and dosing For use in medicine, the compounds of the present invention are usually administered as a pharmaceutical composition.

The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or excipients.

The pharmaceutical composition can be for use in the treatment and/or prophylaxis of any of the conditions described herein.

The invention also provides a method of preparing a pharmaceutical composition comprising a compound of formula (I), as herein defined, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and/or excipients, the method comprising mixing the compound or salt with the one or more pharmaceutically acceptable carriers and/or excipients.

The invention also provides a pharmaceutical composition prepared by said method.

The compounds of formula (I) and/or the pharmaceutical composition may be administered, for example, by oral, parenteral (e. g. intravenous, subcutaneous, or intramuscular), inhaled or nasal administration. Accordingly, the pharmaceutical composition is preferably suitable for oral, parenteral (e. g. intravenous, subcutaneous, or intramuscular), inhaled or nasal administration. More preferably, the pharmaceutical composition is suitable for inhaled or oral administration, e. g. to a mammal such as a human. Inhaled administration involves topical administration to the lung e. g. by aerosol or dry powder composition. Oral administration to a human is most preferred.

A pharmaceutical composition suitable for oral administration can be liquid or solid; for example it can be a syrup, suspension or emulsion, a tablet, a capsule or a lozenge.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable phannaceutically acceptable liquid carrier (s), for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

A pharmaceutical composition suitable for oral administration being a tablet can comprise one or more pharmaceutically acceptable carriers and/or excipients suitable for preparing tablet formulations. Examples of such carriers include lactose and cellulose.

The tablet can also or instead contain one or more pharmaceutically acceptable excipients, for example binding agents, lubricants such as magnesium stearate, and/or tablet disintegrants.

A pharmaceutical composition suitable for oral administration being a capsule can be prepared using encapsulation procedures. For example, pellets containing the active ingredient can be prepared using a suitable pharmaceutically acceptable carrier and then filled into a hard gelatin capsule. Alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutically acceptable carrier, for example an aqueous gum or an oil and the dispersion or suspension then filled into a soft gelatin capsule.

Preferably the composition is in unit dose form such as a tablet or capsule for oral administration, e. g. for oral administration to a human.

A parenteral composition can comprise a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil. Alternatively, the solution can be lyophilised; the lyophilised parenteral pharmaceutical composition can be reconstituted with a suitable solvent just prior to administration.

Compositions for nasal or inhaled administration may conveniently be formulated as aerosols, drops, gels or dry powders.

Aerosol formulations, e. g. for inhaled administration, can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non- aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.

Where the dosage form comprises an aerosol dispenser, it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide, or an organic propellant such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC). Suitable CFC propellants include dichlorodifluoromethane, trichlorofluoromethane and dichlorotetrafluoroethane. Suitable HFC propellants include 1,1, 1,2, 3,3, 3-

heptafluoropropane and 1,1, 1,2-tetrafluoroethane. The aerosol dosage forms can also take the form of a pump-atomiser.

For pharmaceutical compositions suitable and/or adapted for inhaled administration, it is preferred that the compound or salt of formula (I) is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation.

Micronisation usually involves subjecting the compound/salt to collisional and abrasional forces in a fast-flowing circular or spiral/vortex-shaped airstream often including a cyclone component. The preferable particle size (e. g. D50 value) of the size-reduced (e. g. micronised) compound or salt is about 0.5 to about 10 microns, e. g. about 1 to about 5 microns (e. g. as measured using laser diffraction). For example, it is preferable for the compound or salt of formula (I) to have a particle size defined by: a D10 of about 0.3 to about 3 microns (e. g. about 1 micron), and/or a D50 of about 1 to about 5 microns (e. g. about 2-5 or about 2-3 microns), and/or a D90 of about 2 to about 20 microns or about 3 to about 10 microns (e. g. about 5-8 or about 5-6 microns); for example as measured using laser diffraction. The laser diffraction measurement can use a dry method (suspension of compound/salt in airflow crosses laser beam) or a wet method [suspension of compound/salt in liquid dispersing medium, such as isooctane or (e. g. if compound soluble in isooctan) 0. 1% Tween 80 in water, crosses laser beam]. With laser diffraction, particle size is preferably calculated using the Fraunhofer calculation; and/or preferably a Malvern Mastersizer or Sympatec apparatus is used for measurement.

An illustrative non-limiting example of a small-scale micronisation process is now given: Micronisation Example: Micronisation of Example 518 or 518A Purpose : To micronize approximately 600-1000 mg of Example 518 or 518A (described hereinafter) using a Jetpharma MC1 micronizer.

The parent (unmicronised) and micronised materials are analyzed for particle size by laser diffraction and crystallinity by PXRD.

Equipment and material Equipment/material Description and specification Jetpharma MC1 Micronizer Nitrogen supply: Air tank with 275psi rate tubing Analytical balance Sartorius Analytical Top loader balance Mettler PM400 Digital Caliper VWR Electronic caliper Vibrational spatula Auto-spat Dispenser Materials to be micronised Example 518 or 518A

The Jetpharma MC1 Micronizer comprises a horizontal disc-shaped milling housing having: a tubular compound inlet (e. g. angled at ca. 30degrees to the horizontal) for entry of a suspension of unmicronised compound of formula (I) or salt in an gasflow, a separate gas inlet for entry of gases, a gas outlet for exit of gases, and a collection vessel for collecting micronised material. The milling housing has two chambers: an outer annular chamber in gaseous connection with the gas inlet the chamber being for receiving pressurised gas (e. g. air or nitrogen), an disc-shaped inner milling chamber within and coaxial with the outer chamber for micronising the input compound/salt, the two chambers being separated by an annular wall. The annular wall (ring R) has a plurality of narrow-bored holes connecting the inner and outer chambers and circumferentially- spaced-apart around the annular wall. The holes open into the inner chamber directed at an angle (directed part-way between radially and tangentially), and in use act as nozzles directing pressurised gas at high velocity from the outer chamber into the inner chamber and in an inwardly-spiral path (vortex) around the inner chamber (cyclone). The compound inlet is is gaseous communication with the inner chamber via a nozzle directed tangentially to the inner chamber, within and near to the annular wall. Upper and lower broad-diameter exit vents in the central axis of the the inner milling chamber connect to (a) (lower exit) the collection vessel which has no air outlet, and (b) (upper exit) the gas outlet which leads to a collection bag, filter and a gas exhaust. Inside the tubular compound inlet and longitudinally-movable within it is positioned a venturi inlet (V) for entry of gases. The compound inlet also has a bifurcation connecting to an upwardly- directed material inlet port for inputting material.

In use, the narrow head of the venturi inlet (V) is preferably positioned below and slightly forward of the material inlet port so that when the venturi delivers pressurised gas (eg air or nitrogen) the feed material is sucked into the gasstream thorough the compound inlet and accelerates it into the inner milling chamber tangentially at a subsonic speed.

Inside the milling chamber the material is further accelerated to a supersonic speed by the hole/nozzle system around the ring (R) (annular wall) of the milling chamber. The nozzles are slightly angled so that the acceleration pattern of the material is in the form of an inwardly-directed vortex or cyclone. The material inside the milling chamber circulates rapidly and particle collisions occur during the process, causing larger particles to fracture into smaller ones. "Centrifugal"acceleration in the vortex causes the larger particles to remain at the periphery of the inner chamber while progressively smaller particles move closer to the center until they exit the milling chamber, generally through the lower exit, at low pressure and low velocity. The particles that exit the milling chamber are heavier than air and settle downward thorugh the lower exit into the collection vessel, while the exhaust gas rises (together with a miinority of small particles of micronised material) and escapes into the atmosphere at low pressure and low velocity.

Procedure : The micronizer is assembled. The venturi protrusion distance from input port is adjusted to 1. Ocm respectively (e. g. so that the narrow head of the venturi inlet is

positioned below and slightly forward of the material inlet port) and is measured with a micro-caliper to make sure that it is inserted correctly. The ring (R) and venturi (V) pressures are adjusted according to the values specified in the experimental design (refer to experimental section below) by adjusting the valves on the pressure gauges on the micronizer. The setup is checked for leakage by observing if there is any fluctuation in the reading of the pressure gauges.

Note that the venturi (V) pressure is kept at least 2 bars greater than the ring (R) pressure to prevent regurgitation of material, e. g. outwardly from the material inlet port.

Balance performance is checked with calibration weights. Specified amount of the parent material (see section on experimental run) is weighed into a plastic weigh boat.

The material is then fed into the micronizer using a vibrational spatula (e. g. V-shaped in cross-section) at a specified feed rate. The material feeding time and equipment pressures are monitored during the micronization process.

Upon completion of the micronising run, the nitrogen supply is shut off and the collection bag is tapped to allow particles to settle into the recovery/collection vessel at the bottom of the micronizer. The collection bag is removed and set aside. The micronised powder in the recovery vessel (collection vessel) and the cyclone (above the recovery vessel) are collected separately into different weighed+labelled collection vials.

The weight of the micronised material is recorded. The micronizer is disassembled and residual PDE4 compound on the micronizer inner surface is rinsed with 70/30 isopropyl alcohol/water and collected into a flask. The micronizer is then thoroughly cleaned by rinsing and wiping with suitable solvent and dried before subsequent runs are performed.

Preferred Experimental Parameters Parent (unmicronised) material (Procedure 1) : Example 518 or 518A Parent (unmicronised) material (Procedure 2): Example 518 Balance (s) Used: Sartorius analytical Venturi outlet insertion depth: 10.0 mm Material Venturi (V) Intended Time Actual feed-rate Proc-input/ring (R) feed-rate needed to (g/min) edure amount (g) Pressure feed no. (bar) material (min+sec) 1 0.8795g V= 10 bar 200 mg/min 4 min 51 181 mg/min R= 6 bar sec 2 0.9075g V= 8 bar 200 mg/min 4 min 43 192 mg/min R=5. 5bar sec The above parameters can be varied using the skilled person's knowledge.

Results and/or observations % yield = [ (Material from vessel + Material from cyclone) /Material input amount] x 100

In general, very approximately 50-75% yields are achievable using this method.

Procedure 1 has not been completed.

In Procedure 2, a 70.8% yield (0.6427g) of Example 518 micronised material was obtained, including material from collection vessel and material from inside walls of cyclone.

Particle size analysis of Example 518 micronised material from Procedure 2, using laser diffraction measurement with Malvern Mastersizer longbed version, dispersing medium 0. 1% Tween 80 in water, stir rate 1500 rpm, 3 mins sonification prior to final dispersion and analysis, 300 RF (Reverse Fourier) lens, Fraunhofer calculation with Malvern software: - material from collection vessel: D10 = 0.97 microns, D50 = 3.86 microns, D90 = 12.64 microns.

- material from inside walls of cyclone: D10 = 0.95 microns, D50 = 3.42 microns, D90 = 9.42 microns.

Alternative embodiment: Examples of the compounds/salts of the invention other than Examples 518 or 518A can be micronised.

For pharmaceutical compositions suitable and/or adapted for inhaled administration, it is preferred that the pharmaceutical composition is a dry powder inhalable composition. Such a composition can comprise a powder base such as lactose or starch, the compound of formula (I) or salt thereof (preferably in particle-size-reduced form, e. g. in micronised form), and optionally a performance modifier such as L-leucine, mannitol, trehalose and/or magnesium stearate. Preferably, the dry powder inhalable composition comprises a dry powder blend of lactose and the compound of formula (I) or salt thereof. The lactose is preferably lactose hydrate e. g. lactose monohydrate and/or is preferably inhalation-grade and/or fine-grade lactose. Preferably, the particle size of the lactose is defined by 90% or more (by weight or by volume) of the lactose particles being less than 1000 microns (micrometres) (e. g. 10-1000 microns e. g. 30-1000 microns) in diameter, and/or 50% or more of the lactose particles being less than 500 microns (e. g.

10-500 microns) in diameter. More preferably, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 300 microns (e. g. 10-300 microns e. g. 50-300 microns) in diameter, and/or 50% or more of the lactose particles being less than 100 microns in diameter. Optionally, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 100-200 microns in diameter, and/or 50% or more of the lactose particles being less than 40-70 microns in diameter. Most importantly, it is preferable that about 3 to about 30% (e. g. about 10%) (by weight or by volume) of the particles are less than 50 microns or less than 20 microns in diameter. For example, without limitation, a suitable inhalation-grade lactose is E9334 lactose (10% fines) (Borculo Domo Ingredients, Hanzeplein 25,8017 JD Zwolle, Netherlands).

In the dry powder inhalable composition, preferably, the compound of formula (I) or salt thereof is present in about 0. 1% to about 70% (e. g. about 1% to about 50%, e. g. about 5% to about 40%, e. g. about 20 to about 30%) by weight of the composition.

An illustrative non-limiting example of a dry powder inhalable composition follows: Dry Powder Formulation Example-Dry powder Lactose Blend Preparation Using a size-reduced e. g. micronised form of the compound of formula (I) or salt thereof (e. g. as prepared in the Micronisation Example above), the dry powder blend is prepared by mixing the required amount of the compound/salt (e. g. 10 mg, 1 % w/w) with inhalation-grade lactose containing 10% fines (e. g. 990 mg, 99% w/w) in a Teflon (polytetrafluoroethene) pot in a Mikro-dismembrator ball-mill (but without a ball bearing) at 3/4 speed (ca. 2000-2500 rpm) for about 4 hours at each blend concentration. The Mikro-dismembrator (available from B. Braun Biotech International, Schwarzenberger Weg 73-79, D-34212 Melsungen, Germany; www. bbraunbiotech. com) comprises a base with an upwardly-projecting and sidewardly-vibratable arm to which is attached the Teflon TM pot. The vibration of the arm achieves blending.

Other blends : 10% w/w compound/salt (50 mg) + 90% w/w lactose (450 mg, inhalation-grade lactose containing 10% fines).

Serial dilution of the 1 % w/w blend can achieve e. g. 0. 1 % and 0. 3% w/w blends.

Optionally, in particular for dry powder inhalable compositions, a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (e. g. containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device. The container is rupturable or peel-openable on demand and the dose, e. g. of the dry powder composition, can be administered by inhalation via a device such as the DISKUS TM device, marketed by GlaxoSmithKline.

The DISKUS TM inhalation device is usually substantially as described in GB 2,242, 134 A. In such device at least one container for the pharmaceutical composition in powder form (the at least one container preferably being a plurality of sealed dose containers mounted longitudinally in a strip or ribbon) is defined between two members peelably secured to one another; the device comprises: means defining an opening station for the said at least one container; means for peeling the members apart at the opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale the pharmaceutical composition in powder form from the opened container.

In the pharmaceutical composition, a or each dosage unit for oral or parenteral administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base. A or each dosage unit for nasal or inhaled administration

preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

A pharmaceutically acceptable compound or salt of the invention is preferably administered to a mammal (e. g. human) in a daily oral or parenteral dose of 0.001 mg to 50 mg per kg body weight per day (mg/kg/day), for example 0.01 to 20 mg/kg/day or 0.03 to 10 mg/kg/day or 0.1 to 2 mg/kg/day, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

A pharmaceutically acceptable compound or salt of the invention is preferably administered to a mammal (e. g. human) in a daily nasal or inhaled dose of : 0.0001 to 5 mg/kg/day or 0. 0001 to 1 mg/kg/day, e. g. 0. 001 to 1 mg/kg/day or 0. 001 to 0.3 mg/kg/day or 0.001 to 0.1 mg/kg/day or 0.005 to 0.3 mg/kg/day, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

The pharmaceutically acceptable compounds or salts of the invention is preferably administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0. 01 mg to 3000 mg per day or 0.5 to 1000 mg per day e. g. 2 to 500 mg per day, or a nasal or inhaled dose of 0.001 to 300 mg per day or 0.001 to 50 mg per day or 0.01 to 30 mg per day or 0. 01 to 5 mg per day or 0.02 to 2 mg per day, of the compound of the formula (1) or a pharmaceutically acceptable salt thereof, calculated as the free base.

Combinations The compounds, salts and/or pharmaceutical compositions according to the invention may also be used in combination with another therapeutically active agent, for example, a ß2 adrenoreceptor agonist, an anti-histamine, an anti-allergic or an anti-inflammatory agent.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another therapeutically active agent, for example, a (32-adrenoreceptor agonist, an anti-histamine, an anti-allergic, an anti-inflammatory agent or an antiinfective agent.

Preferably, the 3-adrenoreceptor agonist is salmeterol (e. g. as racemate or a single enantiomer such as the R-enantiomer), salbutamol, formoterol, salmefamol, fenoterol or terbutaline, or a salt thereof (e. g. pharmaceutically acceptable salt thereof), for example the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the fumarate salt of formoterol. Long-acting ß2-adrenoreceptor agonists are preferred, especially those having a therapeutic effect over a 12-24 hour period such as salmeterol or formoterol. Preferably, the p-adrenoreceptor agonist is for inhaled administration, e. g. once per day and/or for simultaneous inhaled administration; and more preferably the (32-adrenoreceptor agonist is in particle-size-reduced form e. g. as defined herein.

Preferably, the ß2-adrenoreceptor agonist combination-is for treatment and/or

prophylaxis of COPD or asthma. Salmeterol or a pharmaceutically acceptable salt thereof, e. g. salmeterol xinofoate, is preferably administered to humans at an inhaled dose of 25 to 50 micrograms twice per day (measured as the free base). The combination with a ß2-adrenoreceptor agonist can be as described in WO 00/12078.

Preferred long acting ß2-adrenoreceptor agonists include those described in WO 02/066422A, WO 03/024439, WO 02/070490 and WO 02/076933.

Especially preferred long-acting ß2-adrenoreceptor agonists include compounds of formula (XX) (described in WO 02/066422): or a salt or solvate thereof, wherein in formula (XX): mx is an integer of from 2 to 8 ; nx is an integer of from 3 to 11, with the proviso that mx+nx is 5 to 19, Rllx is-XSO2NR16XR17X wherein X is-(CH2)px-or C2-6 alkenylene; R 16X and Rl7x are independently selected from hydrogen, C1-6alkyl, C3-7cycloalkyl, C (O) NRI8XRI9X, phenyl, and phenyl (C1-4alkyl)-, or R16X and R17X, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring, and Rl6x and Rl7x are each optionally substituted by one or two groups selected from halo, C16alkyl, C106haloalkyl, C1-6alkoxy, hydroxy- substituted C1-6alkoxy, -CO2R18X, -SO2NR18XR19X, -CONR18XR19X, -NR18XC(O)R19X, or a 5-, 6-or 7-membered heterocylic ring; R lgx and Rl9x are independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl, and phenyl (Cl 4alkyl)-; and px is an integer of from 0 to 6, preferably from 0 to 4; Rl2x and Rise are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, halo, phenyl, and C1-6haloalkyl ; and Rl4x and R15X are independently selected from hydrogen and Cl 4alkyl with the proviso that the total number of carbon atoms in Rl4x and Rlsx is not more than 4.

Preferred ß2-adrenoreceptor agonists disclosed in WO 02/066422 include: 3- (4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)- phenyl] ethyl} amino) hexyl] oxy} butyl) benzenesulfonamide and 3- (3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl) phenyl] ethyl}- amino) heptyl] oxy}propyl)benzenesulfonamide.

A preferred ß2-adrenoreceptor agonist disclosed in WO 03/024439 is: 4- {(1R)-2-[(6- {2-[(2, 6-dichlorobenzyl) oxy] ethoxy} hexyl) amino]-1-hydroxyethyl}-2- (hydroxymethyl) phenol.

A combination of a compound of formula (I) or salt together with an anti-histamine is preferably for oral administration (e. g. as a combined composition such as a combined tablet), and can be for treatment and/or prophylaxis of allergic rhinitis. Examples of anti- histamines include methapyrilene, or Hl antagonists such as cetirizine, loratadine (e. g.

Clarityn TM), desloratadine (e. g. Clarinex TM) or fexofenadine (e. g. Allegra TM).

The invention also provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic compound, e. g. a muscarinic (M) receptor antagonist in particular an M1, M2, M1/M2, or M3 receptor antagonist, more preferably a M3 receptor antagonist, still more preferably a M3 receptor antagonist which selectively antagonises (e. g. antagonises 10 times or more strongly) the M3 receptor over the Mi and/or M2 receptor. For combinations of anticholinergic compounds/muscarinic (M) receptor antagonist with PDE4 inhibitors, see for example WO 03/011274 A2 and WO 02/069945 A2/US 2002/0193393 Al and US 2002/052312 Al, and some or all of these publications give examples of anticholinergic compounds/muscarinic (M) receptor antagonists which may be used with the compounds of formula (I) or salts, and/or suitable pharmaceutical compositions.

For example, the muscarinic receptor antagonist can comprise or be an ipratropium salt (e. g. ipratropium bromide), an oxitropium salt (e. g. oxitropium bromide), or more preferably a tiotropium salt (e. g. tiotropium bromide); see e. g. EP 418 716 Al for tiotropium.

The anticholinergic compound or muscarinic (M) receptor antagonist, e. g. M3 receptor antagonist, is preferably for inhaled administration, more preferably in particle-size- reduced form e. g. as defined herein. More preferably, both the muscarinic (M) receptor antagonist and the compound of formula (I) or the pharmaceutically acceptable salt thereof are for inhaled administration. Preferably, the anticholinergic compound or muscarinic receptor antagonist and the compound of formula (I) or salt are for simultaneous administration. The muscarinic receptor antagonist combination is preferably for treatment and/or prophylaxis of COPD.

Other suitable combinations include, for example, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another anti- inflammatory agent such as an anti-inflammatory corticosteroid; or a non-steroidal anti- inflammatory drug (NSAID) such as a leukotriene antagonist (e. g. montelukast), an iNOS inhibitor, a tryptase inhibitor, a elastase inhibitor, a beta-2 integrin antagonist, a adenosine 2a agonist, a CCR3 antagonist, or a 5-lipoxogenase inhibitor); or an

antiinfective agent (e. g. an or antiviral). An iNOS inhibitor is preferably for oral administration. Suitable iNOS inhibitors (inducible nitric oxide synthase inhibitors) include those disclosed in WO 93/13055, WO 98/30537, WO 02/50021, WO 95/34534 and WO 99/62875. Suitable CCR3 inhibitors include those disclosed in WO 02/26722.

In a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with anti-inflammatory corticosteroid (which is preferably for treatment and/or prophylaxis of asthma, COPD or allergic rhinitis), then preferably the anti-inflammatory corticosteroid is fluticasone, fluticasone propionate (e. g. see US patent 4,335, 121), beclomethasone, beclomethasone 17-propionate ester, beclomethasone 17,21-dipropionate ester, dexamethasone or an ester thereof, mometasone or an ester thereof, ciclesonide, budesonide, flunisolide, or a compound as described in WO 02/12266 Al (e. g. as claimed in any of claims 1 to 22 therein), or a pharmaceutically acceptable salt of any of the above. If the anti-inflammatory corticosteroid is a compound as described in WO 02/12266 Al, then preferably it is Example 1 therein {which is 6a, 9a-difluoro-17a- [ (2-furanylcarbonyl) oxy]-l 1 3-hydroxy-16a-methyl-3- oxo-androsta-1, 4-diene-17p-carbothioic acid S-fluoromethyl ester) or Example 41 therein {which is 6a, 9a-difluoro-1 1 3-hydroxy-16a-methyl-17a- [ (4-methyl-1, 3-thiazole-5- carbonyl) oxy]-3-oxo-androsta-1, 4-diene-17p-carbothioic acid S-fluoromethyl ester}, or a pharmaceutically acceptable salt thereof. The anti-inflammatory corticosteroid is preferably for intranasal or inhaled administration. Fluticasone propionate is preferred and is preferably for inhaled administration to a human either (a) at a dose of 250 micrograms once per day or (b) at a dose of 50 to 250 micrograms twice per day.

Also provided is a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with p-adrenoreceptor agonist and an anti-inflammatory corticosteroid, for example as described in WO 03/030939 Al.

Preferably this combination is for treatment and/or prophylaxis of asthma, COPD or allergic rhinitis. The ß2-adrenoreceptor agonist and/or the anti-inflammatory corticosteroid can be as described above and/or as described in WO 03/030939 Al. Most preferably, in this"triple"combination, the ß2-adrenoreceptor agonist is salmeterol or a pharmaceutically acceptable salt thereof (e. g. salmeterol xinafoate) and the anti- inflammatory corticosteroid is fluticasone propionate.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus a pharmaceutical composition comprising a combination as defined above together with one or more pharmaceutically acceptable carriers and/or excipients represent a further aspect of the invention.

The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical composition.

In one embodiment, the combination as defined herein can be for simultaneous inhaled administration and is disposed in a combination inhalation device. Such a combination inhalation device is another aspect of the invention. Such a combination inhalation device can comprise a combined pharmaceutical composition for simultaneous inhaled administration (e. g. dry powder composition), the composition comprising all the individual compounds of the combination, and the composition being incorporated into a plurality of sealed dose containers mounted longitudinally in a strip or ribbon inside the inhalation device, the containers being rupturable or peel-openable on demand; for example such inhalation device can be substantially as described in GB 2,242, 134 A (DISKUS TM) and/or as described above. Alternatively, the combination inhalation device can be such that the individual compounds of the combination are administrable simultaneously but are stored separately (or wholly or partly stored separately for triple combinations), e. g. in separate pharmaceutical compositions, for example as described in PCT/EP03/00598 filed on 22 January 2003 (e. g. as described in the claims thereof e. g. claim 1).

The invention also provides a method of preparing a combination as defined herein, the method comprising either (a) preparing a separate pharmaceutical composition for administration of the individual compounds of the combination either sequentially or simultaneously, or (b) preparing a combined pharmaceutical composition for administration of the individual compounds of the combination simultaneously, wherein the pharmaceutical composition comprises the combination together with one or more pharmaceutically acceptable carriers and/or excipients.

The invention also provides a combination as defined herein, prepared by a method as defined herein.

BIOLOGICAL TEST METHODS PDE 3, PDE 4B, PDE 4D, PDE 5, PDE 6 Primary assay methods The activity of the compounds can be measured in the assay methods shown below.

Preferred compounds of the invention are selective PDE4 inhibitors, i. e. they inhibit PDE4 (e. g. PDE4B and/or PDE4D, preferably PDE4B) more strongly than they inhibit PDE3 and/or more strongly than they inhibit PDE5 and/or more strongly than they inhibit PDE6.

PDE enzyme sources and literature references Human recombinant PDE4B, in particular the 2B splice variant thereof (HSPDE4B2B), is disclosed in WO 94/20079 and also M. M. McLaughlin et al. ,"A low Km, rolipram- sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA", J. Biol. Chem., 1993,268, 6470-6476. For example, in Example 1 of WO 94/20079, human recombinant PDE4B is described as being expressed in the PDE- deficient yeast Saccharomyces cerevisiae strain GL62, e. g. after induction by addition of 150 uM CuS04, and 100,000 x g supernatant fractions of yeast cell lysates are described for use in the harvesting of PDE4B enzyme.

Human recombinant PDE4D (HSPDE4D3A) is disclosed in P. A. Baecker et al., "Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phoshodiesterase (PDE IVD)", Gene, 1994,138, 253-256.

Human recombinant PDE5 is disclosed in K. Loughney et al. ,"Isolation and characterisation of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3', 5'-cyclic nucleotide phosphodiesterase", Gene, 1998,216, 139-147.

PDE3 was purified from bovine aorta as described by H. Coste and P. Grondin, "Characterisation of a novel potent and specific inhibitor of type V phosphodiesterase", Biochem. Pharmacol., 1995,50, 1577-1585.

PDE6 was purified from bovine retina as described by: P. Catty and P. Deterre, "Activation and solubilization of the retinal cGMP-specific phosphodiesterase by limited proteolysis", Eur. J Biochem., 1991,199, 263-269; A. Tar et al. "Purification of bovine retinal cGMP phosphodiesterase", Methods in Enzymology, 1994,238, 3-12; and/or D.

Srivastava et al. "Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase", Biochem. J., 1995,308, 653-658.

Inhibition of PDE 3, PDE 4B, PDE 4D, PDE 5 or PDE 6 activity : radioactive Scintillation Proximity Assay (SPA) The ability of compounds to inhibit catalytic activity at PDE4B or 4D (human recombinant), PDE3 (from bovine aorta), PDE5 (human recombinant) or PDE6 (from bovine retina) was determined by Scintillation Proximity Assay (SPA) in 96-well format.

Test compounds (preferably as a solution in DMSO, e. g. 0.5 to 1 microlitre (ul) volume) were preincubated at ambient temperature (room temperature, e. g. 19-23°C) in Wallac Isoplates (code 1450-514) with PDE enzyme in 50mM Tris-HCl buffer pH 7.5, 8.3mM MgCl2, 1. 7mM EGTA, 0.05% (w/v) bovine serum albumin for 10-30 minutes (usually 30 minutes). The enzyme concentration was adjusted so that no more than 20% hydrolysis of the substrate defined below occurred in control wells without compound, during the incubation. For the PDE3, PDE4B and PDE4D assays, [5', 8-3H] Adenosine 3', 5'-cyclic phosphate (Amersham Pharmacia Biotech, code TRK. 559; or Amersham Biosciences UK Ltd, Pollards Wood, Chalfont St Giles, Buckinghamshire HP8 4SP, UK) was added to give 0.05uCi per well and-lOnM final concentration. For the PDE5 and PDE6 assays, [8-3H] Guanosine 3', 5'-cyclic phosphate (Amersham Pharmacia Biotech, code TRK. 392) was added to give 0.05uCi per well and-36nM final concentration. Plates, e. g. containing approx. 100 ul volume of assay mixture, were mixed on an orbital shaker for 5 minutes and incubated at ambient temperature for 1 hour. Phosphodiesterase SPA beads (Amersham Pharmacia Biotech, code RPNQ 0150) were added (-lmg per well) to terminate the assay. Plates were sealed and shaken and allowed to stand at ambient temperature for 35 minutes to lhour (preferably 35 minutes) to allow the beads to settle.

Bound radioactive product was measured using a WALLAC TRILUX 1450 Microbeta scintillation counter. For inhibition curves, 10 concentrations (1. SnM-30uM) of each compound were assayed. Curves were analysed using ActivityBase and XLfit (ID Business Solutions Limited, 2 Ocean Court, Surrey Research Park, Guildford, Surrey GU2 7QB, United Kindgom) Results were expressed as pICso values.

In an alternative to the above radioactive SPA assay, PDE4B or PDE4D inhibition can be measured in the following Fluorescence Polarisation (FP) assay: Inhibition of PDE4B or PDE4D activity : Fluorescence Polarisation (FP) assay The ability of compounds to inhibit catalytic activity at PDE4B (human recombinant) or PDE4D (human recombinant) was determined by IMAP Fluorescence Polarisation (FP) assay (IMAP Explorer kit, available from Molecular Devices Corporation, Sunnydale, CA, USA; Molecular Devices code: R8062) in 384-well format.

The IMAP FP assay is able to measure PDE activity in an homogenous, non-radioactive assay format. The FP assay uses the ability of immobilised trivalent metal cations, coated onto nanoparticles (tiny beads), to bind the phosphate group of FI-ANT that is produced on the hydrolysis of fluorescein-labelled (Fl) cyclic adenosine mono-phosphate (Fl-cAMP) to the non-cyclic FI-AMP form. Fl-cAMP does not bind. Binding of FI-AMP product to the beads (coated with the immobilised trivalent cations) slows the rotation of

the bound Fl-AMP and leads to an increase in the fluorescence polarisation ratio of parallel to perpendicular light. Inhibition of the PDE reduces/inhibits this signal increase.

Test compounds (small volume, e. g. 0.5 to 1 ul, of solution in DMSO) were preincubated at ambient temperature (room temperature, e. g. 19-23°C) in black 384-well microtitre plates (supplier: NUNC, code 262260) with PDE enzyme in 10mM Tris-HCl buffer pH 7.2, l OmM MgCl2, 0. 1% (w/v) bovine serum albumin, and 0. 05% NaN3 for 10- 30 minutes. The enzyme level was set by experimentation so that reaction was linear throughout the incubation. Fluorescein adenosine 3', 5'-cyclic phosphate (from Molecular Devices Corporation, Molecular Devices code: R7091) was added to give about 40nM final concentration (final assay volume usually ca. 25-40 ul). Plates were mixed on an orbital shaker for 10 seconds and incubated at ambient temperature for 40 minutes. IMAP binding reagent (as described above, from Molecular Devices Corporation, Molecular Devices code: R7207) was added (60ul of a 1 in 400 dilution in binding buffer of the kit stock solution) to terminate the assay. Plates were allowed to stand at ambient temperature for 1 hour. The Fluorescence Polarisation (FP) ratio of parallel to perpendicular light was measured using an AnalystTM plate reader (from Molecular Devices Corporation). For inhibition curves, 10 concentrations (1. 5nM- 30uM) of each compound were assayed. Curves were analysed using ActivityBase and XLfit (ID Businesss Solutions Limited, 2 Ocean Court, Surrey Research Park, Guildford, Surrey GU2 7QB, United Kindgom). Results were expressed as pICgo values.

In the FP assay, all reagents were dispensed using MultidropTM (available from Thermo Labsystems Oy, Ratastie 2, PO Box 100, Vantaa 01620, Finland).

For a given PDE4 inhibitor, the PDE4B (or PDE4D) inhibition values measured using the SPA and FP assays can differ slightly. However, in a regression analysis of 100 test compounds, the pIC50 inhibition values measured using SPA and FP assays have been found generally to agree within 0.5 log units, for PDE4B and PDE4D (linear regression coefficient 0.966 for PDE4B and 0.971 for PDE4D; David R. Mobbs et al.,"Comparison of the IMAP Fluorescence Polarisation Assay with the Scintillation Proximity Assay for Phosphodiesterase Activity", poster to be presented at 2003 Molecular Devices UK & Europe User Meeting, 2nd October 2003, Down Hall, Harlow, Essex, United Kingdom).

Biological Data obtained for some of the Examples (PDE4B inhibitory activity, either as one reading or as an average of ca. 2-6 readings) are as follows, based on current measurements only. In each of the SPA and FP assays, absolute accuracy of measurement is not possible, and the readings given are accurate only up to about 0.5 of a log unit, depending on the number of readings made and averaged: Example number PDE4B pIC50 (~about 0.5) 2 8.0 3 7. 8 6 6. 6 11 7. 4 21 8. 5 22 7. 9 32 7. 7 40 8. 3 63 6. 9 1,36, 39,41, 42,43, 44,47, 7. 0 to 7. 9 48,63, 83,109, 178,187 and 600 100,155, 165,167, 201,8. 2 to 10.0 260,261, 263,265, 266, 267,271, 431,493, 494, 495,498, 518,518A, 528, 551,575, 581,584, 619, 622,624-626, 628,630, 636, 638,643-645, 653, and 677 to 686 196 7. 9 198 8. 5

Examples 1-201 were generally tested for PDE4B inhibition using the radioactive SPA assay. Of Examples 207-665, and 677-686, all or almost all (except perhaps for Examples 451,631-632, 635,652) were tested for PDE4B inhibition; and of these some were tested by the radioactive SPA assay, some were tested by the FP assay. Examples 1-201,207-450, 452-630,633-634, 636-651,653-665, and 677-686, but excluding reference examples 19-20, have PDE4B inhibitory activities in the range of pIC50 = about 6 ( about 0.5) to about 10.0 ( about 0.5). Examples 666-676 are predicted to have PDE4B inhibitory activities in the range of pICso = about 6 ( about 0.5) to about 10.0 ( about 0.5).

The Examples wherein R3 = cyclohexyl (NHR3 = sub-formula (c)), tetrahydro-2H-pyran- 4-yl (NHR3 = group (h) ), 4-oxocyclohexyl (NHR3 = sub-formula (o) ), or certain other types of substituted cyclohexyl or certain heterocycles, usually or often (especially with R1 = ethyl) have a higher level of selectivity for PDE4B over PDE5, as measured in the above enzyme inhibition assays, compared to the selectivities of comparable Examples wherein R3 = cyclopropyl (NHR3 = sub-formula (b) ). For example, based on current measurements only, and subject to cumulative assay inaccuracies : - Examples 21,40, 90,198 and 201 (wherein NHR3 = sub-formula (h), (c), (j), (n) and (o) respectively, R1 = ethyl) have selectivities for PDE4B over PDE5 in the range of about 3 to 20 or more times greater than the selectivity achieved for the equivalent Example 39 wherein R3 = cyclopropyl (NHR3 = sub-formula (b) );

- Examples 43 and 44 (wherein NHR3 = sub-formula (c) and (h) respectively) have selectivities for PDE4B over PDE5 in the range of about 4 to 8 or more times greater than the selectivity achieved for the equivalent R3 = cyclopropyl Example 42; - Examples 22 and 48 (wherein NHR3 = sub-formula (h) and (c) respectively) have selectivities for PDE4B over PDE5 in the of about 2.5 to 10 or more times greater than the selectivity achieved for the equivalent R3 = cyclopropyl Example 47; and - Examples 2 and 3 (wherein NHR3 = sub-formula (c) and (h) respectively) have selectivities for PDE4B over PDE5 in the range of about 2 to 5 or more times greater than the selectivity achieved for the equivalent R3 = cyclopropyl Example 1.

Emesis : Some known PDE4 inhibitors can cause emesis and/or nausea to greater or lesser extents (e. g. see Z. Huang et al., Current Opinion in Chemical Biology, 2001,5 : 432-438, see especially pages 433-434 and refs cited therein). Therefore, it would be preferable, but not essential, if a PDE4 inhibitory compound or salt of the invention were to cause only limited or manageable emetic side-effects. Emetic side-effects can for example be measured by the emetogenic potential of the compound or salt when administered to ferrets; for example one can measure the time to onset, extent, frequency and/or duration of vomiting, retching and/or writhing in ferrets after oral or parenteral administration of the compound or salt. See for example In vivo Assay 4 hereinafter for a measurement method for anti-inflammatory effect, emetic side-effects and therapeutic index (TI) in the ferret. See also for example A. Robichaud et al. ,"Emesis induced by inhibitors of [PDE IV] in the ferret", Neuropharmacology, 1999,38, 289-297, erratum Neuropharmacology, 2001,40, 465-465. However, optionally, emetic side-effects and therapeutic index (TI) in rats can be conveniently measured by monitoring the pica feeding behaviour of rats after administration of the compound or salt of the invention (see In Vivo Assay 2 below).

Other side effects : Some known PDE4 inhibitors can cause other side effects such as headache and other central nervous sytem (CNS-) mediated side effects; and/or gastrointestinal (GI) tract disturbances. Therefore, it would be preferable but not essential if a particular PDE4 inhibitory compound or salt of the invention were to cause only limited or manageable side-effects in one or more of these side-effect categories.

In Vivo Biological Assays The in vitro enzymatic PDE4B inhibition assay described above should be regarded as being the primary test of biological activity. However, additional in vivo biological tests, which are optional and which are not an essential measure of efficacy or side-effects, are described below.

} t Vivo Assay I. LPS-induced pulnozzary xeutrophilia in rats : effect of orally<BR> <BR> <BR> admillistered PDE4 iBlhibitors Pulmonary neutrophil influx has been shown to be a significant component to the family of pulmonary diseases like chronic obstructive pulmonary disease (COPD) which can involve chronic bronchitis and/or emphysema (G. F. Filley, Chest. 2000; 117 (5); 251s-260s). The purpose of this neutrophilia model is to study the potentially anti- inflammatory effects in vivo of orally administered PDE4 inhibitors on neutrophilia induced by inhalation of aerosolized lipopolysaccharide (LPS), modelling the neutrophil inflammatory component (s) of COPD. See the literature section below for scientific background.

Male Lewis rats (Charles River, Raleigh, NC, USA) weighing approximately 300- 400 grams are pretreated with either (a) test compound suspended in 0.5% methylcellulose (obtainable from Sigma-Aldrich, St Louis, MO, USA) in water or (b) vehicle only, delivered orally in a dose volume of 10 ml/kg. Generally, dose response curves are generated using the following doses of PDE4 inhibitors: 10.0, 2.0, 0.4, 0.08 and 0.016 mg/kg. Thirty minutes following pretreatment, the rats are exposed to aerosolized LPS (Serotype E. Coli 026: B6 prepared by trichloroacetic acid extraction, obtainable from Sigma-Aldrich, St Louis, MO, USA), generated from a nebulizer containing a 100 pg/ml LPS solution. Rats are exposed to the LPS aerosol at a rate of 4 L/min for 20 minutes. LPS exposure is carried out in a closed chamber with internal dimensions of 45 cm length x 24 cm width x 20 cm height. The nebulizer and exposure chamber are contained in a certified fume hood. At 4 hours-post LPS exposure the rats are euthanized by overdose with pentobarbital at 90 mg/kg, administered intraperitoneally. Bronchoalveolar lavage (BAL) is preformed through'a 14 gauge blunt needle into the exposed trachea. Five, 5 ml washes are performed to collect a total of 25 ml of BAL fluid. Total cell counts and leukocyte differentials are performed on BAL fluid in order to calculate neutrophil influx into the lung. Percent neutrophil inhibition at each dose (cf. vehicle) is calculated and a variable slope, sigmoidal dose-response curve is generated, usually using Prism Graph-Pad. The dose-response curve is used to calculate an ED50 value (in mg per kg of body weight) for inhibition by the PDE4 inhibitor of the LPS-induced neutrophilia.

Results : Based on current measurements, the compounds of Examples 22,83 and 155, administered orally in the above procedure, exhibited neutrophilia-inhibition ED50 values in the range of about 0.5 mg/kg to about 2 mg/kg.

Alternative method and results : In an alternative embodiment of the procedure, single oral doses of 10 mg/kg or 1.0 mg/kg of the PDE4 inhibitor (or vehicle) is administered to the rats, and percent neutrophil inhibition is calculated and reported for that specific dose. In this embodiment, based on current measurements, the compounds of Examples 21,100, 109,167, 172 and 600, administered orally in the above procedure at a single dose of 1.0 mg/kg, exhibited percent neutrophilia-inhibition in the range of about 19% to about 69% (or in the range of about 32% to about 69% for Examples 21, 100,109, 167 and 600).

Literature : Filley G. F. Comparison of the structural and inflammatory features of COPD and asthma. Chest. 2000 ; 117 (5) 251s-260s.

Howell RE, Jenkins LP, Fielding LE, and Grimes D. Inhibition of antigen- induced pulmonary eosinophilia and neutrophilia by selective inhibitors of

phosphodiesterase types 3 and 4 in brown Norway rats. Pulfraonary Phamacology.

1995 ; 8 : 83-89.

Spend J, Chapman R, Fine J, Jones H, Kreutzer W, Kung TT, Minnicozzi M.

Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (ArifloTM), in a rat model of pulmonary neutrophilia. Pulmonary Pharmacology and Therapeutics. 2001 ; 14 : 157- 164.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DWP, and Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Am J Physiol Lung Cell Mol Physiol. 2000 ; 279 : L895-L902.

In ivo Assay 2. Rat Pica Model of emesis Background : Selective PDE4 inhibitors have been shown to inhibit inflammation in various in vitro and in vivo models by increasing intracellular levels of cAMP of many immune cells (e. g. lymphocytes, monocytes). However, a side effect of some PDE4 inhibitors in many species is emesis. Because many rat models of inflammation are well characterized, they have been used in procedures (see e. g. In Vivo Assay 1 above) to show beneficial anti-inflammatory effects of PDE 4 inhibitors. However rats have no emetic response (they have no vomit reflex), so that the relationship between beneficial anti-inflammatory effects of PDE 4 inhibitors and emesis is difficult to study directly in rats.

However, in 1991, Takeda et al. (see Literature section below) demonstrated that the pica feeding response is analogous to emesis in rats. Pica feeding is a behavioural response to illness in rats wherein rats eat non-nutritive substances such as earth or in particular clay (e. g. kaolin) which may help to absorb toxins. Pica feeding can be induced by motion and chemicals (especially chemicals which are emetic in humans), and can be inhibited pharmacologically with drugs that inhibit emesis in humans. The Rat Pica Model, In Vivo Assay 2, can determine the level of pica response of rats to PDE 4 inhibition at pharmacologically relevant doses in parallel to in vino anti-inflammatory Assays in (a separate set of) rats (e. g. In Vivo Assay 1 above). Anti-inflammatory and pica assays in the same species together can provide data on the"therapeutic index" (TI) in the rat of the compounds/salts of the invention. The Rat TI can for example be calculated as the ratio of a) the potentially-emetic Pica Response ED50 dose from Assay 2 to b) the rat anti-inflammatory ED50 dose (e. g. measured by rat neutrophilia-inhibition in eg In Vivo Assay 1), with larger TI ratios possibly indicating lower emesis at many anti-inflammatory doses. This might allow a choice of a non-emetic or minimal-emetic pharmaceutical dose of the compounds or salts of the invention which has an anti-inflammatory effect. It is recognised however that achieving a low-emetic PDE4 inhibitory compound is not essential.

Procedure : On the first day of the experiment, the rats are housed individually in cages without bedding or"enrichment". The rats are kept off of the cage floor by a wire screen. Pre-weighed food cups containing standard rat chow and clay pellets are placed in the cage. The clay pellets, obtainable from Languna Clay Co, City of Industry, CA, USA, are the same size and shape as the food pellets. The rats are acclimated to the clay for 72 hours, during which time the cups and food and clay debris from the cage are weighed daily on an electronic balance capable of measuring to the nearest 0. 1 grams. By

the end of the 72 hour acclimation period the rats generally show no interest in the clay pellets.

At the end of 72 hours the rats are placed in clean cages and the food cups weighed. Rats that are still consuming clay regularly are removed from the study.

Immediately prior to the dark cycle (the time when the animals are active and should be eating) the animals are split into treatment groups and dosed orally with a dose of the compound/salt of the invention (different doses for different treatment groups) or with vehicle alone, at a dose volume of 2 ml/kg. In this oral dosing, the compound/salt is in the form of a suspension in 0.5% methylcellulose (obtainable Sigma-Aldrich, St. Louis, MO, USA) in water. The food and clay cups and cage debris are weighed the following day and the total clay and food consumed that night by each individual animal is calculated.

A dose response is calculated by first converting the data into quantal response, where animals are either positive or negative for the pica response. A rat is"pica positive"if it consumes greater than or equal to 0.3 grams of clay over the mean of is usually calculated using logistic regression performed by the Statistica software statistical package. A Pica Response ED50 value in mg per kg of body weight can then be calculated.

Results : Using the above procedure, and according to current measurements, the compounds of Examples 22,83 and 155 exhibited a Pica Response ED50 in the range of about 4.8 mg/kg to greater than or equal to about 40 mg/kg. It can be seen that these Pica Response ED50 doses are higher than the neutrophilia-inhibition ED50 values for these three Examples (see In Vivo Assay 1 above), so that a Therapeutic Index (TI) in rats of >2, as measured by Assays 1+2 and according to current measurements, appears at first sight to have been achieved for these three Examples.

The Therapeutic Index (TI) calculated this way is often significantly different to, and often higher than, the TI calculated in the ferret (see In vivo Assay 4 below).

Literature : Beavo JA, Contini, M. , Heaslip, R. J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol. 1994 ; 46: 399-405.

Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, Minnicozzi M.

Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (ArifloT""), in a rat model of pulmonary neutrophilia. Pulmonary Pharmacology and Therapeudtics. 2001 ; 14: 157- 164.

Takeda N, Hasegawa S, Morita M, and Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacology, Biochemist7y and Behavior.

1991; 45: 817-821.

Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A and Matsunaga T. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion-and apomorphine-induced pica in rats. Meth Find Exp Clin Pharmacol.

1995; 17 (9) 589-596.

Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A and Matsunaga T. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Meula Find Exp Clin Pharmacol. 1995; 17 (9) 647-652.

In Vivo Assay 3. LPS izzduced pulnzonary fzeutrophilia in rats : effect of intratracheally ad) ninisteved PDE4 inhibitors This assay is an animal model of inflammation in the lung-specifically neutrophilia induced by lipopolysaccharide (LPS) -and allows the study of putative inhibition of such neutrophilia (anti-inflammatory effect) by intratracheally (i. t.) administered PDE4 inhibitors. The PDE4 inhibitors are preferably in dry powder or wet suspension form. I. t. administration is one model of inhaled administration, allowing topical delivery to the lung.

Animals : Male CD (Sprague Dawley Derived) rats supplied by Charles River, Raleigh, NC, USA were housed in groups of 5 rats per cage, acclimatised after delivery for at least 7 days with bedding/nesting material regularly changed, fed on SDS diet Rl pelleted food given ad lib, and supplied with daily-changed pasteurised animal grade drinking water.

Device for dry powder administration : Disposable 3-way tap between dosing needle and syringe. A 3-way sterile tap (Vycon Ref 876.00) was weighed, the drug blend or inhalation grade lactose (vehicle control) was then added to the tap, the tap closed to prevent loss of drug, and the tap was re-weighed to determine the weight of drug in the tap. After dosing, the tap was weighed again to determine the weight of drug that had left the tap. The needle, a Sigma Z21934-7 syringe needle 19-gauge 152 mm (6 inches) long with luer hub, was cut by engineering to approximately 132 mm (5.2 inches), a blunt end was made to prevent them damaging the rat's trachea, and the needle weighed prior to and after drug delivery to confirm that no drug was retained in the needles after dosing.

Device for wet suspension administration : This is the similar to the above but a blunt dosing needle, whose forward end was slightly angled to the needle axis, was used, with a flexible plastic portex canula inserted into the needle.

Drugs and Materials : Lipopolysaccharide (LPS) (Serotype: 0127: B8) (L3129 Lot 61K4075) was dissolved in phosphate-buffered saline (PBS). PDE4 inhibitors are used in size-reduced (e. g. micronised) form, for example according to the Micronisation Example given above. For dry powder administration of the drug, the Dry Powder Formulation Example given above, comprising drug and inhalation-grade lactose, can be used. The inhalation-grade lactose usually used (Lot E98L4675 Batch 845120) has 10% fines (10% of material under 15um particle size measured by Malvern particle size).

Wet suspensions of the drug can be prepared by adding the required volume of vehicle to the drug; the vehicle used being a mixture of saline/tween (0.2% tween 80). The wet suspension was sonicated for 10 minutes prior to use.

Preparation, and dosing with PDE 4 inhibitor : Rats were anaesthetised by placing the animals in a sealed Perspex chamber and exposing them to a gaseous mixture of isoflourane (4.5 %), nitrous oxide (3 litres. minute-1) and oxygen (1 litre. minute-').

Once anaesthetised, the animals were placed onto a stainless steel i. t. dosing support table. They were positioned on their back at approximately a 35° angle. A light was angled against the outside of the throat to highlight the trachea. The mouth was opened and the opening of the upper airway visualised. The procedure varies for wet suspension and dry powder administration of PDE4 inhibitors as follows: Dosing with a Wet suspension : A portex cannula was introduced via a blunt metal dosing needle that had been carefully inserted into the rat trachea. The animals were intratracheally dosed with vehicle or PDE4 inhibitor via the dosing needle with a new internal canula used for each different drug group. The formulation was slowly (10 seconds) dosed into the trachea using a syringe attached to the dosing needle.

Dosing with a Dry Powder : The three-way tap device and needle were inserted into the rat trachea up to a pre-determined point established to be located approximately 1 cm above the primary bifurcation. Another operator holds the needle at the specified position whilst 2x 4ml of air is delivered through the three-way tap by depressing the syringes (ideally coinciding with the animal inspiring), aiming to expel the entire drug quantity from the tap. After dosing, the needle and tap are removed from the airway and the tap closed off to prevent any retained drug leaving the tap.

After dosing with either wet suspension or dry powder, the animals are then removed from the table and observed constantly until they have recovered from the effects of anaesthesia. The animals are returned to the holding cages and given free access to food and water; they are observed and any unusual behavioural changes noted.

Exposure to LPS : About 2 hours after i. t. dosing with vehicle control or the PDE4 inhibitor, the rats were placed into sealed Perspex containers and exposed to an aerosol of LPS (nebuliser concentration 150 , g. ml-I) for 15 minutes. Aerosols of LPS were generated by a nebuliser (DeVilbiss, USA) and this was directed into the Perspex exposure chamber. Following the 15-minute LPS-exposure period, the animals were returned to the holding cages and allowed free access to both food and water.

[In an alternative embodiment, the rats can exposed to LPS less than 2 hours after i. t. dosing. In another alternative embodiment, the rats can exposed to LPS more than 2 hours (e. g. ca. 4 or ca. 6 hours) after i. t. dosing by vehicle or PDE4 inhibitor, to test whether or not the PDE4 inhibitor has a long duration of action (which is not essential).] Bronchoalveolar lavage : 4 hours after LPS exposure the animals were killed by overdose of sodium pentobarbitone (i. p. ). The trachea was cannulated with polypropylene tubing and the lungs lavaged (washed out) with 3 x 5 mls of heparinised (25 units. ml-1) phosphate buffered saline (PBS).

Neutrophil cell counts : The Bronchoalveolar lavage (BAL) samples were centrifuged at 1300 rpm for 7 minutes. The supernatant was removed and the resulting cell pellet resuspended in 1 ml PBS. A cell slide of the resuspension fluid was prepared by placing 100 ! 11 of resuspended BAL fluid into cytospin holders and then spun at 5000

rpm for 5 minutes. The slides were allowed to air dry and then stained with Leishmans stain (20 minutes) to allow differential cell counting. The total cells were also counted from the resuspension. From these two counts, the total numbers of neutrophils in the BAL were determined. For a measure of PDE4-inhibitor-induced inhibition of neutrophilia, a comparison of the neutrophil count in rats treated with vehicle and rats treated with PDE4 inhibitors is conducted.

By varying the dose of the PDE4 inhibitor used in the dosing step (e. g. 0.2 or 0.1 mg of PDE4 inhibitor per kg of body weight, down to e. g. 0.01 mg/kg), a dose-response curve can be generated.

In Vivo Assay 4. Evaluation of Tiierapeutic Index of PDE 4 inhibitors ill the consciousferret 1. 1 Materials The following materials are used for these studies: PDE4 inhibitors are prepared for oral (p. o.) administration by dissolving in a fixed volume (1 ml) of acetone and then adding cremophor to 20% of the final volume.

Acetone is evaporated by directing a flow of nitrogen gas onto the solution. Once the acetone is removed, the solution is made up to final volume with distilled water.

LPS is dissolved in phosphate buffered saline.

1. 2 Animals Male ferrets (Mustela Pulorius Furo, weighing 1-2 kg) are transported and allowed to acclimatise for not less than 7 days. The diet comprises SDS diet C pelleted food given ad lib with WhiskersTM cat food given 3 times per week. The animals are supplied with pasteurised animal grade drinking water changed daily.

1. 3 Experimental Protocol (s) 1. 3. 1 Dosing with PDE4 inhibitors PDE4 inhibitors are administered orally (p. o. ), using a dose volume of lml/kg.

Ferrets are fasted overnight but allowed free access to water. The animals are orally dosed with vehicle or PDE 4 inhibitor using a 15cm dosing needle that is passed down the back of the throat into the oesophagus. After dosing, the animals are returned to holding cages fitted with perspex doors to allow observation, and given free access to water. The animals are constantly observed and any emetic episodes (retching and vomiting) or behavioural changes are recorded. The animals are allowed access to food 60-90 minutes after p. o. dosing.

1. 3. 2 Exposure to LPS Thirty minutes after oral dosing with compound or vehicle control, the ferrets are placed into sealed perspex containers and exposed to an aerosol of LPS (30 0 Lg/ml) for 10 minutes. Aerosols of LPS are generated by a nebuliser (DeVilbiss, USA) and this is directed into the perspex exposure chamber. Following a 10-minute exposure period, the animals are returned to the holding cages and allowed free access to water, and at a later stage, food. General observation of the animals continues for a period of at least 2.5 hours post oral dosing. All emetic episodes and behavioural changes are recorded.

1. 3. 3 Bronchoalveolar lavage and cell counts Six hours after LPS exposure the animals are killed by overdose of sodium pentobarbitone administered intraperitoneally. The trachea is then cannulated with polypropylene tubing and the lungs lavaged twice with 20 ml heparinised (10 units/ml) phosphate buffered saline (PBS). The bronchoalveolar lavage (BAL) samples are centrifuged at 1300 rpm for 7 minutes. The supernatant is removed and the resulting cell pellet re-suspended in 1 ml PBS. A cell smear of re-suspended fluid is prepared and stained with Leishmans stain to allow differential cell counting. A total cell count is made using the remaining re-suspended sample. From this, the total number of neutrophils in the BAL sample is determined.

1. 3. 4 Pharmacodynamic readouts The following parameters are recorded: a) % inhibition of LPS-induced pulmonary neutrophilia to determine the dose of PDE4 inhibitor which gives 50% inhibition (D50). b) Emetic episodes-the number of vomits and retches are counted to determine the dose of PDE4 inhibitor that gives a 20% incidence of emesis (D20). c) A therapeutic index (TI), using this assay, is then calculated for each PDE4 inhibitor using the following equation: Therapeutic index (TI) = D20 incidence of emesis D50 inhibition of neutrophilia It is noted that the Therapeutic index (TI) calculated using this in vivo Assay 4 is often significantly different to, and often lower than, that calculated using the rat oral inflammation and pica feeding Assays 1+2.

The calculation of TI using the PDE4 inhibitor roflumilast in this Assay 4 is: D20 for emesis = 0. 5mg/kg p. o. , D50 for neutroplilia = 0.49mg/kg p. o. , TI = 1.02 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

EXAMPLES The various aspects of the invention will now be described by reference to the following examples. These examples are merely illustrative and are not to be construed as a limitation of the scope of the present invention. In this section,"Intermediates"represent syntheses of intermediate compounds intended for use in the synthesis of the"Examples".

Abbreviations used herein: DMSO dimethyl sulfoxide DCM dichloromethane EtOAc ethyl acetate Et20 diethyl ether DMF dimethyl formamide MeOH methanol HPLC high pressure liquid chromatography SPE solid phase extraction NMR nuclear magnetic resonance (in which: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet, H = no. of protons) LCMS liquid chromatography/mass spectroscopy TLC thin layer chromatography BEMP 2-t-butylimino-2-diethylamino-1,3-dimethylperhydro-1, 3,2- diazaphosphazine EDC 1- (3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride HATU 0- (7-Azabenzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate HBTU 0- (Benzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate HOBT hydroxybenzotriazole = 1-hydroxybenzotriazole h hours DIPEA diisopropylethyl amine (lPr2NEt) TRET retention time THF Tetrahydrofuran Lawesson's reagent 2,4-bis (4-methoxyphenyl)-1, 3-dithia-2,4-diphosphetane-2, 4- disulphide Room temperature this is usually in the range of about 20 to about 25 °C.

Machine Methods used herein: LCMS (liquid chromatographylmass spectroscopy) Waters ZQ mass spectrometer operating in positive ion electrospray mode, mass range 100-1000 amu.

UV wavelength: 215-330nM Column: 3.3cm x 4.6mm ID, 3ßm ABZ+PLUS

Flow Rate: 3ml/min Injection Volume : all Solvent A: 95% acetonitrile + 0.05% formic acid Solvent B: 0. 1% formic acid + l OmMolar ammonium acetate Gradient: 0% A/0.7min, 0-100% A/3. 5min, 100% A/l. lmin, 100-0% 2min Mass directed autoprep HPLC The prep column used was a Supelcosil ABZplus (10cm x 2.12cm) (usually 10cm x 2.12cm x 5 Rm).

UV wavelength: 200-320nM Flow: 20ml/min Injection Volume: lml ; or more preferably 0.5 ml Solvent A: 0.1% formic acid Solvent B: 95% acetonitrile + 5% formic acid; or more usually 99.95% acetonitrile + 0.05% formic acid Gradient: 100% A/lmin, 100-80% A/9min, 80-1% A/3. 5min, 1% A/1. 4min, 1- 100% A/0. 1min Intermediates and Examples All reagents not detailed in the text below are commercially available from established suppliers such as Sigma-Aldrich. The addresses of the suppliers for some of the starting materials mentioned in the Intermediates and Examples below or the Assays above are as follows: - ABCR GmbH & CO. KG, P. O. Box 21 01 35, 76151 Karlsruhe, Germany - Aceto Color Intermediates (catalogue name), Aceto Corporation, One Hollow Lane, Lake Success, NY, 11042-1215, USA - Acros Organics, A Division of Fisher Scientific Company, 500 American Road, Morris Plains, NJ 07950, USA - Apin Chemicals Ltd. , 82 C Milton Park, Abingdon, Oxon OX14 4RY, United Kingdom - Apollo Scientific Ltd. , Unit 1A, Bingswood Industrial Estate, Whaley Bridge, Derbyshire SK23 7LY, United Kingdom - Aldrich (catalogue name), Sigma-Aldrich Company Ltd. , Dorset, United Kingdom, telephone: +44 1202 733114; Fax: +44 1202 715460; ukcustsv@eumotes. sial. com; or - Aldrich (catalogue name), Sigma-Aldrich Corp. , P. O. Box 14508, St. Louis, MO 63178-9916, USA; telephone: 314-771-5765; fax: 314-771-5757; custserv@sial. com; or - Aldrich (catalogue name), Sigma-Aldrich Chemie Gmbh, Munich, Germany; telephone: +49 89 6513 0; Fax: +49 89 6513 1169; deorders@eumotes. sial. com.

- Alfa Aesar, A Johnson Matthey Company, 30 Bond Street, Ward Hill, MA 01835-8099, USA - Amersham Biosciences UK Ltd, Pollards Wood, Chalfont St Giles, Buckinghamshire HP8 4SP, United Kingdom - Array Biopharma Inc. , 1885 33rd Street, Boulder, CO 80301, USA

- AstaTech, Inc. , 8301 Torresdale Ave., 19C, Philadelphia, PA 19136, USA - Austin Chemical Company, Inc. , 1565 Barclay Blvd. , Buffalo Grove, IL 60089, USA - Avocado Research, Shore Road, Port of Heysham Industrial Park, Heysham Lancashire LA3 2XY, United Kingdom - Bayer AG, Business Group Basic and Fine Chemicals, D-51368 Leverkusen, Germany - Berk Univar plc, Berk House, P. O. Box 56, Basing View, Basingstoke, Hants RG21 2E6, United Kingdom - Butt Park Ltd. , Braysdown Works, Peasedown St. John, Bath BA2 8LL, United Kingdom - Chemical Building Blocks (catalogue name), Ambinter, 46 quai Louis Bleriot, Paris, F-75016, France - ChemBridge Europe, 4 Clark's Hill Rise, Hampton Wood, Evesham, Worcestershire WRl l 6FW, United Kingdom - ChemService Inc., P. O. Box 3108, West Chester, PA 19381, USA - Combi-Blocks Inc. , 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA - Dynamit Nobel GmbH, Germany; also available from: Saville Whittle Ltd (UK agents of Dynamit Nobel), Vickers Street, Manchester M40 8EF, United Kingdom - E. Merck, Germany; or E. Merck (Merck Ltd), Hunter Boulevard, Magna Park, Lutterworth, Leicestershire LE17 4XN, United Kingdom - Esprit Chemical Company, Esprit Plaza, 7680 Matoaka Road, Sarasota, FL 34243, USA - Exploratory Library (catalogue name), Ambinter, 46 quai Louis Bleriot, Paris, F-75016, France - Fluka Chemie AG, Industriestrasse 25, P. O. Box 260, CH-9471 Buchs, Switzerland - Fluorochem Ltd. , Wesley Street, Old Glossop, Derbyshire SK13 7RY, United Kingdom - ICN Biomedicals, Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626, USA -Interchim Intermediates (catalogue name), Interchim, 213 Avenue Kennedy, BP 1140, Montlucon, Cedex, 03103, France - Key Organics Ltd. , 3, Highfield Indusrial Estate, Camelford, Cornwall PL32 9QZ, United Kingdom - Lancaster Synthesis Ltd. , Newgate, White Lund, Morecambe, Lancashire LA3 3DY, United Kingdom - Manchester Organics Ltd. , Unit 2, Ashville Industrial Estate, Sutton Weaver, Runcorn, Cheshire WA7 3PF, United Kingdom - Matrix Scientific, P. O. Box 25067, Columbia, SC 29224-5067, USA - Maybridge Chemical Company Ltd. , Trevillett, Tintagel, Cornwall PL34 OHW, United Kingdom - Maybridge Reactive Intermediates (catalogue name), Maybridge Chemical Company Ltd., Trevillett, Tintagel, Cornwall PL34 OHW, United Kingdom - MicroChemistry Building Blocks (catalogue name), MicroChemistry-RadaPharma, Shosse Entusiastov 56, Moscow, 111123, Russia - Miteni S. p. A. , Via Mecenate 90, Milano, 20138, Italy - Molecular Devices Corporation, Sunnydale, CA, USA - N. D. Zelinsky Institute, Organic Chemistry, Leninsky prospect 47,117913 Moscow B-334, Russia - Optimer Building Block (catalogue name), Array BioPhartna, 3200 Walnut Street, Boulder, CO 80301, USA

- Peakdale Molecular Ltd. , Peakdale Science Park, Sheffield Road, Chapel-en-le-Frith, High Peak SK23 OPG, United Kingdom - Pfaltz & Bauer, Inc. , 172 East Aurora Street, Waterbury, CT 06708, USA - Rare Chemicals (catalogue name), Rare Chemicals GmbH, Schulstrasse 6,24214 Gettorf, Germany - SALOP (catalogue name) (Sigma Aldrich Library of Rare Chemicals), Aldrich Chemical Company Inc, 1001 West Saint Paul Avenue, Milwaukee, WI 53233, USA - Sigma (catalogue name), Sigma-Aldrich Corp. , P. O. Box 14508, St. Louis, MO 63178-9916, USA; see"Aldrich"above for other non-US addresses and other contact details - SIGMA-RBI, One Strathmore Road, Natick, MA 01760-1312, USA - Synchem OHG Heinrich-Plett-Strasse 40, Kassel, D-34132, Germany - Syngene International Pvt Ltd, Hebbagodi, Hosur Road, Bangalore, India.

- TCI America, 9211 North Harborgate Street, Portland, OR 97203, USA - TimTec Building Blocks A, TimTec, Inc. , P O Box 8941, Newark, DE 19714-8941, USA - Trans World Chemicals, Inc. , 14674 Southlawn Lane, Rockville, MD 20850, USA - Ubichem PLC, Mayflower Close, Chandlers Ford Industrial Estate, Eastleigh, Hampshire S053 4AR, United Kingdom - Ultrafine (UFC Ltd. ), Synergy House, Guildhall Close, Manchester Science Park, Manchester M15 6SY, United Kingdom Table of Intermediates Inter-Name mediate Number 1 Ethyl 4-chloro-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate 2 Ethyl 4-ethoxy-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate 3 Ethyl 1-methyl-4-ethoxy-1 H-yrazolo [3,4-b] pyridine-5-carboxylate 4 Ethyl l-benzyl-4-ethoxy-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate 5 Ethyl 4-chloro-1-phenyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxylate 6 1-Acetyl-4-aminopiperidine 1-Methyl-4-aminopiperidine 8 4-Aminotetrahydropyran 8A Tetrahydro-2H-pyran-4-amine hydrochloride = 4-Aminotetrahydropyran hydrochloride 9 (R)- (+)-3-Amino tetrahydrofuran 4-toluene sulphonate 10 (S)- (-)-3-Amino tetrahydrofuran 4-toluene sulphonate 11 Tetrahydro-2H-thiopyran-4-amine 12 Tetrahydro-3-thiopheneamine 13 Tetrahydro-3-thiopheneamine 1,1-dioxide hydrochloride 14 Tetrahydro-2H-thiopyran-4-amine-1, 1-dioxide hydrochloride 15 4-Chloro-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylic acid 16 4-Chloro-1-ethyl-1 H-pyrazolo [3, 4-b] pyridine-5-carbonyl chloride 17 N-Benzyl-4-chloro-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 18 4-Chloro-l-ethyl-N- (2-ethylbutyl)-lH-pyrazolo [3, 4-b] yridine-5-carboxamide 19 4-Chloro-1-ethyl-N- (4-fluorophenyl)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 20 4-Chloro-N-cyclopentyl-1-ethyl-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 21 4-Chloro-1-ethyl-5-(pyrrolidin-1-ylcarbonyl)-lH-pyrazolo [3, 4-b] pyridine 22 4-Chloro-1-ethyl-N-(pyridin-4-ylmethyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 23 4-Chloro-1-ethyl-N-propyl-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 24 4-Chloro-1-ethyl-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 25 Ethyl 4-chloro-1-methyl-IH-pyrazolo [3,4-b] pyridine-5-carboxylate 26 4-Chloro-l-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxylic acid 27 4-Chloro-1-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carbonyl chloride 28 N-Benzyl-4-chloro-1-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 29 4-Chloro-1-methyl-N-(4-fluorophenyl)-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 30 4-Chloro-1-methyl-N-(2-ethylbutyl)-1H-pyrazolo [3,4-b] pyridine-5-carboxamide 31 4-Chloro-l-methyl-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 32 Ethyl 1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxylate 33 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5- carboxylic acid 34 Ethyl 1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-1 H-pyrazolo [3, 4-b] pyridine-5- carboxylate 35 Ethyll-ethyl-4- [ (3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 36 Ethyl 1-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridine- 5-carboxylate 37 Ethyll-ethyl-4- (tetrahydrothien-3-ylamino)-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 38 Ethyl 4-(cyclopropylamino)-l-ethyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylate 39 Ethyl 4-[(1,1-dioxidotetrahydrothien-3-yl)amino]-1-ethyl-1H-pyrazo lo [3,4- b] pyridine-5-carboxylate 40 Ethyl 4-[(1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate 41 l-Ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylic acid 42 Ethyll-ethyl-4- [ (3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylic acid 43 I-Ethyl-4- (tetrahydro-2H-thiopyran-4-ylamino)-IH-pyrazolo [3,4-b] pyridine-5- carboxylic acid 44 1-Ethyl-4- (tetrahydrothien-3-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxylic acid 45 4-(Cyclopropylamino)-1-ethyl-1H-pyrazolo[3, 4-b] pyridine-5-carboxylic acid 46 4- [ (1, 1-Dioxidotetrahydrothien-3-yl) amino]-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxylic acid 47 4- [ (1, 1-Dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxylic acid 48 Ethyl 4- (cyclohexylamino)-lH-pyrazolo [3, 4-b yridine-5-carboxylate 49 4- (Cyclohexylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxylic acid 50 1-n-Propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3, 4-b] pyridine-5- carboxylic acid 51 Ethyl 4-chloro-1-ethyl-6-methyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylate 52 4-(Cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyrid ine-5-carboxylic acid 53 1-Ethyl-6-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazo lo [3, 4-b] pyridine- 5-carboxylic acid 54 4-Aminocyclohexanone hydrochloride 76 1-Ethyl-4-f [ (lSR, 3RS)-3-hydroxycyclohexyl] amino}-lH-pyrazolo [3,4- b yridine-5-carboxylic acid

Intermediate : Ethyl 4-chloro-1-ethyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylate Prepared from commercially available 5-amino-1-ethyl pyrazole as described by G. Yu et. al. inJ. Med Chem., 2001,44, 1025-1027: Intermediate 2: Ethyl 4-ethoxy-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate Can be prepared by oxidative cleavage (SeO2) of l-furanylmethyl derivative, as described by T. M. Bare et. al. In J. Med. Chem., 1989,32, 2561-2573, (further referenced to Zuleski, F. R. , Kirkland, K. R. , Melgar, M. D.; Malbica, J Drug. Metab.

Dispos., 1985,13, 139) Intermediate 3 : Ethyl 1-methyl-4-ethoxy-lH-pyrazolo [3, 4-blpyridine-5-carboxylate

A mixture of Intermediate 2 (0.47g) and anhydrous potassium carbonate (0.83g) (previously dried by heating at 100°C) in anhydrous dimethylformamide (DMF) (4ml) was treated with iodomethane (0. 26ml) and stirred vigorously for 3h. The mixture was then filtered and the filtrate concentrated in vacuo to afford a residual oil, which was partitioned between dichloromethane (DCM) (25ml) and water (25ml). The layers were separated and the aqueous phase was extracted with further DCM (2x25ml). The combined organic extracts were dried over anhydrous sodium sulphate and evaporated to an orange solid which was applied to an SPE cartridge (silica, 20g). The cartridge was eluted sequentially with EtOAc: petrol (1: 4,1 : 2 and 1: 1), then chloroform: methanol (49: 1,19 : 1 and 9: 1). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 3 (0.165g). LCMS showed MH+= 250; TRET = 2. 59 min.

Intermediate 4: Ethyl 1-benzyl-4-ethoxy-lH-pyrazolo [3,4-b] pyridine-5-carboxylate A mixture of Intermediate 2 (0.47g) and anhydrous potassium carbonate (0.83g) (previously dried by heating at 100°C) in anhydrous DMF (4ml) was treated with benzyl bromide (0.72g) then stirred vigorously and heated at 55°C for 4. 5h. The mixture was allowed to cool, then filtered and the filtrate concentrated in vacuo to afford a residual oil, which was partitioned between DCM (25ml) and water (25ml). The layers were separated and the aqueous phase was extracted with further DCM (2x25ml). The combined organic extracts were dried over anhydrous sodium sulphate and evaporated to a yellow oily solid which was dissolved in DCM and applied to an SPE cartridge (silica, 20g). The cartridge was eluted with a gradient of EtOAc: petrol (1: 4,1 : 2 and 1: 1) then chloroform: methanol (49: 1,19 : 1 and 9: 1). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 4 (0.33g). LCMS showed MH+= 326; TE. ET = 3. 24 min.

Intermediate 5: Ethyl 4-chloro-1-phenyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate

A mixture of 5-amino-l-phenyl pyrazole (2. 0g) and diethylethoxymethylene malonate (2. 54ml) was heated under Dean Stark conditions at 120°C for 16h. The solution was cooled, phosphorus oxychloride (16ml) was then added and the mixture heated under reflux for a further 20h. Excess phosphorus oxychloride was removed in vacuo and the residue partitioned between diethyl ether and water, proceeding with extreme caution on addition of water. The ethereal layer was washed with further water, then dried over magnesium sulphate and concentrated in vacuo to afford ethyl 4-chloro-l-phenyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate (2.09g). LCMS showed MH+= 302; TRET = 3.80 min.

Intermediate 6: 1-Acetyl-4-aminopiperidine Prepared from commercially available Nl-benzyl-4-aminopiperidine as described by Yamada et. al. In WO 00/42011:

Intermediate 7: 1-Methyl-4-aminopiperidine Prepared from commercially available N-methyl-4-piperidone as described by C. M.

Anderssonet. al. inWO01/66521 :

Intermediate 8: 4-Aminotetrahydropyran Commercially available from Combi-Blocks Inc. , 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA (CAS 38041-19-9) Intermediate 8A: Tetrahydro-2H-pyran-4-amine hydrochloride = 4-Aminotetrahydropyran hydrochloride

Stepl : N, N-dibenzyltetrahydro-2H-pyran-4-amine Dibenzylamine (34. 5g) and acetic acid (6. 7ml) were added to a stirred solution of tetrahydro-4H-pyran-4-one (16. 4g, commercially available from e. g. Aldrich) in dichloromethane (260ml) at 0 °C to 5 °C. After 2. 5h at 0 °C to 5 °C, sodium triacetoxyborohydride (38.9g) was added portionwise, and the mixture was allowed to warm to room temperature. After stirring at room temperature overnight, the reaction mixture was washed successively with 2M-sodium hydroxide (200ml and 50ml), water (2 x 50ml) and brine (50ml), then dried and evaporated to give a yellow oil (45g). This oil was stirred with methanol (50ml) at 4 °C for 30min to give the product as a white solid (21. 5g). LCMS showed MH+= 282; TRET = 1.98 min.

Step 2 : Tetrahydro-2H-pyrafz-4-amirae hydrochloride N, N-dibenzyltetrahydro-2H-pyran-4-amine (20. 5g) was dissolved in ethanol (210ml) and hydrogenated over 10% palladium on carbon catalyst (4g) at 100 psi for 72h at room temperature. The reaction mixture was filtered and the filtrate was adjusted to pH 1 with 2M-hydrogen chloride in diethyl ether. Evaporation of solvents gave a solid which was triturated with diethyl ether to give the product as a white solid (9. 23g). 1H NMR (400MHz in d6-DMSO, 27°C, Spprn) 8.24 (br. s, 3H), 3.86 (dd, 12,4Hz, 2H), 3.31 (dt, 2, 12Hz, 2H), 3.20 (m, 1H), 1.84 (m, 2H), 1.55 (dq, 4, 12Hz, 2H).

Intermediate 9: (R)- (+)-3-Amino tetrahydrofuran 4-toluenesulphonate Commercially available from Fluka Chemie AG, Germany (CAS 111769-27-8) Intermediate 10: (S)- (-)-3-Amino tetrahydrofuran 4-toluenesulphonate Commercially available from E. Merck, Germany; or from E. Merck (Merck Ltd), Hunter Boulevard, Magna Park, Lutterworth, Leicestershire LE17 4XN, United Kingdom (CAS 104530-80-5)

Intermediate 11: Tetrahydro-2H-thiopyran-4-amine Prepared from commercially available tetrahydrothiopyran-4-one as described by Subramanian et. al., J ; Org Chem., 1981,46, 4376-4383. Subsequent preparation of the hydrochloride salt can be achieved by conventional means.

Intermediate 12: Tetrahydro-3-thiopheneamine Prepared in an analogous manner to Intermediate 11 from commercially available tetrahydrothiophene-4-one. The oxime formation is described by Grigg et. al. , Tetrahedron, 1991,47, 4477-4494 and the oxime reduction by Unterhalt et. al., Arch.

Pharm., 1990,317-318.

Intermediate 13 : Tetrahydro-3-thiopheneamine 1,1-dioxide hydrochloride Commercially available from Sigma Aldrich Library of Rare Chemicals (SALOR) (CAS- 6338-70-1). Preparation of the hydrochloride salt of the amine can be achieved by conventional means.

Intermediate 14 : Tetrahydro-2H-thiopyran-4-amine-1, 1-dioxide hydrochloride Prepared in an analogous manner to Intermediate 11 from commercially available tetrahydrothiophene-4-one. Oxidation to 1, l-dioxo-tetrahydro-1X6-thiopyran-4-one is described by Rule et. al., in J. Org. Chem., 1995,60, 1665-1673. Oxime formation is described by Truce et. al. , in J. Org chem., 1957,617, 620 and oxime reduction by Barkenbus et. al., J. Am. Chern. Soc., 1955,77, 3866. Subsequent preparation of the hydrochloride salt of the amine can be achieved by conventional means. p p N. OH NHZ AcOOH 1 NHZOH HZ/Raney Ni S (s o o/o o o O O O O 0 0 0/\0 o'o Intermediate 15: 4-Chloro-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylic acid

A solution of Intermediate 1 (3. 5g) in dioxane (28ml) was treated with potassium hydroxide (6.3g) as a solution in water (20ml). The mixture was stirred for 2h, then concentrated in vacuo, acidified to pH 3 with 2M aqueous hydrochloric acid and extracted with ethyl acetate. The layers were separated, the organic layer dried over sodium sulphate, then concentrated in vacuo to afford Intermediate 15 as a white solid (2.4g). LCMS showed MH+ = 226; TRET = 2.62min.

Intermediate 17: N-Benzyl-4-chloro-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide That is, Intermediate 17 is : wherein NR4R5 = Intermediate 15 (3. 5g) was dried over phosphorus pentoxide for lh, then treated with thionyl chloride (47g). The mixture was stirred and heated at 75°C for 1.3h. Excess thionyl chloride was removed in vacuo and the residual oil azeotroped with dichloromethane (DCM) to afford Intermediate 16, presumed to be the acid chloride derivative of Intermediate 15, as a white solid (3.3g).

Intermediate 16 (0. 473 g) was dissolved in tetrahydrofuran (THF) (4ml) and treated with N, N-diisopropylethylamine (DIPEA) (0. 509ml), then with benzylamine (0.209g) and the mixture stirred under nitrogen for 0. 5h. The mixture was concentrated in vacuo, then partitioned between dichloromethane and water. The layers were separated and the organics concentrated in vacuo to afford Intermediate 17 (0.574g). LCMS showed MHf =315 ; TRET=2. 90min.

Similarly prepared were the following: NR4R5 Amine reagent MH+ TRET ion (min) Intermediate 2-Ethyl-N-309 3. 07 - <o HNY 1,, 18 J butylamine Intermediate H N st3 F 4-Fluoroaniline 319 3. 08 -19 Intermediate NH Cyclopentylamine 293 2. 76 20 Intermediate Pyrrolidine 279 2. 46 21

Intermediate 22 : 4-Chloro-1-ethyl-N-(pyridin-4-ylmethyl)-lH-pyrazolo [3,4- blpyridine-5-carboxamide Acid chloride Intermediate 16 was synthesised from Intermediate 15 using the method shown above for Intermediate 17. Intermediate 16 (0. 473 g) was dissolved in THF (4ml) and treated with diisopropylethylamine (DIPEA) (0. 509ml), then with 4- (aminomethyl) pyridine (0. 211g) and the mixture stirred under nitrogen for 0. 5h. The mixture was concentrated in vacuo, then partitioned between DCM and water. The layers were separated and the organics concentrated in vacuo, then applied to an SPE cartridge (silica, lOg) which was eluted with a gradient of cyclohexane: EtOAc (2: 1 increasing stepwise up to 0: 1), followed by MeOH : EtOAc (5: 95, then 10: 90). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 22 (0.086g). LCMS showed MH+ = 316 ; TRET = 1. 84min.

Intermediate 23: 4-Chloro-1-ethyl-N-n-propyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide

Acid chloride Intermediate 16 was synthesised from Intermediate 15 using the method shown above for Intermediate 17. Intermediate 16 (0. 473 g) was dissolved in THF (4ml) and treated with DIPEA (0. 509ml), then with n-propyl amine (0. 115g) and the mixture stirred under nitrogen for 0. 5h. A further portion of n-propyl amine (0.023g) was then added and stirring continued for 18h. The mixture was concentrated in vacuo, then partitioned between DCM and water. The layers were separated and the organics concentrated in vacuo to afford Intermediate 23 (0.405g). LCMS showed MH+ = 267; TRET = 2. 54min.

Intermediate 24: 4-Chloro-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxamide Acid chloride Intermediate 16 was synthesised from Intermediate 15 using the method shown above for Intermediate 17. Intermediate 16 (0.30g) was dissolved in THF (3ml) and treated with a 0. 5M solution of ammonia in dioxane (4. 92ml). The mixture was stirred under nitrogen for 18h. A further portion of 0. 5M ammonia in dioxane (4. 92ml) was added and stirring continued for 72h. The mixture was concentrated in vacuo and the residue partitioned between DCM and 2M sodium hydroxide solution. The layers were separated and the organics concentrated to afford Intermediate 24 (0.278g). LCMS showed MH+ = 225; TRET = 2. 10min.

Intermediate 25: Ethyl 4-chloro-1-methyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylate A mixture of 5-amino-1-methyl pyrazole (4. 0g) and diethylethoxymethylene malonate (9. 16ml) was heated at 150°C under Dean Stark conditions for 5h. Phosphorous oxychloride (55ml) was carefully added to the mixture and the resulting solution heated at 130°C under reflux for 18h. The mixture was concentrated in vacuo, then the residual oil cooled in an ice bath and treated carefully with water (100ml) (caution: exotherm). The resulting mixture was extracted with DCM (3xlOOml) and the combined organic extracts were dried over anhydrous sodium sulphate and concentrated in vacuo. The residual solid was purified by Biotage chromatography (silica, 90g), eluting with Et20 : petrol (1: 3).

Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 25 (4.82g). LCMS showed MH+ = 240; TRET = 2. 98min Intermediate 26: 4-Chloro-l-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylic acid

A solution of Intermediate 25 (4. 0g) in dioxane (30ml) was treated with potassium hydroxide (7.54g) as a solution in water (20ml). The mixture was stirred for 16h, then diluted with water (150ml) and acidified to pH 3 with 5M aqueous hydrochloric acid. The mixture was stirred in an ice bath for 15min, then collected by filtration, washed with ice- cold water and dried in vacuo over phosphorous pentoxide to afford Intermediate 26 as a white solid (2.83g). LCMS showed MH+ = 212; TRET = 2. 26min.

Intermediate 28: N-Benzyl-4-chloro-1-methyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide Intermediate 28 Intermediate 26 (2. 5g) (previously dried over phosphorus pentoxide) was treated with thionyl chloride (25ml) and the mixture heated under reflux for lh. Excess thionyl chloride was removed in vacuo to afford Intermediate 27, presumed to be the acid chloride derivative of Intermediate 26, as a white solid (2.7g).

Intermediate 27 (0.68g) was dissolved in THF (10ml) and treated with DIPEA (0. 77ml), then with benzyl amine (0.339g) and the mixture stirred under nitrogen for 3h. The mixture was concentrated in vacuo, then partitioned between DCM (20ml) and water (10ml). The layers were separated and the organics concentrated in vacuo to afford Intermediate 28 (0.90g). LCMS showed MH = 301; TRET = 2.72min.

Similarly prepared were the following: NR4R5 Amine reagent MH+ ion TRET (min) Intermediate HN<F 4-Fluoroaniline 305 2. 91 29 Intermediate 2-Ethyl-N-295 2. 97 30-D, butylamine Intermediate 31 : 4-Chloro-l-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide

Acid chloride Intermediate 27 was synthesised from Intermediate 26 using the method shown above for Intermediate 28. Intermediate 27 (0. 68g) was then treated with a 0. 5M solution of ammonia in dioxane (17. 7ml). Diisopropylethylamine (0. 51ml) was then added and the mixture stirred for 21h. The mixture was then partitioned between DCM (100ml) and water (30ml). An insoluble solid was removed by filtration, washed with water (20ml) and dried in vacuo over phosphorous pentoxide to afford Intermediate 31 (0.544g). LCMS showed MH+ = 211 ; TROT = 1. 84min.

Intermediate 32 (= Example 3): Ethyl 1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxylate Intermediate 1 (0.20g) and triethylamine (0. 55ml) were suspended in ethanol (8ml) and 4- aminotetrahydropyran (0.088g) was added. The mixture was stirred under nitrogen, heated at 80°C for 16h, then concentrated in vacuo. The residue was partitioned between DCM and water. The layers were separated and the organic layer was loaded directly onto an SPE cartridge (silica, 5g) which was eluted sequentially with; (i) DCM, (ii) DCM : Et20 (2: 1), (iii) DCM: Et2O (1: 1), (iv) EtaO and (v) EtOAc. Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 32 (0. 21g). LCMS showed MH+ = 319; TRET = 2.93min.

In an alternative embodiment, Intermediate 32 (= Example 3) can be made as described below under"Example 3", in particular according to"Example 3, Method B"below.

Intermediate : 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxylic acid

A solution of Intermediate 32 (Example 3) (0. 21g) in ethanol: water (95: 5, 10ml) was treated with sodium hydroxide (0.12g). The mixture was heated at 50°C for 8h, then concentrated in vacuo, dissolved in water and acidified to pH 4 with acetic acid. The resultant white solid was removed by filtration and dried under vacuum to afford Intermediate 33 as an off-white solid (0.156g). LCMS showed MH+ = 291; TRET 2. 1 l min.

An alternative preparation of Intermediate 33 is as follows: A solution of Intermediate 32 (Example 3) (37.8g) in ethanol: water (4: 1, 375ml) was treated with sodium hydroxide (18. 9g). The mixture was heated at 50 °C for 5 hours, then concentrated in vacuo, dissolved in water and acidified to pH 2 with aqueous hydrochloric acid (2M). The resultant white solid was removed by filtration and dried under vacuum to afford Intermediate 33 as an off-white solid (29. 65g). LCMS showed MH+ = 291 ; TRET = 2. 17 min.

Intermediate 34 (= Example 8) : Ethyl 1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]- 1H-pyrazolo [3, 4-b] pyridine-5-carboxylate NHR3 N y co 2Et N NN Intermediate 34 NHR3 = HAN} C Intermediate 1 (0. 05g) and (S)-(-)-3-aminotetrahydrofuran 4-toluenesulphonate (0.052g) were suspended in ethanol (lml) and triethylamine (0. 14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 24h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM (2ml) and water (1. 5ml). The layers were separated and the organic layer concentrated to dryness. Purification was carried out using an SPE cartridge (silica, 5g), eluting with a gradient of EtOAc : cyclohexane; (1: 16 then, 1: 8,1 : 4,1 : 2, 1 : 1 and 1: 0). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 34 (= Example 8 ! (0.052g). LCMS showed MHF = 305; TRET 2. 70min.

Similarly prepared were the following : NHR3 Amine Reagent MH Tmm) ion Intermediate N" (R)- (+)-3- 305 2. 73 35 (= Example Aminotetrahydrofuran 9) 4-toluenesulphonate Intermediate HN {) S Intermediate 11 335 3. 21 36 (= Example 10) Intermediate NH hitermediate 12 321 3. 10 37 (= Example s Intermediate Cyclopropylamine 275 2. 98 38 (= Example NH 12)

Intermediate 39 (= Example 13): Ethyl 4-l (1, 1-dioxidotetrahydrothien-3-yl) amino] - 1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate NHR3 CET co2Et N NN O Intermediate 39 NHR3 = HNX °

Intermediate 1 (0. 05g) and Intermediate 13 (0.027g) were suspended in ethanol (lml) and triethylamine (0. 14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 24h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM (2ml) and water (1. 5ml). The layers were separated and the organic layer concentrated to dryness.

Purification was carried out using an SPE cartridge (silica, 5g), eluting with a gradient of EtOAc: cyclohexane; (1: 8 then 1: 4,1 : 2, 1 : 1 and 1: 0). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 39 (= Example 13 (0. 045g) as a mixture of enantiomers. LCMS showed MH+ = 353 ; TRET = 2. 60min.

Similarly prepared was the following: NHR3 Amine Reagent MH+ TRET (min) ion Intermediate e. ° Intermediate 14 367 2. 64 40 (= Example L4)

Intermediate 41 : 1-Ethyl-4-[(3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4- blpyridine-5-carboxylic acid NHR3 NXco2H N\ I N N 9 Intermediate 41 NHR3 = HNk

A solution of Intermediate 34 (0.037g) in ethanol: water (95: 5,3ml) was treated with sodium hydroxide (0.019g). The mixture was heated at 50°C for 16h, then concentrated in vacuo. The residue was dissolved in water (1. 5ml) and acidified to pH 4 with acetic acid.

The resultant white solid precipitate was removed by filtration and dried under vacuum.

The filtrate was extracted with ethyl acetate and the organic layer collected and concentrated in vacuo to afford a further portion of white solid. The two solids were combined to afford Intermediate 41 (0.033g). LCMS showed MH+ = 277; TRET = 2.05 min.

Similarly prepared were the following : NHR3 Startingmaterial MH TRET (min) l ion Intermediate (Intermediate 35 277 2. 05 42 C' Intermediate HN<s Intermediate 36 307 2. 40 43 IllternlediS Intermediate 37 293 2. 59 44 cl Intermediate/\ Intermediate 3 8 247 2. 24 45 NH Intermediate HNsCe Intermediate 39 325 2. 05 46 Intermediate <° Intennediate 40 339 2. 05 47'o Intermediate 48: Ethyl 4-(cyclohexylamino)-lH-pyrazolo [3, 4-b] pyridine-5- carboxylate

Intermediate 2 (0.69g) was suspended in cyclohexylamine (l. Olml), and the mixture was heated at 90 °C for 3h. The residual mixture was allowed to cool to room temperature and partitioned between chloroform (25ml) and water (25ml). The phases were separated and the organic phase was evaporated to dryness. The residue was triturated with Et2O (25ml) and the insoluble solid was collected and dried to afford Intermediate 48 as a beige solid (0.58g). LCMS showed MH+=289 ; TRET = 2. 91min.

Intermediate 49: 4- (Cyclohexylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxylic acid

2M-Sodium hydroxide solution (0. 5ml) was added to a stirred suspension of Intermediate 48 (0.2g) in dioxan (4ml) and water (0. 5ml). After stirring overnight at room temperature, the reaction mixture was heated at 40 °C for 8h. A further quantity of 2M-sodium hydroxide solution (1. 5ml) was added, and the reaction mixture was heated at 40 °C for 48h. The reaction solution was concentrated, diluted with water (lOml) and acidified with glacial acetic acid. The resulting precipitate was collected by filtration, washed with water and dried to give Intermediate 49 (0.18g). LCMS showed MH+ = 261 ; TRET 2. 09min.

Intermediate 50: 1-n-Propyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylic acid 2M-Sodium hydroxide solution (0. 7ml) was added to a stirred suspension of Example 185 (0.23g, described hereinafter) in ethanol (5ml) and water (1. 5ml). After stirring overnight at room temperature, a further quantity of 2M-sodium hydroxide solution (0. 7ml) was added, and the reaction mixture was heated at 43 °C for 2. 5h. The reaction solution was concentrated, diluted with water (5ml) and acidified with 2M-hydrochloric acid. The resulting precipitate was collected by filtration, washed with water and dried to give Intermediate 50 as a white solid (0.14g). LCMS showed MH+ = 305 ; TRET = 2. 42min.

Intermediate 51: Ethyl 4-chloro-1-ethyl-6-methyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxylate

A mixture of 5-amino-1-ethylpyrazole (1.614g, 14. 5mmol) and diethyl 2- (1- ethoxyethylidene) malonate (3.68g, 16. 0mmol, as described by P. P. T. Sah, J Amer.

Chem. Soc., 1931,53, 1836) was heated at 150 °C under Dean Stark conditions for 5 hours. Phosphorous oxychloride (25ml) was carefully added to the mixture and the resulting solution was heated at 130 °C under reflux for 18 hours. The mixture was concentrated in vacuo, then the residual oil was carefully added, with cooling, to water (100ml). The resulting mixture was extracted with DCM (3xlOOml) and the combined organic extracts were dried over anhydrous sodium sulphate and concentrated in vacuo.

The residual oil was purified by Biotage chromatography (silica, 90g) eluting with ethyl acetate-petrol (1: 19). Fractions containing the desired product were combined and concentrated in vacuo to afford Intermediate 51 (1.15g). LCMS showed MH+ = 268; TRET = 3. 18min.

Intermediate 52: 4-(Cyclohexylamino)-1-ethyl-6-methyl-lH-pyrazolo [3,4- b] pyridine-5-carboxylic acid 2M-Sodium hydroxide solution (0. 39ml, 0. 78mmol) was added to Example 190 (0.128g, 0.39mmol, described hereinafter) in ethanol (1. 5ml), and the mixture was heated at 50 °C for 16 hours. The reaction mixture was concentrated, and the resulting aqueous solution was neutralised with 2M-hydrochloric acid to precipitate a solid which was collected by filtration. The filtrate was applied to an OASIS (E) hydrophilic-lipophilic balance (HLB) Extraction cartridge * (lg) which was eluted with water followed by methanol.

Evaporation of the methanol fraction gave a solid which was combined with the initial precipitated solid to afford Intermediate 52 (0.083g) as a white solid, presumed to be the carboxylic acid.

* OASIS @ HLB Extraction cartridges are available from Waters Corporation, 34 Maple Street, Milord, MA 01757, USA. The cartridges include a column containing a

copolymer sorbent having a HLB such that when an aqueous solution is eluted through the column, the solute is absorbed or adsorbed into or onto the sorbent, and such that when organic solvent (e. g. methanol) is eluted the solute is released as an organic (e. g. methanol) solution. This is a way to separate the solute from aqueous solvent. Intermediate 53: 1-Ethyl-6-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylic acid

2M-Sodium hydroxide solution (0. 75ml, 1. 5mmol) was added to Example 189 (0.248g, 0. 75mmol, described hereinafter) in ethanol (2ml), and the mixture was heated at reflux for 16 hours. The reaction mixture was concentrated, diluted with water (lml) and acidified with 2M-hydrochloric acid (0. 75ml) to precipitate a solid which was collected by filtration to afford Intermediate 53 (0.168g). LCMS showed MH+ = 305; TRET = 1. 86min.

Intermediate 54: 4-Aminocyclohexanone hydrochloride

A solution of hydrogen chloride in dioxan (0. 5ml, 2. 0mmol, 4M) was added to a stirred solution of n-butyl 4-oxocyclohexylcarbamate (0.043g, 0. 20mmol, commercially available from Astatech Inc., Philadelphia, USA) in dioxan (0. 5ml) and the mixture was stirred at room temperature. After lh, the reaction mixture was evaporated to give Intermediate 54 as a cream solid (34mg). 1H NMR (400MHz in d6-DMSO, 27°C, 5ppm) 8.09 (br. s, 3H), 3.51 (tt, 11,3. 5Hz, 1H), 2.45 (m, 2H, partially obscured), 2.29 (m, 2H), 2.16 (m, 2H), 1.76 (m, 2H).

Intermediate 54A: N-Benzyl-4- (cyclohexylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide Benzylamine (0. 16ml) was added to a stirred mixture of Intermediate 49 (0. 13g), DIPEA (0. 26ml) and HATU (0.285g) in DMF (3ml). The resultant mixture was heated with stirring at 85 °C for 16 hours. Further portions of HATU (0.14g), DIPEA (0. 13ml) and benzylamine (0. 082ml) were added and the mixture heated for 16 hours at 88 °C. The resultant solution was concentrated, diluted with dichloromethane (20ml) and washed with saturated sodium bicarbonate solution (20ml), separated by hydrophobic frit and the organic layer concentrated. The residue was purified on a SPE cartridge (silica, 20g) eluting with 60-80% ethyl acetate in cyclohexane. The residue was purified further on a SPE cartridge (Isolute SCX sulphonic acid cartridge, 5g x2), eluting with methanol (2x20ml) and 10% ammonia in methanol (4x20ml) ; the basic fractions were combined and concentrated to give Intermediate 54A as a white solid (0.07g). LCMS showed MH+ = 350; TUT = 2.99min.

Intermediate 55: 4-Chloro-1-ethyl-N- { [4-(methyloxy) phenyl] methyl}-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide That is, intermediate 55 is: Where Intermediate 15 (1.04g) was treated with thionyl chloride (13.22g). The mixture was stirred and heated at 75 °C for 2h. Excess thionyl chloride was removed in vacuo and the residual oil azeotroped with toluene to afford Intermediate 16, presumed to be the acid chloride derivative of intermediate 15, as a cream solid (1. 12g).

Intermediate 16 (0.997g) was dissolved in tetrahydrofuran (THF) (25ml) and treated with N, N-diisopropylethylamine (1. 07ml) then with 1- [4- (methyloxy) phenyl] methanamine = 4-methoxybenzylamine (0. 54ml) (obtainable from e. g. Aldrich, Acros, or Tetrahedron Lett., 2002,43 (48), 8735; or Meindl et al., J. Med. Chem., 1984,27 (9), 1111; or Organic Letters, 2002,4 (12), 2055) and the mixture was stirred for 3h. The solution was concentrated in vacuo, then partitioned between DCM and water. The layers were separated and the organics concentrated in vacuo. The solid was then triturated in 1: 1 ethyl acetate: cyclohexane to give Intermediate 55 (1.27g). LCMS showed MH+-345, TRET= 2.86 min.

Similarly prepared were the following: NR4R5 Source of MH'-ion TRET (min) HIER' Intermediate 56 HN/\ N Lis et al., J. Med. 408 2. 60 N Cliem., 1990, 00 33 (10), 2883, see Scheme III and ref. 24 Maybridge-Int ; 341 3. 08 or Aldrich ; or TCI-America Intermediate 58: 1-Ethyl-4- [ (4-oxocyclohexyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxylic acid

A solution of sodium hydroxide (0.053g, 1. 32mmol) in water (0. 41ml) was added to a stirred solution of 205 (O. lg, 0. 303mmol) in ethanol (lml), and the resulting mixture was heated at 50°C. After lh, the cooled reaction mixture was adjusted to pH3 with 2M hydrochloric acid, and extracted with EtOAc (2 x 6ml). The combined organic extracts were dried (Na2S04) and evaporated to give Intermediate 58 (0.072g) as a white solid. LCMS showed MH+ = 303 ; TpET = 2. 13min.

An alternative preparation of Intermediate 58 is as follows: A solution of sodium hydroxide (0.792g, 19. 8mmol) in water (6ml) was added to a stirred solution of Example 205 (1.487g, 4. 5mmol) in ethanol (15ml), and the resulting mixture was heated at 50°C. After 1 hour, the cooled reaction mixture was adjusted to pH4 with 2M hydrochloric acid, and extracted with EtOAc (3 x 30ml). The combined organic extracts were dried (Na2SO4) and evaporated to give Intermediate 58 (1.188g) as a white solid. LCMS showed MHA = 303; TRET = 2. 12min.

Intermediate 58A: Ethyl 1-ethyl-4-(tetrahydro-2H-pyran-3-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate Intermediate 1 (0.76g, 3. 0mmol)) was dissolved in acetonitrile (10ml). Tetrahydro-2H- pyran-3-amine hydrochloride (0. 5g, 3.6mmol, ilnales De Quimica, 1988,84, 148) and N, N-diisopropylethylamine (3. 14ml, 18. 0mmol) were added and the mixture was stirred at 85°C for 24h. After 24h a further portion of tetrahydro-2H-pyran-3-amine hydrochloride (0.14g, 1. 02mmol) was added stirring was continued at 85°C. After a further 8h, the mixture was concentrated in vacuo. The residue was partitioned between DCM (20ml) and water (12ml). The layers were separated and the aqueous layer was extracted with further DCM (12ml). The combined organic extracts were dried (Na2S04), and concentrated in vacuo to give a brown solid which was purified on a SPE cartridge (silica, 20g) eluting with a gradient of ethyl acetate: cyclohexane (1: 16,1 : 8,1 : 4,1 : 2,1 : 1, 1: 0). Fractions containing the desired material were combined and evaporated to afford Intermediate 58A (0.89g). LCMS showed MH+ = 319 ; TRET = 2.92 min.

Intermediate 59: 1-Ethyl-4-(tetrahydro-2H-pyran-3-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxylic acid

A solution of Intermediate 58A (0. 89g, 2.79mmol) in ethanol (16.7ml) was treated with sodium hydroxide (0.47g, 11. 7mmol) as a solution in water (3. 1 ml). The mixture was stirred at 50 °C. After 12h, the reaction mixture was concentrated in vacuo to give a residual oil which was dissolved in water (16ml), then cooled and acidified to pH 3 with 2M hydrochloric acid. After stirring at 0°C for 30min, the resulting precipitate was collected by filtration, washed with cooled water (2ml) and dried in vacuo to afford Intermediate 59 as a white solid (0.73g). LCMS showed MH+ = 291 ; tut = 2. 19min.

Intermediate 60: 4- [ (1-Acetyl-4-piperidinyl) amino]-1-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxylic acid Aqueous sodium hydroxide solution (8. 55ml, 2M) was added to a solution of Example 207 (1. 55g) in EtOH (13ml). The mixture was heated at 50 °C for 18h then neutralised using aqueous hydrochloric acid and evaporated in vacuo to afford a mixture of 1-ethyl- 4- (4-piperidinylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxylic acid and 4- [ (l-acetyl-4- piperidinyl) amino]-l-ethyl-177-pyrazolo [3, 4-b] pyridine-5-carboxylic acid Acetic acid (0. 36ml) was added to a stirred mixture of HATU (2. 41g) and N, N- diisopropylethylamine (2. 21ml) in N, N-dimethylfonnamide (65ml). After stirring for 15 min the mixture was added to the mixture of 1-ethyl-4- (4-piperidinylamino)-1H pyrazolo [3, 4-b] pyridine-5-carboxylic acid and 4- [ (1-acetyl-4-piperidinyl) amino]-1-ethyl- 1H pyrazolo [3, 4-b] pyridine-5-carboxylic acid and the reaction stirred for 15h. The reaction mixture was evaporated in vacuo and the residue purified by chromatography

using Biotage (silica 90g) eluting with DCM: MeOH (0%-5% MeOH) to afford Intermediate 60 (1.36g) as a white solid. LCMS showed MH+ 334; TRET= 2.06 min.

Intermediate 61: 4-(CycloheXylamino)-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxylic acid

A solution of Example 2 (5.37g, 17mmol) in ethanol (30ml) was treated with a solution of sodium hydroxide (2.72g, 68mmol) in water (20ml), and the resulting mixture was stirred at 50°C for 3h. The reaction mixture was concentrated in vacuo, dissolved in water (250ml) and the cooled solution was acidified to pH 1 with 5M-hydrochloric acid. The resultant solid was collected by filtration and dried in vacuo to afford Intermediate 61 as a white solid (4.7g). LCMS showed MH+ = 289; TRET = 2. 83min.

Intermediate 62: Dimethylethyl (4, 4-difluorocyclohexyl) carbamate

(Diethylamino) sulphur trifluoride (DAST), (0. 06ml, 0. 47mmol), was added to a stirred solution of l, l-dimethylethyl (4-oxocyclohexyl) carbamate, (250mg, 1. 17mmol, commercially available from AstaTech Inc., Philadelphia, USA) in anhydrous dichloromethane (5ml) and the mixture was stirred under nitrogen at 20°C. After 22h, the reaction mixture was cooled to 0°C, treated with saturated sodium hydrogen carbonate solution (4ml), and then allowed to warm to ambient temperature. The phases were separated by passage through a hydrophobic frit and the aqueous phase was further extracted with DCM (5ml). The combined organic phases were concentrated in vacuo to give an orange solid (369mg) which was further purified by chromatography using a SPE cartridge (silica, lOg), eluting with DCM to afford Intermediate 62 (140mg) containing

20% of 1,1-dimethylethyl (4-fluoro-3-cyclohexen-1-yl) carbamate. 1H NMR (400MHz in CDC13, 27°C, bppm) Minor component : 85. 11 (dm, 16Hz, 1H), 4.56 (br, 1H), 3.80 (br, 1H) 2.45-1. 45 (m's, 6H excess), 1.43 (s, 9H). Major component: 84. 43 (br, 1H), 3.58 (br, 1H), 2.45-1. 45 (m's, 8H excess), 1.45 (s, 9H).

Intermediate 63: (4, 4-Difluorocyclohexyl) amine hydrochloride A solution of hydrogen chloride in dioxane (4M, 1. 6ml) was added at 20°C to a stirred solution of Intermediate 62 (140mg, 0.6mmol), in dioxane (1. 6ml). After 3h, the reaction mixture was concentrated in vacuo to afford intermediate 63 (96. 5mg) containing 4- Jluoro-3-cyclohexen-1-amine. lH NMR (400MHz in d6-DMSO, 27°C, bppm) Minor component: 68. 22 (br, 3H excess), 5.18 (dm, 16Hz, 1H), 3.28-3. 13 (m, 1H excess), 2.41- 1.53 (m's, 6H excess). Major component: 58. 22 (br, 3H excess), 3.28-3. 13 (m, 1H excess), 2.41-1. 53 (m's, 8H excess). Impurities are also present.

Intermediate 64: 4-Chloro-1-ethyl-N-methyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide Intermediate 15 (0.06g, 0. 266mmol) was treated with thionyl chloride (0. 48ml). The mixture was stirred and heated at 75°C for 2h. Excess thionyl chloride was removed in vacuo and the residual oil azeotroped with dichloromethane (DCM) to afford Intermediate 16, presumed to be the acid chloride derivative of Intermediate 15, as a white solid. Intermediate 16 was dissolved in anhydrous tetrahydrofuran (THF) (2ml) and treated with N, N-diisopropylethylamine (DIPEA) (0. 069ml), then with methylamine (2M in tetrahydrofuran, 0. 15ml) and the mixture stirred under nitrogen for 16h. A further 0. 05ml of methylamine (2M in THF) was added and the solution stirred for 2h. The mixture was concentrated in vacuo, then partitioned between dichloromethane (2ml) and aqueous sodium hydroxide solution (2M, 2ml), then the organic layer washed with water (2ml). The layers were separated and the organics concentrated in vacuo to afford Intermediate 64 (0.052g). LCMS showed MH+ = 239; TRET = 2. 17min.

Intermediate 65: Ethyl 4- [ (l- { [ (l, l-dimethylethyl) oxy] carbonyl}-4- piperidinyl) amino]-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate

A mixture of Intermediate 17 (2. 0g, 6.37mmol), 1, 1-dimethylethyl 4-amino-1- piperidinecarboxylate (2.04g, 10. 2mmol) and N, N,-diisopropylethylamine (5. 54ml, 31. 9mmol) in MeCN (40ml) was heated at 85 °C for 42h. The reaction was evaporated and the residues partitioned between DCM and water. The organic phase was dried (MgS04) then evaporated in vacuo. The residue was chromatographed on silica (Biotage, 90g) eluting with cyclohexane: EtOAc (1: 1) to give Intermediate 65 as a white solid (2.70g). LCMS showed MH+ = 479; TRET = 3. 37min.

Intermediate 67: 3-Amino-N-cyclohexyl-N-methylbenzamide A solution of 3-nitrobenzoyl chloride (2. 0g, 10. 78mmol) in DCM (20ml) was added dropwise to a stirred mixture of N-methylcyclohexylamine (1. 83ml, 14. Olmmol), N, N,- diisopropylethylamine (3. 76ml, 21. 56mmol) and N, N-dimethylaminopyridine (O. Olg) in DCM at 20 °C. The reaction mixture was stirred for 56h then evaporated in vacuo. The residue was partitioned between ethyl acetate and water. The organic phase was washed with aqueous HC1 then dried (MgS04) and evaporated in vacuo. The residue was purified by chromatography on silica eluting with cyclohexane: EtOAc (9: 1 followed by 2: 1) to afford N-cyclohexyl-N-methyl-3-nitrobenzamide (1.40g). MS showed MH+ 263.

A mixture of N-Cyclohexyl-N-methyl-3-nitrobenzamide (1.40g, 5. 35mmol) and palladium on carbon (5%, 0.140g) in ethanol (10ml) was stirred under an atmosphere of hydrogen forl hour. The reaction mixture was filtered through Celite and the filtrate evaporated to afford Intermediate 67 as a brown solid (0.107g). LCMS showed MH+ = 233; TRET = 2. 56min.

Intermediate 68: N-Ethyl-4-oxo-1-piperidinecarboxamide

A solution of ethyl isocyanate (2. 31g, 32. 5mmol) in DCM (40ml) was added, dropwise over 15min, to a vigorously stirred solution of 4-piperidone monohydrate hydrochloride (5. 0g, 32. 5mmol, commercially available from Aldrich) and sodium hydrogen carbonate (8.2g, 97. 5mmol) in water (60ml) at 0°C. The reaction mixture was stirred at room temperature for 20h. Sodium chloride (7. 0g) was added to the reaction mixture and the organic phase was separated. The aqueous phase was extracted with further DCM (3 x 75ml). The combined organic extracts were dried (Na2S04) and evaporated in vacuo to give a white solid (4. 0g). Recrystallisation from ethyl acetate: cyclohexane (10: 1) afforded Intermediate 68 as a white solid (2.3g).

TLC (silica) gave Rf = 0.24 (ethyl acetate). Anal. Found: C, 56.7 ; H, 8.3 ; N, 16.35.

C8Hl4N202 requires C, 56. 5 ; H, 8.3 ; N, 16.5.

Intermediate 69: 4-Amino-N-ethyl-1-piperidinecarboxamide

A solution of Intermediate 68 (1. 5g, 8. 8mmol) and benzylamine (1.04g, 9. 7mmol) in absolute ethanol (60ml) was hydrogenated over pre-reduced 10% palladium on charcoal catalyst (0.6g) in ethanol (20ml) until the uptake of hydrogen had ceased (22h). The reaction mixture was filtered through filter agent (Celite), and then through silica gel (100ml) eluting with ethanol : 0. 88-ammonia (100: 1) to give a black oil. The oil was dissolved in ethanol (30ml) and treated with a solution of hydrogen chloride in ethanol (3M) until the solution was acidic. The solvent was evaporated and the residue was triturated with ethanol to afford Intermediate 69 as a white solid (1.09g).

TLC (silica) gave Rf= 0.73 (ethyl acetate: methanol, 10: 1). Anal. Found: C, 45.9 ; H, 8.4 ; N, 19. 8. CsHlgClN30 requires C, 46.3 ; H, 8.7 ; N, 20.2.

Intermediate 70: 1, 1-Dimethylethyl ({4- [(cyclopropylamino) carbonyl] phenyl} methyl) carbamate Cyclopropylamine (0.136g, 2. 39mmol) and diisopropylethylamine (0. 68ml, 3. 9mmol) were added to a stirred solution of 4-[({[(1,1-dimethylethyl) oxy] carbonyl} amino)- methyl] benzoic acid (0. 501g, 2. 0mmol), EDC (0.612g, 3.2mmol) and HOBT (0.35g, 2.6mmol) in DMF (2ml). The resulting mixture was stirred at room temperature overnight. Solvents were removed in vacuo, and the residue was dissolved in ethyl acetate (20ml) and washed with 0. 5M-hydrochloric acid (3 x 20ml). The organic phase was dried (Na2S04) and evaporated in vacuo to give the crude product which was purified by Biotage chromatography (silica) eluting with ethyl acetate: cyclohexane (1.3 : 1) to afford Intermediate 70 as a white solid (0.512g). LCMS showed MH+ = 291 ; TRET = 2.75min.

Intermediate 71: 4-(Aminomethyl)-N-cyclopropylbenzamide hydrochloride

Intermediate 70 (0.506g, 1. 74mmol) was dissolved in a solution of hydrogen chloride in dioxan (20ml, 4M) under nitrogen. After lh, methanol (3ml) was added to the mixture and stirring was continued at room temperature overnight. Solvents were removed in vacuo to afford Intermediate 71 as a white solid (0. 416g). LCMS showed MH+ = 191 ; TRET = 0. 82min.

Intermediate 72 Intermediate 33 (1.36g, 4. 7mmol), EDC (1.26g, 6.57mmol) and HOBT (0.76g, 5. 62mmol) were suspended in DMF (50ml) and stirred vigorously at room temperature for 0. 5h, before adding 1, 1-dimethylethyl 4- (aminomethyl)-l-piperidinecarboxylate (1.3g, 6.07mmol, commercially available from Maybridge Chemical Co. Ltd. ,). After stirring at room temperature overnight, a further quantity of 1, 1-dimethylethyl 4- (aminomethyl)-l-piperidinecarboxylate (l. Olg, 4. 7mmol) was added to the reaction mixture which was then heated at 50°C. After 6h, diisopropylethylamine (0. 25ml, 1.44mmol) was added, and the mixture was maintained at 50°C for a further 6h. Solvents were removed in vacuo and the residue was partitioned between DCM (100ml) and water (100ml). The phases were separated by passage through a hydrophobic frit, and the organic phase was evaporated in vacuo to give the crude product. Further purification using SPE cartridges (aminopropyl followed by silica) afford Intermediate 72 as a cream solid (1.24g). LCMS showed MH+ = 487; TRET = 2. 97min.

Intermediate 73 Intermediate 73 is used in situ in the general procedure for Examples 360-414.

Intermediate 74 : 1, 1-Dimethylethyl ({3- [ (acetylamino) methyl] phenyl} methyl) carbamate

Acetic anhydride (0. 52ml, 5. 5mmol) was added to a mixture of tert-butyl N [3- aminomethyl) benzyl] carbamate (l. lg, 4. 65mmol commercially available from Astatech) and triethylamine (0. 7ml, 5mmol) in THF (20ml). The reaction mixture was stirred at 20 °C from 16h then concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic phase was dried (MgS04) and evaporated in vacuo. The residue was chromatographed over silica eluting with hexanes: EtOAc (1: 1) followed by EtOAc to afford Intermediate 74 (1.2g) as a colourless oil. Anal. Found: C, 64.79 ; H, 7.93 ; N, 10.10. C15H22N203 requires C, 64.73 ; H, 7.97 ; N, 10.06. MS (M+Na) + 301.

Intermediate 75 : N-{[3-(Aminomethyl) phenyl] methyl} acetamide hydrochloride Hydrogen chloride in dioxane (4ml, 4M) was added to a solution of Intermediate 74 (1. Og, 3.6mmol) in dioxane (10ml) and the resultant mixture stirred for 6 hours at 20 °C.

The reaction was diluted with Et20 (20ml) and filtered to afford Intermediate 75 (0.7g) as a white solid. MS MH+ 179. 1H NMR (300MHz in d6-DMSO, 27°C, bppm) 8 8.6-8. 4 (br m, 3H), 7.38-7. 26 (m, 3H), 7.22 (bm, 1H), 4.24 (d, J = 5.7Hz, 2H), 3.95 (dd, J = 11. 6,5. 7Hz, 2H), 1.87 (s, 3H).

Intermediate76 1-Ethyl-4-{[(1fR, 3RS)-3-hydroxycyclohexyl] amino}-lH- pyrazolo [3, 4-b] pyridine-5-carboxylic acid (cis-3-hydroxycyclohex-1-ylamino group, racemic) A solution of Example 665 (0. 681 g, 2. 05mmol) in ethanol (7ml) was treated with a solution of sodium hydroxide (0.362g, 9. 05mmol) in water (2. 9ml). The resulting mixture was stirred at 50°C. After 3h, the reaction mixture was concentrated in vacuo to give a residual oil which was dissolved in water (3ml), then cooled and acidified to pH 3 with 2M-hydrochloric acid. After stirring at 0°C for lh, the resulting precipitate was collected by filtration, washed with cooled water (0. 5ml) and dried in vacuo to afford Intermediate 76 as a white solid (0. 491g). LCMS showed MH+ = 305; TRET = 2. 14min.

Table of Examples Example Name Number 1 Ethyl 4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-ca rboxylate 2 Ethyl4- (cyclohexylamino)-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxylate 3 Ethyl 1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridine-5- carboxylate 5 Ethyl 4-[(1-acetylpiperidin-4-yl) amino]-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 6 Ethyl 4-(cyclopentylamino)-1-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate 7 Ethyll-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 8 Ethyll-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 9 Ethyll-ethyl-4- [ (3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 10 Ethyl 1-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine- 5-carboxylate 11 Ethyl 1-ethyl-4- (tetrahydrothien-3-ylamino)-IH-pyrazolo [3, 4-b] pyridine-5- carboxylate 12 Ethyl 4-(cyclopropylamino)-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate 13 Ethyl 4- [ (1, 1-dioxidotetrahydrothien-3-yl) amino]-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxylate 14 Ethyl 4- [ (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate 21 N-Benzyl-l-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazo lo [3,4- b] pyridine-5-carboxamide 22 1-Ethyl-N- (4-fluorophenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide 23 N-Cyclopentyl-4- (cyclopentylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 24 4- (Cyclohexylamino)-N-cyclopentyl-1-ethyl-1 H-pyrazolo [3, 4-b] pyridine-5- carboxamide 25 N-Cyclopentyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b]pyridine-5-carboxamide 27 4- [ (1-Acetylpiperidin-4-yl) amino]-N-cyclopentyl-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 28 N-Cyclopentyl-1-ethyl-5- (pyrrolidin-1-ylcarbonyl)-IH-pyrazolo [3,4-b] pyridin-4- amine 29 N-Cyclohexyl-l-ethyl-5-(pyrrolidin-l-ylcarbonyl)-lH-pyrazolo [3,4-b] pyridin-4- amine 30 1-Ethyl-5-(pyrrolidin-1-ylcarbonyl)-N-tetrahydro-2H-pyran-4- yl-1 H-pyrazolo [3, 4- b] pyridin-4-amine 31 4-(Cyclopentylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-lH-pyraz olo [3,4- b] pyridine-5-carboxamide 32 4-(Cyclohexylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-1 H-pyrazolo [3, 4-b] pyridine- 5-carboxamide 33 1-Ethyl-N-(pyridin-4-ylethyl)-4-(tetrahydro-2H-pyran-4-ylami no)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 34 4-(Cyclopentylamino)-1-ethyl-lH-pyrazolo [3, 4-b]pyridine-5-carboxamide 35 4-(Cyclohexylamino)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 36 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide 39 N-Benzyl-4- (cyclopentylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 40 N-Benzyl-4- (cyclohexylamino)-1-ethyl-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide 41 4-[(1-Acetylpiperidin-4-yl) amino]-N-benzyl-1-ethyl-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 42 4-(Cyclopentylamino)-1-ethyl-N-(2-ethylbutyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 43 4-(Cyclohexylamino)-1-ethyl-N-(2-ethylbutyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 44 1-Ethyl-N-(2-ethylbutyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 45 1-Ethyl-N-(2-ethylbutyl)-4-[(1-methylpiperidin-4-yl)amino]-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 46 4-[(1-Acetylpiperidin-4-yl)amino]-1-ethyl-N-(2-ethylbutyl)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 47 4- (Cyclopentylamino)-1-ethyl-N- (4-fluorophenyl)-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide 48 4-(Cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3 , 4-b] pyridine-5- carboxamide 49 1-Ethyl-N- (4-fluorophenyl)-4- [ ( 1-methylpiperidin-4-yl) amino]-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 50 4-[(1-Acetylpiperidin-4-yl)amino]-1-ethyl-N-(4-fluorophenyl) -1H-pyrazolo [3,4- b] pyridine-5-carboxamide 51 4-(Cyclopentylaino)-1-ethy1-N-n-propyl-1H-pyrazolo [3,4-b] pyridine-5- carboxamide 52 4- (Cyclohexylamino)-1-ethyl-N-n-propyl-1H-pyrazolo [3,4-b] pyridine-5- carboxamide 53 1-Ethyl-N-n-propyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 55 4- [ (1-Acetylpiperidin-4-yl) amino]-1-ethyl-N-n-propyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 57 4- [ (l-Acetylpiperidin-4-yl) amino]-l-ethyl-N- (pyridin-4-ylmethyl)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 61 N-Benzyl-4-(cyclopentylamino-1-methyl-1H-pyrazolo[3, 4-b] pyridine-5- carboxamide 62 N-Benzyl-4-(cyclohexylamino)-1-methyl-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide 63 N-Benzyl-l-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 64 4-(Cyclopentylamino)-N-(2-ethylbutyl)-1-methyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide 65 4-(Cyclohexylamino)-N-(2-ethylbutyl)-1-methyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 66 N- (2-Ethylbutyl)-1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 67 4- (Cyclopentylamino)-N- (4-fluorophenyl)-l-methyl-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 68 4-(Cyclohexylamino)-N-(4-fluorophenyl)-1-methyl-1H-pyrazolo[ 3, 4-b] pyridine-5- carboxamide 69 N- (4-Fluorophenyl)-1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 70 4-(Cyclopentylamino)-1-methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 71 4-(Cyclohexylamino)-1-methyl-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 74 4-[(1-Acetylpiperidin-4-yl) amino]-N-benzyl-1-methyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 81 1-Ethyl-N-methyl-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazol o [3,4- b] pyridine-5-carboxamide 82 1-Ethyl-N, N-dimethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 83 1-Ethyl-N-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine- 5-carboxamide 84 1-Ethyl-N-isopropyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 85 N-Benzyl-1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 86 N-Benzyl-l-ethyl-4- [ (3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 87 N-Benzyl-I-ethyl-4-(tetrahydrothien-3-ylamino)-1 H-pyrazolo [3, 4-bXpyridine-5- carboxamide 88 N-Benzyl-4-(cyclopropylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 89 N-Benzyl-4- [ (1, 1-dioxidotetrahydrothien-3-yl) amino]-1-ethyl-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 90 N-Benzyl-4- [ (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-1H- pyrazolo[3,4-b]pyridine-5-carboxamide 91 N-Benzyl-1-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-1H-py razolo[3,4- b] pyridine-5-carboxamide 92 1-Ethyl-N-(4-fluorophenyl)-4-[(3S)-tetrahydrofuran-3-ylamino ]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 93 1-Ethyl-N- (4-fluorophenyl)-4- [ (3R)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 94 1-Ethyl-N- (4-fluorophenyl)-4- (tetrahydro-2H-thiopyran-4-ylamino)-1H- pyrazolo [3, 4-b pyridine-5-carboxamide 95 1-Ethyl-N-(4-fluorophenyl)-4-(tetrahydrofuran-3-ylamino)-1H- pyrazolo[3, 4- b] pyridine-5-carboxamide 96 4-(Cyclopropylamino)-1-ethyl-N-(4-fluorophenyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 97 4- [ (1, 1-Dioxidotetrahydrothien-3-yl) amino]-1-ethyl-N- (4-fluorophenyl)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 98 4- [ (l, 1-Dioxidotetrahydro-2H-thiopyran-4-yl) amino]-1-ethyl-N- (4-fluorophenyl)- lH-pyrazolo [3,4-b] pyridine-5-carboxamide Example No. Name 100 1-Ethyl-N-[4-(methylsulfony)benzyl]-4-(tetrahydro-2H-pyran-4 - ylamino)-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 102 1-Ethyl-N-[3-(methylsulfonyl) benzyl]-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 103 1-Ethyl-5-{[5-methoxy-6-(trifluoromethyl)-2,3-dihydro-1H-ind ol-1- yl] carbonyl}-N-tetrahydro-2H-pyran-4-yl-lH-pyrazolo [3, 4-b] pyridin-4- amine 104 N-[(5-Chloropyridin-2-yl)methyl]-1-ethyl-4-(tetrahydro-2H-py ran-4- ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 105 N-(4-Chlorobenzyl)-1-ethyl-N-isopropyl-4-(tetrahydro-2H-pyra n-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 106 N-(3-Chlorobenzyl)-1-ethyl-N-(2-hydroxyethyl)-4-(tetrahydro- 2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 107 1-Ethyl-N-[(5-methyl-3-phenylisoxazol-4-yl)methyl]-4-(tetrah ydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 108 N-(2-tert-Butoxyethyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo 3, 4-b] pyridine-5-carboxamide 109 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(1, 3-thiazol-2-ylmethyl) - 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 110 1-Ethyl-N-@yrimidin-4-ylmethyl)-4-(tetrahydro-2H-pyran-4-yla mino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 111 1-Ethyl-N-[(2-methyl-1, 3-thiazol-4-yl) methyl]-4(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 112 N-[3-(tert-Butoxymethyl)benzyl]-1-ethyl-4-(tetrahydro-2H-pyr an-4- ylamino)-1H-pyrazolo [3, 4-b] yridine-5-carboxamide 113 1-Ethyl-N {2-[methyl (methylsulfonyl) amino] ethyl}-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 114 1-Ethyl-N-(pyrazin-2-ylmethyl)-4-(tetrahydro-2H-pyran-4-ylam ino)-1H- pyrazolo[3,4-b]pyridine-5-carboxamide 115 1-Ethyl-5-{[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]carbonyl} -N- tetrahydro-2H-pyran-4-yl-lH-pyrazolo [3, 4-b yridin-4-amine 116 N-(2-Chloro-6-fluorobenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4 - ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 117 1-Ethyl-N-[(6-oxo-1,6-dihydropyridin-3-yl)methyl]-4-(tetrahy dro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 118 N-[3-(Aminocarbonyl)benzyl]-1-ethyl-4-(tetrahydro-2H-pyran-4 - ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 119 l-Ethyl-N-f4- [ (methylamino) carbonyl] phenyl}-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 120 1-Ethyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-4-(tetrahydro -2H- pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 121 N-{2[(Anilinocarbonyl)amino]ethyl}-1-ethyl-4-(tetrahydro-2H- pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 122 1-Ethyl-N-(1H-tetraazol-5-ylmethyl)-4-(tetrahydro-2H-pyran-4 - ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide hydrochloride 123 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-[2-(lH-1, 2, 4-triazol-1- yl) ethyl]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 125 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-[4- (trifluoromethyl) phenyl]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 126 tert-Butyl 4-({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] yridin-5-yl carbonyl} amino) piperidine-l-carboxylate 127 1-Ethyl-N- {3-[(methylsulfonyl)amino]propyl}-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 128 N-[2-Dimethylamino)benzyl]-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 129 1-Ethyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-4-(tetrahydro-2H- pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 130 1-Ethyl-N (tetrahydrofuran-2-ylmethyl)-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] yridine-5-carboxamide 131 1-ethyl-N-tetrahydro-2H-pyran-4-yl-4-(tetrahydro-2H-pyran-4- ylamino)- 1H-pyrazolo [3, 4-b pyridine-5-carboxamide 132 N- {4-[(Dimethylamino) sulfonyl] benzyl}-1-ethyl-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 133 1-Ethyl-N-{3-[(methylsulfonyl) amino] benzyl}-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b pyridine-5-carboxamide 135 1-Ethyl-N-(4-methyoxyphenyl)-4-(tetrahydro-2H-pyran-4-ylamin o)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 136 1-Ethyl-N-[3-(2-oXopyrrolidin-l-yl) propyl]-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 137 1-Ethyl-N- [2-(1-methylpyrrolidin-2-yl)ethyl]-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 138 1-Ethyl-N-(pyridin-3-ylmethyl)-4-(tetrahydro-2H-pyran-4-ylam ino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 139 1-Ethyl-N-(1-methylpiperidin-4-yl)-4-(tetrahydro-2H-pyran-4- ylamino)- 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 140 1-Ethyl-N-(1-tethylpropyl)-4-(tetrahydro-2H-pyran-4-ylamino) -1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 141 1-Ethyl-N-(2-piperidin-1-ylethyl)-4-(tetrahydro-2H-pyran-4-y lamino)- 1Hpyrazolo[3,4-b]pyridine-5-carboxamide 142 1-Ethyl-N-(3-morpholin-4-ylpropyl)-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b yridine-5-carboxamide 143 N-(3-Ethoxypropyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino) -1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 144 N-(Cyclohexylmethyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamin o)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 145 N-[3-(Dimethylamino)propyl]-1-ethyl-4-(tetrahydro-2H-pyran-4 - ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 146 1-Ethyl-N-neopentyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 147 1-ethyl-N-(4-methoxybenzyl)-4-(tetrahydro-2H-pyran-4-ylamino )-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 148 1-Ethyl-N-{2-[(phenylsulfonyl)amino]ethyl}-4-(tetrahydro-2H- pyran-4- lamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 149 N-[2-(Acetylamino)ethyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-yl amino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 150 1-Ethyl-N- {2-[(methylsulfonyl) amino] ethyl}-4-(tetrahydro-2H-pyran-4- ylamino)-1H-pyrazolo [3, 4-b] yridine-5-carboxamide 152 1-Ethyl-N- {2-[(2-methoxyphenyl) (methyl) amino] ethyl}-4- (tetrahydro- 2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 153 1-Ethyl-N (2-oxo-2-phenylethyl)-4- (tetrahydro-2H-pyran-4-ylamino)- lH-pyrazolo [3, 4-b] pridine-5-carboxamide 154 N-(2,5-Difluorobenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylam ino)-1H- pyrazolo [3, 4-b]pyridine-5-carboxamide 155 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-[4- (trifluoromethyl) benzyl]-lH-pyrazolo [3, 4-b] yridine-5-carboxamide 156 N, 1-Diethyl-N-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 157 N-Cyclopropyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 158 N-(2-amino-2-oxoethyl)-1-ethyl1-4-(tetrahydro-2H-pyran-4-yla mino)- lH-pyrazolo [3, 4-b] yridine-5-carboxamide 159 1-Ethyl-N-(3-methyoxyphenyl)-4-(tetrahydro-2H-pyran-4-ylamin o)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 160 N-(3, 4-Difluorobenzyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] yridine-5-carboxamide 161 Ethyl 3-({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridin-5-yl] carbonyl} amino) propanoate 162 N-(1-Benzylpiperidin-4-yl)-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)- 1H pyrazolo [3, 4-b]pyridine-5-carboxamide 163 N-Butyl-4- {[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo[3,4-b]pyridin-5-yl]carbonyl}piperazine-1-carboxamid e 164 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(1, 3,4-thiadiazol-2-yl)- 1H-pyrazolo [3, 4-b] yridine-5-carboxamide 165 N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-(tetrahydro-2H-pyran -4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 166 1-Ethyl-N- [2-(2-oxoimidazolidin-1-yl)ethyl]-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] yridine-5-carboxamide 167 N-(3,4-Dimethyoxybenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-yl amino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 168 N-(3-Chlorobenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino) -1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 169 1-Ethyl-5-[(4-methylpiperazin-1-yl) carbonyl]-N-tetrahydro-2H-pyran-4- yl-1H-pyrazolo[3,4-b]pyridin-4-amine 170 1-Ethyl-N-(2-hydroxyethyl)-4-(tetrahydro-2H-pyran-4-ylamino) -1H- pyrazolo [3, 4-b] yrdine-5-carboxamide 171 1-Ethyl-5- {[4-(4-methoxyphenyl) piperazin-1-yl] carbonyl}-N-tetrahydro- 2H-pyr-4-yl-lH-pyrazolo [3, 4-b] pyridin-4-amine 172 1-Ethyl-N-{4-[(methylsulfonyl) methyl] phenyl}-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] yridine-5-carboxamide 173 N- [3- (dimethylamino)-3-oxopropyl]-1-ethyl-4- (tetrahydro-2H-pyran-4- ylammo)-lH-pyrazolo [3, 4-b]pyridine-5-carboxamide 174 l-Ethyl-N-[(l-methyl-lH-imidazol-5-yl) methyl]-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 175 l-Ethyl-N- {4-[(methylamino) sulfonyl] phenyl}-4-(tetrahydro-2H-pyran- 4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 176 N-(2-Cyanoethyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H- pyrazolo [3, 4-b] pyridine-5-carboxamide 178 l-Ethyl-N-[(l-methyl-lH-pyrazol-4-yl) methyl]-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 179 1-Ethyl-N-methyl-N-[(1-Methyl-1H-indiazol-2-yl)methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide 180 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(2-thien-2-yleth yl)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 181 N-[2-(4-Chlorophenyl) ethyl]-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 182 1-Ethyl-N-[2-(2-methoxyphenyl) ethyl]-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 183 Ethyl4- (cyclohexylamino)-1- (3-ethoxy-3-oxopropyl)-1H pyrazolo [3, 4-b] pyridine-5-carboxylate 185 Ethyl 1-n-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxylate 186 Ethyl 1-(2-hydroxyethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b yridine-5-carboxylate 187 N-[4-(methylsulfonyl)benzyl]-1-n-propyl-4-(tetrahydro-2H-pyr an-4- ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 188 N-(4-Fluorophyenyl)-1-n-propyl-4(tetrahydro-2H-pyran-4-ylami no)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 189 Ethyl 1-ethyl-6-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate 190 Ethyl 4-(cyclohexylamino)-1-ethyl-6-methyl-lH-pyrazolo [3,4- b] pyridine-5-carboxylate 191 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(methylsulfonyl) benzyl] - 1H pyrazolo [3, 4-b] pyridine-5-carboxamide 192 N-Benzyl-4-(cyclohexylamino)-1-ethyl-6-methyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 193 4-(Cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)-6-methyl-1H- pyrazolo [3, 4-b] yridine-5-carboxamide 194 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(trifluoromethyl) benzyl] - 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 195 4-(Cyclohexylamino)-N-(2, 3-dihydro-lH-inden-2-yl)-1-ethyl-6-methyl- lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 196 N-Benzyl-1-ethyl-6-methyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 197 N-Benzyl-1-ethyl-4-[(2-oxoazepan-3-yl) amino]-lH-pyrazolo [3,4- b pyridine-5-carboxamide 198 N-Benzyl-1-ethyl-4-[(3-hydroxycyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide ; also called N-benzyl-l-ethyl-4-[(3-hydroxycyclohexan-1-yl) amino]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 199 N-Benzyl-1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide; also called N-benzyl-1-ethyl-4-[(4-hydroxycyclohexan-1-yl)amino]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 200 N-Benzyl-1-ethyl-4-[(3-hydroxycyclopentyl)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide ; also called N-benzyl-1-ethyl-4-[(3-hydroxycyclopentan-1-yl)amino]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 201 N-Benzyl-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide ; also called N-Benzyl-1-ethyl-4-[(4-oxocyclohexan-1-yl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 202 1-Ethyl-N-(2-hydroxy-1-methylethyl)-4-(tetrahydro-2H-pyran-4 - ylamino)-1H-pyrazolo[3,4-b-]pyridine-5-carboxamide 203 Methyl (2S)-2- { [1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pridin-5-yl] carbonyl} amino)-3-hydroxypropanoate Exa-Name mple no.

204 Ethyll-ethyl-4- [ (4-hydroxycyclohexyl) amino]-lH-pyrazolo [3,4-b] pyridine-5-carboxylate 205 Ethyll-ethyl-4- [ (4-oxocyclohexyl) amino]-lH-pyrazolo [3,4-b] pyridine-5-carboxylate 207 Ethyl 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5-carboxylate 209 Ethyl 4- [ (4-aminocyclohexyl) amino]-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5-carboxylate 210 Ethyl-N- [ (l-oxido-3-pyridinyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 211 1-Ethyl-N-[(l-oxido-2-pyridinyl) methyl]-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 212 1-Ethyl-N- [ (l-oxido-4-pyridinyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 214 4-[(cis-4-Aminocyclohexyl) amino]-1-ethyl-N-(phenylmethyl)-1 H-pyrazolo [3, 4-b] pyridine- 5-carboxamide 221 4-(Cyclobutylamino)-1-ethyl-N-(phenylmethyl)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 222 4-(Cycloheptylamino)-1-ethyl-N-(phenylmethyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 223 1-Ethyl-4- [ (4-methylcyclohexyl) amino]-N- (phenylmethyl)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 224 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-py razolo[3, 4-b] pyridine-5- carboxamide 225 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-py razolo [3,4-b] pyridine-5- carboxamide 226 4-[(1R, 2R, 4S) -Bicyclo [2.2. 1] hept-2-ylamino]-1-ethyl-N-(phenylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 227 4-[(1R, 2S, 4S) -Bicyclo [2.2. 1] hept-2-ylamino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 228 1-Ethyl-4-{[(3S)-2-oxo-3-pyrrolidinyl]amino}-N-(phenylmethyl )-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 229 4- [ (2, 5-Dioxo-3-pyrrolidinyl) amino]-1-ethyl-N- (phenylmethyl)-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 230 4- (l-Azabicyclo [2.2. 2] oct-3-ylamino)-1-ethyl-N- (phenylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 231 1-Ethyl-4-[(1-methylcyclohexyl) amino]-N- {[4-(methyloxy) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 233 4-(Cyclobutylamino)-1-ethyl-N-{[4-(methyloxy phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 234 4-(Cycloheptylamino)-1-ethyl-N- { [4- (methyloxy) phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 235 4-[(lR, 2R, 4S)-Bicyclo [2.2. 1] hept-2-ylamino]-1-ethyl-N-{[4-(methyloxy) phenyl] methyl}- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 236 1-Ethyl-4- [ (4-methylcyclohexyl) amino] -N- { [4- (methyloxy) phenyl] methyl}-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 237 1-Ethyl-4- [ (3-methylcyclohexyl) amino] -N- { [4- (methyloxy) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 238 4-[(lR, 2S, 4S) -Bicyclo [2.2. 1] hetp-2-ylamino]-1-ethyl-N-{[4-(methyloxy) phenyl] methyl}- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 239 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-{[4-(methyloxy) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 240 4-(Cycloheptylamino)-1-ethyl-N-({4-[(methylsulfonyl) amino] phenyl} methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 241 4- (Cyclobutylamino)-l-ethyl-N- (f4- [ (methylsulfonyl) amino] phenyl} methyl)-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 242 4-[(lR, 2R, 4S)-Bicyclo [2.2. 1] hept-2-ylamino]-1-ethyl-N- ( {4- [(methylsulfonyl) amino] phenyl} methyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 243 4-[(lR, 2S, 4S)-Bicyclo [2.2. 1] hept-2-ylamino]-1-ethyl-N- ( {4- [(methylsulfonyl) amino] phenyl} methyl)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 244 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-({4-[(methylsulfonyl )amino]phenyl}methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 245 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-({4-[(methylsuflonyl )amino]phenyl}methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 247 1-Ethyl-4-[(1-methylcycloheXyl) amino]-N-({4-[(methylSulfonyl) amino] phenyl} methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 248 4-[(cis-4-AminocycloheXyl) amino]-l-ethyl-N-({4-[(methylSulfonyl) amino] phenyl} methyl)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 249 4-(Cyclohexylamino)-1-ethyl-N-({4-[(methylsuflonyl) amino] phenyl} methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 250 4-(Cyclohepylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H -pyrazolo [3,4-b] pyridine- 5-carboxamide 251 4-(Cyclobutylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H -pyrazolo [3,4-b] pyridine-5- carboxamide 253 N-(2, 3-Dihydro-lH-inden-2-yl)-1-ethyl-4-[(3-methylcyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 254 N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(4-methylcyclohexyl )amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 255 4-[(1R, 2R, 4S) -Bicyclo [2.2. 1] hept-2-ylamino]-N- (2, 3-dihydro-lH-inden-2-yl)-1-ethyl-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 256 4-[(1R, 2S, 4S) -Bicyclo [2.2. 1] hept-2-ylamino]-N- (2, 3-dihydro-lH-inden-2-yl)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 257 N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(1-methylcyclohexyl )amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 258 4-[(cis-4-Aminocyclohexyl)amino]-N-(2,3-dihydro-1H-inden-2-y l)-1-ethyl-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 259 1-Ethyl-N- {4- [ (methylsulfonyl) methyl] phenyl}-4-[(4-oxocycloheXyl) amino]-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 260 N- [ (2, 4-Dimethylphenyl) methyl]-l-ethyl-4- [ (4-oxocyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 261 N- [ (3, 4-Dimethylphenyl) methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 262 N- [ (3, 4-Dichlorophenyl) methyl]-1-ethyl-4-[(4-oxocyclohexy)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 263 1-Ethyl-N- {[4-(methyloxy) phenyl] methyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 264 1-Ethyl-N-({4-[(methylSulfonyl) amino] phenyl} methyl)-4-[(4-oXocycloheXyl) amino]-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 265 N-{[4-(Dimethylamino)phenyl]methy}-1-ethyl-4-[(4-oxocyclohex yl)amino]-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 266 N- ({4-[(Difluromethyl) oxy] phenyl} methyl)-1-ethyl-4- [ (4-oxocyclohexyl) amino]-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 267 1-Ethyl-4-[(4-oxocyclohexyl) amino]-N- {[4-(trifluoromethyl) phenyl] methyl}-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 268 1-Ethyl-N-{ [4-(methylsulfonyl) phenylJmethyl}-4-[(4-oxocyclohexyl) amino]-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 269 1-Ethyl-N-(4-fluorophenyl)-4-[(4-oXocyclohexyl) amino]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide 270 l-Ethyl-4- [ (4-oxocyclohexyl) amino]-N- (2-pyridinylmethyl)-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide trifluoroacetate 271 N-(2, 3-Dihydro-lH-inden-2-yl)-1-ethyl-4-[(4-oxocyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 272 N- (l-Acetyl-4-piperidinyl)-l-ethyl-4- [ (4-oxocyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 273 1-Ethyl-N-[(l-methyl-lH-pyrazol-4-yl) methyl]-4-[(4-oxocycloheXyl) amino]-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 274 N, 1-Diethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo [3,4-b] pyridine-5-carboxamide 275 1-Ethyl-4- [ (4-oxocyclohexyl) amino]-N- (1, 3-thiazol-2-ylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 276 1-Ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-3-ylamino)-l H-pyrazolo [3,4-b] pyridine- 5-carboxamide 277 N- ( {4- [ (Difluoromethyl) oxy] phenyl}methyl)-1-ethy-4-(tetrahydro-2H-pyran-3-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 278 1-Ethyl-4-(tetrahydro-2H-pyran-3-ylamino)-N-{[4-(trifluorome thyl) phenylJmethyl}-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 279 1-Ethyl-N- { [4- (methylsulfonyl) phenyl] methyl}-4-(tetrahydro-2H-pyran-3-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 280 l-Ethyl-N-14- [ (methylsulfonyl) methyl] phenyl}-4-(tetrahydro-2H-pyran-3-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 281 1-Ethyl-N-(4-fluorophenyl)-4-(tetrahydro-2H-pyran-3-ylamino) -lH-pyrazolo [3,4- b] pyridine-5-carboxamide 282 1-Ethyl-N-(2-pyridinylmethyl)-4-(tetrahydro-2H-pyran-3-ylami no)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide trifluoroacetate 283 N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-(tetrahydro-2H-pyran -3-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 284 N- (1-Acetyl-4-piperidinyl)-1-ethyl-4- (tetrahydro-2H-pyran-3-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 285 1-Ethyl-N-[(l-methyl-lH-pyrazol-4-yl) methyl]-4-(tetrahydro-2H-pyran-3-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 286 N, l-Diethyl-4-(tetrahydro-2H-pyran-3-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 287 1-Ethyl-4-(tetrahydro-2H-pyran-3-ylamino)-N-(1, 3-thiazol-2-ylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 288 4- [ (4, 4-Difluorocyclohexyl) amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 289 1-Ethyl-4-[(4-fluoro-3-cyclohexen-1-yl)amino]-N-(phenylmethy l)-1H-pyrzolo [3,4- b] pyridine-5-carboxamide.

290 4- [ (l-Acetyl-4-piperidinyl) amino]-N- (2, 3-dihydro-lH-inden-2-yl)-1-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 291 4- [ (1-Acetyl-4-piperidinyl) amino]-N- [ (3, 4-dichlorophenyl) methyl]-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 292 4- [ (1-Acetyl-4-piperidinyl) amino]-1-ethyl-N- [ (3-fluorophenyl) methyl]-IH-pyrazolo [3,4- b] pyridine-5-carboxamide 293 4- [ (1-Acetyl-4-piperidinyl) amino]-N- [ (3, 4-difluorophenyl) methyl]-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 294 4- [(1-Acetyl-4-piperidinyl) amino]-N- [(2, 5-difluorophenyl) methyl]-1-ethyl-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 295 4- [ (l-Acetyl-4-piperidinyl) amino]-l-ethyl-N- { [3- (trifluoromethyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 296 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-{[4-(trifluorome thyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 297 4-[(1-Acetyl-4-piperidinyl) amino]-N-[(2, 6-difluorophenyl) methyl]-l-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 298 4- [ (1-Acetyl-4-piperidinyl) amino]-N- [ (3-chlorophenyl) methyl]-1-ethyl-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 299 4- [ (I-Acetyl-4-piperidinyl) amino]-l-ethyl-N-1 [4- (methyloxy) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 300 4- [ (1-Acetyl-4-piperidinyl) amino]-1-ethyl-N- [4- (methyloxy) phenyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 301 4-[(1-Acetyl-4-piperidinyl)amino]-N-{[4-[(dimethylamino) sulfonyl] phenyl} methyl)-1-ethyl- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 302 4- [ (l-Acetyl-4-piperidinyl) amino]-l-ethyl-N- (1, 2,3, 4-tetrahydro-1-naphthalenyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 303 4- [ (l-Acetyl-4-piperidinyl) amino]-N-1 [2- (dimethylamino) phenyl] methyll-1-ethyl-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 304 4- [ (l-Acetyl-4-piperidinyl) amino]-N- [ (2, 4-dichlorophenyl) methylJ-l-ethyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 305 4-[(1-Acetyl-4-piperidinyl) amino]-1-ethyl-N-[(2-fluorophenyl) methyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 306 4-[(1-Acetyl-4-piperidinyl) amino]-N-[(2-chloro-6-fluorophenyl) methyl]-1-ethyl-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 307 4- [ (l-Acetyl-4-piperidinyl) amino]-N- ( {4- [ (difluoromethyl) oxy] phenyl} methyl)-1-ethyl-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 308 4-[(1-Acetyl-4-piperidinyl)amino]-N-{[3-chloro-4-(methyloxy) phenyl] methyl}-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 309 4- [ (l-Acetyl-4-piperidinyl) amino]-N- [ (5-chloro-2-pyridinyl) methyl]-1-ethyl-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 310 4- [ (l-Acetyl-4-piperidinyl) amino]-N- (5-chloro-2, 3-dihydro-lH-inden-2-yl)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 311 4-[(1-Acetyl-4-piperidinyl) amino]-1-ethyl-N-(l, 3-thiazol-2-ylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 312 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N- { [4- (methylsulfonyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 313 4- [ (l-Acetyl-4-piperidinyl) amino]-N- (2, 2-diphenylethyl)-l-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 314 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-({4-[(methylsulf onyl)amino]phenyl}methyl)- 1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 315 4-[(1-Acetyl-4-piperidinyl)amino]-l-ethyl-N-({4-[(methylsulf onyl)carbonyl]phenyl}methyl)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 316 4-[(1-Acetyl-4-piperidinyl) amino]-N-{[4-(aminosulfonyl) phenyl] methyl}-1-ethyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 317 4-[(1-Acetyl-4-piperidinyl)amino]-l-ethyl-N-({3[(methylamino ) carbonyl] phenyl} methyl)- 1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 318 4-[(1-Acetyl-4-piperidinyl)amino]-N-{[4-(aminocarbonyl) phenyl] methyl}-1-ethyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 319 4-[(1-Acetyl-4-piperidinyl)amino]-l-ethyl-N-{[6-(methyloxy-3 -pyridingyl]methyl}-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 320 1-Ethyl-N-4-piperidinyl-4-(tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4-b] pyridine-5- carboxamide 321 1-Ethyl-N- (4-piperidinylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 322 1-Ethyl-N- [l- (ethylsulfonyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 323 1-Ethyl-N- {1- [ (1-methyl ethyl) sulfonyl]-4-pip eri dinyl}-4- (tetrahydro-2H-pyran-4-ylamino) - 1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 324 N- [1- (Cyclopentylsulfonyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 325 1-Ethyl-N- [l- (methylsulfonyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 326 1-Ethyl-N- {1-[(phenylmethyl) sulfonyl]-4-piperidinyl}-4-(tetrahydro-2H-pyran-4-ylamino)- lH-pyrazolo [3,4-b] pyridine-5-carboxamide 327 1-Ethyl-N- [1- (phenylsulfonyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 328 1-Ethyl-N-[l-(propylSulfonyl)-4-piperidinyl]-4-(tetrahydro-2 H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 329 N- [1- (Cyclopropylcarbonyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 330 1-Ethyl-N- [l- (3-furanylcarbonyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 331 N- [1- (3, 3-Dimethylbutanoyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 332 1-Ethyl-N- [1- (2-ethylbutanoyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 333 N- [1- (Cyclopentylacetyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 334 1-Ethyl-N- [l- (2-methylpropanoyl)-4-piperidinyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 335 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- [l- (tetrahydro-2H-pyran-4-ylcarbonyl)-4- piperidinyl]-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 336 1-Ethyl-N-(l-propanoyl-4-piperidinyl)-4-(tetrahydro-2H-pyran -4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 337 N- [1- (N-Acetylglycyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 338 1-Ethyl-N-[l-(4-morpholinylacetyl)-4-piperidinyl]-4-(tetrahy dro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 339 1-Ethyl-N-11- [ (4-oxocyclohexyl) carbonyl]-4-piperidinyll-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 340 1-Ethyl-N-[l-(1-piperidinylacetyl)-4-piperidinyl]-4-(tetrahy dro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 341 1-Ethyl-N- 1- [ (1-methyl-5-oxo-3-pyrrolidinyl) carbonyl]-4-piperidinyl}-4- (tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 342 1-Ethyl-N- {1- [ (3-methyl-3-oxetanyl) carbonyl]-4-piperidinyl}-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 343 1-Ethyl-N- 1-[(4-fluorophenyl)acetyl]-4-piperidinyl}-4-(tetrahydro-2H-p yran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide <BR> <BR> <BR> 344 N-{[1-(3, 3-Dimethylbutanoyl) -4-piperidinyl] methyl}-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 345 N-1 [1- (Cyclopentylacetyl)-4-piperidinyl] methyl)-l-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 346 N-{[1-(Cyclopropylcarbonyl)-4-piperidinyl]methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 347 1-Ethyl-N- ({1-[(4-oxocyclohexyl)carbonyl]-4-piperidinyl}methyl)-4-(tet rahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 348 1-Ethyl-N- ({1-[(4-fluorophenyl)acetyl]-4-piperidinyl}methyl)-4-(tetrah ydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 349 1-Ethyl-N-({1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperi dinyl} methyl) -4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 350 Methyl3- [ (1-ethyl-5- ( [ (phenylmethyl) amino] carbonyl}-1h-pyrazolo [3, 4-b] pyridin-4- yl) amino] cyclohexanecarboxylate 351 3-[(1-Ethyl-5- { [(phenylmethyl) amino] carbonyl}-lH-pyrazolo [3,4-b] pyridin-4- yl) amino] cyclohexanecarboxylic acid 352 1-Ethyl-N-(phenylmethyl)-4-(4-piperidinylamino)-1H-pyrazolo[ 3 4-b] pyridine-5- carboxamide 353 Ethyl 1-ethyl-4- ({1-[(methyloxy)acetyl]-4-piperidinyl}amino)-1H-pyrazolo [3,4-b] pyridine- 5-carboxylate 354 Ethyll- (1-methylethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 355 4-(Cyclohexylamino)-1-ethyl-N-methyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 356 1-Ethyl-N-(4-fluorophenyl)-6-methyl-4-(tekahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 357 1-Ethyl-6-methyl-N-{[4-(methylSulfonyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 358 N- (2, 3-Dihydro-lH-inden-2-yl)-1-ethyl-6-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 360 1-Ethyl-N- [3- (1-piperidinylcarbonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 361 1-Ethyl-N- [4- (l-methylethyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 362 1-Ethyl-N- (2-fluorophenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 363 N- {3-[(Dimethylamino) carbonyl] phenyl}-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 364 N- {4-[(Difluoromethyl)oxy]pyenyl}-1-ethyl-4-(tetrahydro-2H-pyr an-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 365 N- {4- [Acetyl (methyl) amino] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 366 1-Ethyl-N- (4-hydroxyphenyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4- b] pyridine-5-carboxamide 367 1-Ethyl-N- [4- (4-morpholinyl)-2- (trifluoromethyl) phenyl]-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 368 1-Ethyl-N-4-pyridinyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 369 1-Ethyl-N- {4- [ (4-methyl-1-piperazinyl) carbonyl] phenyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 370 1-Ethyl-N-[2-(2-oxo-1-pyrrolidinyl) phenyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 371 1-Ethyl-N- [3- (methylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 372 N- {3- [Acetyl (methyl) amino] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 373 1-Ethyl-N- {3-[(methylsulfonyl) amino] phenyl}-4-(tekahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 374 1-Ethyl-N- (4-fluoro-2-hydroxyphenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 375 N- (4-Chlorophenyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide 376 N- (3-Chloro-2-cyanophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3, 4- b] pyridine-5-carboxamide 377 1-Ethyl-N- [3- (l-piperidinylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 379 l-Ethyl-N- [2- (methylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 380 N- {2- [Acetyl (methyl) amino] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 381 l-Ethyl-N- [3- (4-morpholinylcarbonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 382 N- (4-Chloro-3-cyanophenyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 383 l-Ethyl-N- (3-hydroxyphenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 384 N- (3-Chlorophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 386 N- [3- [ (Acetylamino) methyl]-4- (methyloxy) phenyl]-l-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-IH-pyrazolo [3,4-b] pyridine-5-carboxamide 387 1-Ethyl-N- [4- (l-piperidinylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 388 N- (3- { [Cyclohexyl (methyl) amino] carbonyl} phenyl)-l-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 389 1-Ethyl-N- [2- (4-morpholinyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 390 N- {3-[(Acetylamino) sulfonyl] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 391 N- (3-Chloro-4-hydroxyphenyl)-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 392 1-Ethyl-N- {4- [ (methylsulfonyl) amino] phenyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 393 1-Ethyl-N-{3-[(methylamino) carbonyl] phenyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 394 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- [3- (trifluoromethyl) phenyl]-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 395 1-Ethyl-N-3-pyridinyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 396 N- (3, 4-Dichlorophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide 397 N- [3- (Aminosulfonyl)-4-chlorophenyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 398 1-Ethyl-N- [3- (4-morpholinyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 399 l-Ethyl-N- [4- (4-morpholinylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 400 1-Ethyl-N- {2- [ (4-methyl-1-piperazinyl) carbonyl] phenyl}-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 401 N- {2- [ (Dimethylamino) carbonyl] phenyl}-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 402 N- [2-Chloro-4- (trifluoromethyl) phenyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 403 N-{2-[(Acetylamino) methyl] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 404 N- (2-Chlorophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 405 N- (3-Chloro-2-fluorophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 406 1-Ethyl-N- (3-fluorophenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 407 N- (2-Cyano-3-fluorophenyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 408 1-Ethyl-N- [4- (propylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 409 N- {4-[(Dimethylamino) carbonyl] phenyl}-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 411 1-Ethyl-N- [4- (methylsulfonyl) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 413 N- {4-[(Acetylamino) methyl] phenyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 414 1-Ethyl-4- (tetrahydro-2H-pyran-3-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 415 N- [2- (Aminosulfonyl) ethyl]-4- (cyclohexylamino)-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5- carboxamide 416 N- (2-Amino-2-oxoethyl)-4- (cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide (non-preferred name) 417 4-(Cyclohexylamino)-1-ethyl-N- {2-[(methylsulfonyl) amino] ethyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 418 4-(Cyclohexylamino)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H- pyrazolo [3,4-b] pyridine-5- carboxamide 419 4- (Cyclohexylamino)-1-ethyl-N- [ (l-methyl-lH-pyrazol-4-yl) methyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 420 4-(Cyclohexylamino)-1-ethyl-N- { [3-(methylsulfonyl) phenyl] methyl}-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 421 N- { [3- (Aminocarbonyl) phenyl] methyl}-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3, 4- b] pyridine-5-carboxamide 422 4-(Cyclohexylamino)-1-ethyl-N-(tetrahydro-2-furanylmethyl)-1 H-pyrazolo [3,4-b] pyridine- 5-carboxamide 423 4- (Cyclohexylamino)-N- ( f 4- [ (dimethylamino) sulfonyl] phenyl} methyl)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 424 N- [ (5-Chloro-2-pyridinyl) methyl]-4- (cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 425 4-(Cyclohexylamino)-1-ethyl-N-{[4-(methylsulfonyl) phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 426 4-(Cyclohexylamino)-1-ethyl-N- { [6-(methyloxy)-3-pyridinyl] methyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 427 4-(Cyclohexylamino)-1-ethyl-N- {4-[(methylamino) carbonyl] phenyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 428 4-(Cyclohexylamino)-1-ethyl-N-({3-[(methylamino) carbonyl] phenyl} methyl)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 429 N-{[4-(Aminocarbonyl) phenyl] methyl}-4- (cyclohexylamino)-1-ethyl-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 430 4-(Cyclohexylamino)-1-ethyl-N- [(4-hydroxyphenyl) methyl]-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 431 4-(Cyclohexylamino)-1-ethyl-N-{[4-(methyloxy_ phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 432 4- (Cyclohexylamino)-N- [ (3, 4-difluorophenyl) methyl]-1-ethyl-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 433 4-(Cyclohexylamino)-1-ethyl-N-{[4-(trifluoromethyl) phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 434 4-(Cyclohexylamino)-1-ethyl-N-({3-[(methylsulfonyl)amino]phy enyl}methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 435 4-(Cyclohexylamino)-N-[(2, 5-difluorophenyl) methyl]-1-ethyl-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 436 4- (Cyclohexylamino)-1-ethyl-N- [ (4-methylphenyl) methyl]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide 438 4-(Cyclohexylamino)-1-ethyl-N-(2- {4-[(methylsulfonyl) amino] phenyl} ethyl)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 439 4- (Cyclohexylamino)-1-ethyl-N- [ (2-hydroxyphenyl) methyl]-1H-pyrazolo [3,4-b] pyridine-5- carboxamide 440 4- (Cyclohexylamino)-N- [ (3, 4-dichlorophenyl) methyl]-1-ethyl-1 H-pyrazolo [3, 4-b] pyridine- 5-carboxamide 441 4- (Cyclohexylamino)-N- [ (3, 5-dichlorophenyl) methyl]-1-ethyl-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 442 4-(Cyclohexylamino)-1-ethyl-N-(2-phenylethyl)-1H-pyrazolo[3, 4-b] pyridine-5-carboxamide 443 4-(Cyclohexylamino)-1-ethyl-N-(1, 2,3, 4-tetrahydro-1-naphthalenyl)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 444 4-(Cyclohexylamino)-1-ethyl-N- {[2-(methylsulfinyl) phenyl] methyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 445 4-(Cyclohexylamino)-1-ethyl-N-[2-(4-hydroxyphenyl)ethyl]-1H- pyrazolo [3,4-b] pyridine-5- carboxamide 446 N- {2- [4- (Aminosulfonyl) phenyl] ethyl}-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 447 4- (Cyclohexylamino)-1-ethyl-N- ( {2- [ (methylamino) carbonyl] phenyl} methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 448 4- (Cyclohexylamino)-1-ethyl-N- { [2- (methylsulfonyl) phenyl] methyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 449 Methyl 2-[( {[4-(cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 450 4- (Cyclohexylamino)-1-ethyl-N- {2- [4- (methylsulfonyl) phenyl] ethyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 451 N- [4, 5-Bis (methyloxy)-2, 3-dihydro-1H-inden-2-yl]-4- (cyclohexylamino)-1-ethyl-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 452 4-(Cyclohexylamino)-1-ethyl-N- { [2-fluoro-3- (trifluoromethyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 453 4- (Cyclohexylamino)-N- [ (3, 4-dimethylphenyl) methyl]-1-ethyl-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 454 4-(Cyclohexylamino)-1-ethyl-N-[2-(4-fluorophenyl)ethyl]-1H-p yrazolo [3,4-b] pyridine-5- carboxamide 455 4- (Cyclohexylamino)-1-ethyl-N- [2- (4-methylphenyl) ethyl]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 456 4- (Cyclohexylamino)-1-ethyl-N- {2- [4- (methyloxy) phenyl] ethyl}-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 457 4-(Cyclohexylamino)-1-ethyl-N-(2-pyridinylmethyl)-1H-pyrazol o [3,4-b] pyridine-5- carboxamide trifluoroacetate 458 4- (Cyclohexylamino)-N- [ (3, 5-difluorophenyl) methyl]-1-ethyl-1 H-pyrazolo [3,4-b] pyridine- 5-carboxamide 459 4- (Cyclohexylamino)-N- (2, 3-dihydro-1H-inden-1-yl)-1-ethyl-1H-pyrazolo [3,4-b] pyridine-5- carboxamide 460 4-(Cyclohexylamino)-N-{[4-(dimethylamino) phenyl] methyl}-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide trifluoroacetate 461 4-(Cyclohexylamino)-1-ethyl-N-[(2-fluorophenyl) methyl]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 462 N- { [2,4-Bis (methyloxy) phenyl] methyl}-4-(cyclohexylamino)-1-ethl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 463 N- [ (6-Chloro-2-pyridinyl) methyl]-4- (cyclohexylamino)- 1-ethyl-I H-pyrazolo [3,4- b] pyridine-5-carboxamide trifluoroacetate 464 N- ( {2- [Acetyl (methyl) amino] phenyl} methyl)-4- (cyclohexylamino)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 465 4-(Cyclohexylamino)-1-ethyl-N-{[4-fluoro-3-(trifluoromethyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 466 4-(Cyclohexylamino)-N-[(lR)-2, 3-dihydro-lH-inden-l-yl]-1-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 467 4- (Cyclohexylamino)-N- [ (2, 6-dichlorophenyl) methyl]-1-ethyl-1H-pyrazolo [3,4-b] pyridine- 5-carboxamide 468 Methyl-3-[( { [4-(cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 469 4-(Cyclohexylamino)-N-(2, 3-dihydro-lH-inden-2-yl)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 470 Methyl 4-[( { [4- (cyclohexylamino)-l-ethyl-IH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 471 4- (Cyclohexylamino)-1-ethyl-N- (lH-tetrazol-5-ylmethyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 472 4-(Cyclohexylamino)-N-({4-[(difluoromethyl) oxy] phenyl} methyl)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 473 4-(Cyclohexylamino)-1-ethyl-N-[(2-methyl-1, 3-thiazol-4-yl) methyl]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 474 N-[(2-Chloro-6-fluorophenyl) methyl]-4-(cyclohexylamino)-1-ethyl-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 475 N- [2- (Aminocarbonyl) phenyl] methyl}-4- (cyclohexylamino)-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 477 4- (Cyclohexylamino)-N- { [2- (dimethylamino) phenyl] methyl}-1-ethyl-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 478 4- (Cyclohexylamino)-l-ethyl-N- [ (4-fluorophenyl) methyl]-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide 479 4-(Cyclohexylamino)-1-ethyl-N-{[3-(trifluoromethyl) phenyl] methyl}-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 480 4-(Cyclohexylamino)-N-[(2, 6-difluorophenyl) methyl]-l-ethyl-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 481 4- (Cyclohexylamino)-1-ethyl-N- [ (3-fluorophenyl) methyl]-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide 482 4- (Cyclohexylamino)-1-ethyl-N- { [2- (trifluoromethyl) phenyl] methyl}-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 483 N- (5-Chloro-2, 3-dihydro-1H-inden-2-yl)-4- (cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 484 4-(Cyclohexylamino)-1-ethyl-N-({4-[methylamino) carbonyl] phenyl}methyl)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 485 4- (Cyclohexylamino)-1-ethyl-N- [4- (methyloxy) phenyl]-lH-pyrazolo [3,4-b] pyridine-5- carboxamide 486 4-(cyclohexylamino)-1-ethyl-N-[(6-oxo-1,6-dihydro-3-pyridiny l)methyl]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 487 4- (Cyclohexylamino)-1-ethyl-N- (3-pyridinylmethyl)-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide 488 4- {[4-(Cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoic acid 489 3- [ [4-(Cyclohexylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoic acid 490 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H -pyrazolo [3,4-b] pyridine-5- carboxamide hydrochloride 491 4- (Cyclohexylamino)-N- (2, 3-dihydro-1 H-inden-2-yl)-1-ethyl-1 H-pyrazolo [3,4-b] pyridine-5- carboxamide methanesulphonate 492 N- ( {2- [(1, 1-Dimethylethyl) oxy]-3-pyridinyl} methyl)-1-ethyl-4-(tekahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 493 N- [ (3-Chloro-4-methylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 494 N- [ (4-Chloro-2-methylphenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 495 N- ( {2- [ (Difluoromethyl) oxy] phenyl} methyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 496 l-Ethyl-N- {2-[(1-methylethyl) oxy] phenyl} methyl)-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 497 l-Ethyl-N- (f 3- [ (l-methylethyl) oxy] phenyl} methyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 498 N- ( {3- [ (Difluoromethyl) oxy] phenyl} methyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 499 1-Ethyl-N-{[4-hydroxy-3- (methyloxy) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 500 N- [ (5-Acetyl-2-hydroxyphenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 501 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- {2- [3- (trifluoromethyl) phenyl] ethyl}-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 502 N- { [4- (Acetylamino) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 503 1-Ethyl-N- [2- (3-hydroxyphenyl) ethyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 504 N- [2- (3-Chlorophenyl) ethyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 505 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- (2- {4- [ (trifluoromethyl) oxy] phenyl} ethyl) - 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 506 1-Ethyl-N-{2-[3-(methyloxy) phenyl] ethyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 507 N-[2-(4-Acetylphenyl) ethyl]-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 508 N- [2- (3, 4-Dichlorophenyl) ethyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 509 N- {2- [3- (Aminosulfonyl) phenyl] ethyl}-1-ethy-4-(etetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 510 N- {2- [3, 4-Bis (methyloxy) phenyl] ethyl}-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 512 N- [2- (2, 3-Dichlorophenyl) ethyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 513 N- {2- [3, 5-Bis (methyloxy) phenyl] ethyl}-l-ethyl-4- (tetrahydro-2H-pyran-4-ylammo)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 514 1-Ethyl-N-{2-[3-methyl-4-(methyloxy) phenyl] ethyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 515 N- [2- (2, 6-Difluorophenyl) ethyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 516 N- {2- [2, 6-Bis (methyloxy) phenyl] ethyl}-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 517 l-Ethyl-N- [2- (2-methylphenyl) ethyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 518 N- [ (3, 4-Dimethylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 519 N- [4, 5-Bis (methyloxy)-2, 3-dihydro-lH-inden-2-yl]-l-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 521 N- 2- [4- (Aminosulfonyl) phenyl] ethyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 522 1-Ethyl-N- { [2- (methylsulfmyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 523 1-Ethyl-N- (2-phenylethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 524 N- { [4- (Dimethylamino) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 525 1-Ethyl-N-[2-(4-fluorophenyl) ethyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 526 1-Ethyl-N-[2-(4-methylphenyl)ethyl]-4-(tetrahydro-2H-pyran-4 -ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 527 N-f [3- (Aminosulfonyl) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 528 1-Ethyl-N- [ (4-methylphenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 530 1-Ethyl-N- { [4-fluoro-3- (trifluoromethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 531 Methyl 2-[({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 532 N-[(6-Chloro-2-pyridinyl) methyl]-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 533 N- (2, 3-Dihydro-lH-inden-1-yl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 534 N- ( {2- [Acetyl (methyl) amino] phenyl} methyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 535 N- [ (lS)-2, 3-Dihydro-lH-inden-1-yl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 536 N-[(lR)-2, 3-Dihydro-lH-inden-l-yl]-1-ethyl-4-(tekahydro-2H-pyran-4-yla mino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 537 1-Ethyl-N-({3-[(methylSulfonyl) amino] phenyl} methyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 538 l-Ethyl-N- (phenylmethyl)-N-propyl-4- (tetrahydro-2H-pyran-4-ylammo)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 540 N- [2- (Dimethylamino) ethyl]-l-ethyl-N- (phenylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)- lH-pyrazolo [3,4-b] pyridine-5-carboxamide 541 N-Butyl-l-ethyl-N- (phenylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 542 N, 1-Diethyl-N- (phenylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 544 1-Ethyl-N- (1-phenyl-4-piperidinyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 545 1-ethyl-N- {1- [(ethylamino) c arbonyl]-4-pip eridinyl}-4-(tekahydro-2H-pyran-4-yl amino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 546 Formic acid-1-ethyl-N- [l-methyl-2- (4-methyl-1-piperazinyl) ethyl]-4- (tetrahydro-2H-pyran- 4-ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide (1 : 1) 547 Methyl [4-( { [1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} amino)-1-piperidinyl] acetate 548 1-Ethyl-N-{[4-(4-morpholinylmethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)- lH-pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 549 1-Ethyl-N- ( {3- [ (4-methyl-1-piperazinyl) methyl] phenyl} methyl)-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b]pyridine-5-carboxamide trifluorocacetate 550 N-{[5-(Aminocarbonyl)-3-pyridinyl]methyl1}-1-ethyl-4-(tetrah ydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 551 1-Ethyl-N-{[4-(1-methylethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 552 N-{[3-(Cyclopentyloxy)-4-(methyloxy) phenyl] methyl}-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 553 l-Ethyl-N- {4-[(4-methyl-1-piperazinyl) methyl] phenyl} methyl)-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 554 N- [ (2, 4-Dichlorophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 555 N- [ (2, 4-Difluorophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 556 N-[(2-Chloro-4-fluorophenyl)methyl]-1-ethyl-4-(tetrahydro-2H -pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 557 N- {2- [2-Chloro-3- (methyloxy) phenyl] ethyl}-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 558 Methyl 3-[({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 559 1-Ethyl-N- {[3-(1-pyrrolidinylmethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide trifluoroacetate 560 1-Ethyl-N-(2- {4-[(methylsulfonyl) amino] phenyl} ethyl)-4-(tekahydro-2H-pyran-4-ylamino)- lH-pyrazolo [3,4-b] pyridine-5-carboxamide 561 N- { [2,5-Bis (methyloxy) phenyl] methyl}-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 562 N- { [2,6-Bis (methyloxy) phenyl] methyl}-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 563 l-Ethyl-N-[(2-fluorophenyl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3n4 b] pyridine-5-carboxamide 564 N- [ (3, 5-Difluorophenyl) methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 565 N- [ (4-Chlorophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 567 N-Cyclohexyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-py razolo[3, 4-b] pyridine-5- carboxamide 568 1-Ethyl-N- {2- [4- (methylsulfonyl) phenyl] ethyl}-4- amino)-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 569 1-Ethyl-N- { [2-fluoro-3- (trifluoromethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 570 N- ({4-[(Cyclopropylamino) carbonyl] phenyl} methyl)-1-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-1H-pyrazolo [3, 4-blpyridine-5-carboxamide 571 1-Ethyl-N- [4- (4-methyl-1-piperazinyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 572 1-Ethyl-N-{[4-(1-pyrrolidinylmethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 573 1-Ethyl-N- [6- (methyloxy)-1-oxo-2, 3-dihydro-1H-inden-2-yl]-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 574 N- [ (2, 5-Dichlorophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 575 N- [ (3, 5-Diethylphenyl) methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 576 N- [ (2, 3-Difluorophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 577 1-Ethyl-N- { [2-(methylsulfonyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 578 1-Ethyl-N- [ (3-hydroxyphenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 579 N- { [3,5-Bis (methyloxy) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 580 l-Ethyl-N- [2- (4-hydroxyphenyl) ethyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 581 N- [ (3, 5-Dichlorophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 582 N- { [2,4-Bis (methyloxy) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H pyrazolo [3,4-b] pyridine-5-carboxamide 583 1-Ethyl-N-{[2-(methyloxy) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 584 N- [ (2, 4-Dimethylphenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 585 1-Ethyl-N- ({2-[(methylamino) carbonyl] phenyl} methyl)-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3, 4-b] pyridine-5-carboxamide 586 1-Ethyl-N- {2- [4- (methyloxy) phenyl] ethyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 587 N- [ (2-Chlorophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 588 1-Ethyl-N- [ (2-hydroxyphenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide 589 N-(1, 3-Benzodioxol-5-ylmethyl)-1-ethyl-4-(tekahydro-2H-pyran-4-yl amino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 590 1-Ethyl-N- [3- (methyloxy) phenyl]-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3,4- b] pyridine-5-carboxamide 591 N- (Cyclohexylmethyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 592 1-Ethyl-N- (1, 2,3, 4-tetrahydro-1-naphthalenyl)-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 593 Methyl 4-[({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoate 594 N- [ (3, 4-Dichlorophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylammo)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 595 N- { [4- (Aminocarbonyl) phenyl] methyl}-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 596 N-[(2, 6-Difluorophenyl) methyl]-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 597 N-{[3-(Aminocarbonyl) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 598 l-Ethyl-N- [ (4-hydroxyphenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 599 l-Ethyl-N- { [6- (methyloxy)-3-pyridinyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 600 1-Ethyl-N- (2-pyridinylmethyl)-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 601 l-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- { [3- (trifluoromethyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 602 N- [4- (2-Amino-2-oxoethyl) phenyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 603 1-Ethyl-N-({4-[(methylamino) carbonyl] phenyl} methyl)-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 604 1-Ethyl-N- {4- [2- (methylamino)-2-oxoethyl] phenyl}-4- (tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 605 1-Ethyl-N-[(3-fluorophenyl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 606 1-Ethyl-N- ( {4- [ (methylsulfonyl) amino] phenyl} methyl)-4- (tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 607 N-{[4-(Aminosulfonyl) phenyl] methyl}-I-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 608 N- { [2-(Aminocarbonyl) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 609 N- ({4-[Difluoromethyl) oxy] phenyl} methyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 610 N- ({3-[(Dimethylamino) methyl] phenyl} methyl)-l-ethyl-4-(tekahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 611 N-{[3-Chloro-4-(methyloxy) phenyl] methyl}-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 612 N- (1-Acetyl-4-piperidinyl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1 H-pyrazolo [3, 4- b] pyridine-5-carboxamide 613 1-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- { [2- (trifluoromethyl) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 615 N- (5-Chloro-2, 3-dihydro-lH-inden-2-yl)-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 616 N- {3-[(Acetylamino) methyl] phenyl} methyl)-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 617 1-Ethyl-N-[(4-fluorophenyl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 618 1-Ethyl-N-{[4-fluoro-2-(trifluoromethyl) phenyl] methyl}-4-(tekahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 619 1-Ethyl-N- [ (2-ethylphenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 620 1-Ethyl-N- { [2-fluoro-5- (trifluoromethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 621 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-[(2, 3, 4-trifluorophenyl) methyl]-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 622 N-[(4-Chloro-2-fluorophenyl)methyl]-1-ethyl-4-(tetrahydro-2H -pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 623 N- [ (4-Bromo-2-fluorophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 624 N- [ (3, 5-Dimethylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 625 N- [ (2, 3-Dimethylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 626 N-[(2, 3-Dichlorophenyl) methyl]-1-ethyl-4-(tekahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 627 N- [ (4-Cyanophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 628 N- [ (4-Bromophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 629 1-Ethyl-N-{[5-fluoro-2-(trifluoromethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 630 1-Ethyl-N- [ (4-iodophenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 631 N-{[4-(1, 1-Dimethylethyl) phenyl] methyl}-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 632 N- [ (3-Cyanophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 633 N- [ (2, 6-Dichlorophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 634 N- [ (5-Chloro-2-methylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 635 N- [ (3, 5-Dibromophenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 636 1-Ethyl-N-[(4-ethylphenyl) methyl]-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 637 1-Ethyl-N- { [3-fluoro-4- (trifluoromethyl) phenyl] methyl)-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 638 1-Ethyl-N- [ (2-iodophenyl) methyl]-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide 639 N- [ (2-Bromophenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 640 1-Ethyl-N- { [4- (hydroxymethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 641 1-Ethyl-N- { [3- (hydroxymethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 642 1-Ethyl-N- { [3- (hydroxymethyl)-2-methylphenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 643 N- { [2, 3-Dichloro-6-(hydroxymethyl) phenyl] methyl}-1-ethyl-4-(tekahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 644 N- [ (2, 4-Dichloro-6-methylphenyl) methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 645 1-Ethyl-N- { [4- (2-methylpropyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 646 N- [ (2, 5-dimethylphenyl) methyl]-l-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 647 l-Ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-N- [ (2, 4, 5-trifluorophenyl) methyl]-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 648 1-Ethyl-N- { [2-fluoro-4- (trifluoromethyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4- ylamino)-1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 649 N- [ (2-Chloro-6-methylphenyl) methyl]-1-ethyl-4- (tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 650 4-[( { [1-Ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridin-5-

yl] carbonyl} amino) methyl] benzoic acid sodium salt 651 3- {[1-Ethyl-4-(tekahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoic acid 652 Ethyl 1-ethyl-4-{[4-(hydroxyimino) cyclohexyl] amino}-1H-pyrazolo [3,4-b] pyridine-5- carboxylate 653 1-Ethyl-4- { [4- (hydroxyimino) cyclohexyl] amino}-N-{[4-(methyloxy) phenyl] methyl}-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 654 N-{[4-(Dimethylamino) phenyl] methyl}-1-ethyl-4-{[4-(hydroxyimino) cyclohexyl] amino}- 1H-pyrazolo [3,4-b] pyridine-5-carboxamide 655 1-Ethyl-4- {4-[(ethyloxy) imino] cyclohexyl} amino)-N- { [4- (methyloxy) phenyl] methyl}-1 H- pyrazolo [3,4-b] pyridine-5-carboxamide 656 l-Ethyl-4- ( {4- [ (methyloxy) imino] cyclohexyl} amino)-N-{[4-(methyloxy) phenyl] methyl}- 1 H-pyrazolo [3,4-b] pyridine-5-carboxamide 657 4- [ (4-1 [ (1, 1-Dimethylethyl) oxy] imino} cyclohexyl) amino]-1-ethyl-N- { [4- (methyloxy) phenyl] methyl}-lH-pyrazolo [3,4-b] pyridine-5-carboxamide 658 1-Ethyl-N-{[4-(methyloxy) phenyl] methyl}-4- [ (7-oxohexahydro-lH-azepin-4-yl) amino]-lH- pyrazolo [3,4-b] pyridine-5-carboxamide 659 Ethyll-ethyl-4- [ (7-oxohexahydro-lH-azepin-4-yl) amino]-lH-pyrazolo [3,4-b] pyridine-5- carboxylate 660 4- { [cis-4- (Butylamino) cyclohexyl] amino}-N- (2, 3-dihydro-lH-inden-2-yl)-1-ethyl-1H- pyrazolo [3,4-b] pyridine-5-carboxamide 661 4-[(trans-4-Aminocyclohexyl) amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 662 4- [ (trans-2-Aminocyclohexyl) amino]-l-ethyl-N- (phenylmethyl)-lH-pyrazolo [3,4- b] pyridine-5-carboxamide 663 4- [ (cis-2-Aminocyclohexyl) amino]-1-ethyl-N- (phenylmethyl)-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide 664 4- [ (3-Aminocyclohexyl) amino]-l-ethyl-N- (phenylmethyl)-lH-pyrazolo [3,4-b] pyridine-5- carboxamide Example Name No.

665 Ethyl l-ethyl-4- {[(lSR, 3RS)-3-hydroxycyclohexyl] amino}-lH-pyrazolo [3,4- b] pyridine-5-carboxylate 666 N, 1-Diethyl-4- {[(1SR,3RS)-3-hydroxycyclohexyl]amino}-1H-pyrazolo [3,4- b] pyridine-5-carboxamide 667 1-Ethyl-N-(4-fluorophenyl)-4-{[(lSR, 3RS)-3-hydroxycycloheXyl] amino}-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 668 1-Ethyl-4- { [(1 SR, 3RS)-3-hydroxycyclohexyl] amino}-N-(1, 3-thiazol-2-ylmethyl)- 1H pyrazolo [3, 4-b] pyridine-5-carboxamide 669 1-ethyl-N-[(4-fluorophenyl) methyl]-4-{[(lSR, 3RS)-3-hydroxycycloheXyl] amino}- 1H pyrazolo [3, 4-b] pyridine-5-carboxamide

670 1-ethyl-4-{[1SR,3RS)-3-hydroxycyclohexyl]amino}-N-{[4- (methylsulfonyl) phenyl] methyl}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 671 N { [3, 4-bis (methyloxy) phenyl] methyl}-1-ethyl-4-{[(1SR,3RS)-3- hydroxycyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 672 1-ethyl-4- [ (1 SR, 3RS)-3-hydroxycyclohexyl] amino}-N (2-pyridinylmethyl)-1 - pyrazolo [3, 4-b] pyridine-5-carboxamide 673 1-ethyl-4-{[(1RS,3RS)-3-hydroxycyclohexyl]amino}-N-[(1-methy l-1H-pyrazol-4- yl) methyl]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 674 N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-{[(1SR,3RS)-3- hydroxycyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 675 1-ethyl-4- [ (1SR,3RS)-3-hydroxycyclohexyl]amino}-N-{ [4- (methyloxy) phenyl] methyl}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 676 N-[(2, 4-dimethylphenyl) methyl]-1-ethyl-4- { [ (I SR, 3RS)-3- hydroxycyclohexyl] amino}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 667 N-[(2, 3-Dichlorophenyl) methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide 678 N-[(3-Chloro-4-methylphenyl) methyl]-1-ethyl-4-[(4-oXocycloheXyl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 679 N-[(4-Chloro-2-methylphenyl) methyl]-1-ethyl-4-[(4-oXocycloheXyl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 680 N-[(2, 4-Dimethylphenyl) methyl]-1-ethyl-4-{[4- (hydroxyimino) cyclohexyl] amino}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 681 N [ (3, 4-Dimethylphenyl) methyl]-1-ethyl-4- {[4- (hydroxyimino) cyclohexyl] amino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 682 N-[(2, 3-Dichlorophenyl) methyl]-1-ethyl-4-{[4- (hydroxyimino) cyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 683 N-[(3-Chloro-4-methylphenyl)methyl]-1-ethyl-4-{[4- (hydroxyimino) cyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 684 N-[(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-{[40 (hydroxyimino) cyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide 685 N-({4-[Difluoromethyl) oxy] phenyl} methyl)1-ethyl-4-{[4- (hydroxyimino) cyclohexyl] amino}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide 686 1-Ethyl-4-{[4-(hydroxyimino) cyclohexyl] amino}-N { [4- (trifluoromethyl) phenyl] methyl}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 1: Ethyl 4-(cyclopentylamino)-1-ethyl-lH-pyrazolo [3,4-b] pyridine-5- carboxylate That is, Example 1 is

Intermediate 1 (0. 051g) and cyclopentyl amine (0.019g) were suspended in ethanol (2ml) and triethylamine (0. 14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 16h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between dichloromethane (DCM) and water. The layers were separated and the organic layer was loaded directly onto an solid phase extraction (SPE) cartridge (silica, 5g) which was eluted sequentially with; (i) DCM, (ii) DCM: Et20 (2: 1), (iii) DCM: Et20 (1: 1), (iv) Et20, (v) EtOAc, (vi) MeOH.

Fractions containing desired material were combined and concentrated in vacuo to afford Example 1 (0.074g). LCMS showed MH+ = 303; TRET = 3. 45min.

Similarly prepared were the following: NHR3 Amine reagent MH+ ion TRET (min) Example 2 HNe Cyclohexyl amine 317 3. 65 Example 3 HNSO 4-Amino 319 2. 93 (= Intermediate 32) tetrahydropyran Example 5 HN4If Intermediate 6 360 3. 20 (= Example 207*) * For alternative synthesis of Example 5, see Example 207 hereinafter Example 3 (=Intermediate 32): Ethyl 1-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate

Instead of the method shown above for Examples 1-5 (called Method A), the compound of Example 3 can also be made: either using the minor variation of Method A described in detail under"Intermediate 32"hereinabove, or using the following Method B: Example 3, Method B: Intermediate 1 (2. 5g) was dissolved in acetonitrile (15ml).

4-Aminotetrahydropyran hydrochloride (1. lg) and N, N-diisopropylethylamine (9. 4ml) were added and the mixture stirred under nitrogen at 85°C for 16h. A trace of starting material remained, so an additional portion of 4-aminotetrahydropyran hydrochloride (O. l lg) was added and stirring continued at 85°C for a further 16h. The mixture was then concentrated in vacuo. The residue was partitioned between DCM and water. The layers were separated and the organic layer was washed with further water (2x20ml) then dried (Na2S04) and concentrated in vacuo. The residue was further purified by chromatography using Biotage (silica, 90g), eluting with cyclohexane: ethyl acetate to afford Example 3 (2.45g). LCMS showed MH+ = 319 ; TRET = 2. 90min. <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 6 Ethyl 4-(cyclopentylamino)-1-methyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxylate Intermediate 3 (0.045g) was placed in a Reactivial and treated with cyclopentyl amine (0. 07ml). The mixture was heated at 90°C for 2h, then allowed to cool to room temperature and partitioned between chloroform (2ml) and water (lml). The layers were separated and the organic phase was evaporated to a brown solid, which was purified by mass directed autoprep HPLC, to afford Example 6 as a white solid (0. 008g). LCMS showed MH+= 289; TRET = 3.22 min.

Example 7: Ethyl 1-methyl-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3,4- b] pyridine-5-carboxylate

Intermediate 3 (0.035g) was placed in a Reactivial and treated with 4-amino tetrahydropyran (0. 06ml). The mixture was heated at 90°C for 2h, then allowed to cool to room temperature and partitioned between chloroform (2ml) and water (lml). The layers were separated and the organic phase was concentrated, then applied to a preparative TLC plate (silica, 20cm x 20cm x lamm) which was eluted with ethyl acetate. The required band was removed from the plate and the silica washed with ethyl acetate (2 x 15ml). Concentration of the ethyl acetate solution in vacuo afforded Example 7 as a white solid (0. 008g). LCMS showed MH+= 305; TT = 2.67 min.

Example 8: Ethyl l-ethyl-4-[(3S)-tetrahydrofuran-3-ylamino]-lH-pyrazolo [3,4- b] pyridine-5-carboxylate Intermediate 1 (0. 05g) and (S)- (-)-3-aminotetrahydrofuran 4-toluene sulphonate (0.052g) were suspended in ethanol (lml) and triethylamine (0. 14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 24h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM (2ml) and water (1. 5ml). The layers were separated and the organic layer concentrated to dryness. Purification was carried out using an SPE cartridge (silica, 5g), eluting with a gradient of EtOAc : cyclohexane; (1: 16 then, 1: 8,1 : 4,1 : 2,1 : 1 and 1: 0). Fractions containing desired material were combined and concentrated in vacuo to afford Example 8 (0.052g). LCMS showed MH+ = 305; TROT = 2. 70min.

Similarly prepared were the following: NHR3 Amine Reagent MEI+ TRET (min) ion Example 9 NH (R)- (+)-3- 305 2. 73 Aminotetrahydrofuran 4-toluene sulphonate Example 10 HN-- (s Intermediate 11 335 3. 21 Example 11 CNH Intermediate 12 321 3. 10 (mixture of s enantiomers) Example 12 A Cyclopropylamine 275 2. 98 NH

Example 13: Ethyl 4- [ (1, 1-dioxidotetrahydrothien-3-yl) amino]-1-ethyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate NHR3 OEt N N co2Et NN/O 9 Example 13 NHR3 = HNX ° Intermediate 1 (0. 05g) and Intermediate 13 (0.027g) were suspended in ethanol (lml) and triethylamine (0. 14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 24h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM (2ml) and water (1. 5ml). The layers were separated and the organic layer concentrated to dryness. Purification was carried out using an SPE cartridge (silica, 5g), eluting with a gradient of EtOAc: cyclohexane; (1: 8 then 1: 4,1 : 2,1 : 1 and 1: 0). Fractions containing desired material were combined and concentrated in vacuo to afford Example 13 (0.045g) as a mixture of enantiomers. LCMS showed MH+ = 353; TRET = 2. 60min.

Similarly prepared was the following: NHR3 Amine Reagent MH+ TRET (nun) ion Example HN-S, ° Intermediate 14 367 2. 64 14° 14

Example 19 (reference example, as an intermediate) : Ethyl 4- (cyclopentylamino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxylate NHR3 NaACO2Et N I H N Example 19 NHR3 = HNX

Intermediate 2 (0.035g) was placed in a Reactivial and treated with cyclopentyl amine (0. 05ml). The mixture was heated at 90°C for 1.5h, then allowed to cool to room temperature and partitioned between chloroform (2ml) and water (lml). The layers were separated and the organic phase was concentrated. The residual solid was triturated with Et20 and the insoluble off-white solid collected and air-dried to afford Example 19 (0. 016g). LCMS showed MH+= 275; TRET= 2.58 min.

Example 20 (reference example, as an intermediate): Ethyl 4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxylate

NHR3 Cet N\ 1 14 that is : N N Example 20 NHR3 =HN H p HN- ('o

Intermediate 2 (0. 035g) was placed in a Reactivial and treated with 4- aminotetrahydropyran (0. 05ml). The mixture was heated at 90°C for 1.5h, then allowed to cool to room temperature and partitioned between chloroform (2ml) and water (lml). The layers were separated and the organic phase was concentrated. The crude product was purified by mass directed autoprep HPLC to afford Example 20 as an off-white solid (0. 01 Ig). LCMS showed MH+= 291 ; HOBT = 2.08 min.

Alternative synthetic method for Example 20: Intermediate 2 (2g) was suspended in 4-aminotetrahydropyran (2g), and the mixture was heated at 90 °C for 6h. The residual mixture was allowed to cool to room temperature and partitioned between chloroform (50ml) and water (50ml). The phases were separated and the organic phase was evaporated to dryness. The residue was triturated with Et20 (30ml) and the insoluble solid was collected and dried to afford Example 20 as a cream solid (2.24g). LCMS showed MH+= 291 ; TRET = 2. 19min.

Example 21: N-benzyl-l-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazo lo [3,4- b] pyridine-5-carboxamide

NHR3 O 1 5 wherein NR4R5 = HN<3 zu-l that is, Example 21 is : N I NR R N N NHR3 = HN N NHR HN- (O Et Three alternative methods, A, B and C, have been used to make Example 21, as follows: Example 21, Method A: A solution of the 4-chloro Intermediate 17 (0.031g, 0.1 mmol) in ethanol (1. 9ml) was treated with triethylamine (0. 07ml, 0.5 mmol), followed by a 0. 1M ethanolic solution of 4-aminotetrahydropyran (Intermediate 8, l. lml of the 0. 1M ethanolic solution = 0. 11 mmol). The mixture was heated at reflux (80°C) for 18h. A further portion of 4-amino- tetrahydropyran (0. Olml of undiluted amine, not a solution thereof) was then added and heating continued for a further 24h. Volatiles were removed in vacuo and the residue dissolved in dichloromethane (DCM), then applied to an solid phase extraction (SPE) cartridge (aminopropyl, lg) which was eluted first with DCM, then with methanol.

Fractions containing desired material were concentrated in vacuo to afford Example 21 (0.004g). LCMS showed MH+ = 380; TRET = 2. 92min.

Example 21, Method B: Intermediate 17 (0. 031g, 0.1 mmol) was dissolved in acetonitrile (lml).

4-Aminotetrahydropyran hydrochloride (Intermediate 8A, 0. 015g, 0.11 mmol) and N, N- diisopropylethylamine (0. 08ml, 0.5 mmol) were added and the mixture stirred under nitrogen at 85°C for 16h, then concentrated in vacuo. The residue was partitioned between dichloromethane (DCM) and water. The layers were separated and the organic layer was concentrated in vacuo to afford Example 21 (0.027g). LCMS showed MH+ = 380 ; TRET = 2. 92 min.

Example 21, Method C: This alternative route C to Example 21 involves formation of the ester of Example 3 = Intermediate 32 using one of the methods described above, conversion of the ester of Example 3/Intermediate 32 into the carboxylic acid (Intermediate 33) using the method given above for Intermediate 33, and then amide bond formation to form Example 21 using the method of Examples 81-84 below.

The following compounds can be similarly prepared using one or more of Methods A, B or C above, preferably Method A or B: NR4R5 NHR3 Starting Amine Reagent MH+ TRET Material (for ion (min) Method A or B) Example HN-F HN-CO Intennediate 19 4-amino 384 3. 09 22 tetrahydropyran Example OwNH HN O Intermediate 20 Cyclopentyl 342 3. 29 23 amine Example NH HN Intermediate 20 Cyclohexyl 356 3. 47 24 amine Example NH HN-CO Intermediate 20 4-amino 358 2. 79 25 tetrahydropyran Example OwNH HN<Nf Intermediate 20 Intermediate 6 400 2. 64 27 Example HN O Intermediate 21 Cyclopentyl 328 2. 69 28 amine Example HN Intermediate 21 Cyclohexyl 342 2. 87 amine Example N HN {3O Intermediate 21 4-amino 344 2. 33 30 tetrahydropyran Example HN-0 Intennediate 22 Cyclopentyl 365 2. 38 31 amine 31amine Example HNn HNoO Intermediate 22 Cyclohexyl 379 2. 54 32 amine Example HN i NN-o Intermediate 22 4-amino 381 2. 09 33tetrahydropyran Example NH : 2 HN O Intermediate 24 Cyclopentyl 274 2. 59 34 amine Example NH2 HNE Intermediate 24 Cyclohexyl 288 2. 79 35 amine Example NH2 HN-CO Intermediate 24 4-amino 290 2. 22 36 tetrahydropyran

Example 39: N-Benzyl-4-(cyclopentylamino)-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide NHR3 O N/' NR4R5 wherein NR4R5 = HN N that is, Example 39 is : IN N NHR3 = HN N NHR3 = HN Et A solution of Intermediate 17 (0.031g, 0.1 mmol) in ethanol (lml) was treated with triethylamine (0. 07ml, 0.5 mmol), followed by a 0. 1M ethanolic solution of cyclopentyl amine (l. lml of the 0. 1M ethanolic solution = 0. 11 mmol). The mixture was heated at reflux (80°C) for 18h. A further portion of cyclopentyl amine (0. 009ml of undiluted amine, not a solution thereof) was then added and heating continued for a further 24h. Volatiles were removed in vacuo and the residue dissolved in DCM, then applied to an SPE cartridge (aminopropyl, lg) which was eluted first with DCM, then with methanol.

The DCM fraction was concentrated in vacuo, then applied to an SPE cartridge (silica, 0. 5g) which was eluted sequentially with (i) DCM, (ii) Et20, (iii) EtOAc and (iv) MeOH. Fractions containing desired material were combined to afford Example 39 (0.007g).

LCMS showed MH+ = 364; TRET = 3. 38min.

Similarly prepared were the following: NR4R5 NHR3 Starting Amine MH+ TRET Material reagent ion (min) Example HN-0 Intermediate Cyclohexyl 378 3. 43 40 17 amine Example hitennediate Intermediate 421 2. 75 41 17 6 jtl"176 Example Hm HN-0 Intermediate Cyclopentyl 358 3. 63 42 s 18 amine Example"HN-- Intermediate Cyclohexyl 372 3. 79 18 amine Example"H'1"N- (O Intermediate 4-amino 374 3. 13 44 s 18 tekahydro- pyran Example 1 HN4I Intermediate Intermediate 387 2. 37 jt5-18J7 Example HN HN-CN 0 Intermediate Intermediate 415 2. 92 46 18 6 Example HN<F nN Intermediate Cyclopentyl 368 3. 61 47 19 amine Example HN-C-F HN-0 intermediate Cyclohexyl 382 3. 76 48 19 amine Example HN-0-F HN-C2-hiten-nediate Intermediate 397 2. 29 49 19 7 Example HN--O-F HN-CN Intermediate hitermediate 425 2. 88 50 19 6 Example HN""' Intermediate Cyclopentyl 316 3. 05 51 23 amine Example HN~ HNe Intermediate Cyclohexyl 330 3. 26 52 23 amine Example HN~ HN {) o Intermediate 4-amino 332 2. 58 53 23 tetrahydro- pyran Example HN"HN-CN- Intermediate Intermediate 373 2. 46 55 23 6 Example 57: 4- [ (1-Acetylpiperidin-4-yl) amino]-1-ethyl-N- (pyridin-4-ylmethyl)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide

NHR 3 0 wherein NR4R5 = HN \\/\ 4 5 \ N that is, Example 57 is : N i4 NR4R5 N IN N+ NHR3 = HNiNXo Et Et A solution of Intermediate 22 (0. 03g, ca. 0.1 mmol) in ethanol (lml) was treated with triethylamine (0. 07ml, 0.5 mmol), followed by a 0. 1M ethanolic solution of Intermediate 6 (l. lml of the solution = 0. 11 mmol). The mixture was heated at reflux (80°C) for 18h.

A further portion of Intermediate 6 (0. Olml, undiluted) was then added and heating continued for a further 24h. Volatiles were removed in vacuo and the residue dissolved in DCM, then applied to an SPE cartridge (aminopropyl, I g) which was eluted first with DCM, then with methanol.

The DCM fraction was concentrated in vacuo, then applied to an SPE cartridge (silica, 0. 5g) eluting with (I) DCM, (ii) EtOAc and (iii) a stepwise gradient of chloroform: methanol (from 99: 1 up to 4: 1). Fractions containing desired material were combined to afford Example 57 (0. 003g). LCMS showed MH+ = 422; TRET = 2. 1min.

Example 61: N-Benzyl-4-(cyclopentylamino)-1-methyl-lH-pyrazolo [3,4-b] pyridine- 5-carboxamide NHR3 ° NS NR4R5 Example 61 NR4R5 =HN N\ I NR R"o N N NHR3 = HN Me A solution of Intermediate 28 (0. 03g, 0.1 mmol) in ethanol (1 ml) was treated with a 0. 1M ethanolic solution of cyclopentyl amine (l. lml of solution = 0. 11 mmol). Triethylamine (0. 07ml, 0.5 mmol) was then added and the mixture heated at reflux (85°C), under

nitrogen for 12h. A further portion of cyclopentyl amine (0. 009ml, undiluted) was then added and heating continued for a further 36h. The mixtures were concentrated in vacuo and the residue treated with chloroform. A small amount of insoluble material was collected by filtration, then the filtrate applied to an SPE cartridge (aminopropyl, Ig) which was eluted first with DCM, then with methanol. Fractions containing desired material were combined to afford Example 61 (0.039g). LCMS showed MH+ = 350 ; TRET = 2. 88min.

Similarly prepared were the following: NR4R5 NHR3 Starting Amine Reagent MH TRET Material + (min) ion Example 62 HN-0 Intermediate 28 Cyclohexyl 364 3. 05 amine Example 63 HN<3 HN4o Intermediate 28 4-amino 366 2. 52 tetrahydropyran Example 64 3/HN O Intermediate 30 Cyclopentyl 344 3. 06 amine Example 65 HN HN-0 Intermediate 30 Cyclohexyl 358 3. 23 amine Example 66 HN4O Intermediate 30 4-amino 360 2. 69 tetrahydropyran Example 67 HN-C-F HN-0 Intermediate 29 Cyclopentyl 354 3. 17 amine Example 68 HN< F HNoO Intennediate 29 Cyclohexyl 368 3. 33 amine Example 69 HN t F HN4O Intermediate 29 4-amino 370 2. 72 tetrahydropyran Example 70 NH2 HN Intermediate 31 Cyclopentyl 260 2. 10 amine Example 71 NH2 HNe Intermediate 31 Cyclohexyl 274 2. 29 amine Example 74: 4- [ (l-Acetylpiperidin-4-yl) amino]-N-benzyl-l-methyl-lH-pyrazolo [3,4- b] pyridine-5-carboxamide

NHR3 ° that is, Example 74 is : N, INR4R5'-0 0 ll N/\NJ NHR3 = _NH N I Me A solution of Intermediate 28 (0. 03g, 0.1 mmol) in ethanol (lml) was treated with a 0. 1M ethanolic solution of Intermediate 6 (l. lml of solution = 0. 11 mmol). Triethylamine (0. 07ml, 0.5 mmol) was then added and the mixture heated at reflux (85°C), under nitrogen for 12h. A further portion of Intermediate 6 (0.1 mmol) was then added and heating continued for a further 36h. The mixtures were concentrated in vacuo and the residue treated with chloroform. A small amount of insoluble material was collected by filtration, then the filtrate applied to an SPE cartridge (aminopropyl, 1 g) which was eluted first with DCM, then with methanol. Fractions containing desired material were combined and concentrated in vacuo. The residue was further purified by SPE (silica, 0. 5g) eluting with (i) DCM, (ii) chloroform, (iii) EtOAc and (iv) a stepwise gradient of chloroform: methanol (from 99: 1 up to 4: 1). Fractions containing desired material were combined to afford Example 74 (0.029g). LCMS showed MH+ = 407; TRET = 2.57 min.

Example 81: 1-Ethyl-N-methyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide Example 81 NR4R5 = NHMe To a stirred suspension of Intermediate 33 (0.025g, ca. 0.08 to 0.09 mmol) in chloroform (2ml) was added thionyl chloride (0. 025ml) and the mixture stirred at room temperature

for lh. The mixture was cooled to 0°C and methylamine added (2M solution in THF, 0. 69ml = 1. 38 mmol). After returning to room temperature the mixture was stirred for a further lh, then quenched by addition of water (4ml) and the layers separated. The organic layer was concentrated then applied to an SPE cartridge (silica, lg) which was eluted with (i) DCM, (ii) Et20 (2: 1), (iii) EtOAc, (iv) MeOH : EtOAc (1: 9). Fractions containing desired material were combined to afford Example 81 (0.019g). LCMS showed MH+ = 304; TRET = 2. 19min.

Similarly prepared: NR4R5 Amine reagent MH+ TRET ion (min) Example NMe2 Dimethylamine (2M in THF) 318 2.06 82 Example NHEt Ethylamine (2M in THF) 318 2.31 83 Example NHiPr Isopropylamine (2M in THF) 332 2.44 84 Example 83: N, 1-Diethyl-4- (tetrahydro-2H-pyran-4-ylamino)-IH-pyrazolo [3,4- b] pyridine-5-carboxamide ; also named 1-ethyl-N-ethyl-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide In an alternative embodiment to the process described for Examples 81-84 above, Example 83 can be made according to the following method: A mixture of Intermediate 33 (3. 0g, 10.33mmol), EDC (2.25g, 11. 7mmol), and HOBT (1.68g, 12. 4mmol) was stirred at room temperature for 1 hour. Ethylamine (6. 2ml,

12.4mmol, 2M-solution in THF) was added, and stirring was continued at room temperature for 22 hours. The solvents were removed in vacuo, and the residual solid was dissolved in chloroform (250ml) and washed successively with water (70ml) and 5%- sodium hydrogen carbonate solution (70ml). After drying over anhydrous sodium sulphate, the organic solution was evaporated in vacuo to give a pale orange solid (4. 15g). This solid was dissolved in a mixture of dichloromethane (15ml) and chloroform (5ml) and purified by-column chromatography (Biotage, silica, 100g), eluting initially with EtOAc-cyclohexane (2: 1) and finally with neat EtOAc. The product containing fractions were combined and evaporated to give Example 83 as a pale yellow solid (3. 05g). LCMS showed MH+ = 318; TRET = 2. 33min. 1H NMR (400MHz in d6-DMSO, 27°C, bppm) 9.76 (d, 1H) 8. 35 (s, 1H) 7.94 (s, 1H) 5.99 (br m, 1H) 4.47 (q, 2H) 4.16- 4.01 (m's, 3H) 3.62 (m, 2H) 3.48 (m, 2H) 2.13 (m, 2H) 1.77 (m, 2H) 1.49 (t, 3H) 1.28 (t, 3H).

Example 85: N-Benzyl-1-ethyl-4- [ (3S)-tetrahydrofuran-3-ylamino]-1H-pyrazolo [3,4- b] pyridine-5-carboxamide That is, Example 85 is: Intermediate 41 (0.017g, 0.062 mmol) was dissolved in DMF (2ml), then treated with HATU (0. 023g) followed by diisopropylethyl amine (0. 021ml) and the mixture stirred for 10 min. Benzylamine (0. 007ml) was then added and stirring continued for a further 64h.

The mixture was concentrated in vacuo and the residue dissolved in DCM (1. 5ml) then treated with saturated aqueous sodium bicarbonate solution (1. 5ml). This mixture was stirred for 30 min, then the layers were separated and the organic layer was applied to an SPE cartridge (silica, lg) which was eluted sequentially with a gradient of ethyl acetate: cyclohexane (1: 4, then 1: 2,1 : 1,2 : 1 and 1: 0). Fractions containing desired material were concentrated in vacuo to afford Example 85 (0.017g). LCMS showed MH+ = 366; TRET 2. 80min.

Similarly prepared were the following: NHR3 Starting material MH+ TRET ion (min) Example 86 N Intermediate 42 366 2. 80 o Example 87 SNH Intermediate 44 382 3. 11 s Example 88 A Intermediate 45 336 3. 00 NH Example 89"N, o Intermediate 46 414 2. 69 u\ Example 90 HN-s o hltermediate 47 428 2. 75 o

Example 91: N-Benzyl-l-ethyl-4-(tetrahydro-2H-thiopyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide

Intermediate 43 (0.019g) was dissolved in DMF (2ml), then treated with HATU (0.024g) followed by diisopropylethyl amine (0. 022ml) and the mixture stirred for 10 min.

Benzylamine (0. 007ml) was then added and stirring continued for a further 64h. The mixture was concentrated in vacuo and the residue dissolved in DCM (1. 5ml) then treated with saturated aqueous sodium bicarbonate solution (1. 5ml). This mixture was stirred for 30 min, then the layers were separated and the organic layer applied to an SPE cartridge (silica, Ig) which was eluted sequentially with a gradient of ethyl acetate: cyclohexane (1: 4, then 1: 2,1 : 1 and 1: 0). Fractions containing desired material were concentrated in vacuo to afford Example 91 (0.023g). LCMS showed MH+ = 396; TpBT = 3. 26min.

Example 92: 1-Ethyl-N-(4-fluorophenyl)-4-[(3S)-tetrahydrofuran-3-ylamino ]-1H- pyrazolo [3, 4-b] pyridine-5-carboxamide

NHR3 O/I F N that is, Example 92 ! s : N"M-wherein NHR3 = HN""< j N wherein NHR3 = HNæ GO Intermediate 41 (0.017g) was dissolved in DMF (2ml), then treated with HATU (0.023g) followed by diisopropylethyl amine (0. 021ml) and the mixture stirred for 10 min. 4- Fluoroaniline (0. 006ml) was then added and stirring continued for a further 64h. The mixture was concentrated in vacuo and the residue dissolved in DCM (1. 5ml) then treated with saturated aqueous sodium bicarbonate solution (1. 5ml). This mixture was stirred for 30 min, then the layers were separated and the organic layer concentrated in vacuo. The crude mixture was purified by mass directed autoprep HPLC to afford Example 92 (0.013g). LCMS showed MH+ = 370; TRET = 2. 91min.

Similarly prepared were the following: NHR3 Starting material MH+ TRET ion (min) Example 93 Intermediate 42 370 2. 91 Example 94 HN {3S Intermediate 43 400 3. 37 Example 95 \/Intermediate 44 386 3. 27 s Example 96 A Intermediate 45 340 3. 21 NH Example 97"N, o Intermediate 46 418 2. 80 LA zozo Example 98 HN<S"O Intermediate 47 432 2. 84 po

Example 99 In all of Examples 22 to 98, where a 4-amino 5-carboxamide Example of the following Formula I has been synthesised from the 4-chloro derivative, then an alternative final-step synthesis is as follows:

Formula IV Formula I An intermediate of Formula IV above (0. lmmol) was dissolved in acetonitrile (lml). An amine of formula R3NH2 (O. l lmmol, 1.1 mole equivalents) and N, N- diisopropylethylamine (0. 5mmol, 5 mole equivalents) were added and the mixture stirred under nitrogen at 85°C for 16h. After concentration in vacuo, the residue was partitioned between dichloromethane (DCM) and water. The layers were separated and the organic layer was concentrated in vacuo to afford an Example of Formula I.

Example 100 0 aN H 0 z NR4Rs ZON N N N Example 100 NR4R5 = o 0

Intermediate 33 (0. 048mmol) was dissolved in DMF (0. 5ml), then treated with HATU (0. 048mmol) followed by diisopropylethyl amine (0. 096mmol) and the mixture stirred for 10 min. 4-Methylsulfonylbenzylamine (0.052mmol, available from Acros Organics) was then added and stirring continued for a further 16 hours. The mixture was concentrated in vacuo. The crude mixture was purified by mass directed autoprep HPLC to afford Example 100 (0. 013g). LCMS showed MH+= 458; TRET = 2. 22min.

Similarly prepared, but replacing the 4-methylsulfonylbenzylamine with the same or similar number of moles of another amine R4R5NH, were the following compounds (Examples 102 to 182): NR4R5 (the N Source of R4R5NH Starting MH TRET atom linking R4 Material + ion (min) and R5 to the - CO-pyrazolo- pyridine moiety is underlined) Example 102 J. Chem. Soc., 1945, Intermediate 458 2. 2 HN w S 3 633 33 0 Example 103 F F WO 98/52943 Intermediate 490 2. 66 e ; 33 CH3 CH, CH3 Example 104 J Org. Cliem., 1979, Intermediate 415 2. 28 44 (3), 396 33 Example 105 l SerEya Intermediate 456 2. 65 Khimicheskaya, 1989, 33 (7), 1694 Example 106 SALOR (Aldrich) Intermediate 458 2. 32 HO ß 33 ci ci Example 107 H3c o Maybridge Chemical Intermediate 461 2. 5 HNs, N Company Ltd. 33 Trevillett Tintagel Cornwall PL34 OHW United Kingdom Example 108 H3CXCH3 MicroChemistry-Intermediate 390 2. 28 ° CH RadaPharma 33 Shosse Entusiastov 56 Moscow, 111123 Russia Example 109 N MicroChemistry-Intermediate 387 2. 13 HN RadaPharma 33 s Shosse Entusiastov 56 Moscow, 111123 Russia. Alternatively, available from : Matrix Scientific (USA), or Synthesis 1998, 641, or Tetrahedron 1995, 51, 12731 Example 110 Bulletin des Societes Intermediate 382 1. 98 Chiniiques Belges, 33 (1982), 91 (2), 153 Example 111 HN N MicroChemistry-Intermediate 401 2. 14 3 RadaPharma 33 s Shosse Entusiastov 56 Moscow, 111123 Russia Example 112 HN I ° cH3 Intermediate 466 2. 67 * ijN ! OCH, H3C CH3 33 Example 113 HN °\\Sz° Ultrafine (UFC Ltd.), hltermediate 425 2 CH3 see above for address 33 CH3 Example 114 \ Austin Chemical Intermediate 382 2 Company, hic. 33 p Y 1565 Barclay Blvd. Buffalo Grove, IL, 60089 USA Example 115 3 WO 02/83624 Intermediate 464 1. 97 r'N"-r 33 N N Example 116 Fluka Chemie AG Intermediate 432 2. 52 33 HN Z Example 117 HNXl MicroChemistry-Intermediate 397 1. 96 HN ) N o RadaPharma 33 H Shosse Entusiastov 56 Moscow, 111123 Russia Example 118 WO 02/85860 Intermediate 423 2. 09 HN NH2 33 0 Example 119 HN'AH Butt Park Ltd. Intermediate 423 2. 19 wNCH3 Braysdown Works 33 ° Peasedown St. John Bath, BA2 8LL, United Kingdom Example 120 HNN-CH3 Sigma Intermediate 398 1. 77 Nt/33 Example 121 HN<NH H US 4562184 Intermediate 452 2. 21 N , FNe 33 W Example 122 HN N\ Dynamit Nobel GmbH, Intermediate 372 1. 93 N Germany ; or Saville 33 N. N Whittle Ltd (UK agents of Dynamit Nobel), Vickers Street, Manchester M40 8EF, United Kingdom Example 123 HO NON WO 02/66470 Intermediate 385 1. 93 1 N Nit/33 Example 125 HNon Aldrich Intermediate 434 2. 84 vif 33 F F Example 126 HNst AstaTech, Inc. Intermediate 473 2. 5 yBCH Y ,"3 8301 Torresdale Ave. 33 19C, Philadelphia, PA, 19136, USA Example 127 ~o Ós+O Intermediate 425 1. 99 0 0 33 Example 128 1 J ; Org Chem., 2001, Intermediate 423 1. 97 HN 66 (6), 1999 33 HIC CHUG Example 129 HN Acros Organics Intermediate 401 1. 82 33 6". Example 130 HN Aldrich Intermediate 374 2. 08 33 0 Example 131 HN Combi-Blocks Inc., Intermediate 374 2. 04 0 7949 Silverton Av., 33 Suite 915, San Diego, CA 92126, USA (see also Intermediate 8A) Example 132 N"J. Og. Chem., 1955, Intermediate 487 2. 39 YY 20, 1657 33 sssO zu O Example 133 HN J. Med. Chem., 1999, Intermediate 473 2. 24 42 (14), 2504 ; 33 or variation of : Lis et MH NH al., J. Med. Chem., -SCH3 0 1990, 33 (10), 2883, see Scheme III and ref. 24 Example 135 HN Aldrich Intermediate 396 2. 42 Oc"a 33 U Example 136 HN Aldrich Intermediate 415 2. 03 33 90 Example 137 fez Aldrich Intermediate 401 1. 78 HN N 33 Example 138 HN X Aldrich Intermediate 381 1. 81 33 No Example 139 HN MicroChemistry-Intermediate 387 1. 74 RadaPharma 33 CH3 Shosse Entusiastov 56 Moscow, 111123 Russia Example 140 CH3 Aldrich Intermediate 360 2. 16 HN 33 CH3 Example 141 ! IN Aldrich Intermediate 401 1. 81 33 Example 142 HN Aldrich Intermediate 417 1. 75 33 N 0 Example 143 _~OwCH3 Aldrich Intermediate 376 2. 16 33 Example 144 HN Aldrich ; or Baruah et Intermediate 386 2. 59 XJ al., Synlett, 1999, 4, 33 409 Example 145 Aldrich Intermediate 375 1. 73 33 " CH, 33 Example 146 H3C CH Fluorochem Ltd. Intermediate 360 2. 16 HN Wesley Street 33 CH3 Old Glossop Derbyshire SK13 7RY United Kingdom Example 147 HN\ Aldrich ; or Acros ; or Intermediate 410 2. 4 Jung et al., 33 Tetrahedron Lett., 0 2002, 43 (48), 8735 ; or i H3C Meindl et al., J. Med. Chem., 1984, 27 (9), 1111 ; or Organic Lett., 2002, 4 (12), 2055 Example 148 HN N, s Berk Univar plc Intermediate 473 2. 26 Berk House 33 P. O. Box 56 Basing View Basingstoke Hants RG21 2E6, United Kingdom Example 149 0 Aldrich Intermediate 375 1. 9 C3 33 H Example 150 HNs °\\S"O MicroChemistry-Intermediate 411 1. 95 HN Is, O H CH RadaPharma 33 Shosse Entusiastov 56 Moscow, 111123 Russia Example 152 HN Nippon Kagaku Intermediate 453 1. 96 N, CH3 Zasshi., 1960, 81 33 p. 962. CH3 Example 153 Aldrich Intermediate 408 2. 35 Han 33 Example 154 HN F Aldrich Intermediate 416 2. 5 33 F Example 155 F Aldrich ; or Meindl et Intermediate 448 2. 68 A F al., J. Med. Chem., 33 HN\/H 1984, 27 (9), 1111 ; or Organic Letters, 2002, 4 (12), 2055 Example 156 CH3 Alfa Aesar, Intermediate 360 2. 16 A Johnson Matthey 33 Company 30 Bond Street Ward Hill, MA 01835-8099 USA Example 157 HN-__7 Aldrich Intermediate 330 2. 04 33 Example 158 0 Aldrich Intennediate 347 1. 83 HN 33 NHR Example 159 HN/Aldrich Intermediate 396 2. 49 kJ" 0 \/NH2 Aldnch htermedi X Example 160 HN Aldrich Intermediate 416 2. 53 33 F F Example 161 Aldrich Intermediate 390 2. 18 0 33 Example 162 HNn cq Aldrich Intermediate 463 1. 96 33 Example 163 N US 4987132 Intermediate 458 2. 13 N 33 H CH, Example 164 HNN\ Aldrich Intermediate 374 2. 22 N 33 S Example 165 Aldrich ; or TCI-Intermediate 406 2. 53 America ; or 33 Maybridge-Int. Example 166//Maybridge Chemical Intermediate 402 1. 93 NH Company Ltd. 33 Trevillett Tintagel Cornwall PL34 OHW United Kingdom Example 167 HN Aldrich ; or Baruah et Intermediate 440 2. 3 al., Synlett, 1999, 4, 33 409 H3c o H, C-° Example 168 HN Aldrich ; or Meindl et Intermediate 414 2. 58 al., J. Med. Cheyn., 33 1984, 27 (9), 1111 ; or Organic Letters, ci 2002, 4 (12), 2055 Example 169 Aldrich Intermediate 373 1. 64 T'33 T N 33 '\/sCH3 Example 170 OH Aldrich Intermediate 334 1. 85 33 33 Example 171 N Aldrich Intermediate 465 2. 29 r 33 H, C "3 P Example 172 <1 °\, o EP 666258 Intermediate 458 2. 25 % o s/33 _S\CH, 33 Example 173 HN N"3 J. Claem. Soc., 1954, Intermediate 389 1. 98 1171 33 0 Example 174 HN CH3 Peakdale Molecular Intermediate 384 1. 76 N Ltd, Peakdale Science 33 //Park, Sheffield Road, N Chapel-en-le-Frith, High Peak SK23 OPG, United Kingdom Example 175 HNon Fluorochem Ltd. Intermediate 459 2. 36 , s c"3 Wesley Street 33 //,-o Old Glossop Derbyshire SK13 7RY United Kingdom Example 176 HN Lancaster Synthesis Intermediate 343 2. 01 N Ltd, Newgate, White 33 Lund, Morecambe, Lancashire LA3 3DY, United Kingdom Example 178 HN TimTec, Inc. Intermediate 384 2. 03 P O Box 8941 33 Newark, DE, 19714- N-N 8941 CH3 USA Example 179 lCH3 ChemBridge Europe, Intermediate 398 1. 70 4 Clark's Hill Rise, 33 Hampton Wood, Evesham, Worcestershire WR11 6FW, United Kingdom Example 180 HN Aldrich Intermediate 400 2. 41 sJ 33 Example 181 HN Aldrich Intermediate 428 2. 61 cl 33. Example 182 0 CH3 Aldrich Intermediate 424 2. 49 HN--6 33 i

Example 109: 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-N-(1, 3-thiazol-2- ylmethyl)-1H pyrazolo [3, 4-b] pyridine-5-carboxamide

An alternative process for preparing Example 109 is given below: 1-Hydroxybenzotriazole (0.215g, 1. 59mmol) and 1- [3- (dimethylamino) propyl] -3-ethyl- carbodiimide hydrochloride (0.357g, 1. 86mmol) were added to a suspension of Intermediate 33 (0.384g, 1. 32mmol) in DMF (10ml). After stirring at room temperature for 30 minutes, (1, 3-thiazol-2-ylmethyl) amine (0. 182g, 1. 59mmol) (commercially available from MicroChemistry Building Blocks (Russia) or Matrix Scientific (USA), or preparable as disclosed in Synthesis 1998,641, or Tetrahedron 1995,51, 12731) was added. The reaction was stirred for 18 hours and then partitioned between ether and water. The organic phase was washed with brine, dried (MgS04) and evaporated in

vacuo. The residue was purified by chromatography (Biotage, silica90g) eluting with cyclohexane: EtOAc followed by EtOAc. The material was triturated with cyclohexane and filtered to afford Example 109 (0.244g) as a pale yellow solid. LCMS showed MH+ 387 ; TRET = 2. 49min. 1H NMR (400MHz in CDC13, 8ppm) 5 9.74 (d, 1H) 8.50 (s, 1H) 7.94 (s, 1H) 7.74 (d, 1H), 7. 33 (d, 1H), 7.17 (m, 1H), 4.94 (d, 2H) 4.45 (q, 2H) 4.15- 4.00 (m, 3H), 3.63 (m, 2H). 2.15 (m, 2H) 1.85-1. 73 (m, 3H) 1.48 (t, 3H).

Example 167: N-{[3, 4-Bis (methyloxy) phenyl] methyl}-l-ethyl-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide

In an alternative embodiment to the process described above for Examples 100-182, Example 167 can be made according to the following method: A mixture of Intermediate 33 (0.498g, 1. 72mmol), EDC (0.46g, 2. 41mmol), and HOBT (0.278g, 1. 68mmol) was stirred at room temperature for 0.25 hours. Veratrylamine (3,4-dimethoxybenzylamine, 0. 3 lml, 2. 05mmol, obtainable from Aldrich or Synlett, 1999,4, 409) was added, and stirring was continued at room temperature for 22 hours.

The reaction mixture was partitioned between Et2O and water. The aqueous phase was extracted with Et20 and the combined organic phases washed with brine, dried (MgS04) and evaporated in vacuo. The residue was purified by chromatography (Biotage, silica 40g) eluting with EtOAc: cyclohexane (2: 1). The material was further purified by SPE (SCX-2, lOg) eluting with methanol then ammonia in methanol (0. 5M). The ammonia methanol fractions were combined and evaporated in vacuo to afford Example 167 as a white foam (0.633g). LCMS showed MH+ = 440; TRET = 2. 65min. 1H NMR (400MHz in CDC13, 27°C, bppm) 9.78 (d, 1H) 8.37 (s, 1H) 7.94 (s, 1H) 6.94-6. 82 (m, 3H) 6.29 (br m, 1H) 4.56 (d, 2H) 4.46 (q, 2H) 4.15-4. 01 (m's, 3H) 3.89 (s, 6H) 3.63 (m, 2H) 2.15 (m, 2H) 1.78 (m, 2H) 1.49 (t, 3H).

Example 178 1-Ethyl-N-[(l-methyl-lH-pyrazol-4-yl) methyl]-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide The 1H NMR data for Example 178 (as prepared by the process described in Examples 100-182 above) was as follows:

1H NMR (400MHz in CDC13, bppm) 8 9. 90 (m, 1H) 8. 37 (s, 1H) 7.94 (s, 1H) 7.49 (s, 1H), 7.40 (s, 1H) 6.39 (m, 1H0 4.50-4.42 (m, 4H) 4.15-4.00 (m, 3H) 3.89 (s,3H), 3.63 (m, 2H) 2.52 (m, 2H) 2.20-2. 10 (m, 2H) 1. 85-1. 73 (m, 3H) 1. 48 (t, 3H).

Example 183: Ethyl 4-(cyclohexylamino)-1-(3-ethoxy-3-oxopropyl)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate

A vigorously stirred mixture of Intermediate 48 (40mg), anhydrous potassium carbonate (57mg) and ethyl 3-bromopropanoate (0. 027ml) in anhydrous DMF (lml) was heated at 65 °C overnight. The reaction mixture was concentrated, and the residue was partitioned between dichloromethane (5ml) and water (5ml). The phases were separated and the organic phase was evaporated to a residual oil which was purified by mass directed autoprep HPLC to afford Example 183 (5mg). LCMS showed MH+= 389 ; TRET = 3. 65min.

Example 185: Ethyl l-n-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate

Sodium hydride (0.067g, 60% dispersion in oil) was added to a stirred solution of Example 20 (0.47g) in DMF (19ml), followed by n-propyl iodide (0. 17ml). The mixture was stirred at 23 °C for 16 hours, then concentrated, diluted with chloroform (30ml) and washed with 1: 1 water: brine solution (30ml), separated and the organic layer concentrated. The residue was purified on a SPE catridge (silica, l Og) eluting with 10ml volumes of dichloromethane, 1: 1 diethyl ether: cyclohexane, and diethyl ether. The

combined 1: 1 diethyl ether: cyclohexane, and diethyl ether, fractions were concentrated to give Example 185 as a clear gum (0.23g). LCMS showed MH+ = 333; TRET = 3. 14min.

Example 186: Ethyl 1-(2-hydroxyethyl)-4-(tetrahydro-2H-pyran-4-ylamino)- 1H pyrazolo [3, 4-b] pyridine-5-carboxylate

2-Bromoethanol (0. 008ml) was added to a solution of Example 20 (0.03g) in anhydrous DMF (1. 5ml), with 2-tert-butylimino-2-diethylamino-1, 3-dimethyl-perhydro-1, 3,2- diazaphosphorine (polymer bound, 2.3mmol/g loading, 0.045g). The mixture was shaken at 23 °C for 16 hours, then the solution drained from the resin, and the resin was washed with DMF. The combined organics were concentrated, and the residue purified on a SPE cartridge (silica, 1 g) eluting with 70-100% ethyl acetate in cyclohexane. The combined fractions were concentrated to give Example 186 as a white solid (0. 01 lg). LCMS showed MH+ =335; TRET = 2.47min.

Example 187 : N-[4-(Methylsulfonyl) benzyl]-l-n-propyl-4-(tetrahydro-2H- pyran-4-ylamino)-1H pyrazolo [3, 4-b] pyridine-5-carboxamide

Intermediate 50 (0.03g) was stirred in DMF (lml) with DIPEA (0. 035ml) and HATU (0. 038g) for 20 min. 4-(Methylsulfonyl) benzylamine hydrochloride (0.024g) was added to the mixture and the solution was stirred for 8 hours at 23 °C. The solution was concentrated and the residue dissolved in dichloromethane (6ml) then washed with saturated sodium bicarbonate solution (6ml) and 1: 1 brine: water (6ml), separated by hydrophobic frit. The organic layer was concentrated to give Example 187 as a white solid (0.039g). LCMS showed MH+ = 472; TRET = 2. 67min.

Example 188 : N (4-Fluorophenyl)-1-n-propyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide The synthetic method is as described in Example 187, except that in place of 4- (methylsulfonyl) benzylamine hydrochloride, 4-fluoroaniline (0. Olml) was added to the mixture. The resultant product required further purification, which was performed by mass directed autoprep HPLC, giving Example 188 as a clear gum (0. 03g). LCMS showed MH+ = 398; TRET = 3.13min.

Example 189 : Ethyl 1-ethyl-6-methyl-4- (tetrahydro-2H-pyran-4-ylamino)- 1H-pyrazolo [3, 4-b] pyridine-5-carboxylate 4-Aminotetrahydropyran hydrochloride (Intermediate 8A, 0. 413g, 3. 0mmol) was added to a mixture of Intermediate 51 (0.268g, l. Ommol) and N, N-diisopropylethylamine (0. 87ml, 5. 0mmol) in acetonitrile (3ml). The resulting mixture was heated at 85 °C for 24 hours. Volatiles were removed in vacuo and the residue was dissolved in chloroform (1. 5ml) and applied to a SPE cartridge (silica, 5g). The cartridge was eluted successively with Et20, EtOAc and EtOAc-MeOH (9/1). Fractions containing the desired product were combined and concentrated in vacuo to give the desired product contaminated with starting material (Intermediate 51). Further purification using a SPE cartridge (silica, 5g) eluting with ethyl acetate-cyclohexane (1/3) afforded Example 189 (0.248g). LCMS showed MH+ = 333; TRET = 2.75min.

Example 190: Ethyl 4-(cyclohexylamino)-1-ethyl-6-methyl-lH-pyrazolo [3,4- b] pyridine-5-carb oxylate

Cyclohexylamine (0.149g, 1. 5mmol) was added to a mixture of Intermediate 51 (0. 201g, 0. 75mmol) and N, N-diisopropylethylamine (0. 65ml, 3.73mmol) in acetonitrile (3ml). The resulting mixture was heated at 85 °C for 40 hours. Volatiles were removed in vacuo and the residue was dissolved in chloroform (1. 5ml) and applied to a SPE cartridge (silica, 5g). The cartridge was eluted successively with Et2O, EtOAc and MeOH. Fractions containing the desired product were combined and concentrated in vacuo to afford Example 190 (0.128g). LCMS showed MH+ = 331 ; TRET = 3.64min.

Example 191: 4-(Cyclohexylamino)-l-ethyl-6-methyl-N-[4- (methylsulfonyl) benzyl]-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide A mixture of Intermediate 52 (0.014g, 0.046mmol), HATU (0.018g, 0. 048mmol) and DIPEA (0. 022ml, 0. 125mmol) in DMF (lml) was shaken at room temperature for lOmin.

1- [4- (Methylsulfonyl) phenyl] methanamine (0.009g, 0. 046mmol) was then added, and the mixture was shaken for several minutes to give a solution. This solution was stored at room temperature for 16 hours. The solution was concentrated in vacuo, and the residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g).

The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc-MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo to afford Example 191 (0. 005g). LCMS showed MH+ = 470; TRET = 2.54min.

Example 192: N-Benzyl-4-(cyclohexylamino)-1-ethyl-6-methyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide

Example 192 was prepared from Intermediate 52 using a method analagous to Example 191. LCMS showed MHA = 392: TRET = 2. 43.

Example 193: 4- (Cyclohexylamino)-l-ethyl-N-(4-fluorophenyl)-6-methyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide Example 193 was prepared from Intermediate 52 using an analagous method to Example 191. LCMS showed MH+ = 396; TRET = 2. 6min.

Example 194: 4-(Cyclohexylamino)-l-ethyl-6-methyl-N-[4- (trifluoromethyl) benzyl]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 194 was prepared from Intermediate 52 using an analagous method to Example 191. LCMS showed MH+ = 460; TRET = 2. 74min.

Example 195: 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-6- methyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide

Example 195 was prepared from Intermediate 52 using an analagous method to Example 191. LCMS showed MH+= 418; TRET = 2. 55min.

Example 196: N-Benzyl-l-ethyl-6-methyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 196 was prepared from Intermediate 53 using an analagous method to Example 191. LCMS showed MH+ = 394; TRET = 2. 02min.

Example 197: N-Benzyl-l-ethyl-4-[(2-oxoazepan-3-yl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide 3-Aminoazepan-2-one (0.043g, 0. 335mmol, commercially available from Sigma-Aldrich Company Ltd) was added to a mixture of Intermediate 17 (0. 021g, 0. 067mmol) and DIPEA (0. 058ml, 0.335mmol) in acetonitrile (0. 5ml). The resulting mixture was heated at

85 °C for 48 hours. Volatiles were removed in vacuo, and the residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (silica, 0. 5g) which was eluted successively with diethyl ether (1. 5ml), ethyl acetate (1. 5ml) and ethyl acetate-methanol (9/1,1. 5ml). Fractions containing the desired material were concentrated in vacuo to afford Example 197 (0.009g). LCMS showed MH+ = 407; TRET = 2. 81min.

Similarly prepared, but replacing the 3-aminoazepan-2-one with the same or similar number of moles of another amine R3NH2 were the following compounds:

Example NHR3 Source of Starting MH+ ion TRET Number R3NH2 Material (min) Example OH J. Chem. Intermediate 394 2. 75 198 HN Soc., 17 PeYkih Trans. 1, 1994, 537 Example/\ Aldrich ; or Intermediate 394 2. 82 199 HN< OH TCI-17 America Example OH us Intennediate 380 2. 70 200 HN 4219660 17

Example 201: N-Benzyl-l-ethyl-4- [ (4-oxocyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxamide

Intermediate 54 (0.048g, 0. 32mmol) was added to a mixture of Intermediate 17 (0. 050g, 0. 16mmol) and DIPEA (0. 17ml, 0. 98mmol) in acetonitrile (3ml). The resulting mixture was heated under reflux. After 12 hours, further quantities of Intermediate 54 (0.044g, 0.29mmol), DIPEA (0. 17ml, 0. 98mmol) and acetonitrile (lml) were added to reaction mixture which was maintained under reflux. After 36 hours, the reaction mixture was concentated in vacuo, and the residual oil was dissolved in dichloromethane (8ml) and washed with 5% sodium bicarbonate solution (2ml). Evaporation of the organic solution gave a viscous oil which was dissolved in dichloromethane (2ml) and applied to a SPE cartridge (silica, 5g). The cartridge was eluted successively with a gradient of ethyl acetate-cyclohexane (1: 16, then 1: 8,1 : 4,1 : 2,1 : 1 and 1: 0). Fractions containing the desired material were concentrated in vacuo to afford Example 201 (0. 018g). LCMS showed MH+ = 392; TRET = 2. 95min.

Example 202: 1-Ethyl-N-(2-hydroxy-1-methylethyl)-4-(tetrahydro-2H-pyran-4 - ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Intermediate 33 (0. lg, 0. 34mmol), EDC (0.066g, 0.34mmol) and HOBT (0. 05g, 0. 37mmol) were suspended in DMF (2ml) and stirred at room temperature under nitrogen for 15 min. 2-aminopropan-1-ol (0.026g, 0. 34mmol) and triethylamine (0.036g, 0. 36mmol) were added and the mixture was stirred at room temperature under nitrogen for 6 hours. Solvents were removed in vacuo and the residue partitioned between DCM and water. The organic layer was concentrated and applied to an SPE cartridge (aminopropyl, 5g), which was eluted with methanol. Concentration in vacuo afforded Example 202 (0.095g). LCMS showed MH+ = 348, TRET= 2. 15min.

Example 203: Methyl (2S)-2-({[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH- pyrazolo [3, 4-b] pyridin-5-yl] carbonyl} amino) -3-hydroxypropanoate

Reaction scheme: L OATH °H OH C02H f N''CO Me hydrochloride NH O l l | H2N CO2Me NsNAN< mf H CO2Me EDC, HOBT, Et3N, DMF "N N Intermediate 33 Intermediate 33 (0. lg, 0. 34mmol), EDC (0.066g, 0.34mmol) and HOBT (0. 05g, 0. 37mmol) were suspended in DMF (2ml) and stirred at room temperature under nitrogen for 15 mins. L-Serine methyl ester hydrochloride (0.054g, 0.34mmol) and triethylamine (0.036g, 0. 36mmol) were added and the mixture stirred at room temperature under nitrogen for 18 hours. Solvents were removed in vacuo and the residue was partitioned between DCM and water. The organic layer was concentrated in vacuo and applied to an SPE cartridge (aminopropyl, 5g), which was eluted with methanol. Concentration in vacuo afforded an impure residue which was further purified by SPE cartridge (silica, 5g), eluting with ethyl acetate followed by 5% methanol/ethyl acetate. The desired fractions were concentrated in vacuo to afford Example 203 (0. 055g). LCMS showed MH+ = 393; TRET = 2. 22min.

Example 204 Ethyl l-ethyl-4-[(4-hydroxycyclohexyl) amino]-lH-pyrazolo [3,4- b] pyridine-5-carboxylate Intermediate 1 (1.5g, 5. 9mmol) was dissolved in acetonitrile (80ml). Trans-4- aminocyclohexanol (0.817g, 7. 1mmol, commercially available from TCI-America; alternatively (e. g. as the HC1 salt) from Aldrich) and diisopropylethylamine (6. 18ml, 35. 5mmol) were added and the mixture was stirred at 85°C for 16h. The mixture was concentrated in vacuo, and the residue was partitioned between DCM (120ml) and water (30ml). The phases were separated and the organic phase was dried (Na2S04) and evaporated to give a pale yellow solid. The solid was dissolved in a mixture of DCM (10ml) and chloroform (3ml), and applied in equal portions to two SPE cartridges (silica, 20g) which were eluted sequentially with a gradient of EtOAc: cyclohexane (1: 16, then 1: 8,1 : 4,1 : 2,1 : 1 and 1: 0). Fractions containing the desired material were combined and evaporated in vacuo to give Example 204 (1. 893g) as a white solid. LCMS showed MH+ = 333 ; TRET = 2. 79min.

Example 205: Ethyl 1-ethyl-4- [ (4-oxocyclohexyl) amino]-1H pyrazolo [3,4- b] pyridine-5-carboxylate Example 204 (1.893g, 5. 7mmol) was suspended in acetone (12ml) and the stirred suspension was treated at 0°C with Jones reagent (1. 81ml). After 30min, a further quantity of Jones reagent (1. 8 lml) was added to the reaction mixture which was maintained at 0°C. After a further 2h, a final portion of Jones reagent (1. 44ml) was added to the reaction mixture, and stirring at 0°C was continued for lh. Isopropanol (3. 8ml) was added to the reaction mixture, followed by water (15ml). The resulting mixture was extracted with ethyl acetate (2 x 40ml). The combined organic extracts were washed with water (8ml), dried (Na2SO4) and evaporated to a grey solid. The solid was dissolved in DCM (10ml) and applied in equal portions to two SPE cartridges (silica, 20g) which were eluted sequentially with a gradient of ethyl acetate: cyclohexane (1: 16, then 1: 8,1 : 4,1 : 2, and 1: 1). Fractions containing the desired material were combined and evaporated in vacuo to give Example 205 (1.893g) as a white solid. LCMS showed MH+ = 331 ; TRET = 2. 84min.

Example 207 (= Example 5): Ethyl 4- [ (1-acetyl-4-piperidinyl) amino]-1-ethyl-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate Intermediate 1 (2.58g), Intermediate 6 (2. 0g) and N, N-diisopropylethylamine (8. 9ml) were dissolved in acetonitrile (98ml). The reaction mixture was heated at 85 °C for 24h then an additional portion of Intermediate 6 (0. 18g) was added and heating continued for a further l Oh. The reaction was concentrated in vacuo and the residues partitioned between DCM and water. The phases were separated and the organic phase evaporated in vacuo. The residue was purified by chromatography using Biotage (silica 90g) eluting with DCM: MeOH (5%) to afford Example 207 (1. 55g) as a white solid. LCMS showed MH+ 360; TROT= 2.71 min.

Example 209: Ethyl 4- [ (4-aminocyclohexyl) amino]-l-ethyl-lH-pyrazolo [3,4- b] pyridine-5-carboxylate Example 209 was prepared from Intermediate 1 and (4-aminocyclohexyl) amine using an analogous method to that used for the preparation of Example 207. LCMS showed MH+ = 332; TRET = 2. 18min <BR> <BR> Example 210: 1-Ethyl-N-[(l-oxido-3-pyridinyl) methyl]-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3,4-b] pyridine-5-carboxamide.

A solution of meta-chloroperoxybenzoic acid (45mg, 0. 26mmol) in chloroform (lml) was added dropwise at 0 C to a stirred solution of Example 138 (0.1 g, 0.26mmol) in chloroform (1. 5ml). After 1.5h at 0 C, a further quantity of meta-chloroperoxybenzoic acid (45mg, 0. 26mmol) in chloroform (lml) was added, and stirring was continued at or 1.5h. A trace of starting material remained, so an additional quantity of meta- chloroperoxydbenzoid acid (22mg, 0.13mmol) in chloroform (0.6ml) was added. After 3.5h at 0°C, 2M sodium carbonate solution (lml), was added to the reaction mixture.

The phases were separated by passage through a hydrophobic frit and the aqueous phase was extracted with more chloroform (2ml). The combined organic extracts were evaporated to a residual foam which was purified by mass directed autoprep HPLC to afford Example 210 (44mg). LCMS showed MH+ = 397; TRET = 2. 13min. <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 211: 1-Ethyl-N-[(l-oxido-2-pyridinyl) methyl]-4-(tetrahydro-2H-pyran- 4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 211 was prepared from Example 600 using an analogous method to that used for the preparation of Example 210. LCMS showed MH+ = 397; TRET = 2. 20min <BR> <BR> Example 212: 1-Ethyl-N [ (1-oxido-4-pyridinyl) methyl]-4- (tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 212 was prepared from Example 33 using an analogous method to that used for the preparation of Example 210. LCMS showed MH+ = 397; TROT = 2. 13min Examples 214 to 230 General Procedure Intermediate 17 (0. 15mmol) was treated with an aliquot of the amine (0. 95ml, equivalent to 0. 19mmol) from a stock solution in acetonitrile (0. 2M) and N, N- diisopropylethylamine (0.24mmol). The mixture was heated at reflux for 20h then concentrated in vacuo. The residue was purified by SPE (silica) to give the desired product. Example no. NHR'Source of Starting MH LC-MC R3NH2 Material + Retention ion time 214 H2N NH J Med Cliem., Intermediate 393 2. 16 1994, 37 (17), 17 2360 221 Aldrich Intermediate 350 3. 18 Nu 17 222 Aldrich Intermediate 392 3. 62 Je) 17 NU 223 HC Aldrich Intermediate 392 3. 63, 3. 68 ,-ans 17 NU 224 Pfaltz-Bauer Intermediate 392 3. 61, 3. 66 H3CaNH 17 225 \/\ J ; Org Chem., Intermediate 392 3. 54 1985, 50 (11), 17 1859 226 Aldrich Intermediate 390 3. 56 17 NH 227 Aldrich Intermediate 390 3. 52 17 H'NH 228 NH WO 99/12933 Intermediate 379 2. 66 1 17 0 229 nu EP 1188744 Intermediate 393 2. 58 N"17 0 0 230 NH N Aldrich Intermediate 405 2. 19 17 Example 225: 1-ethyl-4- [ (1-methylcyclohexyl) amino]-N (phenylmethyl)-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide A preferred method for the preparation of Example 225 involving 1- methylcyclohexylamine and a longer reaction time is as follows: A solution of Intermediate 17 (46mg), 1-methylcyclohexylamine (26mg) and diisopropylethylamine (94mg) in acetonitrile (lml) was stirred and heated at reflux for 77h. More 1-methylcyclohexylamine (102mg), diisopropylethylamine (93mg) and acetonitrile (lml) were added and the reaction mixture was heated at reflux for a further 68h. The solution was cooled and concentrated iii vacuo. The residue was triturated in ethyl acetate and filtered. The filtrate was purified by mass directed autoprep. HPLC to give Example 225 (19mg). LCMS showed MH+ = 392; TRET 3. 46min.

Examples 231,247 and 257, shown below and also involving 1- methylcyclohexylamine, can also preferably be prepared in a similar manner.

Examples 231-239 General Procedure Intermediate 55 (0. 15mmol) was treated with an aliquot of the amine (0. 95ml, equivalent to 0. 19mmol) from a stock solution in acetonitrile (0.2M) and N, N- diisopropylethylamine (0. 24mmol). The mixture was heated at reflux for 20h then concentrated in vacuo. The residue was purified by SPE (silica) to give the desire product. Example no. NHR'Source of Starting MH LC-MC R3H2 Material + Retention ion time 231 NHn J. Org. Chem., Intermediate 422 3. 43 1985, 50 (11), 55 1859 233 n Aldrich Intermediate 380 3. 20 Nu 55 234 Aldrich Intermediate 422 3. 58 55 N 235 Aldrich Intermediate 420 3. 52 55 NH H'NH 236 H3Cß Aldrich Intermediate 422 3. 57, 3. 64 55 NH 237 Pfaltz-Bauer hitemediate 422 3. 56, 3. 62 55 238 tHt, Aldrich Intermediate 420 3. 48 55 - 239 H2Ns, J Med. Clzem., Intermediate 423 2. 16 1994, 37 (17), 55 nu 2360 Examples 240-249 General Procedure Intermediate 56 (0. 15mmol) was treated with an aliquot of the amine (0. 95ml, equivalent to 0. 19mmol) from a stock solution in acetonitrile (0.2M) and N, N- diisopropylethylamine (0. 24mmol). The mixture was heated at reflux for 20h then concentrated in vacuo. The residue was purified by SPE (silica) to give the desire product. Example no. NHR3 Source of Starting MH LC-MC NH2R3 Material + Retention ion time 240 Aldrich Intermediate 485 3. 26 56 NH 241 Aldrich Intermediate 443 2. 94 NHJI56 242 Aldrich Intermediate 483 3. 20 cL" H NH 243 Aldrich Intermediate 483 3. 14 56 H"NH 244 3C Aldrich Intermediate 485 3. 25, 3. 33 NH 'NH 245 n Pfatlz-Bauer Intermediate 485 3. 24, 3. 31 J\JL 56 H3C<NH 56 247 NH J. Org. Chem., Intermediate 483 3. 10 1985, 50 (11), 56 1859 248 zN J. Med. Claem., Intermediate 486 2. 05 Li 1994, 37 (17), 56 nu 2360 249 Aldrich Intermediate 471 3. 21 ans 56 nu Examples 250-258 General Procedure Intermediate 57 (0. 15mmol) was treated with an aliquot of the amine (0. 95ml, equivalent to 0. 19mmol) from a stock solution in acetonitrile (0.2M) and N, N- diisopropylethylamine (0. 24mmol). The mixture was heated at reflux for 20h then concentrated in vacuo. The residue was purified by SPE (silica) to give the desire product. Example no. NHR3 Source of Starting MH LC-MC NH2R3 Material + Retention ion time 250 Aldrich Intermediate 418 3. 78 Je/57 NH 251 Aldrich Intermediate 376 3. 42 NHJI 7 253 Pfaltz-Bauer Intermediate 418 3. 78, 3. 84 H3C NH 7 254 H3Cuou Aldrich Intermediate 418 3. 82, 3. 86 57 NH 255 Aldrich Intermediate 416 3. 66 57 H NU 256 H Aldrich Intermediate 416 3. 77 57 H'"NH 257 NH\\ J Org. Chem., Intermediate 418 3. 74 1985, 50 (11), 57 1859 258 H2N, J. Med. Chem., Intermediate 419 2. 38 hI 1994, 37 (17), 57 ZU 2360 Examples 259-275 General Procedure A mixture of Intermediate 58 (0. lmmol), HATU (0. lmmol) and DIPEA (0.4mmol) in DMF (0. 4ml) was shaken at room temperature for 10 min. A solution of the amine (0. lmmol) in DMF (0. 2ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16 hours then concentrated in vacuo. The residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g). The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc: MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo and the residue purified by mass directed autoprep HPLC. Example no. NRW Source of Starting MH LC-MC HNR4R5 Material + Retention ion time 201 NHX Aldrich Intermediate 392 2. 60 58 259"3 EP 666258 Intermediate 470 2. 44 olf ! 58 nu NH 260 NH CH3 Salor ; or ICN Intermediate 420 3. 09 Biomedicals, 58 Inc. ; or Synthesis, 1982, 12, 1036 261 NH CHMSRV-AS ; Intermediate 420 3. 09 or Matrix 58 uCH Scientific, or 'Chem. Ber., 1969, 102, 2770 262 Aldrich ; or Intermediate 454 3. 20 + Meindl et al., J. 58 vGI Med. Chem., 1984, 27 (9), 1111. 263 Acres ; or Intermediate 422 2. 86 Aldrich ; 58 Tetrahedron I Lett., 2002, CH, 43 (48), 8735 ; or J. Med. Chem., 1984, 27 (9), 1111 ; or Org. Lett., 2002, 4 (12), 2055 264 Lis et al., J. Intermediate 485 2. 64 NoSss Med. Chem., 58 1990, 33 (10), 2883 ; see Scheme III and ref. 24 265 oN4/\ Aldrich Intermediate 435 2. 54 zu 58 1 266 <° Fluorochem ; or Intermediate 458 2. 81 WO 98145268 58 267 WF Aldrich ; or Intennediate 460 2. 96 Meindl et al., J. 58 Med. Chem., 1984, 27 (9), 1111 ; or Org Lett., 2002, 4 (12), 2055 268 NH Peakdale Intermediate 470 2. 39 \/ ° 58 269 NH F Aldrich Intermediate 396 2. 80 58 270 (as N"N_ Aldrich Intermediate 393 1. 89 CF3CO2H w 58 salt) 271 TCI-America ; Intermediate 418 2. 77 or Aldrich ; or 58 Maybridge-ht 272 NH-- (N/° WO 99/38877 Intermediate 427 2. 13 58 273-NH/ N N. D. Zelinsky Intermediate 396 2. 15 N Institute 58 274 NH Aldrich Intermediate 330 2. 10 58 275/I Matrix Intermediate 399 2. 29 Scientific 58 Example 260 (Alternative Procedure) N-[(2, 4-dimethylphenyl) methyl]-1-ethyl-4- [ (4-oxocyclohexyl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide Alternative procedure for preparing Example 260: A solution of Intermediate 58 (45mg), HATU (63mg) and DIPEA (39mg) in acetonitrile (5ml) was stirred for 10min. A solution of 2,4-dimethylbenzylamine (24mg) (available from Salor; or ICN Biomedicals, Inc. ; or Synthesis, 1982,12, 1036) in acetonitrile (lml) was added. The reaction mixture was stirred for 18h. The solution was concentrated and the residue partitioned between ethyl acetate (25ml) and 0. 5M sodium bicarbonate (20ml). The organic phase was separated, washed with water (20ml), dried over Na2S04 and concentrated to leave a gum which was applied to an SPE cartridge (5g). The cartridge was eluted with ethyl acetate. Fractions containing the desired compound were combined and concentrated in vacuo to give Example 260 (32mg). LC-MS showed MH+ = 420; TRET = 3. 16min. OH (CDC13) : 1.49 (3H, t), 2.11 (2H, m), 2.33 (3H, s), 2.35 (3H, s), 2.40 (2H, m), 2.52 (2H, m), 2.61 (2H, m), 4. 36 (1H, m), 4.47 (2H, q), 4. 55 (2H, d), 6.14 (1H, t), 7.01 + 7.18 (2H, AA'BB'), 7.04 (1H, s), 8.01 (1H, s), 8.36 (1H, s), 9.96 (1H, d).

Example 276-287 General Procedure A mixture of Intermediate 59 (O. lmmol), HATU (O. lmmol) and DIPEA (0. 4mmol) in DMF (0. 4ml) was shaken at room temperature for 10 min. A solution of the amine (0. lmmol) in DMF (0. 2ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16 hours then concentrated in vacuo. The residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g). The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc: MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo and the residue purified by mass directed autoprep HPLC. Example no. Wu source of Starting MH LC-MC HNR4R5 Material + Retention ion time 276 NH Aldrich Intermediate 392 2. 60 59 277 nu 0 Fluorochem ; or Intermediate 446 2. 84 wu 98/45268 59 278 NH F Aldrich ; or Intermediate 448 3. 0 Meindl et al., J. 59 Med. CAeM., 1984, 27 (9), 1111 ; or Org Lett., 2002, 4 (12), 2055 279 NH//0 Acros Intermediate 458 2. 40 \ 59 280 EP 382570 Intermediate 458 2. 47 4~ 59 281 NH F Aldrich Intermediate 384 2. 85 59 282 (as NH N=\ Aldrich Intermediate 381 1. 89 CF3CO2H 59 salt) 283 TCI-America ; Intermediate 406 2. 80 or Aldrich ; or 59 Maybridge-Int 284 WO 99/38877 Intermediate 415 2. 14 / 59 285 tN N. D. Zelinsky Intermediate 384 2. 16 Institute 59 286 Aldrich Intermediate 318 2. 11 59 287 NH N Matrix Intennediate 399 2. 29 s Scientific 59 Example 288: 4-[(4, 4-Difluorocyclohexyl) amino]-l-ethyl-N-(phenylmethyl)-lH-<BR> <BR> pyrazolo [3, 4-b] pyridine-5-carboxamide and Example 289: 1-Ethyl-4- [ (4-fluoro- 3-cyclohexen-1-yl) amino]-N-(phenylmethyl)-lH-pyrazolo [3, 4-b] pyridine-5- carboxamide.

Example 288 Example 289 Diisopropylethylamine (0. 113ml, 0. 65mmol) was added to a stirred mixture of Intermediate 17 (40mg, 0.13mmol) and Intermediate 63 (45mg, 0. 26mmol) in acetonitrile (2ml). The mixture was stirred at 85°C. After 18h, a further portion of Intermediate 63 (22. 5mg, 0. 13mmol) and diisopropylethylamine (0. 113ml, 0. 65mmol) was added to the reaction mixture and stirring was continued at 90°C for 24h. The mixture was then concentrated in vacuo and the residue was partitioned between DCM (20ml) and water (5ml). The phases were separated and the aqueous phase was extracted with further DCM (10ml). The combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give a brown oil (65mg) which was partially purified on a SPE cartridge (silica, lOg), eluting with ethyl acetate: petroleum ether (1: 8; 1: 4; 1: 2; 1 : 1 and 1: 0). The resulting two-component pale-brown oil (34mg) was separated by mass directed auto prep HPLC to give Example 288 (19mg) as a white foam (LCMS showed MH+ = 414; TRET = 3. 24min) and Example 289 (9mg) as a white solid (LCMS showed MH+ = 394 ; TRET = 3. 21min).

Examples 290-319 General Procedure A mixture of Intermediate 60 (0. lmmol), HATU (0. lmmol) and DIPEA (0. 4mmol) in DMF (0. 4ml) was shaken at room temperature for 10 min. A solution of the amine (0. lmmol) in DMF (0. 2ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16 hours then concentrated in vacuo. The residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g). The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc: MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo and the residue purified by mass directed autoprep HPLC. Example no. NIEW Source of Starting MH LC-MC HNR4Rs Material + Retention ion time 290 NH-Aldrich ; or Intermediate 447 2. 96 TCI-America ; 60 or Maybridge- hit 291 ci Aldrich ; or Intermediate 488/3. 16 NH/\ ci Meindl et al., J. 60 490 Med. Chem., 1984, 27 (9), 1111. 292 F Aldrich ; or Intermediate 439 2. 84 Meindl et al., J. 60 Med. Chem., 1984, 27 (9), 1111 ; or Org. Lett., 2002, 4 (12), 2055 293 F Aldrich Intermediate 457 2. 92 NH \- F 60 294 F Aldrich Intermediate 457 2. 87 Nu/\ 60 F 295 F F Aldrich ; or Intermediate 489 3. 06 NH F Meindl et al., J 60 /\ Med. Cltem., 1984, 27 (9), 1111. 296 NH Aldrich ; or Intermediate 489 3. 08 F Meindl et al., J. 60 F Med. Claem., 1984, 27 (9), 1111 ; or Org Lett., 2002, 4 (12), 2055 297 NH F Aldrich Intermediate 457 2. 82 60 F 298 NH cl Aldrich ; or Intermediate 455 2. 98 Meindl et al., J. 60 \=/Med. Chem., 1984, 27 (9), 1111 ; or Org. Lett., 2002, 4 (12), 2055 299 nu Aldrich ; or Intermediate 451 2. 79 acres ; or Jung et 60 al., Tetrahedron Lett., 2002, 43 (48), 8735 ; or Meindl et al., J. Med. Chem., 1984, 27 (9), 1111 ; or Org Lett., 2002, 4 (12), 2055 300/\ Aldrich Intermediate 437 2. 82 301 NH 0 301 NH/\ ° /Peakdale hitermediate 528 2. 76 Molecular Ltd 60 302 NH Aldrich Intermediate 461 3. 00 60 r 303 N/Peakdale Intermediate 464 2. 31 NH Molecular Ltd 60 304 NH Aldrich ; or lntennediate 489 3. 16 Meindl et al., 60 ci J. Med. Cliein., 1984, 27 (9), 1111. 305 nu Aldrich ; or Org. Intermediate 439 2. 84 Lett., 2002, 60 F 4 (12), 2055 306 93 Fluka Intermediate 473 2. 92 nu/\ 60 F 307 F Fluorochem Intermediate 487 2. 95 0 Ltd ; or 60 WO 98/45268 308 Apin Intermediate 485 2. 94 to\ 60 309 NH N cl Key Organics Intermediate 456 2. 65 Ltd 60 310 J. Med. Chem., Intermediate 481 3. 16 2001, 44 (26), 60 4628 311 NH s Manchester Intermediate 428 2. 28 N Organics Ltd 60 312 91l Acros Chimica Intermediate 499 2. 37 s- 60 313 1 3 Aldrich Intermediate 511 3. 18 60 NU 314"I s Lis et al., J. Intermediate 514 2. 60 Med. Chem., 60 s N, "° 1990, 33 (10), 2883, see Scheme III and ref 24 315 H WO 94/17035 Intermediate 478 2. 47 + Ns 60 0 316 Sigma Intermediate 500 2. 50 W 60 L : O 11 0 317 o Peakdale Intermediate 478 2. 49 HN<No Molecular Ltd 60 V 318 NN WO 02185860 Intermediate 464 2. 42 NHR 60 0 319 LN N Syngene hitennediate 452 2. 45 'o 60 1 I Example 320 1-Ethyl-N-4-piperidinyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH - pyrazolo [3, 4-b] pyridine-5-carboxamide A solution of hydrogen chloride in dioxan (30ml, 4M, 0. 12mol) was added to a suspension of Example 126 (1.3g, 2.75mmol), in dioxan (10ml) and the mixture was stirred at room temperature for 6h. The reaction mixture was left to stand for 14h, then the solution was evaporated, azeotroping with DCM to give a white solid the hydrochloride salt. The solid was suspended in ethyl acetate (50ml) and washed with sodium hydroxide solution (2N, 50ml). The organic layer was dried over Na2S04 and concentrated in vacuo to give Example 318 as a white solid (995mg). LCMS showed MH+= 373; TRET = 1. 89min. <BR> <BR> <P>Example 321 1-Ethyl-N-(4-piperidinylmethyl)-4-(tetrahydro-2H-pyran-4-< ;BR> ylamino)-lH-pyrazolo [3, 4-blpyridine-5-carboxamide A solution of hydrogen chloride in dioxan (30ml, 4M, 0. 12mol) was added to a suspension of Intermediate 72 (1.2g, 2. 5mmol), in dioxan (10ml) and the mixture was stirred at room temperature for 6h. The reaction mixture was left to stand for 14h, then the solution was evaporated, azeotroping with DCM to give a white solid (1.24g). A portion of the solid (68mg) was suspended in ethyl acetate and washed with 2M-sodium hydroxide solution. The organic layer was dried over Na2S04 and concentrated in vacuo to afford Example 321 as a white solid (60mg). LCMS showed Mt = 387; TRET = 1. 92min.

Example 322 1-Ethyl-N-[l-(ethylsulfonyl)-4-piperidinyl]-4-(tetrahydro-2H - pyran-4-ylamino)-1H-pyrazolo [3, 4-b] pyridine-5-carboxamide Triethylamine (0. 023ml, 0. 16mmol) was added to a solution of Example 320 (0.043g, 0. 115mol) in DCM (lml). The mixture was cooled (ice/water bath for 1 Omin) and ethane sulfonyl chloride (0. 014ml, 0. 138mmol) was added. The resultant solution was stirred at room temperature for 18h, then the solvent was removed with a steam of nitrogen. The residue was dissolved in dichloromethane (1. 5ml) and stirred with water (1. 5ml). The organic layer was separated and blown down with nitrogen, and applied to a SPE cartridge (silica, 2g) eluting with 60%-100% ethyl acetate in cyclohexane.

The desired fractions were concentrated in vacuo to afford Example 322 as a white solid (32mg). LCMS showed MH+ = 465, TRET = 2. 52min Similarly prepared were the following, using the same or a similar number of moles of reagents and the same or similar volumes of solvents: Example no. NR4R5 Sulfonyl Source of MH LC-MC chloride sulfonyl + ion Retention chloride time '323foo Aldrich 479 2. 58 H, C z2 z H, C'i/10 ;/s cl NH 324 rA, o r, o J. 0. 505 2. 75 "N""', CM., _ 1952, 17, Nu 1529 325 H° HP Aldrich 451 2. 41 0 0 NU 326 ¢) C Aldrich 527 2. 90 SN, 1 % CI li N 0La hLH ci NH 327 ° o ° ° Aldrich 513 2. 66 Such NU "'aNH 328 Po°^ , ° Aldrich 479 2. 42 H3CSN, 1 H3CSCI -NH Example 329 N (1- (Cyclopropylcarbonyl)-4-piperidinyl]-1-ethyl-4- (tetrahydro-<BR> 2H-pyran-4-ylamino)-lH-pyrazolol3, 4-b] pyridine-5-carboxamide Cyclopropane carboxylic acid (0. Ollml, 0. 138mmol), EDC (0.031g, 0. 161mmol) and HOBT (0. 019g, 0. 138mmol) were suspended in DMF (2ml) and stirred at room temperature for lh. Example 320 (0.043g, 0. 115mmol) was added and the mixture was stirred at room temperature for 16 hours. Most of the solvent was removed using a stream of nitrogen and the residue was partitioned between DCM (3ml) and water (3ml). The organic layer was blown down with nitrogen and applied to a SPE cartridge (aminopropyl, lg), which was eluted with methanol. Concentration by blowing down with nitrogen afforded an impure residue which was further purified by SPE cartridge (silica, I g), eluting with 50-100% EtOAc in cyclohexane followed by 5% methanol inEtOAc. The desired fractions were concentrated in vacuo to afford Example 329 as a white solid (49mg). LCMS showed MH+ = 441 ; TRET = 2. 23min Similarly prepared, using the same or similar numbers of moles of reagents and volumes of solvents, and using Example 320 as the starting material to make Examples 330 to 343, but using Example 321 (similar number of moles) instead of Example 320 as the starting material to make Examples 344 to 349, were the following: Example no. NieW Carboxylic Source of MH+ LC-MC acid Carboxylic ion Retention acid time 330 0 0 Aldrich 467 2. 50 NI^ o O" N OH LH '331FTnAldrich'4712. 73 H3C<IN 3 CH3 NH hLH 332 CH, 0 Aldrich 471 2. 72 N ou NU 333/1 q/ O Aldrich 483 2. 81 nu nu NH Aldrich 443 2. 27 'N CH ' m 3 °I H3 v'NH 335 ° ° Combi-Blocks 485 2. 17 N-OH O II O NH 336 ° ° Aldrich 429 2. 38 H3C H3C NH I NH H Aldrich 472 2. 20 Tf N, 1'OH 0 N-H 0 338 Synchem OHG 500 1. 91 'NU 339 o9aNH J. Med. Chem., 497 2. 17 Oh 1998, 41 (5), 0 NH 0' 760 Micro-498 1. 94 OH Chemistry Building v'NH Blocks 341 A Interchim 498 2. 07 Intermediates NU HIC HFC 342 °^ ° DE 3618135 471 2. 33 N, 1 OH nu 343 s'Y) j ? Aldrich 509 2. 75 N ou NH 344 ? H OH Aldrich 485 2. 78 H, C C'\ H N^lI H, C O 1 H'OH NH 345 Aldrich 497 2. 85 C : NH NH 346 0OH Aldrich 455 2. 50 NH NH 511 2. 42 347 J oH J. Nled. Chem., o NH 1998, 41 (5), 760 348 4 4, í"Aldl Uh 523 2. 78 N, 1 oh MU 349 Ll t InterChim 512 2. 29 °,'N °'OH NH , Intermediates H3C ; HC Example 350 Methyl 3-[(1-ethyl-5-{[(phenylmethyl) amino] carbonyl}-lH- pyrazolo [3, 4-b] pyridin-4-yl) amino] cyclohexanecarboxylate Example 350 was prepared from Intermediate 17 and using an analogous method to that used for the preparation of Example 207. LCMS showed MH+ = 436; TRET = 3.20. <BR> <BR> <P>Example 351 3-[(1-Ethyl-5-{[(phenylmethyl) amino] carbonyl}-lH-pyrazolo [3,4- b] pyridin-4-yl) amino] cyclohexanecarboxylic acid 2M-Sodium hydroxide solution (0. 5ml) was added to a stirred suspension of Example 350 (0.12g, 0. 275mmol) in methanol (3. 5ml) and water (0. 8ml). After stirring overnight at room temperature, the reaction solution was concentrated, diluted with water (3ml) and acidified with 2M-hydrochloric acid. The resulting precipitate was collected by filtration, washed with water and dried to give Example 351, as a white solid (0. 105g). LCMS showed MH+ = 422; TRET = 2.95min.

Example 352: 1-Ethyl-N-(phenylmethyl)-4-(4-piperidinylamino)-lH-pyrazolo [3, 4- b] pyridine-5-carb oxamide Aqueous hydrochloric acid (20ml, 5M) was added to a solution of Intermediate 65 (2.58g, 5.40mmol) in tetrahydrofuran (10ml). The reaction mixture was stirred at 20 °C for 22h then evaporated in vacuo. The residue was partitoned between DCM and water. The aqueous phase was basified with aqueous sodium hydroxide solution (2M) and extracted with diethyl ether. The organic phases was evaporated in vacuo to give Example 352 as a white solid (2.04g). LCMS showed MH+ = 379; TRET = 2. 10min.

Example 353: Ethyl l-ethyl-4-({1-[(methyloxy) acetyl]-4-piperidinyl} amino)-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate Methoxyacetyl chloride (0.016mg, 0. 144mmol) and triethylamine (0. 02mol, 0. 144mmol) were added to a solution of Example 352 (0.046g, 0. 122mmol) in DCM in a Reactivial. The reaction was stirred for 22h at 20 °C then diluted with DCM and washed with aqueous sodium hydrogen carbonate solution. The organic phase was separated and applied directly to a SPE cartridge (silica 2g). The cartridge was eluted with DCM: MeOH (1% followed by 3%) to give Example 353 as a white solid (0. 05g). LCMS showed MIT"=451 ; TpET = 2. 66min.

Example 354: Ethyl 1-(1-methylethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate Prepared in a similar manner to example 186 using Example 20 (0. 03g, O. lmmol), with isopropylbromide (lOuL, 0. 1 lmmol), a further O. l lmmol of alkylating agent was added after 16 hours. The final compound was formed as a clear gum (16mg). LCMS showed MH+ = 333 ; TRET = 3. 16min.

Example 355: 4-(Cyclohexylamino)-l-ethyl-N-methyl-lH-pyrazolo [3, 4- b] pyridine-5-carboxamide Intermediate 64 (0.02g, 0.084mmol) and diisopropylethylamine (0. 044ml, 0. 252mmol) were suspended in N-methyl pyrrolidinone (lml) and cyclohexylamine (0. 012ml, 0. 1mmol) was added. The mixture was heated at 85°C with stirring in a ReactivialTM for 8h, then concentrated in vacuo. The residue was partitioned between DCM (2ml) and water (2ml). The layers were separated and the organic layer was concentrated in vacuo, then purified by mass directed autoprep HPLC to afford Example 355 (0.012g). LCMS showed MH+ = 302; TRET = 2. 85min.

Example 356: 1-Ethyl-N-(4-fluorophenyl)-6-methyl-4- (tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 356 was prepared from Intermediate 53 using an analogous method to Example 191. LCMS showed MH+ = 398; TpBT = 2. 18min.

Example 357 : 1-Ethyl-6-methyl-N-{ [4-(methylsulfonyl) phenyl] methyl}-4- (tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 357 was prepared from Intermediate 53 using an analogous method to Example 191. LCMS showed MH+ = 472; TROT = 2. 15min. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 358 : N-(2, 3-Dihydro-lH-inden-2-yl)-1-ethyl-6-methyl-4-(tetrahydro- 2H-pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide Example 358 was prepared from Intermediate 53 using an analogous method to Example 191. LCMS showed MH+ = 394; TRET = 2.04min.

Examples 360-414 General Procedure Intermediate 33 (1.89g) was treated with thionyl chloride (10ml) and the mixture heated under reflux for 2h. Excess thionyl chloride was removed in vacuo to afford Intermediate 73, presumed to be the acid chloride of Intermediate 33 as a cream solid. The solid was suspended in tetrahydrofuran (32. 5ml) and an aliquot of the suspension added to a mixture of the amine (0. 1 lmmol) and N, N-diisopropylethylamine (0.165- 0. 22mmol) in THF (0. 5ml). The reaction mixture was agitated for 24h and the solvent removed in vacuo. The residue was purified by mass directed autoprep HPLC. Example NR4R'Source of Starting MH LC-MC Number HNR4R5 Material + Retention ion time 360 interchim Intermediate 477 2. 98 Intermediates 33 361 Aldrich Intermediate 408 3. 45 nu 'nu 362 F Aldrich Intermediate 384 3. 09 LA. 33 aNH 33 363 in Butt Park Ltd. Intermediate 437 2. 69 IfNH 0 zozo 364 Aldrich Intermediate 432 3. 21 F NH 33 365 Maybridge Intermediate 437 2. 72 ° I Chemical 33 Company Ltd. 366 XNH Aldrich Intermediate 382 2. 67 NH 33 367 N Interchim Intermediate 519 3. 01 Intermediates 33 FXNH -. F F 368 NA Aldrich Intermediate 367 2. 19 33 \NH 33 369 Butt Park Ltd. Intermediate 492 2. 21 33 33 370 e J ; Chem. Soc. C, Intermediate 449 2. 72 nu 1969, 1444 33 -0 371 A Peakdale Intermediate 444 2. 81 sNH Technologies 33 Limited m 372 J Heterocycl. Intermediate 437 2. 74 Cliein., 1975, 33 12 (2), 225 373 ° o Interclum Intermediate 459 2. 79 /H NH Intennediates 33 374 F Apollo Scientific Intermediate 400 2. 99 Ltd. 33 _NH 375 ci Aldrich Intermediate 400 3. 35 nu 33 NH 376 cl Lancaster Intermediate 425 3. 07 33 NH 377 oS Maybridge Intermediate 513 3. 33 CombiChem 33 0 379 Peakdale Intermediate 444 2. 99 Technologies 33 Limited - so 0 380 J. Heterocycl. Intermediate 437 2. 64 I ?- NH Chem., 1975, 33 0yN'-12 (2), 225 381 SN C Interchim Intermediate 479 2. 68 Intermediates 33 N 382 Aceto Intermediate 425 3. 38 Corporation 33 zum NU 383 OH Aldrich Intermediate 382 2. 78 i I 33 NH 384 l l Aldrich Intermediate 400 3. 38 CINH 33 NH 386 ° WO 03/32986 Intermediate 467 2. 65 HN 33 NH 387 o Maybridge Intermediate 513 3. 35 N// Chemical nu Company Ltd. 388 | lí 8 Intermediate 67 Intermediate 505 3. 23 0 ELH 33 0 389 Lancaster Intermediate 451 3. 17 XNH 33 cor 390", aNH EP 538945 Intermediate 487 2. 80 zu 33 391 ° Aldrich Intermediate 416 2. 99 Zinc 33 NH 392 N Interchim Intermediate 459 2. 74 NH Intermediates 33 "NH 393 H Butt Park Ltd. Intermediate 423 2. 66 33 0 394 Aldrich hitennediate 434 3. 43 NU 33 F F 395 I Aldrich Intermediate 367 2. 40 33 \_N H 'NH 396 Aldrich ; or Intermediate 434 3. 67 CloA Reetz, Synthesis, 33 NH 1999, 9, 1555 397 clH3 Bayer AG Intermediate 479 2. 89 nu °'r NH 398 s Exploratory Intermediate 451 2. 91 NU Library 33 oi 399 Maybridge Intermediate 515 3. 02 Nv/i Chemical +Se Company Ltd. X 400 tNH TimTec Intermediate 492 2. 20 NH 33 oNC N 401 Exploratory Intermediate 437 2. 68 NH Library 33 \ ? O 402 F F Lancaster Intermediate 468 3. 53 a 33 NH 0 403 Heterocycles, Intermediate 437 2. 70 a H 1983 20 (3), 445 33 NH _NU 404 ci Aldrich Intermediate 400 3. 09 33 NH 405 Aldrich Intermediate 418 3. 21 F 33 NU 406 Aldrich Intermediate 384 3. 19 NH _NU 407 N Aldrich Intermediate 409 2. 95 i I 33 NH 408 ~s/Helv. Chim. Intermediate 472 3. 07 tNH Acta, 1983 33 66 (4), 1046 409 Butt Park Ltd. Intermediate 437 2. 68 \I I 33 NH 411°\cH, SalorIntermediate444 2. 69 s \\o 33 NH 413 Nt Peakdale Intermediate 437 2. 35 YYH Molecular Limited 33 RUZ Example 414: 1-Ethyl-4-(tetrahydro-2H-pyran-3-ylamino)-1H-pyrazolo [3,4- b]pyridine-5-carboxamide Example 414 was prepared from Intermediate 59 using the general method described for examples 360-413 method. LCMS showed MH+ = 398; TRET = 2.90min.

Examples 415-487 General Procedure A mixture of Intermediate 61 (0. lmmol), HATU (0. lmmol) and DIPEA (0.4mmol) in DMF (0. 4ml) was shaken at room temperature for 10 min. A solution of the amine (0. lmmol) in DMF (0. 2ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16 hours then concentrated in vacuo. The residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g). The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc: MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo and the residue purified by mass directed autoprep HPLC. Example NR''R'Source of Starting MH LC-MC number HNR4Rs Material + Retention ion time 415 H, N 0 Rare Intermediate 395 2. 80 /SNH Chemicals 61 GmbH 416"ZNNH Aldrich Intermediate 345 2. 64 o 61 417 o\ N Ultrafine Intermediate 409 2. 84 (LJFC Ltd) 61 zozo 418 A Intermediate Intermediate 372 3. 03 °\/ 8A ; or 61 Intermediate 8 (Combi- Blocks) 419 NH N. D. Zelinsky Intermediate 382 2. 96 Institute 61 Organic Chemistry 420 "s'Peakdale Intermediate 456 3. 22 Molecular 61 Ltd. 421 Peakdale Intermediate 421 3. 03 HzN I \ Molecular 61 Ltd. 422 OeNH Aldrich Intermediate 372 3. 09 61 423 0 N-U i Org. Intermediate 485 3. 44 " sNzS\ò Chem., 1955, 61 20, 1657 424 N Key Organics Intermediate 413 3. 39 NH Ltd 61 425 NH Acros Intermediate 456 3. 19 Somme 61 S02Me 426 wo 00/17163 Intermediate 409 3. 3 Ni 61 , oMe 427 NHME Peakdale Intermediate 421 3. 23 Molecular Ltd 61 0 428 Al Peakdale Intermediate 435 3. 07 NH'I \NHMe Molecular Ltd 61 429 Peakdale Intermediate 421 2. 97 NH, Molecular Ltd 61 o 430 NH Apin Intennediate 394 3. 25 OH 61 431 NH Acros ; or Intermediate 408 3. 51 Aldrich ; or 61 OMe . i Jung et al., Tetrahedron Lett., 2002, 43 (48), 8735 ; or Meindl et al., J. Med. Chem., 1984, 27 (9), 1111 ; or Org. Lett., 2002, 4, 2055 432 NH F Aldrich Intermediate 414 3. 68 NH ll l 61 433 Aldrich ; or Intermediate 446 3. 81 Meindl et al., J. 61 CF3 Med. Chem., 1984, 27 (9), 1111. NHSO Mu 434 NH a J. Med. Intermediate 471 3. 23 Chem., 1999, 61 42 (14), 2504 435 NH F Aldrich Intermediate 414 3. 66 61 r F 436 euh Aldrich ; or Intermediate 392 3. 69 Organic 61 Setters, 2002, 4 (12), 2055 438 3vNe Key Organics Intermediate 485 3. 25 H, C N U Ltd 61 439 OH Buttpark Intermediate 394 3. 52 NH 61 440 c'\ NH Aldrich ; or Intermediate 446 4 Meindl et al., J. 61 Cl Med. Cllem., 1984, 27 (9), 1111. 441 c'I \ NH Lancaster ; or Intermediate 446 4. 08 Meindl et al., J 61 Med. Chem., '"1984, 27 (9), 1111. 442 Aldrich Intermediate 392 3. 62 XNH 61 NH 443 Aldrich Intermediate 418 3. 83 , O 61 NH 444 H3c. S WO 01/38323 Intermediate 440 3. 07 6t NH / 445 Ho Aldrich Intermediate 408 3. 31 \ 49 NH 446 H2N, ° Acros Intermediate 471 3. 13 61 NH 447 ICH3 Peakdale Intermediate 435 3. 13 HN Molecular Ltd 61 6----NH 448 CH, Peakdale Intermediate 456 3. 32 Molecular Ltd 61 NH 449 i"3 Peakdale Intermediate 436 3. 56 Molecular Ltd 61 NU 450 H3Cssp Aldrich Intermediate 471 2. 79 < NH 61 _ 451 H3CX J. Med. Intermediate 465 3. 11 Chem., 1982, 61 H3C-O NH 25 (12), 1442 452 F F F ABCR Interxnediate 464 3. 47 H 61 F- 453 HC NH Matrix Intermediate 407 3. 35 Scientific ; or 61 Clieiii. Ber., 1969, 102, 2770 454 F Aldrich Intermediate 411 3. 18 NH 455 H3CAHN Aldrich Intermediate 407 3. 3 NH 456 H3C, °> Aldrich Intermediate 423 3. 09 NH 61 457 (as N NH Aldrich Intermediate 379 2. 92 CF3C (O) OH 61 salt) 458 F <NH Aldrich Intermediate 414 3. 68 F 61 F 459 Aldrich Intermediate 404 3. 72 fy-NH 61 460 (as NH Aldrich Intermediate 421 3. 29 CF3C (O) OH H3C>N/W 61 salt) CH3 CH 3 461 F Aldrich Intermediate 396 3. 58 ¢NH 61 462 H3Cso Aldrich Intermediate 438 3. 53 NH 61 0- I CH3 463 (as ci N NH Inorganic Intermediate 413 3. 4 CF3C (O) OH XJ Chemistry, 61 salt) 1997, 36 (9), 1967 464 (as CH3 Peakdale Intermediate 449 3. 18 CF3C (O) OH oN- Molecular Ltd 61 salt) (r NH 465 FF ABCR hitennediate 422 3. 77 <NH 61 FOB 466 Aldrich Intermediate 404 3. 72 (51--NH 61 467 ci Pfaltz-Bauer ; Intermediate 446 3. 85 NH or Meindl et 61 /ail., J. Med. Chem ;, 1984, 27 (9), 1111. 468 NH Peakdale Intermediate 436 3. 53 Molecular Ltd 61 0 0 CH, CH3 469 Aldrich Intermediate 404 3. 66 NH 61 470 NH 0-Aldrich Intermediate 435 3. 52 1-o 61 471 NH N N Esprit Intermediate 370 2. 82 N_N 61 N 472 F Apollo Intermediate 444 3. 63 61 473 Ns N H Micro Chemist Intermediate 399 3. 16 ray-61 '\ jj ry-61 RadaPharma 474 ?'Fluka Intermediate 430 3. 72 NH 61 475 H2NNZO J. Am. Chem. Intermediate 421 3. 04 Soc., 1977, 61 NH 99, 3075 i 477 H3CNiCH3 J Ong. Intermediate 421 2. 89 Chem., 2001, 61 f RSNH 66 (6), 1999 v 478 NH Aldrich Intermediate 396 3. 59 F 479 F3 \ NH Aldrich ; or Intermediate 446 3. 80 Meindl et al., J. 61 Med. Chem., 1984, 27 (9), 1111. 480 Aldrich Intermediate 414 3. 57 I \ NH 61 F 481 F I \ NH Aldrich ; or Intermediate 396 3. 62 Meindl et al., J. 61 Med. Gherra., 1984, 27 (9), 1111. 482 Aldrich Intermediate 446 3. 82 \ nu 61 i 483 Cl NH J ; Med. htermediate 438 3. 95 ~ CZzem., 2001, 61 44 (26), 4628 484 \NH WO 9417035 Intermediate 61 H 0 485 NH o Aldrich Intermediate 394 3. 61 -a \ 61 486 wN ° MicroChemist htermediate 395 2. 78 H ry-61 RadaPharma 487 N" Aldrich Intermediate 379 2. 71 61 Example 488: 4-[({ [4-(CycloheXylamino)-l-ethyl-lH-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoic acid 2M-Sodium hydroxide solution (29µL, 0. 058mmol) was added to a stirred solution of Example 470 (6mg, 0.014mmol) in methanol (28gel) and water (2gel). The resulting solution was stirred at 50°C under nitrogen. After 16h, the mixture was diluted with water (0. 5ml) and adjusted to pH 4 with acetic acid. The precipitated solid was collected by filtration and dried in vacuo to afford Example 488 as a white solid (4. 5mg). LCMS showed MH+ = 422 ; TT = 3.26min.

Example 489 : 3-[({[4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo [3, 4-b] pyridin-5- yl] carbonyl} amino) methyl] benzoic acid 2M-Sodium hydroxide solution (83µL, 0. 166mmol) was added to a stirred solution of Example 468 (18mg, 0. 042mmol) in methanol (88pL) and water (5uL). The resulting solution was stirred at 50°C under nitrogen. After 16h, a further quantity of 2M- sodium hydroxide solution (29pL, 0. 058mmol) was added to the reaction mixture.

After 24h, the reaction mixture was diluted with water (0. 5ml) and adjusted to pH 4 with acetic acid. The mixture was extracted with ethyl acetate (2 x 0. 5ml), and the combined extracts were dried (Na2S04) and evaporated in vacuo to give a solid (21mg). This solid was purified on an SPE cartridge (silica, lg) eluting with ethyl acetate: cyclohexane (1: 1) followed by methanol. Fractions containing the desired product were combined and concentrated to afford Example 489 as a white solid (4.6mg). LCMS showed MH+ = 422; Trek= 3. 22min.

Example 490 : 4-(CycloheXylamino)-N-(2, 3-dihydro-lH-inden-2-yl)-1-ethyl-lH- pyrazolo [3, 4-b]pyridine-5-carboxamide hydrochloride A solution of Example 469 (71mg, 0. 17mmol) in anhydrous THF (2ml) was treated with hydrogen chloride in dioxane (4M, 0. 3ml). After standing at ambient temperature for 16 hours the resulting solid was collected by filtration and dried under vacuum to give Example 490 as rod like crystals (36mg). LCMS showed MH+= 404; TRET= 3. 60min.

Example 491: 4-(CycloheXylamino)-N-(2, 3-dihydro-lH-inden-2-yl)-1-ethyl-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide methanesulphonate A solution of Example 469 (71mg, 0. 17mmol) in anhydrous THF (2ml) was treated with anhydrous methane sulphonic acid (11. 411L, 0. 17mmol). After standing at ambient temperature for 16 hours the resulting solid was collected by filtration and dried under vacuum to give Example 491 as rod like crystals (23mg). LCMS showed MH+=404 ; TRET= 3. 59min.

Examples 492-649 General Procedure A mixture of Intermediate 33 (0. lmmol), HATU (0. lmmol) and DIPEA (0.4mmol) in DMF (0. 4ml) was shaken at room temperature for 10 min. A solution of the amine (0. lmmol) in DMF (0. 2ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16 hours then concentrated in vacuo. The residue was dissolved in chloroform (0. 5ml) and applied to a SPE cartridge (aminopropyl, 0. 5g). The cartridge was eluted successively with chloroform (1. 5ml), EtOAc (1. 5ml) and EtOAc: MeOH (9: 1, 1. 5ml). Fractions containing the desired product were concentrated in vacuo and the residue purified by mass directed autoprep HPLC. Example NR4Rs Source of Starting MH LC-MC number HNR4Rs Material + Retention ion time 492 (as ~\NH Peakdale Intermediate 453 2. 90 CF3C (0) OH L. i Molecular 33 salt) Ltd. salt) - 493 ci NH Maybridge Intermediate 428 2. 92 Chemical 33 Company Ltd. ; or WO 01/30745 494 Trans World Intermediate 428 2. 91 Chemicals, 33 Inc. ; or DE 1953059 495 Fluorochem Intermediate 446 2. 70 Ltd. 33 NH 496 Peakdale Intermediate 438 2. 83 Molecular 33 NH Ltd. 497 \NH Peakdale Intermediate 438 2. 79 Molecular 33 y Ltd. 498 NH Fluorochem Intermediate 446 2. 73 Ltd. 33 Fro 'F 499 Aldrich Intermediate 426 2. 50 HODS 33 HOLZ 500 9"Mppon Intermediate 438 2. 62 NH Kagaku 33 Zasshi ; 1952, 73 ; 393 So 501 F Apollo Intermediate 462 2. 88 Scientific Ltd. 33 F 502 Jl JS Apin Intermediate 437 2. 19 Chemicals 33 Ltd. 503 C Sigma Intermediate 410 2. 60 33 NH 504 Aldrich Intermediate 428 2. 80 14) 33 33 _NH 505 F 0 Miteni S. p. A. Intermediate 478 2. 97 nu 33 506 sO Aldrich Intermediate 424 2. 58 33 NH 507 J. Med. Intermediate 436 2. 44 t Chem., 1997, 33 20 (9), 1210 508 Fluorochem Intermediate 462 2. 99 Ltd. 33 NH 509 JP 11080156 Intermediate 473 2. 2 o"S\ NH 33 510 NH Aldrich Intermediate 454 2. 41 33 o "lo 512 Synchem Intermediate 462 2. 96 OHG 33 NH 513 su Apin Intermediate 454 2. 59 Chemicals 33 sO NH Ltd. - Ltd. 514 J Chenz. Soc. Intermediate 438 2. 75 Perkin Trans. 33 /9NH 1, 1977, 386 515 F SIGMA-RBI Intermediate 430 2. 65 N" 33 F 516 ! WO 9303022 Intermediate 454 2. 67 u 33 NH I 517 SIGMA-RABI Intermediate 408 2. 73 WNH 33 518"'C \ NH Matrix Intermediate 408 3. 2 Scientific ; or 33 H3 Chem. Ber., 1969, 102, 2770 519"3° J. Med. Intermediate 466 3 °t) Chem., 1982 33 H C-0 NH 25 (12), 1442 3 521 o./° Acres Intermediate 473 2. 62 H2N Yq 33 vNH NH NH 522 g~NH WO 01/38323 Intermediate 445 2. 55 33 CH3 C"3 523 Aldrich Intermediate 394 3 33 NH 524 NH Aldrich Intermediate 423 2. 51 H3c., 33 N C3 L, H 525 F Aldrich Intermediate 412 3. 06 33 NH 526 CA Aldrich Intermediate 408 3. 16 33 NH 527 NH Yakugaku Intermediate 459 2. 6 Zasshi ; 1950 33 70, 71 H, N-I=O I I 0 528 NH Aldrich ; or Intermediate 394 3. 08 Organic 33 Letters, 2002, 4 (12), 2055 530 F F Lancaster Intermediate 466 3. 31 NH 33 Fez F 531 ENH J. Am. Chem. Intermediate 438 3 0 Soc., 1976, 33 78 (22), 6978 0 H3C' 532 (as NH Inorganic Intermediate 415 2. 82 CF3C (O) OH Chemistry, 33 salt) 1997, 36 (9), c1967 533 Aldrich Intermediate 406 3. 14 33 61 nu 534/NH Peakdale Intermediate 451 2. 71 u, CH3 Molecular 33 N'Ltd. H, CO 535 Aldrich Intermediate 406 3. 15 N 33 _- 536 Aldrich Intermediate 406 3. 15 W NH N H 537 O\\/N J. Med. Intermediate 473 2. 58 Chem., 1999, 33 42 (14), 2504 538 Chemical Intermediate 422 2. 92 Building 33 Blocks CHUG 540 Aldrich Intermediate 451 2. 13 33 N N W 33 541 h Aldrich Intermediate 436 3. 15 33 N CH, 542 N Aldrich Intermediate 408 2. 85 iQ 33 CH3 544 i I Janssen Intermediate 449 2. 67 Pharma-33 ! ! ceuticals NH 545 1°l Intermediate Intermediate 444 2. 34 , ty HN CH 69 33 NH 546 (as NcH3 Arzneimittel Intermediate 430 1. 95 H-C (O) OH NJ Forschung, 33 salt = formic N 1974, 24 (4a), acid addition Je 584 salt) NH CH3 547 r, N 7 CCHa WO 97/25323 Intermediate 445 1. 96 nu 33 NH 548 (as on <E WO 03/32980 Intermediate 479 2. 21 CF3C (O) OH 33 salt) 549 (as NH WO 03/32980 Intermediate 492 2. 24 CF3C (O) OH 33 salt) Zon J C 550 (as NH WO 02/85860 Intermediate 424 2. 33 CF3C (O) OH 33 salt) H2N 40 551 i NH Salor Intermediate 422 3. 36 H, c w 33 CH, 552 WO 95/00516 Intermediate 494 3. 22 Y 33 NU CH 553 (as"' "WO 03/32980 Intermediate 492 2. 21 CF3C (O) OH 33 salt) 554 ci Aldrich ; or Intermediate 448 3. 4 NH Meindl et al., 33 JJ J. Med. cl/9 Chem., 1984, 27 (9), 1111. 555 Aldrich Intermediate 416 3. 06 XNH 33 i F 556 ici Salor Intermediate 432 3. 21 \ NH 33 i F 557 n DE 2300018 Intermediate 458 3. 12 H3co9 NH 33 Cl 0 5589\/Peakdale Intermediate 436 3. 41 ° Molecular Ltd 33 w 559 (as ~\NH JP 10045736 Intermediate 463 2. 28 CF3C (O) OH , 33 salt) C ? 560 H WO 02/16318 Intermediate 487 2. 74 EP 338793 33 L !] 0 0 561 H 3 C Maybridge Intermediate 440 2. 99 Chemical 33 Company Ltd. HFC 562 Lancaster Intermediate 440 3. 00 33 CH. C"3 563 Aldrich Intermediate 398 3. 01 \ nu 33 564 F I NH Aldrich ; or Intermediate 416 3. 11 Meindl et al., 33 J. Med. F Chem., 1984, 27 (9), 1111. 565 NH Aldrich ; or Intermediate 414 3. 19 Organic 33 Letters, 2002, 4 (12), 2055 567 Aldrich Intermediate 372 3. 01 jQ NH"10 33 568 N" s°c J. Biol. Chenz., Intermediate 472 2. 69 \ 1997, 272 (3), 33 1493 569 Fluorochem Intermediate 466 3. 29 N_F Ltd. 33 NH 570 NH Intermediate Intermediate 463 2. 66 71 33 571 T-\ Maybridge Intermediate 478 2. 25 Reactive 33 intermediates 572 WO 99/67204 Intermediate 463 2. 24 C 33 573 _ os Eur. J. Med. Intermediate 450 2. 90 NH I Chem., 1987, 33 22 (5), 417 574 Lancaster Intermediate 446/3. 3 5 NH 33 448/ 450 ce 575 Eur. J. Med. Intermediate 436 3. 48 chez., 1987, 33 33 (5), 363 576 F F Avocado Intermediate 416 3. 06 33 '577WO 02/30930 Intermediate 458 2. 80 NH) 33 Nu 578 OH Apin Intermediate 458 2. 80 33 Nl\-6 33 579 °-Aldrich Intermediate 458 2. 80 NH 33 \/ 580 N"oN Aldrich Intermediate 33 581 81 Cl Lancaster ; or Intermediate 446/2. 80 /J. Med. 33 448/ 9 Chem., 1984, 450 ci 27 (9), 1111. 582 NH g Aldrich Intermediate 440 2. 96 NH 33 to\ 583/Aldrich Intermediate 410 2. 98 < 33 Nu 584 ICN Intermediate 408 3. 18 Biomedicals, 33 Inc. ; or Salor ; or Synthesis, 1982, 12, 1036 585 N-WO 03/32986 Intermediate 437 2. 62 z Nu 586 NH-", Aldrich Intermediate 424 3. 05 33 587 Aldrich Intermediate 414/3. 13 Ni 33 416 588 HO Buttpark Intermediate 396 2. 14 33 < 33 589 o) Aldrich Intermediate 424 2. 76 0 33 590 0-Lancaster Intermediate 396 2. 95 NH 33 591 NH Aldrich ; or Intermediate 386 3. 10 Synlett, 1999, 33 4, 409 592 NH Aldrich Intermediate (c 33 i 593 NH ° Apin Intermediate 438 2. 82 o_ 33 594 ci Aldrich ; or Intermediate 448/3. 26 Meindl et al., 33 450/ J. Med. 452 Chem., 1984, 27 (9), 1111. 595 wNH2 WO 02/85860 Intermediate 423 2. 29 nu= 33 596 N F _ Aldrich Intermediate 416 3. 0 33 F 597 NH Aldrich Intermediate 423 2. 56 33 NH, 0 598 NH OH Apin Intermediate 396 2. 54 33 599 NH/=N WO 00/17163 Intermediate 411 2. 72 <\ 33 600 NH N Aldrich ; or Intermediate 381 1. 89 XY J. Med. 33 Chem., 2003, 46 (4), 461. 601 F Aldrich ; or Intermediate 448 2. 96 Meindl et al., 33 J. Med. Chem., 1984, 27 (9), 1111. 602 Peakdale Intermediate 423 2. 28 o Molecular 33 N Limited 603 WO 94/17035 Intermediate 437 2. 28 Nle, 33 H N I/ 604 J. Pharm Sci., Intermediate 437 2. 34 1987, 76 (1), 33 N 18-20 605 Aldrich ; or Intermediate 398 2. 71 If Meindl et al., 33 J. Med. Chem., 1984, 27 (9), 1111 ; or Organic Letters, 2002, 4 (12), 2055 606 NHO o Lis et al., J. Intermediate 473 2. 40 , s. Med. Chern. 33 o H 1990, 33 (10), 2883, see Scheme III and ref. 24 607 NH"l Sigma Intermediate 459 2. 31 S. NHZ 33 ouzo 0 608 H2N o Peakdale Intermediate 423 2. 55 Molecular 33 NH-Y, (ij Ltd. 609 XolF F luorochem Intermediate 446 2. 82 0), F Ltd. 33 610 NH N DE Intermediate 437 1. 86 I/I 19937494 611 NH Cl FluorochemL Intermediate 444 2. 80 -nf 33 0 1 612 NH WO00/72834 Intermediate 415 2. 12 'ON'r 0 33 613 F Aldrich Intermediate 448 2. 96 NH AVd ''' 615/=\ c J. Med. Intermediate 440 3. 03 Chem., 2001, 33 NH 44 (26), 4628 616 Intermediate Intermediate 451 2. 62 NH 75 (asHCl 33 salut) salt) 617 Aldrich ; or Intermediate 398 2. 90 Organic 33 Letters, 2002, 4 (12), 2055 618 Alfa Intermediate 466 2. 98 33 F 619 Eaegy & Intermediate 408 2. 86 Fuels, (1994), 33 8 (4), 990- 1001 620 F Alfa Intermediate 466 2. 94 33 CF, 621 Apollo Intermediate 434 2. 82 "rY"33 F 622 Acros Intermediate 432 2. 9 33 a hou 33 ber 624 nu Apollo ; or Intermediate 408 2. 88 Eur. J. Med. 33 T Chem 1998, 33 (5), 363 625 Maybridge Intermediate 408 2. 83 < 33 626 Lancaster Intermediate 448 3. 02 33 627 Apin Intermediate 405 2. 56 "L JL 33 33 N 628 Ubi-Chem Intermediate 458 2. 89 33 usr 33 629 ABCR Intermediate 466 2. 97 NH 33 F 630 NH Lancaster Intermediate 505. 2. 97 ut, 33 9 631- I I Apollo Intermediate 436 3. 11 33 632 WO Intermediate 405 2. 55 98/33767 ; or 33 Meindl et al., J. Med. Chem., 1984, 27 (9), 1111. 633 a Pfaltz-Bauer ; Intermediate 448 2. 88 or Meindl et 33 al., J. Med. Chem., 1984, 27 (9), 1111 634 Transworld Intermediate 428 3. 22 herz 33 a 635 Apin | Intermediate 536 3. 47 LJ (HNR4R5 33 used as HCl salt) 636 Matrix Intermediate 408 3. 18 33 637 N+ Avocado Intermediate 466 3. 25 33 _ 638 l Pfaltz-Bauer lntermediate 505. 2. 92 33 9 639 Br Alfa Intermediate 458 3. 10 nu 33 640 WO 03/35621 Intermediate 410 2. 49 JL (HNR4R5 33 used as HCI salt) 641 OH WO 03/35621 Intermediate 410 2. 51 kj' (HNR4R5 33 used as HUI salt) 642 DE 2136624 Intermediate 424 2. 55 ! Y°" (HNR4p5 33 used as HCl salt) 643 Intermediate 478 2. 96 NH (HNR4R5 33 NH used as HC1 a salt) a 644 Aldrich Intermediate 462 3. 13 33 na 33 645 _< Intermediate 436 3. 18 33 646 Matrix Intermediate 408 2. 84 Nah 33 647 F Apollo Intermediate 434 2. 80 33 F F 648 ABCR Intermediate 466 2. 99 M 33 XCF3 33 649 Lancaster Intermediate 428 2. 87 - i I 33 a Example 518: N [ (3, 4-dimethylphenyl) methyl]-1-ethyl-4-(tetrahydro-2H-pyran- 4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide ; also known as: N-(3, 4-dimethylbenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)- lH- pyrazolo [3, 4-b] pyridine-5-carboxamide An alternative process for preparing Example 518 is given below: To a solution of Intermediate 33 (3. 5g, 12.07mmol) in DMF (500ml) was added HATU (4. 5g, 12. 07mmol) and the mixture stirred at room temperature for 30 min.

3, 4-Dimethylbenzylamine (1.63g, 12.07mmol, obtainable from Matrix Scientific, Columbia, USA or by a process described in Chem. Ber., 1969,102, 2770) was added followed by DIPEA (4. 5ml, 26. 55mmol) and the solution stirred at room temperature for 16 hours. The solvent was removed under reduced pressure and the residue partitioned between saturated aqueous NaHCO3 (200ml) and ethyl acetate (250ml), the aqueous phase re-extracted with ethyl acetate (2x200ml), the organic extracts combined, dried (Na2S04) and evaporated. The resultant viscous oil was recrystallised from hot ethyl acetate (ca. 100ml) to give the title compound as a white crystalline solid (3.36g, 80%). LCMS showed MH+= 408; Tret = 3. 06min. 8H (D6 DMSO) 1.36 (3H, t), 1.51 (2H, m), 2.00 (2H, m), 2.18 (3H, s), 2.19 (3H, s), 2.50 (2H, m), 3.61 (2H. m), 3.83 (2H, m), 4.17 (1H, m), 4.36 (2H, q), 4.38 (2H, d), 7.02-7. 09 (3H, m), 8.17 (1H, s), 8.62 (1H, s), 8.93 (1H, t), 9.96 (1H, d): 8c (D6 DMSO) 14.65, 18.91, 19.33, 32.81, 41.06, 41.86, 48.57, 64.94, 101.69, 102.18, 124.44, 128.22, 129.24, 133.28, 134.31, 135.78, 136.91, 149.26, 149.59, 151.36, 168.81 Example 518A: N[(3,4-dimethylphenyl)methyl]-1-ethyl-4-(tetrahydro-2H- pyran-4-ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide hydrochloride; also known as: N-(3, 4-dimethylbenzyl)-1-ethyl-4-(tetrahydro-2H-pyran-4- ylamino)-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide hydrochloride A solution of Example 518 (1.3g, 3. 19mmol) in anhydrous tetrahydrofuran (200ml) was treated with a solution of hydrogen chloride in dioxane (4M, 8ml) and the mixture stirred at ambient temperature for 16 hours. The resultant white precipitate was collected by filtration and recrystallised from hot methanol (100ml) to give the title compound Example 518A as a white crystalline solid (1.12g, 79%).

LCMS showed MH+= 408 ; Tret = 3. 21min. 8H (D6 DMSO) 1.39 (3H, t), 1.59 (2H, m), 2.01 (2H, m), 2.19 (3H, s), 2.20 (3H, s), 3.64 (2H, t), 3.83 (2H, m), 4.28 (1H, m), 4.40 (2H, d), 4. 50 (2H, q), 7.04-7. 11 (3H, m), 9.40 (1H, s (br) ), 10.72 (1H, s (br)).

Example 650: 4- [({[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-!h-pyrazolo[3, 4- b] pyridin-5-yl] carbonyl} amino) methyl] benzoic acid sodium salt.

2M-Sodium hydroxide solution (98µL, 0. 196mmol) was added to a stirred solution of Example 593 (22mg, 0.049mmol) in methanol (1041lu) and water (6µL). The resulting solution was stirred at 50°C under nitrogen. After 16h, the reaction mixture was diluted with water (0. 5ml) and adjusted to pH 4 with acetic acid. The mixture was extracted with ethyl acetate (2 x 0. 5ml), and the combined extracts were dried (Na2S04) and evaporated in vacuo to give a solid (15mg). This solid was suspended in water (0. 5ml) and treated with 2M-sodium hydroxide solution (l5pL). Evaporation of solvent in vacuo afforded Example 650 as a white solid (1 lmg). LCMS showed MH+ = 425 ; TRET = 2.69min.

Example 651: 3- [({[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3, 4- b] pyridin-5-yl] carbonyl} amino) methyl] benzoic acid 2M-Sodium hydroxide solution (98µL, 0.196mmol) was added to a stirred solution of Example 558 (22mg, 0. 049mmol) in methanol (104µL) and water (6llL). The resulting solution was stirred at 50°C under nitrogen. After 16h, the reaction mixture was diluted with water (0. 5ml) and adjusted to pH 4 with acetic acid. The precipitated solid was collected by filtration and dried in vacuo to afford Example 651 as a white solid (15mg). LCMS showed MH+ = 425; Trek= 2.72min.

Example 652: Ethyl l-ethyl-4-{[4-(hydroxyimino) cyclohexyl] amino}-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate A mixture of Example 205 (200mg), hydroxylamine hydrochloride (50mg) and anhydrous potassium carbonate (420mg) in acetonitrile (10 ml) was stirred and heated at reflux for 17 hours. The solution was cooled and concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic phase was separated, dried over Na2S04 and concentrated in vacuo to give Example 652 as a white powder (203mg). LCMS showed MH+ = 346; TRET = 2. 84min.

Example 653 : 1-Ethyl-4-{ [4-(hydroxyimino) cyclohexyl] amino}-N-{ [4- (methyloxy) phenyl] methyl}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide A mixture of Example 263 (217mg), hydroxylamine hydrochloride (43mg) and anhydrous potassium carbonate (355mg) in acetonitrile (10 ml) was stirred and heated at reflux for 17 hours. The solution was cooled and concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic phase was separated, dried over Na2S04 and concentrated in vacuo to give Example 653 as a yellow solid (186mg). LCMS showed MH+ = 437; Trek= 2. 82min. 8H (CDC13) 1.49 (3H, t), 1.80 (2H, m), 2.2-2. 4 (4H, m), 2.54 (1H, m), 3.13 (1H, dt), 3.81 (3H, s), 4.13 (1H, m), 4.46 (2H, q), 4.54 (2H, d), 6.28 (1H, t), 6.90 + 7.28 (4H, AA'BB'), 7.98 (1H, s), 8.36 (1H, s), 9.84 (1H, d). Hydroxyl proton not visible.

The following examples were prepared by a similar procedure, e. g. using the same or a similar number of moles of reagents and the same or similar volumes of solvents: 4 5 Example No. NR R Source of Starting MH LC-MC HNR4Rs Material + Retention ion time 654 I NH Aldrich Example 265 450 2. 35 I. I 680 NH CH3 Salor ; or ICN Example 260 435 3. 10 Biomedicals, CH, Inc. ; or '. Synthesis, 1982, 12, 1036 681 NH CHMSRV-Example 261 435 3. 08 CH, AS ; or WCH3 Matrix Scientific ; or Chem. Ber., 1969, 102, 2770 682 ci Lancaster Example 677 475 3. 20 ""T 683 NH Maybridge Example 678 455 3. 17 Chemical Company CH3 Ltd. ; or WO 01/30745 684 NH CH3 Trans World Example 679 455 3. 17 Chemicals, Inc. ; or DE 1953059 685 <° Fluorochem ; Example 266 473 3. 00 or WO 98/45268 686 NH-F Aldrich ; or Example 267 475 3. 13 F Meindl et al., J. Med. CJaena., 1984, 27 (9), 1111 ; or Org. Lett, 2002, 4 (12), 2055 See later for alternative preparation of Example 681. <BR> <BR> <BR> <P>Example 655: 1-Ethyl-4-({4- [(ethyloxy) imino] cyclohexyl} amino)-N-{ [4- (methyloxy) phenyl] methyl}-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide A mixture of Example 263 (25mg), ethoxyamine hydrochloride (R260NH2 where R26 = Et, 20mg) and diisopropylethylamine (30mg) in acetonitrile (3 ml) was stirred and heated at reflux for 3.25 hours. The solution was cooled and concentrated in vacuo. The residue was applied to an SPE cartridge (5g). The cartridge was eluted with EtOAc. Fractions containing the desired product were concentrated in vacuo to give Example 655 as a colourless gum (20mg). LCMS showed MH+ = 465; TRET = 3. 28min.

The following examples were prepared by a similar procedure, e. g. using the same or a similar number of moles of reagents and the same or similar volumes of solvents: Example No. R26 Source of Starting MH LC-MC R26ONH2 Material + Retention ion time 656 Me Aldrich Example 263 451 2. 52 657 tBu Aldrich Example 263 493 3.66 Example 658: l-Ethyl-N-{ [4-(methyloxy) phenyl] methyl}-4-[(7-oxohexahydro-lH- azepin-4-yl) amino]-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide A suspension of cyanuric chloride (2,4, 6-trichloro-1, 3,5-triazine) (150mg) in DMF (0.2 ml) was stirred for 30 minutes at room temperature. The suspension was diluted to 7ml with DMF, with stirring. A 1. Oml portion of the resultant suspension was removed and added to Example 653 (52mg). The resultant solution was stirred for 90 hours at room temperature, then concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic phase was separated and washed consecutively with saturated sodium carbonate, 10% w/v citric acid and saturated brine, dried over Na2S04 and concentrated in vacuo. The residue was applied to an SPE cartridge (2g). The cartridge was eluted successively with EtOAc: cyclohexane (1: 1), EtOAc then a (100: 8: 1) mixture of dichloromethane, ethanol and ammonia.

Fractions containing the desired product (eluted in the ammoniacal solution) were concentrated in vacuo to give Example 658 as a colourless oil (1 lmg). LCMS showed MH+ = 437; TRET = 2. 50min.

Example 659: Ethyl l-ethyl-4- [ (7-oxohexahydro-lH-azepin-4-yl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxylate Example 659 was prepared from Example 652, using an identical procedure to that used for Example 658. LCMS showed MH+ = 346; TRET = 2.56min.

Example 660: 4-{[cis-4-(Butylamino) cyclohexyl] amino}-N-(2, 3-dihydro-lH- inden-2-yl)-1-ethyl-lH-pyrazolo [3, 4-b] pyridine-5-carboxamide A solution of Example 258 (25mg), butyraldehyde (5mg) and glacial acetic acid (30mg) in DCM (3ml) was stirred for 10min. Sodium triacetoxyborohydride (21mg) was added. The reaction mixture was stirred for 1.5 hours. Sodium bicarbonate (l. OMolar, 3ml) was added dropwise, with stirring. After stirring for 5 min. the phases were separated. The organic phase was dried over Na2S04 and applied to an SPE cartridge (5g). The cartridge was eluted with a (100: 8: 1) mixture of dichloromethane, ethanol and ammonia. Fractions containing the desired product were concentrated in vacuo to give Example 660 as an amorphous, cream solid (19mg). LCMS showed MH+ = 346; Trek= 2. 56min.

Examples 661 to 664 General Procedure: Intermediate 17 (0.16mmol) in acetonitrile (lml) was treated with the R3NH2 amine (0. 8mmol) in acetonitrile (lml) and N, N-diisopropylethylamine (0. 8mmol). The mixture was heated at 50°C for 18h then concentrated in vacuo. The residue was diluted with water (3ml) and extracted with dichloromethane (2 x 5ml). The combined organic extracts were evaporated, and the residue was purified by mass directed autoprep HPLC to give the desired product containing formic acid. This material was dissolved in chloroform-methanol (10/1, 5. 5ml) and washed with 5% sodium hydrogen carbonate solution (lml) to give after evaporation of solvents the pure product. Example no. NHR3 ** Source of Starting MH LC-MC R3NH2 Material + Retention ion time 214 H N- (} NH J ed. Chem., Intermediate 393 2. 16 u 1994, 37 (17), 17 2360 661/-\ Aldrich Intermediate 393 2. 16 17 U 17 662 NH, AldrichIntermediate 393 2. 29 17 "-""NH 663 NH2 Aldrich Intermediate 393 2. 30 L 17 ANH 17 664 H2N Peakdale Intermediate 393 2. 21 Molecular Ltd 17 NH ** For NHR3 in Examples 214 and 661-663, NHR3 is the cis or trasts isomer as shown. For Examples 662-664, NHR3 is the 3-amino-or 2-amino-cyclohex-1- ylamino group in a racemic form.

Example 665 Ethyl 1-ethyl-4-{[(1SR,3RS)-3-hydroxycyclohexyl]amino}-1H- pyrazolo [3, 4-b] pyridine-5-carboxylate [cis- (3-hydroxycyclohex-1-yl) amino group, racemic] 3-Aminocyclohexanol (0.677g, 5.9mmol, as described in J Chem. Soc., Perkin Trans 1, 1994, 537) in acetonitrile (lOml) and ethanol (lml) was added at room temperature to a stirred solution of Intermediate 1 (1.24g, 4. 9mmol) and diisopropylethylamine (4. 26ml, 24. 5mmol) in acetonitrile (25ml). The resulting mixture was stirred at 85°C for 17h. The mixture was concentrated in vacuo, and the residue was partitioned between DCM (50ml) and water (10ml). The phases were separated and the organic phase was dried (Na2S04) and evaporated to give an orange-brown oil. The oil was purified by Biotage chromatography (silica 100g) eluting with 30-50% EtOAc in cyclohexane to give Example 665 as a white foam (0. 681g). LCMS showed MH+= 333; TRET= 2. 76min.

Examples 666-676 [cis- (3-hydroxycyclohex-1-yl) amino group, racemic] General Procedure: A mixture of Intermediate 76 (0. lmmol), HATU (0. lmmol) and DIPEA (0. 4mmol) in DMF (0.5ml) was shaken at room temperature for 10min. A solution of the amine HNR4R5 (0. 12mmol) in DMF (0. 5ml) was then added and the mixture agitated for several minutes to give a solution. The solution was stored at room temperature for 16h, then concentrated in vacuo. The residue was purified by mass directed autoprep HPLC. Example no. NIeR5 Source of Starting MH LC-MC HNR4R5 Material + Retention ion time 666 Aldrich Intermediate 332 2. 35 76 667 Aldrich Intermediate 398 2. 96 76 668/I Manchester Intermediate 401 2. 48 s Organics Ltd 76 669 NH F Aldrich Intermediate 412 2. 88 76 670 ws"-o Acros Intermediate 472 2. 57 76 671 NH, = (Aldrich Intermediate 454 2. 67 wo\ 76 672 NH N Aldrich Intermediate 395 2. 15 76 673 NH N N. D. Zelinsky Intermediate 398 2. 35 Institute 674 Matrix Intermediate 422 3. 08 Scientific ; or 76 Chem. Ber., 1969, 102, 2770 675 N" o Aldrich Intennediate 424 2. 81 76 676 NH-ICN Intermediate 422 3. 08 Biomedicals, 76 Inc. ; or Salor ; or Synthesis, 1982, 12, 1036 Example 260 (Alternative Procedure) N-[(2, 4-dimethylphenyl) methyl]-1-ethyl-4-[(4-oXocycloheXyl) amino]-lH- pyrazolo [3, 4-b] pyridine-5-carboxamide Alternative procedure for preparing Example 260: A solution of Intermediate 58 (45mg), HATU (63mg) and DIPEA (39mg) in acetonitrile (5ml) was stirred for 10min. A solution of 2,4-dimethylbenzylamine (24mg) (available from Salor; or ICN Biomedicals, Inc. ; or Synthesis, 1982,12, 1036) in acetonitrile (lml) was added. The reaction mixture was stirred for 18h. The solution was concentrated and the residue partitioned between ethyl acetate (25ml) and 0.5M sodium bicarbonate (20ml). The organic phase was separated, washed with water (20ml), dried over Na2S04 and concentrated to leave a gum which was applied to an SPE cartridge (5g). The cartridge was eluted with ethyl acetate. Fractions containing the desired compound were combined and concentrated in vacuo to give Example 260 (32mg). LC-MS showed MH+ = 420; TUT = 3. 16min. on (CDC13) : 1.49 (3H, t), 2.11 (2H, m), 2.33 (3H, s), 2.35 (3H, s), 2.40 (2H, m), 2.52 (2H, m), 2.61 (2H, m), 4. 36 (1H, m), 4.47 (2H, q), 4. 55 (2H, d), 6.14 (1H, t), 7.01 + 7. 18 (2H, AA'BB'), 7.04 (1H, s), 8.01 (1H, s), 8.36 (1H, s), 9.96 (1H, d).

The following Examples 677-679 were prepared in a similar manner to Example 260 (alternative procedure above), for example using the same or a similar number of moles of reagents and the same or similar volumes of solvents: Example no. NIEW Source of Starting MH LC-MC HNIER Material + Retention ion time 677 Ci Lancaster Intermediate 460 3. 28 NHtCI 58 678 NH Maybridge Intermediate 440 3. 25 ci Chemical 58 Company Ltd. ; CH3 or "3 or WO 01/30745 679 NH Trans World Intermediate 440 3. 24 Chemicals, Inc. ; 58 or DE 1953059 Cl Examples 680-686 and their preparation are shown above together with Example 653.

Alternative Preparation of Example 681: N [ (3, 4-dimethylphenyl) methyl]-1- ethyl-4-{[4-(hydroxyimino) cyclohexyl] amino}-1H-pyrazolo [3, 4-b] pyridine-5- carboxamide A mixture of Example 261 (35mg), hydroxylamine hydrochloride (lOmg) and diisopropylethylamine (26mg) in acetonitrile (4 ml) was stirred and heated at reflux for 2.5 hours. The solution was cooled and concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic phase was separated, dried over Na2S04 and concentrated in vacuo. The residue was applied to an SPE cartridge (lOg). The cartridge was eluted with EtOAc: cyclohexane (1: 1) and then EtOAc.

Fractions containing the desired compound were combined and concentrated in vacuo to give Example 681 as a white, amorphous solid (18mg). LCMS showed MGF = 435 ; TRET = 3. 08min. 8H (CDC13) 1.49 (3H, t), 1.79 (2H, m), 2.24 (6H, s), 2.19-2. 38 (4H, m), 2.56 (2H, dt), 4.13 (1H, m), 4.46 (2H, q), 4.53 (2H, d), 6.36 (1H, t), 7.09 (2H, t), 7.12 (1H, s), 7.98 (1H, s), 8.38 (1H, s), 9.79 (1H, d). Hydroxyl proton not visible.